<u>Luis A. Cruz</u>

i c
S≡2
□ □
5 = s
8

03-16-00

Certificate of Mailing Label Number: EL488650049US Date of Deposit __March 15, 2000 I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Printed name of person mailing corres	e of person mailing correspondence			
UTILITY PATENT	APPLICATION TRANSMITT	AL UNDER 37 CFR §1.53(b)		
Attorney Docket Number	50110/002005			
Applicant	Michael R. Hayden et al.			
Title	METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS			
PRIORITY INFORMATION:				
U.S. Provisional Application No	. 60/138,048, filed June 8, 199	on No. 60/124,702, filed March 15, 1999, 9, U.S. Provisional Application No. tion No. 60/151,977, filed September 1,		
APPLICATION ELEMENTS:				
Cover sheet	1 pages			
Specification	84 pages			
Claims	15 pages			
Abstract	1 pages			
Drawing	68 pages			
Combined Declaration and POA □ Unsigned; □ Newly signed for this application □ A copy from prior application the entire disclosure of the prior being part of the disclosure of the hereby incorporated by reference	3 pages			
Statement Deleting Inventors	[**] pages			
Sequence Statement	2 pages			
Sequence Listing on Paper		84 pages		
Sequence Listing on Diskette	1 diskette			

Small Entity Statement, which is: ☐ Unsigned; ☐ Newly signed for this application; ☐ A copy from prior application [**SERIAL NUMBER**] and such small entity status is still proper and desired.	2 pages
Preliminary Amendment	[**] pages
IDS	[**] pages
Form PTO 1449	[**] pages
Cited References	[**] pages
Recordation Form Cover Sheet and Assignment	[**] pages
Assignee's Statement	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$345	\$345.00
Excess Claims Fee: 127-20= 107 x \$9 =	\$963.00
Excess Independent Claims Fee: 43 - 3=40 x \$39=	\$1,560.00
Multiple Dependent Claims Fee: \$130	\$130.00
Total Fees:	\$2998.00
 Enclosed is a check for \$2,998.00 to cover the total fees. Charge [**AMOUNT**] to Deposit Account No. 03-2095 to The filing fee is not being paid at this time. Please apply any other charges, or any credits, to Deposit 	

CORRESPONDENCE ADDRESS:

Paul T. Clark Reg. No. 30,162 Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

May hox Juntara Reg. No. 36, 268 Signature March 15, 2000

Date

Applicant or Patentee Serial or Patent No.

: Michael R. Hayden et al.

Filed or Issued

: March 15, 2000

Title

: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION

l hereby d	declare that I am an official empowered to act on behalf of the nonprofit organization identified below:
Address	Organization: The University of British Columbia of Organization: 2329 West Mall, Vancouver, British Columbia, V6T 1Z4 Canada Organization:
	 University or Other Institution of Higher Education Tax Exempt under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)) Nonprofit Scientific or Educational under Statute of State of the United States of America Name of Statute: Citation of Statute: Would Qualify as Tax Exempt under Internal Revenue Service Code (26 Usc 501(a) and 501(c)(3)) If Located in the United States of America Would Qualify as Nonprofit Scientific or Educational under Statute of State of the United States of America If Located in the United States of America Name of State: Citation of Statute:
purposes METHOD and Simo	declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled SS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS by inventors Michael R. Hayden, Angela R. Wilson, in N. Pimstone described in [X] the specification filed herewith. [] application serial No. , filed . [] patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**].
I hereby o	patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**]. declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to e identified invention.
invention small bus	its held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a siness concern under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR a nonprofit organization under 37 CFR 1.9(e).
	*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)
Full Nam Address:	ne: Xenon Bioresearch, Inc. : 3250 East Mall, Vancouver, British Columbia, V6T 1W5 Canada [] INDIVIDUAL [X] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION
small enti	ledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to ity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on atus as a small entity is no longer appropriate. (37 CFR 1.28(b))
belief are like so ma such willf	declare that all statements made herein of my own knowledge are true and that all statements made on information and be believed to be true; and further that these statements were made with the knowledge that willful false statements and the ade are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that ful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.
Name:	Angus Livingstone
Title:	Managing Director
Address	:: The University of British Columbia, 2329 West Mall, Vancouver, B.C. CANADA V6T 1Z4
Signatur	Date:

on

Applicant or Patentee Serial or Patent No.

: Michael R. Hayden et al.

Filed or Issued

: March 15, 2000

Title

: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS

(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN
I hereby declare that I am
[] the owner of the small business concern identified below: [X] an official of the small business concern empowered to act on behalf of the concern identified below:
Name of Small Business Concern: Xenon Bioresearch Inc.,
Address of Small Business Concern: 3250 East Mall, Vancouver, B.C. V6T 1W5 Canada
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.
I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS by inventors Michael R. Hayden, Angela R. Wilson, and Simon N. Pimstone described in
[X] the specification filed herewith. [] application serial no. , filed [] patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**].
If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)
Assignee Name:
Assignee Address:
[]INDIVIDUAL []SMALL BUSINESS CONCERN []NONPROFIT ORGANIZATION
I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date of which status as a small entity is no longer appropriate. (37 CFR 1.28(b))
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.
Name: Michael R. Hayden, M.D. Ph.D.
Title: Chief Scientific Officer
Address: Xenon Bioresearch, Inc., NRC Innovation Centre, 3250 East Mall, Vancouver, BC V6T 1W5
Signature: Date:

Certificate of Mailing				
Date of Deposit <u>March 15, 2000</u>	Label Number: <u>EL488650049US</u>			
I hereby certify under 37 CFR 1.10 that this correspondence is "Express Mail Post Office to Addressee" with sufficient pos PATENT APPLICATION, Assistant Commissioner of Patents, Luis A. Cruz Printed name of person mailing correspondence	tage on the date indicated above and is addressed to BOX			

APPLICATION

FOR

UNITED STATES LETTERS PATENT

APPLICANT

MICHAEL R. HAYDEN, ANGELA R. WILSON,

SIMON N. PIMSTONE

TITLE

METHODS AND REAGENTS FOR MODULATING

CHOLESTEROL LEVELS

25

5

10

METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

Cross-Reference to Related Applications

This application claims priority from U.S. Provisional Application No. 60/124,702, filed March 15, 1999, U.S. Provisional Application No. 60/138,048, filed June 8, 1999, U.S. Provisional Application No. 60/139,600, filed June 17, 1999, and U.S. Provisional Application No. 60/151,977, filed September 1, 1999.

Background of the Invention

Low HDL cholesterol (HDL-C), or hypoalphalipoproteinemia, is a blood lipid abnormality which correlates with a high risk of cardiovascular disease (CVD), in particular coronary artery disease (CAD), but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. HDL, or 'good cholesterol' levels are influenced by both environmental and genetic factors.

Epidemiological studies have consistently demonstrated that plasma HDL-C concentration is inversely related to the incidence of CAD. HDL-C levels are a strong graded and independent cardiovascular risk factor. Protective effects of an elevated HDL-C persist until 80 years of age. A low HDL-C is associated with an increased CAD risk even with normal (<5.2 mmol/l) total plasma cholesterol levels. Coronary disease risk is increased by 2% in men and 3% in women for every 1 mg/dL (0.026 mmol/l) reduction in HDL-C and in the majority of studies this relationship is statistically significant even after adjustment for other lipid and non-lipid risk factors. Decreased HDL-C levels are the most common lipoprotein abnormality seen in patients with premature CAD. Four percent of patients with

25

5

premature CAD with have an isolated form of decreased HDL-C levels with no other lipoprotein abnormalities while 25% have low HDL levels with accompanying hypertriglyceridemia.

Even in the face of other dyslipidemias or secondary factors, HDL-C levels are important predictors of CAD. In a cohort of diabetics, those with isolated low HDL cholesterol had a 65% increased death rate compared to diabetics with normal HDL cholesterol levels (>0.9 mmol/l). Furthermore, it has been shown that even within high risk populations, such as those with familial hypercholesterolemia, HDL cholesterol level is an important predictor of CAD. Low HDL cholesterol levels thus constitute a major, independent, risk for CAD.

These findings have led to increased attention to HDL cholesterol levels as a focus for treatment, following the recommendations of the National Cholesterol Education Program. These guidelines suggest that HDL cholesterol values below 0.9 mmol/l confer a significant risk for men and women. As such, nearly half of patients with CAD would have low HDL cholesterol. It is therefore crucial that we obtain a better understanding of factors which contribute to this phenotype. In view of the fact that pharmacological intervention of low HDL cholesterol levels has so far proven unsatisfactory, it is also important to understand the factors that regulate these levels in the circulation as this understanding may reveal new therapeutic targets.

Absolute levels of HDL cholesterol may not always predict risk of CAD. In the case of CETP deficiency, individuals display an increased risk of developing CAD, despite increased HDL cholesterol levels. What seems to be important in this case is the functional activity of the reverse cholesterol transport pathway, the process by which intracellular cholesterol is trafficked out of the cell to acceptor proteins such as ApoAI or HDL. Other important genetic determinants of HDL

25

5

cholesterol levels, and its inverse relation with CAD, may reside in the processes leading to HDL formation and intracellular cholesterol trafficking and efflux. To date, this process is poorly understood, however, and clearly not all of the components of this pathway have been identified. Thus, defects preventing proper HDL-mediated cholesterol efflux may be important predictors of CAD. Therefore it is critical to identify and understand novel genes involved in the intracellular cholesterol trafficking and efflux pathways.

HDL particles are central to the process of reverse cholesterol transport and thus to the maintenance of tissue cholesterol homeostasis. This process has multiple steps which include the binding of HDL to cell surface components, the acquisition of cholesterol by passive absorption, the esterification of this cholesterol by LCAT and the subsequent transfer of esterified cholesterol by CETP, to VLDL and chylomicron remnants for liver uptake. Each of these steps is known to impact the plasma concentration of HDL.

Changes in genes for ApoAI-CIII, lipoprotein lipase, CETP, hepatic lipase, and LCAT all contribute to determination of HDL-C levels in humans. One rare form of genetic HDL deficiency is Tangier disease (TD), diagnosed in approximately 40 patients world-wide, and associated with almost complete absence of HDL cholesterol (HDL-C) levels (listed in OMIM as an autosomal recessive trait (OMIM 205400)). These patients have very low HDL cholesterol and ApoAI levels, which have been ascribed to hypercatabolism of nascent HDL and ApoAI, due to a delayed acquisition of lipid and resulting failure of conversion to mature HDL. TD patients accumulate cholesterol esters in several tissues, resulting in characteristic features, such as enlarged yellow tonsils, hepatosplenomegaly, peripheral neuropathy, and cholesterol ester deposition in the rectal mucosa. Defective removal of cellular cholesterol and phospholipids by

25

5

ApoAI as well as a marked deficiency in HDL mediated efflux of intracellular cholesterol has been demonstrated in TD fibroblasts. Even though this is a rare disorder, defining its molecular basis could identify pathways relevant for cholesterol regulation in the general population. The decreased availability of free cholesterol for efflux in the surface membranes of cells in Tangier Disease patients appears to be due to a defect in cellular lipid metabolism or trafficking.

Approximately 45% of Tangier patients have signs of premature CAD, suggesting a strong link between decreased cholesterol efflux, low HDL cholesterol and CAD. As increased cholesterol is observed in the rectal mucosa of persons with TD, the molecular mechanism responsible for TD may also regulate cholesterol adsorption from the gastrointestinal (GI) tract.

A more common form of genetic HDL deficiency occurs in patients who have low plasma HDL cholesterol usually below the 5th percentile for age and sex (OMIM 10768), but an absence of clinical manifestations specific to Tangier disease (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999; Marcil et al., Arterioscler. Thromb. Vasc. Biol. 15:1015-1024, 1995). These patients have no obvious environmental factors associated with this lipid phenotype, and do not have severe hypertriglyceridemia nor have known causes of severe HDL deficiency (mutations in ApoAI, LCAT, or LPL deficiency) and are not diabetic. The pattern of inheritance of this condition is most consistent with a Mendelian dominant trait (OMIM 10768).

The development of drugs that regulate cholesterol metabolism has so far progressed slowly. Thus, there is a need for a better understanding of the genetic components of the cholesterol efflux pathway. Newly-discovered components can then serve as targets for drug design.

Low HDL levels are likely to be due to multiple genetic factors. The use of

25

pharmacogenomics in the aid of designing treatment tailored to the patient makes it desirable to identify polymorphisms in components of the cholesterol efflux pathway. An understanding of the effect of these polymorphisms on protein function would allow for the design of a therapy that is optimal for the patient.

5

Summary of the Invention

In a first aspect, the invention features a substantially pure ABC1 polypeptide having ABC1 biological activity. Preferably, the ABC1 polypeptide is human ABC1 (e.g., one that includes amino acids 1 to 60 or amino acids 61 to 2261 of SEQ ID NO: 1). In one preferred embodiment, the ABC1 polypeptide includes amino acids 1 to 2261 of SEQ ID NO: 1.

Specifically excluded from the polypeptides of the invention are the polypeptide having the exact amino acid sequence as GenBank accession number CAA10005.1 and the nucleic acid having the exact sequence as AJ012376.1. Also excluded is protein having the exact amino acid sequence as GenBank accession number X75926.

In a related aspect, the invention features a substantially pure ABC1 polypeptide that includes amino acids 1 to 2261 of SEQ ID NO: 1.

In another aspect, the invention features a substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity (e.g., a nucleic acid molecule that includes nucleotides 75 to 254 or nucleotides 255 to 6858 of SEQ ID NO: 2). In one preferred embodiment, the nucleic acid molecule includes nucleotides 75 to 6858 of SEQ ID NO: 2.

In a related aspect, the invention features an expression vector, a cell, or a non-human mammal that includes the nucleic acid molecule of the invention.

In yet another aspect, the invention features a substantially pure nucleic acid

25

5

molecule that includes nucleotides 75 to 254 of SEQ ID NO: 2, nucleotides 255 to 6858 of SEQ ID NO: 2, or nucleotides 75 to 6858 of SEQ ID NO: 2.

In still another aspect, the invention features a substantially pure nucleic acid molecule that includes at least fifteen nucleotides corresponding to the 5' or 3' untranslated region from a human ABC1 gene. Preferably, the 3' untranslated region includes nucleotides 7015-7860 of SEQ ID NO: 2.

In a related aspect, the invention features a substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.

In another aspect, the invention features a method of treating a human having low HDL cholesterol or a cardiovascular disease, including administering to the human an ABC1 polypeptide, or cholesterol-regulating fragment thereof, or a nucleic acid molecule encoding an ABC1 polypeptide, or cholesterol-regulating fragment thereof. In a preferred embodiment, the human has a low HDL cholesterol level relative to normal. Preferably, the ABC1 polypeptide is wild-type ABC1, or has a mutation increases its stability or its biological activity. A preferred biological activity is regulation of cholesterol.

In a related aspect, the invention features a method of preventing or treating cardiovascular disease, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

In another related aspect, the invention features a method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

25

5

In still another aspect, the invention features a method of treating or preventing cardiovascular disease, including administering to an animal (e.g., a human) a compound that mimes the activity of wild-type ABC1 or modulates the biological activity of ABC1.

One preferred cardiovascular disease that can be treated using the methods of the invention is coronary artery disease. Others include cerebrovascular disease and peripheral vascular disease.

The discovery that the ABC1 gene and protein are involved in cholesterol transport that affects serum HDL levels allows the ABC1 protein and gene to be used in a variety of diagnostic tests and assays for identification of HDL-increasing or CVD-inhibiting drugs. In one family of such assays, the ability of domains of the ABC1 protein to bind ATP is utilized; compounds that enhance this binding are potential HDL-increasing drugs. Similarly, the anion transport capabilities and membrane pore-forming functions in cell membranes can be used for drug screening.

ABC1 expression can also serve as a diagnostic tool for low HDL or CVD; determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype (referred to as pharmacogenomics), including prediction of the patient's response (e.g., increased or decreased efficacy or undesired side effects upon administration of a compound or drug.

Antibodies to an ABC1 polypeptide can be used both as therapeutics and diagnostics. Antibodies are produced by immunologically challenging a B-cell-containing biological system, e.g., an animal such as a mouse, with an ABC1

25

5

polypeptide to stimulate production of anti-ABC1 protein by the B-cells, followed by isolation of the antibody from the biological system. Such antibodies can be used to measure ABC1 polypeptide in a biological sample such as serum, by contacting the sample with the antibody and then measuring immune complexes as a measure of the ABC1 polypeptide in the sample. Antibodies to ABC1 can also be used as therapeutics for the modulation of ABC1 biological activity.

Thus, in another aspect, the invention features a purified antibody that specifically binds to ABC1.

In yet another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 biological activity, comprising:

(a) providing an ABC1 polypeptide; (b) contacting the ABC1 polypeptide with the candidate compound; and (c) measuring ABC1 biological activity, wherein altered ABC1 biological activity, relative to an ABC1 polypeptide not contacted with the compound, indicates that the candidate compound modulates ABC1 biological activity. Preferably, the ABC1 polypeptide is in a cell or is in a cell-free assay system.

In still another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 expression. The method includes (a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate compound; and (c) measuring reporter gene expression, wherein altered reporter gene expression, relative to a nucleic acid molecule not contacted with the compound, indicates that the candidate compound modulates ABC1 expression.

In another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels, the method including the steps of: (a) providing an ABC1 polypeptide; (b) contacting the

25

5

polypeptide with the candidate compound; and (c) measuring binding of the ABC1 polypeptide, wherein binding of the ABC1 polypeptide indicates that the candidate compound is useful for modulating cholesterol levels.

In a related aspect, the invention features method for determining whether a candidate compound mimics ABC1 biological activity. The method includes (a) providing a cell that is not expressing an ABC1 polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring ABC1 biological activity of the cell, wherein altered ABC1 biological activity, relative to a cell not contacted with the compound, indicates that the candidate compound modulates ABC1 biological activity. Preferably, the cell has an *ABC1* null mutation. In one preferred embodiment, the cell is in a mouse or a chicken (e.g., a WHAM chicken) in which its *ABC1* gene has been mutated.

In still another aspect, the invention features a method for determining whether a candidate compound is useful for the treatment of low HDL cholesterol. The method includes (a) providing an ABC transporter (e.g., ABC1); (b) contacting the transporter with the candidate compound; and (c) measuring ABC transporter biological activity, wherein increased ABC transporter biological activity, relative to a transporter not contacted with the compound, indicates that the candidate compound is useful for the treatment of low HDL cholesterol. Preferably the ABC transporter is in a cell or a cell free assay system.

In yet another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels. The method includes (a) providing a nucleic acid molecule comprising an ABC transporter promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate compound; and (c) measuring expression of the reporter gene, wherein increased expression of the reporter gene, relative to a

25

5

nucleic acid molecule not contacted with the compound, indicates that the candidate compound is useful for modulating cholesterol levels.

In still another aspect, the invention features a method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. The method includes (a) providing an ABC transporter polypeptide; (b) contacting the transporter with the candidate compound; and (c) measuring the half-life of the ABC transporter polypeptide, wherein an increase in the half-life, relative to a transporter not contacted with the compound, indicates that the candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. Preferably the ABC transporter is in a cell or a cell free assay system.

In a preferred embodiment of the screening methods of the present invention, the cell is in an animal. The preferred ABC transporters are ABC1, ABC2, ABCR, and ABC8, and the preferred biological activity is transport of cholesterol (e.g., HDL cholesterol or LDL cholesterol) or interleukin-1, or is binding or hydrolysis of ATP by the ABC1 polypeptide.

Preferably, the ABC1 polypeptide used in the screening methods includes amino acids 1-60 of SEQ ID NO: 1. Alternatively, the ABC1 polypeptide can include a region encoded by a nucleotide sequence that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2.

In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes determining whether an *ABC1* gene of the patient has a mutation, wherein a mutation indicates that the patient has an increased risk for cardiovascular disease.

In related aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes

25

5

determining whether an *ABC1* gene of the patient has a polymorphism, wherein a polymorphism indicates that the patient has an increased risk for cardiovascular disease.

In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring ABC1 biological activity in the patient, wherein increased or decreased levels in the ABC1 biological activity, relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease.

In still another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring ABC1 expression in the patient, wherein decreased levels in the ABC1 expression relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease. Preferably, the ABC1 expression is determined by measuring levels of ABC1 polypeptide or *ABC1* RNA.

In another aspect, the invention features a non-human mammal having a transgene comprising a nucleic acid molecule encoding a mutated ABC1 polypeptide. In one embodiment, the mutation is a dominant-negative mutation.

In a related aspect, the invention features a non-human mammal, having a transgene that includes a nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

In another related aspect, the invention features a cell from a non-human mammal having a transgene that includes a nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

In still another aspect, the invention features a method for determining whether a candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide. The method includes (a) providing a cell expressing a

25

5

dominant-negative ABC1 polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring ABC1 biological activity of the cell, wherein an increase in the ABC1 biological activity, relative to a cell not contacted with the compound, indicates that the candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.

By "polypeptide" is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.

By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% identity to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

25

5

By "high stringency conditions" is meant hybridization in 2X SSC at 40°C with a DNA probe length of at least 40 nucleotides. For other definitions of high stringency conditions, see F. Ausubel et al., *Current Protocols in Molecular Biology*, pp. 6.3.1-6.3.6, John Wiley & Sons, New York, NY, 1994, hereby incorporated by reference.

By "substantially pure polypeptide" is meant a polypeptide that has been separated from the components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the polypeptide is an ABC1 polypeptide that is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, pure. A substantially pure ABC1 polypeptide may be obtained, for example, by extraction from a natural source (e.g., a pancreatic cell), by expression of a recombinant nucleic acid encoding a ABC1 polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A polypeptide is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus, a polypeptide which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those which naturally occur in eukaryotic organisms but are synthesized in *E. coli* or other prokaryotes.

By "substantially pure nucleic acid" is meant nucleic acid that is free of the genes which, in the naturally-occurring genome of the organism from which the

25

5

nucleic acid of the invention is derived, flank the nucleic acid. The term therefore includes, for example, a recombinant nucleic acid that is incorporated into a vector; into an autonomously replicating plasmid or virus; into the genomic nucleic acid of a prokaryote or a eukaryote cell; or that exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid that is part of a hybrid gene encoding additional polypeptide sequence.

By "modulates" is meant increase or decrease. Preferably, a compound that modulates cholesterol levels (e.g., HDL-cholesterol levels, LDL-cholesterol levels, or total cholesterol levels), or ABC1 biological activity, expression, stability, or degradation does so by at least 10%, more preferably by at least 25%, and most preferably by at least 50%.

By "purified antibody" is meant antibody which is at least 60%, by weight, free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody. A purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

By "specifically binds" is meant an antibody that recognizes and binds to, for example, a human ABC1 polypeptide but does not substantially recognize and bind to other non-ABC1 molecules in a sample, e.g., a biological sample, that naturally includes protein. A preferred antibody binds to the ABC1 polypeptide sequence of Fig. 9A (SEQ ID NO: 1).

By "polymorphism" is meant that a nucleotide or nucleotide region is characterized as occurring in several different forms. A "mutation" is a form of a

20

25

5

polymorphism in which the expression level, stability, function, or biological activity of the encoded protein is substantially altered.

By "ABC transporter" or "ABC polypeptide" is meant any transporter that hydrolyzes ATP and transports a substance across a membrane. Preferably, an ABC transporter polypeptide includes an ATP Binding Cassette and a transmembrane region. Examples of ABC transporters include, but are not limited to, ABC1, ABC2, ABCR, and ABC8.

By "ABC1 polypeptide" is meant a polypeptide having substantial identity to an ABC1 polypeptide having the amino acid sequence of SEQ ID NO: 1.

By "ABC biological activity" or "ABC1 biological activity" is meant hydrolysis or binding of ATP, transport of a compound (e.g., cholesterol, interleukin-1) or ion across a membrane, or regulation of cholesterol or phospholipid levels (e.g., either by increasing or decreasing HDL-cholesterol or LDL-cholesterol levels).

The invention provides screening procedures for identifying therapeutic compounds (cholesterol-modulating or anti-CVD pharmaceuticals) which can be used in human patients. Compounds that modulate ABC biological activity (e.g., ABC1 biological activity) are considered useful in the invention, as are compounds that modulate ABC concentration, protein stability, regulated catabolism, or its ability to bind other proteins or factors. In general, the screening methods of the invention involve screening any number of compounds for therapeutically active agents by employing any number of *in vitro* or *in vivo* experimental systems. Exemplary methods useful for the identification of such compounds are detailed below.

The methods of the invention simplify the evaluation, identification and development of active agents for the treatment and prevention of low HDL and

25

5

CVD. In general, the screening methods provide a facile means for selecting natural product extracts or compounds of interest from a large population which are further evaluated and condensed to a few active and selective materials. Constitutes of this pool are then purified and evaluated in the methods of the invention to determine their HDL-raising or anti-CVD activities or both.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

Figs. 1A and 1B are schematic illustrations showing two pedigrees with Tangier Disease, (TD-1 and TD-2). Square and circle symbols represent males and females, respectively. Diagonal lines are placed through the symbols of all deceased individuals. A shaded symbol on both alleles indicates the probands with Tangier Disease. Individuals with half shaded symbols have HDL-C levels at or below the 10th percentile for age and sex, while those with quarter shaded symbols have HDL-C between the 11th and 20th percentiles.

Each individual's ID number, age at the time of lipid measurement, triglyceride level and HDL cholesterol level followed by their percentile ranking for age and sex are listed below the pedigree symbol. Markers spanning the 9q31.1 region are displayed to the left of the pedigree. The affected allele is represented by the darkened bars which illustrate the mapping of the limits of the shared haplotype region as seen in Fig. 3. Parentheses connote inferred marker data, questions marks indicate unknown genotypes, and large arrows show the probands.

Fig. 1C shows ApoAI (10 μ g/mL) -mediated cellular cholesterol efflux in control fibroblasts (n=5, normalized to 100%) and two subjects with Tangier

25

5

disease (TD). Cells were 3 H-cholesterol (0.2 μ Ci/mL) labeled during growth and cholesterol (20 μ g/mL) loaded in growth arrest. Cholesterol efflux is determined as 3 H medium/(3 H cell + 3 H medium)

Fig. 2A - 2D are schematic illustrations showing four French Canadian pedigrees with FHA (FHA-1 to -4). The notations are as in Fig. 1. Exclamation points on either side of a genotype (as noted in Families FHA-3 and FHA-4) are used when the marker data appears to be inconsistent due to potential microsatellite repeat expansions. A bar that becomes a single thin line suggests that the haplotype is indeterminate at that marker.

Figs. 3A - 3E are a schematic illustration showing a genetic and physical map of 9q31 spanning 35 cM. Fig. 3A: YACs from the region of 9q22-34 were identified and a YAC contig spanning this region was constructed. Fig. 3B: A total of 22 polymorphic CA microsatellite markers were mapped to the contig and used in haplotype analysis in TD-1 and TD-2. Fig 3C: The mutant haplotypes for probands in TD-1 and -2 indicate a significant region of homozygosity in TD-2, while the proband in TD-1 has 2 different mutant haplotypes. The candidate region can be narrowed to the region of homozygosity for CA markers in proband 2. A critical crossover at D9S1690 in TD-1 (A)* also provides a centromeric boundary for the region containing the gene. Three candidate genes in this region (ABC1, LPA-R and RGS-3) are shown. Fig. 3D: Meiotic recombinations in the FHA families (A-H) refine the minimal critical region to 1.2 cM between D9S277 and D9S1866. The heterozygosity of the TD-2 proband at D9S127, which ends a continuous region of homozygosity in TD-2, further refines the region to less than 1 cM. This is the region to which ABC1 has been mapped. Fig. 3E: Isolated YAC DNA and selected markers from the region were used to probe high-density BAC grid filters, selecting BACs which via STS-content mapping produced an 800 Kb

25

5

contig. Four BACs containing ABC1 were sequenced using high-throughput methods.

Fig. 4A shows sequence of one mutation in family TD-1. Patient III-01 is heterozygous for a T to C transition at nucleotide 4503 of the cDNA; the control is homozygous for T at this position. This mutation corresponds to a cysteine to arginine substitution in the ABC1 protein (C1477R).

Fig 4B shows the amino acid sequence conservation of residue 1477 in mouse and human, but not a related *C. elegans* gene. A change from cysteine to arginine likely has an important effect on the protein secondary and tertiary structure, as noted by its negative scores in most substitution matrices (Schuler et al., A Practical Guide to the Analysis of Genes and Proteins, eds. Baxevanis, A.D. & Ouellette, B.F.F. 145:171, 1998). The DNA sequences of the normal and mutant genes are shown above and below the amino acid sequences, respectively.

Fig. 4C shows the segregation of the T4503C mutation in TD-1. The presence of the T4503C mutation (+) was assayed by restriction enzyme digestion with HgaI, which cuts only the mutant (C) allele (\downarrow). Thus, in the absence of the mutation, only the 194 bp PCR product (amplified between \rightarrow and \leftarrow) is observed, while in its presence the PCR product is cleaved into fragments of 134 bp and 60 bp. The proband (individual III.01) was observed to be heterozygous for this mutation (as indicated by both the 194 bp and 134 bp bands), as were his daughter, father, and three paternal cousins. A fourth cousin and three of the father's siblings were not carriers of this mutation.

Fig. 4D shows Northern blot analysis with probes spanning the complete ABC1 gene reveal the expected ~8 Kb transcript and, in addition, a ~3.5 kb truncated transcript only seen in the proband TD-1 and not in TD-2 or control. This was detected by probes spanning exons 1-49 (a), 1-41 (b), 1-22 (c), and 23-29

25

5

(d), but not with probes spanning exons 30-41 (e) or 42-49 (f).

Fig. 5A shows the sequence of the mutation in family TD-2. Patient IV-10 is homozygous for an A to G transition at nucleotide 1864 of the cDNA (SEQ ID NO: 2); the control is homozygous for A at this position. This mutation corresponds to a glutamine to arginine substitution in the ABC1 protein (Q597R).

Fig. 5B shows that the glutamine amino acid, which is mutated in the TD-2 proband, is conserved in human and mouse ABC1 as well as in an ABC orthologue from *C. elegans*, revealing the specific importance of this residue in the structure/function of this ABC protein in both worms and mammals. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 5C shows the segregation of the A1864G mutation in TD-2. The presence of the A1864G mutation (indicated by +) was assayed by restriction enzyme digestion with *Aci*I. The 360 bp PCR product has one invariant *Aci*I recognition site (1), and a second one is created by the A1864G mutation. The wild-type allele is thus cleaved to fragments of 215 bp and 145 bp, while the mutant allele (G-allele) is cleaved to fragments of 185 bp, 145 bp and 30 bp. The proband (individual IV-10), the product of a consanguineous mating, was homozygous for the A1864G mutation (+/+), as evidenced by the presence of only the 185 bp and 145 bp bands, while four other family members for whom DNA was tested are heterozygous carriers of this mutation (both the 215 bp and 185 bp fragments were present). Two unaffected individuals (-/-), with only the 215 bp and 145 bp bands are shown for comparison.

Fig. 6A shows a sequence of the mutation in family FHA-1. Patient III-01 is heterozygous for a deletion of nucleotides 2151-2153 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first

25

5

nucleotide after the deletion. This corresponds to deletion of leucine 693 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6B is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of Δ L693. L693 is also conserved in *C. elegans*. This highly conserved residue lies within a predicted transmembrane domain. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 6C shows segregation of the Δ L693 mutation in FHA-1, as assayed by EarI restriction digestion. Two invariant EarI restriction sites (indicated by \downarrow) are present within the 297 bp PCR product located between the horizontal arrows (\rightarrow -) while a third site is present in the wild-type allele only. The presence of the mutant allele is thus distinguished by the presence of a 210 bp fragment (+), while the normal allele produces a 151 bp fragment (-). The proband of this family (III.01) is heterozygous for this mutation, as indicated by the presence of both the 210 and 151 bp bands.

Fig. 6D shows a sequence of the mutation in family FHA-3. Patient III-01 is heterozygous for a deletion of nucleotides 5752-5757 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first nucleotide after the deletion. This corresponds to deletion of glutamic acid 1893 and aspartic acid 1894 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6E is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of $\Delta 5752-5757$. This region is highly conserved in *C. elegans*. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

25

5

Fig. 6F shows a sequence of the mutation in family FHA-2. Patient III-01 is heterozygous for a for a C to T transition at nucleotide 6504 of the cDNA (SEQ ID NO: 2). This alteration converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein.

Figs. 7A and 7B show cholesterol efflux from human skin fibroblasts treated with ABC1 antisense oligonucleotides. Fibroblasts from a control subject were labeled with ³H cholesterol (0.2 μCi/mL) during growth for 48 hours and transfected with 500 nM ABC1 antisense AN-1 (5'-GCA GAG GGC ATG GCT TTA TTT G-3'; SEQ ID NO: 3) with 7.5 µg lipofectin for 4 hours. Following transfection, cells were cholesterol loaded (20 µg/mL) for 12 hours and allowed to equilibrate for 6 hours. Cells were either then harvested for total RNA and 10 µg was used for Northern blot analysis. Cholesterol efflux experiments were carried out as described herein. Fig. 7A: AN-1 was the oligonucleotide that resulted in a predictable decrease in ABC1 RNA transcript levels. Fig. 7B: A double antisense transfection method was used. In this method, cells were labeled and transfected with AN-1 as above, allowed to recover for 20 hours, cholesterol loaded for 24 hours, and then re-transfected with AN-1. Twenty hours after the second transfection, the cholesterol efflux as measured. A ~50% decrease in ABC1 transcript levels was associated with a significant decrease in cholesterol efflux intermediate between that seen in wild-type and TD fibroblasts.

Fig. 7C shows show cholesterol efflux from human skin fibroblasts treated with antisense oligonucleotides directed to the region encoding the amino-terminal 60 amino acids. Note that the antisense oligonucleotide AN-6, which is directed to the previously unrecognized translation start site, produces a substantial decrease in cellular cholesterol efflux.

25

5

Fig. 8 is a schematic illustration showing predicted topology, mutations, and polymorphisms of ABC1 in Tangier disease and FHA. The two transmembrane and ATP binding domains are indicated. The locations of mutations are indicated by the arrows with the amino acid changes, which are predicted from the human *ABC1* cDNA sequence. These mutations occur in different regions of the ABC1 protein.

Fig. 9A shows the amino acid sequence of the human ABC1 protein (SEQ ID NO: 1).

Figs. 9B - 9E show the nucleotide sequence of the human *ABC1* cDNA (SEQ ID NO: 2).

Fig. 10 shows the 5' and 3' nucleotide sequences suitable for use as 5' and 3' PCR primers, respectively, for the amplification of the indicated ABC1 exon.

Fig. 11 shows a summary of alterations found in ABC1, including sequencing errors, mutations, and polymorphisms.

Fig. 12 shows a series of genomic contigs (SEQ ID NOS. 14-29) containing the ABC1 promoter (SEQ ID NO: 14), as well as exons 1-49 (and flanking intronic sequence) of ABC1. The exons (capitalized letters) are found in the contigs as follows: SEQ ID NO: 14--exon 1; SEQ ID NO: 15--exon 2; SEQ ID NO: 16--exon 3; SEQ ID NO: 17--exon 4; SEQ ID NO: 18--exon 5; SEQ ID NO: 19--exon 6; SEQ ID NO: 20--exons 7 and 8; SEQ ID NO: 21--exons 9 through 22; SEQ ID NO: 22--exons 23 through 28; SEQ ID NO: 23--exon 29; SEQ ID NO: 24--exons 30 and 31; SEQ ID NO: 25--exon 32; SEQ ID NO: 26--exons 33 through 36; SEQ ID NO: 27--exons 37 through 41; SEQ ID NO: 28--exons 42-45; SEQ ID NO: 29--exons 46-49.

Fig. 13 is a series of illustrations showing that the amino-terminal 60 amino acid region of ABC1 is protein-coding. Lysates of normal human fibroblasts were

25

5

immunoblotted in parallel with a rabbit polyclonal antibody to amino acids 1-20 of human ABC1 (1); a rabbit polyclonal antibody to amino acids 1430-1449 of human ABC1 (2); and a mouse monoclonal antibody to amino acids 2236-2259 of human ABC1. The additional bands detected in lane 2 may be due to a lack of specificity of that antibody or the presence of degradation products of ABC1.

Fig. 14 is a schematic illustration showing that the WHAM chicken contains a non-conservative substitution (G265A) resulting in an amino acid change (E89K).

Fig. 15 is a schematic illustration showing that the mutation in the WHAM chicken is at an amino acid that is conserved among human, mouse, and chicken.

Fig. 16 show a summary of locations of consensus transcription factor binding sites in the human ABC1 promoter (nucleotides 1-8238 of SEQ ID NO: 14). The abbreviations are as follows: PPRE=peroxisome proliferator-activated receptor. SRE=steroid response element-binding protein site. ROR=RAR-related orphan receptor.

<u>Detailed Description</u>

Genes play a significant role influencing HDL levels. Tangier disease (TD) was the first reported genetic HDL deficiency. The molecular basis for TD is unknown, but has been mapped to 9q31 in three families. We have identified two additional probands and their families, and confirmed linkage and refined the locus to a limited genomic region. Mutations in the *ABC1* gene accounting for all four alleles in these two families were detected. A more frequent cause of low HDL levels is a distinct disorder, familial HDL deficiency (FHA). On the basis of independent linkage, meiotic recombinants and disease associated haplotypes, FHA was localized to a small genomic region encompassing the *ABC1* gene. A

25

5

mutation in a conserved residue in ABC1 segregated with FHA. Antisense reduction of the *ABC1* transcript in fibroblasts was associated with a significant decrease in cholesterol efflux.

Cholesterol is normally assembled with intracellular lipids and secreted, but in TD the process is diverted and cholesterol is degraded in lysosomes. This disturbance in intracellular trafficking of cholesterol results in an increase in intracellular cholesterol ester accumulation associated with morphological changes of lysosomes and the Golgi apparatus and cholesteryl ester storage in histiocytes, Schwann cells, smooth muscle cells, mast cells and fibroblasts.

The clinical and biochemical heterogeneity in patients with TD has led to the possibility that genetic heterogeneity may also underlie this disorder. Considering this, we initially performed linkage analysis on these two families of different ancestries (TD-1 is Dutch, TD-2 is British; Frohlich et al., Clin. Invest. Med. 10:377-382, 1987) and confirmed that the genetic mutations underlying TD in these families were localized to the same 9q31 region, to which a large family with TD had been assigned (Rust et al., Nature Genetics 20:96-98, 1998). Detailed haplotype analysis, together with the construction of a physical map, refined the localization of this gene. Mutations in the ABC1 gene were found in TD.

FHA is much more common than TD, although its precise frequency is not known. While TD has been described to date in only 40 families, we have identified more than 40 FHA families in the Netherlands and Quebec alone. After initial suggestions of linkage to 9q31, thirteen polymorphic markers spanning approximately 10 cM in this region were typed and demonstrated the highest LOD score at D9S277. Analysis of the homozygosity of markers in the TD-2 proband, who was expected to be homozygous for markers close to TD due to his parents' consanguinity, placed the TD gene distal to D95127. Combined genetic data from

25

5

TD and FHA families pointed to the same genomic segment spanning approximately 1,000 kb between D9S127 and D9S1866. The ABC1 transporter gene was contained within the minimal genomic region. RT-PCR analysis in one family demonstrated a deletion of leucine at residue 693 (Δ 693) in the first transmembrane domain of ABC1, which segregated with the phenotype of HDL deficiency in this family.

ABC1 is part of the ATP-binding cassette (ABC transporter) superfamily, which is involved in energy-dependent transport of a wide variety of substrates across membranes (Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). These proteins have characteristic motifs conserved throughout evolution which distinguish this class of proteins from other ATP binding proteins. In humans these genes essentially encode two ATP binding segments and two transmembrane domains (Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). We have now shown that the ABC1 transporter is crucial for intracellular cholesterol transport.

We have demonstrated that reduction of the *ABC1* transcript using oligonucleotide antisense approaches results in decreased efflux, clearly demonstrating the link between alterations in this gene and its functional effects. TD and FHA now join the growing list of genetic diseases due to defects in the ABC group of proteins including cystic fibrosis (Zielenski, et al., Annu. Rev. Genet. 29:777-807, 1995), adrenoleukodystrophy (Mosser et al., Nature 361: 726-730, 1993), Zellweger syndrome (Gärtner et al., Nat. Genet. 1:23, 1992), progressive familial intrahepatic cholestatis (Bull et al., Nat. Genet. 18:219-224, 1998), and different eye disorders including Stargardt disease (Allikmets et al., Nat. Genet.15:236-246, 1997), autosomal recessive retinitis pigmentosa (Allikmets et al., Science 277:1805-1807, 1997), and cone-rod dystrophy (Cremers et al., Hum. Mol. Genet. 7:355-362, 1998).

25

5

Patients with TD have been distinguished from patients with FHA on the basis that Tangier disease was an autosomal recessive disorder (OMIM 20540) while FHA is inherited as an autosomal dominant trait (OMIM 10768). Furthermore, patients with TD have obvious evidence for intracellular cholesterol accumulation which is not seen in FHA patients. It is now evident that heterozygotes for TD do have reduced HDL levels and that the same mechanisms underlie the HDL deficiency and cholesterol efflux defects seen in heterozygotes for TD as well as FHA. Furthermore, the more severe phenotype in TD represents loss of function from both alleles of the *ABC1* gene.

ABC1 is activated by protein kinases, presumably via phosphorylation, which also provides one explanation for the essential role of activation of protein kinase C in promoting cholesterol efflux (Drobnick et al., Arterioscler. Thromb. Vasc. Biol. 15: 1369-1377, 1995). Brefeldin, which inhibits trafficking between the endoplasmic reticulum and the Golgi, significantly inhibits cholesterol efflux, essentially reproducing the effect of mutations in ABC1, presumably through the inhibition of ABC1 biological activity. This finding has significance for the understanding of mechanisms leading to premature atherosclerosis. TD homozygotes develop premature coronary artery disease, as seen in the proband of TD-1 (III-01) who had evidence for coronary artery disease at 38 years. This is particular noteworthy as TD patients, in addition to exhibiting significantly reduced HDL, also have low LDL cholesterol, and yet they develop atherosclerosis despite this. This highlights the importance of HDL intracellular transport as an important mechanism in atherogenesis. There is significant evidence that heterozygotes for TD are also at increased risk for premature vascular disease (Schaefer et al., Ann. Int. Med. 93:261-266, 1980; Serfaty-Lacrosniere et al., Atherosclerosis 107:85-98, 1994). There is also preliminary evidence for

25

5

premature atherosclerosis in some probands with FHA (Fig. 2B), *e.g.*, the proband in FHA-2 (III-01) had a coronary artery bypass graft at 46 years while the proband in FHA-3 (Fig. 2C) had evidence for CAD around 50 years of age. The TD-1 proband had more severe efflux deficiency than the TD-2 proband (Fig. 1C). Interestingly, the TD-2 proband had no evidence for CAD by 62 when he died of unrelated causes, providing preliminary evidence for a relationship between the degree of cholesterol efflux (mediated in part by the nature of the mutation) and the likelihood of atherosclerosis.

The *ABC1* gene plays a crucial role in cholesterol transport and, in particular, intracellular cholesterol trafficking in monocytes and fibroblasts. It also appears to play a significant role in other tissues such as the nervous system, GI tract, and the cornea. Completely defective intracellular cholesterol transport results in peripheral neuropathy, corneal opacities, and deposition of cholesterol esters in the rectal mucosa.

HDL deficiency is heterogeneous in nature. The delineation of the genetic basis of TD and FHA underlies the importance of this particular pathway in intracellular cholesterol transport, and its role in the pathogenesis of atherosclerosis. Unraveling of the molecular basis for TD and FHA defines a key step in a poorly defined pathway of cholesterol efflux from cells and could lead to new approaches to treatment of patients with HDL deficiency in the general population.

HDL has been implicated in numerous other biological processes, including but not limited to: prevention of lipoprotein oxidation; absorption of endotoxins; protection against *Trypanosoma brucei* infection; modulation of endothelial cells; and prevention of platelet aggregation (see Genest et al., J. Invest. Med. 47: 31-42, 1999, hereby incorporated by reference). Any compound that modulates HDL

25

5

levels may be useful in modulating one or more of the foregoing processes. The present discovery that ABC1 functions to regulate HDL levels links, for the first time, ABC1 with the foregoing processes.

The following examples are to illustrate the invention. They are not meant to limit the invention in any way.

Analysis of TD Families

Studies of cholesterol efflux

Both probands had evidence of marked deficiency of cholesterol efflux similar to that previously demonstrated in TD patients (Fig. 1C). TD-1 is of Dutch descent while TD-2 is of British descent.

Linkage analysis and establishment of a physical map

Multiple DNA markers were genotyped in the region of 9q31 to which linkage to TD had been described (Rust et al., Nat. Genet. 20, 96-98, 1998). Two point linkage analysis gave a maximal peak LOD score of 6.49 at D9S1832 (Table 1) with significant evidence of linkage to all markers in a ~10 cM interval. Recombination with the most proximal marker, D9S1690 was seen in II-09 in Family TD-1 (A* in Fig. 3D) providing a centromeric boundary for the disease gene. Multipoint linkage analysis of these data did not increase the precision of the positioning of the disease trait locus.

A physical map spanning approximately 10 cM in this region was established with the development of a YAC contig (Fig. 3A). In addition, 22 other polymorphic multi-allelic markers which spanned this particular region were mapped to the contig (Fig. 3B) and a subset of these were used in construction of a

TABLE 1

Two Point Linkage Analysis of TD-1 and TD-2

	LOD Score at recombination fraction						
Marker Locus	0	0.01	0.05	0.10	0.20	0.30	0.40
D9S1690	-infini	4.25	4.52	4.26	3.39	2.30	1.07
D9\$277	6.22	6.11	5.67	5.10	3.90	2.60	1.17
D9S1866	4.97	4.87	4.49	4.00	2.96	1.85	0.70
D9S1784	5.50	5.40	5.00	4.47	3.36	2.17	0.92
D9S1832	6.49	6.37	5.91	5.31	4.05	2.69	1.21
D9S1677	4.60	4.51	4.18	3.76	2.88	1.93	0.93

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

TABLE 2. Microsatellite markers used in this study

Genetic Markers	Type	Hetero- zygocity	Number of alleles	Allele frequency
D9S283	C.A	0.80	10	size.br (proportion)
D3040J	C.7	0.00	iu	179(0.04); 181(0.34); 183(0.19); 185(0.20); 189(0.05); 193(0.04); 197(0.07); 199(0.02); 201(0.04); 203(0.04)
D9S176	C.A	0.82	9	129(0.03); 131(0.16); 133(0.25); 135(0.12); 137(0.25); 139(0.03); 141(0.01); 145(0.05); 147(0.05)
D9S1690	C.A	0.79	8	225(0.38); 227(0.14); 229(0.0-); 231(0.12); 233(0.05); 235(0.16); 237(0.05); 239(0.05)
D9S277	CA	0.89	15	167(0.07); 171(0.02); 173(0.15); 175(0.11); 177(0.07); 179(0.04); 181(0.17); 183(0.06); 185(0.02); 187(0.02); 189(0.13); 191(0.13); 193(0.02); 197(0.00); 199(0.00)
D9S127	CA	0.72	6	149(0.11); 151(0.07); 153(0.25); 155(0.03); 157(0.45); 159(0.06)
D9S306	C.A	0.87	13	102(0.06); 104(0.01); 110(0.03; 112(0.08); 114(0.16); 116(0.15); 118(0.11); 120(0.23); 122(0.06); 124(0.06); 126(0.03); 134(0.02); 136(0.01)
D9S1866	C.A	0.62	11	248(0.06); 252(0.04); 254(0.01); 256(58); 258(0.03); 260(0.06); 262(0.02); 264(0.12); 266(0.06); 268(0.03); 270(0.01)
D9S1784	CA	0.86	15	174(0.10); 176(0.02); 178(0.05); 180(0.05); 182(0.11); 184(0.22); 186(0.15); 188(0.06); 190(0.04); 192(0.07); 194(0.05); 196(0.07); 198(0.01); 200(0.01); 202(0.01)
AFMa107xf9	CA	n.a.	n.a.	n.a.
D9S2170	C.Ā [*]	n.a.	n.a.	n.a.
D9S2171	CA	n.a.	n.a.	n.a.
D9S 2 107	CA	0.63	5	n.a.
D9\$172	CA	0.54	5	291(0.00); 297(0.05); 299(0.32); 303(0.62); 305(0.02)
D9S2109	CA	0.51	3	1(0.42); 2(0.56); 3(0.02)
D9S1832	CA	0.88	12	161(0.04); 163(0.02); 167(0.02); 169(0.04); 171(0.10); 173(0.09); 175(0.15); 177(0.28); 179(0.19); 181(0.04); 183(0.01); 185(0.01)
D9S1835	CA	0.48	4	110(0.02); 112(0.23); 116(0.68); 118(0.07)
D9S1801	CA	0.77	10	166(0.10); 172(0.04); 174(0.02); 182(0.02);184(0.19); 186(0.40); 188(0.15); 190(0.04); 192(0.02); 194(0.02)
D9S261	CA	0.63	7	90(0.02); 92(0.52); 94(0.02); 98(0.02); 100(0.29); 102(0.04); 104(0.08)
D9S160	CA	0.62	6	136(0.25); 138(0.53); 140(0.01); 142(0.12); 144(0.00); 146(0.07)
D9S1677	CA	0.81	10	251(0.27); 257(0.27); 259(0.07); 261(0.09); 263(0.27); 265(0.14); 267(0.02); 269(0.02); 271(0.04); 273(0.02)
D9S279	CA	0.78	6	244(0.09); 246(0.18); 248(0.29); 250(0.29); 252(0.07); 254(0.09)
D9S275	CA	0.62	4	190(0.31); 196(0.07); 198(G.52); 200(0.09)

In a Caucasian population of French Canadian or French descent (J. Weissenbach, Personnal Communication 1993).

n.a = not assessed.

These polymorphic microsatellite markers were used for DNA typing in the region of 9q31 seen in Fig.3. The majority come from the last version of the Généthon human linkage map ⁵³. The frequency of heterozygosity, the number of alleles as well as the allele frequency of each marker are presented.

25

5

haplotype for further analysis (Figs. 1A and 1B; Table 2). The condensed haplotype in these families is shown in Figs. 1A and 1B.

While the family of Dutch decent did not demonstrate any consanguinity, the proband in TD-2 was the offspring of a first-cousin consanguineous marriage (Fig. 1B). We postulated, therefore, that it was most likely that this proband would be homozygous for the mutation while the proband in the Dutch family was likely to be a compound heterozygote. The Dutch proband shows completely different mutation bearing haplotypes, supporting this hypothesis (Fig. 3C).

The TD-2 proband was homozygous for all markers tested (Fig. 1B) distal to D9S127 but was heterozygous at D9S127 and DNA markers centromeric to it (Fig. 3C). This suggested that the gene for TD was likely located to the genomic region telomeric of D9S127 and encompassed by the markers demonstrating homozygosity (Fig. 3B).

Mutation detection

Based on the defect in intracellular cholesterol transport in patients with TD, we reviewed the EST database for genes in this region which might be relevant to playing a role in this process. One gene that we reviewed as a candidate was the lysophosphatidic acid (LPA) receptor (*EDG2*) which mapped near D9S1801 (Fig. 3C). This receptor binds LPA and stimulates phospholipase-C (PLC), and is expressed in fibroblasts. It has previously been shown that the coordinate regulation of PLC that is necessary for normal HDL3 mediated cholesterol efflux is impaired in TD (Walter et al., J. Clin. Invest. 98:2315-2323, 1996). Therefore this gene represented an excellent candidate for the TD gene. Detailed assessment of this gene, using Northern blot and RT-PCR and sequencing analysis, revealed no changes segregating with the mutant phenotype in this

25

5

family, in all likelihood excluding this gene as the cause for TD. Polymorphisms were detected, however, in the RT-PCR product, indicating expression of transcripts from both alleles.

The second candidate gene (*RGS3*) encodes a member of a family regulating G protein signaling which could also be involved in influencing cholesterol efflux (Mendez et al., Trans. Assoc. Amer. Phys. 104:48-53, 1991). This gene mapped 0.7 cM telomeric to the LPA-receptor (Fig. 3C), and is expressed in fibroblasts. It was assessed by exon-specific amplification, as its genomic organization was published (Chatterjee et al., Genomics 45:429-433, 1997). No significant sequence changes were detected.

The *ABC1* transporter gene had previously been mapped to 9q31, but its precise physical location had not been determined (Luciani et al., Genomics 21:150-159, 1994). The *ABC1* gene is a member of the ATP binding cassette transporters which represents a super family of highly conserved proteins involved in membrane transport of diverse substrates including amino acids, peptides, vitamins and steroid hormones (Luciani et al., Genomics 21:150-159, 1994; Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). Primers to the 3' UTR of this gene mapped to YACs spanning D9S306 (887-B2 and 930-D3) compatible with it being a strong candidate for TD. We initiated large scale genomic sequencing of BACs spanning approximately 800 kb around marker D9S306 (BACs 269, 274, 279 and 291) (Fig 3E). The *ABC1* gene was revealed encompassing 49 exons and a minimum of 75 Kb of genomic sequence. In view of the potential function of a gene in this family as a cholesterol transporter, its expression in fibroblasts and localization to the minimal genomic segment underlying TD, we formally assessed ABC1 as a candidate.

Patient and control total fibroblast RNA was used in Northern blot analysis

25

5

and RT-PCR and sequence analyses. RT-PCR and sequence analysis of TD-1 revealed a heterozygous T to C substitution (Fig. 4A) in the TD-1 proband, which would result in a substitution of arginine for cysteine at a conserved residue between mouse and man (Fig. 4B). This mutation, confirmed by sequencing exon 30 of the ABC1 gene, exhibited complete segregation with the phenotype on one side of this family (Fig. 4C). This substitution creates a *HgaI* site, allowing for RFLP analysis of amplified genomic DNA and confirmation of the mutation (Fig. 4C). The point mutation in exon 30 was not seen on over 200 normal chromosomes from unaffected persons of Dutch decent, and 250 chromosomes of Western European decent, indicating it is unlikely to be a polymorphism. Northern blot analysis of fibroblast RNA from this patient, using a cDNA encompassing exons 1 to 49 of the gene, revealed a normal sized ~8 Kb transcript and a truncated mutant transcript which was not visible in control RNA or in RNA from other patients with HDL deficiency (Fig. 4D). Additionally, Northern blot analysis using clones encompassing discrete regions of the cDNA revealed that the mutant transcript was detected with a cDNA compassing exons 1 to 49 (a), 1 to 41 (b), 1 to 22 (c), much more faintly with a probe spanning exon 23 to 29 (d) and not seen with probes encompassing exons 30 to 42 (e), but not seen with cDNA fragment spanning exons 30 to 49 (f). This was repeated on multiple filters with control RNA, RNA from other patients with HDL deficiency and the other TD proband, and only in TD-1 was the truncated transcript observed. Sequence analysis of the coding region did not reveal an alteration in sequence that could account for this finding. Furthermore, DNA analysis by Southern blot did not reveal any major rearrangements. Completion of exon sequencing in genomic DNA showed that this mutation was a G to C transversion at position (+1) of intron 24, (Fig. 11) affecting a splice donor site and causing aberrant splicing.

25

5

RT-PCR analysis of fibroblast RNA encoding the *ABC1* gene from the proband in TD-2 (Fig. 1B) revealed a homozygous nucleotide change of A to G at nucleotide 1864 of SEQ ID NO: 2 in exon 13 (Fig. 5A), resulting in a substitution of arginine for glutamine at residue 597 of SEQ ID NO: 1 (Fig. 5B), occurring just proximal to the first predicted transmembrane domain of ABC1 (Fig. 8) at a residue conserved in mouse and as well as a *C. elegans* homolog. This mutation creates a second *Aci*I site within exon 13. Segregation analysis of the mutation in this family revealed complete concordance between the mutation and the low HDL phenotype as predicted (Fig 5C). The proband in TD-2 is homozygous for this mutation, consistent with our expectation of a disease causing mutation in this consanguineous family.

Analysis of FHA families

Linkage analysis and refinement of the minimal genomic region containing the gene for FHA

Data from microsatellite typing of individual family members from the four pedigrees of French Canadian origin were analyzed (Fig. 2). A maximum LOD score of 9.67 at a recombination fraction of 0.0 was detected at D9S277 on chromosome 9q31 (Fig. 3; Table 3). Thereafter, 22 markers were typed in a region spanning 10 cM around this locus in these families (Figs. 2 and 3). The frequency for these markers were estimated from a sample of unrelated and unaffected subjects of French ancestry (Table 2).

TD and FHA have thus far been deemed distinct with separate clinical and biochemical characteristics. Even though the genes for these disorders mapped to the same region, it was uncertain whether FHA and TD were due to mutations in the same gene or, alternatively, due to mutations in genes in a similar region.

TABLE 3
Two Point Linkage Analysis in FHA

	LOD Score at recombination fraction							
Marker Locus	0	0.01	0.05	0.10	0.20	0.30	0.40	
D9S2S3	-infini	-2.57	0.51	1.48	1.84	1.48	0.76	
D9S176	-infini	1.42	3.07	3.39	3.05	2.22	1.12	
D9S1890	-infini	3.11	4.04	4.04	3.33	2.24	0.96	
D9S277	9.67	9.51	8.89	8.06	6.29	4.30	2.10	
D9S306	5.60	5.51	5.13	4.62	3.55	2.36	1.11	
D9S1866	-infini	7.24	7.35	6.87	5.50	3.82	1.91	
D9S1784	-infini	9.85	9.76	9.03	7.09	4.78	2.25	
D9S172	-infini	2.63	3.00	2.87	2.26	1.50	0.67	
D9\$1832	-infini	5.20	5.97	5.75	4.59	3.02	1.30	
D9S1801	0.14	0.13	0.11	0.09	0.06	0.03	0.01	
D9S1677	-infini	7.83	7.90	7.38	5.90	4.08	2.01	
D9S279	-infini	3.43	• 3.80	3.66	3.01	2.12	1.05	
D9S275	-infini	2.57	2.98	2.91	2.41	1.69	0.81	

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

25

5

Refinement of the region containing the gene for FHA was possible by examining haplotype sharing and identification of critical recombination events (Fig. 2). Seven separate meiotic recombination events were seen in these families ("A" through "G" in Figs. 2 and 3), clearly indicating that the minimal genomic region containing the potential disease gene was a region of approximately 4.4 cM genomic DNA spanned by marker D9S1690 and D9S1866 (Figs. 2 and 3). This region is consistent with the results of two point linkage analysis which revealed maximal LOD scores with markers D9S277 and D9S306 and essentially excluded the region centromeric to D9S1690 or telomeric to D9S1866. An 8th meiotic recombination event ("H" in Fig. 3) further refined the FHA region to distal to D9S277.

As described herein, the *ABC1* gene mapped within this interval. The overlapping genetic data strongly suggested that FHA may in fact be allelic to TD. Utilization of sets of genetic data from FHA and TD provided a telomeric boundary at D9S1866 (meiotic recombinant) (Fig. 3D) and a centromeric marker at D9S127 based on the homozygosity data of TD-2. This refined the locus to approximately 1 Mb between D9S127 and D9S1866. The *ABC1* gene mapped within this minimal region (Fig. 3E).

Mutation detection in FHA

Mutation assessment of the ABC1 gene was undertaken in FHA-1 (Fig. 2A). Using primers that spanned overlapping segments of the mRNA we performed RT-PCR analysis and subjected these fragments to mutational analysis. A deletion of three nucleotides is evident in the RT-PCR sequence of FHA-1 III.01 (Fig. 6A), resulting in a loss of nucleotides 2151-2153 of SEQ ID NO: 2 and deletion of a leucine (Δ L693) at amino acid position 693 of SEQ ID NO: 1 (Fig. 6A). This

25

5

leucine is conserved in mouse and *C. elegans* (Fig. 6B). The alteration was detected in the RT-PCR products as well as in genomic sequence from exon 14 specific amplification. This mutation results in a loss of an *EarI* restriction site. Analysis of genomic DNA from the family indicated that the mutation segregated completely with the phenotype of HDL deficiency. The loss of the *EarI* site results in a larger fragment being remaining in persons heterozygous for this mutation (Fig. 6C). This mutation maps to the first putative transmembrane domain of ABC1 (Fig. 8) and was not seen in 130 chromosomes from persons of French Canadian descent nor seen in over 400 chromosomes from persons of other Western European ancestry.

A mutation has also been found in patient genomic DNA in pedigree FHA-3 from Quebec. The alteration, a 6 bp deletion of nucleotides 5752-5757 of SEQ ID NO: 2 within exon 41, results in a deletion of amino acids 1893 (Glu) and 1894 (Asp) of SEQ ID NO: 1. The deletion was detected as a double, superimposed, sequence starting from the point of the deletion (Fig. 6D), and was detected in sequence reads in both directions. The deletion can be detected on 3% agarose or 10% polyacrylamide gels, and segregates with disease in FHA-3. It was not seen in 128 normal chromosomes of French-Canadian origin or in 434 other control chromosomes. Amino acids 1893 and 1894 are in a region of the ABC1 protein that is conserved between human, mouse, and *C. elegans* (Fig. 6E), implying that it is of functional importance.

An additional mutation has been found in patient genomic DNA in pedigree FHA-2 from Quebec (Fig. 6F). The alteration, a C to T transition at position 6504 of SEQ ID NO: 2, converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein. This alteration segregates with disease in family FHA-2.

25

5

A summary of all mutations and polymorphisms found in ABC1 is shown in Fig. 11. Each variant indicated as a mutation segregates with low HDL in its family, and was not seen in several hundred control chromosomes.

Functional relationship between changes in ABC1 transcript levels and cholesterol efflux

Antisense approaches were undertaken to decrease the ABC1 transcript and assess the effect of alteration of the transcript on intracellular cholesterol transport. The use of antisense primers to the 5' end of ABC1 clearly resulted in a decrease to approximately 50% of normal RNA levels (Fig. 7A). This would be expected to mimic in part the loss of function due to mutations on one allele, similar to that seen in heterozygotes for TD and patients with FHA. Importantly, reduction in the mRNA for the ABC1 gene resulted in a significant reduction in cellular cholesterol efflux (Fig. 7B), further establishing the role of this protein in reverse cholesterol transport and providing evidence that the mutations detected are likely to constitute loss of function mutations. Furthermore, these data support the functional importance of the first 60 amino acids of the protein. Antisense oligonucleotide AN-6 is directed to the novel start codon 5' to the one indicated in AJ012376.1; this antisense oligonucleotide effectively suppresses efflux.

The above-described results were obtained using the following materials and methods.

Patient selection

The probands in TD families had previously been diagnosed as suffering from TD based on clinical and biochemical data. Study subjects with FHA were selected from the Cardiology Clinic of the Clinical Research Institute of Montréal.

The main criterion was an HDL-C level <5th percentile for age and gender, with a plasma concentration of triglycerides <95th percentile in the proband and a first-degree relative with the same lipid abnormality. In addition, the patients did not have diabetes.

5

Biochemical studies

Blood was withdrawn in EDTA-containing tubes for plasma lipid, lipoprotein cholesterol, ApoAI, and triglyceride analyses, as well as storage at -80°C. Leukocytes were isolated from the buffy coat for DNA extraction.

Lipoprotein measurement was performed on fresh plasma as described elsewhere (Rogler et al., Arterioscler. Thromb. Vasc. Biol. 15:683-690, 1995). The laboratory participates and meets the criteria of the Lipid Research Program Standardization Program. Lipids, cholesterol and triglyceride levels were determined in total plasma and plasma at density d<1.006 g/mL (obtained after preparative ultracentrifugation) before and after precipitation with dextran manganese. Apolipoprotein measurement was performed by nephelometry for ApoB and ApoAI.

Linkage analysis

20

Linkage between the trait locus and microsatellite loci was analyzed using the FASTLINK version (4.0 P). FASTLINK/MLINK was used for two-point linkage analysis assuming an autosomal dominant trait with complete penetrance. In FHA and TD heterozygotes, the phenotype was HDL deficiency <5th percentile for age and sex. The disease allele frequency was estimated to be 0.005. Marker allele frequencies were estimated from the genotypes of the founders in the pedigrees using NEWPREP. Multipoint linkage analysis was carried out using

25

FASTLINK/LINKMAP.

Genomic clone assembly and physical map construction of the 9q31 region

Using the Whitehead Institute/MIT Center for Genome Research map as a reference, the genetic markers of interest at 9q31 were identified within YAC contigs. Additional markers that mapped to the approximate 9q31 interval from public databases and the literature were then assayed against the YAC clones by PCR and hybridization analysis. The order of markers was based on their presence or absence in the anchored YAC contigs and later in the BAC contig. Based on the haplotype analysis, the region between D9S277 and D9S306 was targeted for higher resolution physical mapping studies using bacterial artificial chromosomes (BACs). BACs within the region of interest were isolated by hybridization of DNA marker probes and whole YACs to high-density filters containing clones from the RPCI-11 human BAC library (Fig. 3).

Sequence retrieval and alignment

The human *ABC1* mRNA sequence was retrieved from GenBank using the Entrez nucleotide query (Baxevanis et al., A Practical Guide to the Analysis of Genes and Proteins, eds. Baxevanis, A.D. & Ouellette, B.F.F. 98:120, 1998) as GenBank accession number AJ012376.1. The version of the protein sequence we used as wild-type (normal) was CAA10005.1.

We identified an additional 60 amino acids in-frame with the previously-believed start methionine (Fig. 9A). Bioinformatic analysis of the additional amino acids indicates the presence of a short stretch of basic amino acid residues, followed by a hydrophobic stretch, then several polar residues. This may represent a leader sequence, or another transmembrane or membrane-associated region of

20

25

5

25

5

the ABC1 protein. In order to differentiate among the foregoing possibilities, antibodies directed to the region of amino acids 1-60 are raised against and used to determine the physical relationship of amino acids 1-60 in relation to the cell membrane. Other standard methods can also be employed, including, for example, expression of fusion proteins and cell fractionation.

We also identified six errors in the previously-reported nucleotide sequence (at positions 839, 4738, 5017, 5995, 6557, and 6899 of SEQ ID NO: 2; Fig. 11). Hence, the sequence of the ABC1 polypeptide of Fig. 9A differs from CAA10005.1 as follows: Thr⇒Ile at position 1554; Pro⇒Leu at position 1642; Arg⇒Lys at position 1973; and Pro⇒Leu at position 2167. We also identified 5' and 3' UTR sequence (Figs. 9B - 9E).

The mouse *ABC1* sequence used has accession number X75926. It is very likely that this mouse sequence is incomplete, as it lacks the additional 60 amino acids described herein for human ABC1.

Version 1.7 of ClustalW was used for multiple sequence alignments with BOXSHADE for graphical enhancement (http://www.isrec.isb-sib.ch:8080/software/BOX_form.html) with the default parameter. A *Caenorhabditis elegans* ABC1 orthologue was identified with BLAST (version 2.08) using CAA1005.1 (see above) as a query, with the default parameter except for doing an organism filter for *C. elegans*. The selected protein sequence has accession version number AAC69223.1 with a score of 375, and an E value of 103.

Genomic DNA sequencing

BAC DNA was extracted from bacterial cultures using NucleoBond Plasmid Maxi Kits (Clontech, Palo Alto, CA). For DNA sequencing, a sublibrary was first constructed from each of the BAC DNAs (Rowen et al., Automated DNA

25

5

Sequencing and Analysis, eds. Adams, M.D., Fields, C. & Venter, J.C., 1994). In brief, the BAC DNA was isolated and randomly sheared by nebulization. The sheared DNA was then size fractionated by agarose gel electrophoresis and fragments above 2 kb were collected, treated with Mung Bean nuclease followed by T4 DNA polymerase and klenow enzyme to ensure blunt-ends, and cloned into *SmaI*-cut M13mp19. Random clones were sequenced with an ABI373 or 377 sequencer and fluorescently labeled primers (Applied BioSystems, Foster City, CA). DNAStar software was used for gel trace analysis and contig assembly. All DNA sequences were examined against available public databases primarily using BLASTn with RepeatMasker (University of Washington).

Reverse transcription (RT)-PCR amplification and sequence analysis

Total RNA was isolated from the cultured fibroblasts of TD and FHA patients, and reverse transcribed with a CDS primer containing oligo d(T)18 using 250 units of SuperScript II reverse transcriptase (Life Technologies, Inc., Rockville, MD) as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). cDNA was amplified with Taq DNA polymerase using primers derived from the published human *ABC1* cDNA sequence (Luciani et al., Genomics 21:150-159, 1994). Six sets of primer pairs were designed to amplify each cDNA sample, generating six DNA fragments which are sequentially overlapped covering 135 to 7014 bp of the full-length human *ABC1* cDNA. The nucleotides are numbered according to the order of the published human cDNA sequence (AJ012376.1). Primer pairs (1): 135-158 (f) and 1183-1199 (r); (2): 1080-1107 (f) and 2247-2273 (r); (3): 2171-2197 (f) and 3376-3404 (r); (4): 3323-3353 (f) and 4587-4617 (r); (5) 4515-4539 (f) and 5782-5811 (r); (6): 5742-5769 (f) and 6985-7014 (r). RT-PCR products were purified by Qiagen spin columns. Sequencing was carried out

25

5

in a Model 373A Automated DNA sequencer (Applied Biosystems) using Taq dideoxy terminator cycle sequencing and Big Dye Kits according to the manufacturer's protocol.

Northern blot analysis

Northern transfer and hybridizations were performed essentially as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). Briefly, 20 µg of total fibroblast RNA samples were resolved by electrophoresis in a denaturing agarose (1.2%; w/v) gel in the presence of 7% formaldehyde, and transferred to nylon membranes. The filters were probed with ³²P-labeled human ABC1 cDNA as indicated. Pre-hybridization and hybridizations were carried out in an ExpressHyb solution (ClonTech) at 68°C according to the manufacturer's protocol.

Detection of the mutations in TD

Genotyping for the T4503C and A1864G variants was performed by PCR amplification of exon 30 followed by restriction digestion with *Hga*I and amplification of exon 13 followed by digestion with *Aci*I, respectively. PCR was carried out in a total volume of 50 μL with 1.5 mM MgCl₂, 187.5 nM of each dNTP, 2.5U Taq polymerase and 15 pmol of each primer (forward primer in exon 30: 5'-CTG CCA GGC AGG GGA GGA AGA GTG-3' (SEQ ID NO: 4); reverse primer spanning the junction of exon 30 and intron 30: 5'-GAA AGT GAC TCA CTT GTG GAG GA-3' (SEQ ID NO: 5); forward primer in intron 12: 5'-AAA GGG GCT TGG TAA GGG TA-3' (SEQ ID NO: 6); reverse in intron 13: 5'-CAT GCA CAT GCA CAC ACA TA -3' (SEQ ID NO: 7)). Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 58°C

25

5

30 seconds, 72°C 30 seconds were performed, with a final extension of 10 minutes at 72°C. For detection of the T4503C mutation, 15 μL of exon 30 PCR product was incubated with 4 U *Hga*I in a total volume of 25 μL, for 2 hours at 37°C, and the resulting fragments were separated on a 1.5% agarose gel. The presence of the T4503C mutation creates a restriction site for *Hga*I, and thus the 194 bp PCR product will be cut into fragments of 134 and 60 bp in the presence of the T4503C variant, but not in its absence. For detection of the A1864G mutation, 15 μL of exon 13 PCR products were digested with 8 U *Aci*I for three hours at 37°C. Products were separated on 2% agarose gels. The presence of the A1864G mutation creates a second *Aci*I site within the PCR product. Thus, the 360 bp PCR product is cleaved into fragments of 215 bp and 145 bp on the wild-type allele, but 185 bp, 145 bp and 30 bp on the mutant allele.

Detection of mutation in FHA

Genotyping for the $\Delta 693$ variant was performed by PCR amplification of exon 14 followed by restriction enzyme digestion with EarI. PCR was carried out in a total volume of 80 μ L with 1.5 mM MgCl₂, 187.5 nM of each dNTP, 2.5 U Taq polymerase and 20 pmol of each primer (forward primer in exon 14: 5'- CTT TCT GCG GGT GAT GAG CCG GTC AAT-3' (SEQ ID NO: 8); reverse primer in intron 14: 5'-CCT TAG CCC GTG TTG AGC TA-3' (SEQ ID NO: 9)). Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 55°C 30 seconds, 72°C 30 seconds were performed, with a final extension of 10 minutes at 72°C. Twenty microliters of PCR product was incubated with 4 U EarI in a total volume of 25 μ L, for two hours at 37°C, and the fragments were separated on a 2 % agarose gel. The presence of the $\Delta 693$ mutation destroys a restriction site for EarI, and thus the 297 bp PCR product will

25

5

be cut into fragments of 151 bp, 59 bp, 48 bp and 39 bp in the presence of a wild-type allele, but only fragments of 210 bp, 48 bp and 39 bp in the presence of the deletion.

A 6 bp deletion encompassing nucleotides 5752-5757 (inclusive), was detected in exon 41 in the proband of family FHA-3 by genomic sequencing using primers located within the introns flanking this exon. Genotyping of this mutation in family FHA-3 and controls was carried out by PCR with forward (5'-CCT GTA AAT GCA AAG CTA TCT CCT CT-3' (SEQ ID NO: 10)) and reverse primers (5'-CGT CAA CTC CTT GAT TTC TAA GAT GT (SEQ ID NO: 11)) located near the 5' and 3' ends of exon 41, respectively. Each PCR was carried out as for the genotyping of the 693 variant, but with annealing temperature of 58°C. Twenty microliters of PCR product was resolved on 3% agarose or 10% acrylamide gels. The wild type allele was detected as a 117 bp band and the mutant allele as a 111 bp band upon staining with ethidium bromide.

A C to T transition was detected at nucleotide 6504 in genomic DNA of the proband of family FHA-2. It was detectable as a double C and T peak in the genomic sequence of exon 48 of this individual, who is heterozygous for the alteration. This mutation, which creates a STOP codon that results in truncation of the last 118 amino acids of the ABC1 protein, also destroys an *RsaI* restriction site that is present in the wild type sequence. Genotyping of this mutation in family FHA-2 and controls was carried out by PCR with forward (5'-GGG TTC CCA GGG TTC AGT AT-3') (SEQ ID NO: 12)) and reverse (5'-GAT CAG GAA TTC AAG CAC CAA-3') (SEQ ID NO: 13)) primers directed to the intronic sequences flanking exon 48. PCR was done as for the 693 variant. Fifteen microliters of PCR product was digested with 5 Units of *RsaI* at 37°C for two hours and the digestion products resolved on 1.5% agarose gels. The mutant allele is detected as

25

5

an uncut 436 bp band. The normal sequence is cut by *RsaI* to produce 332 and 104 bp bands.

Cell culture

Skin fibroblast cultures were established from 3.0 mm punch biopsies of the forearm of FHD patients and healthy control subjects as described (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999).

Cellular cholesterol labeling and loading

The protocol for cellular cholesterol efflux experiments was described in detail elsewhere (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999). The cells were ³H-cholesterol labeled during growth and free cholesterol loaded in growth arrest.

Cholesterol efflux studies

Efflux studies were carried out from 0 to 24 hours in the presence of purified ApoAI (10 µg protein/mL medium). Efflux was determined as a percent of free cholesterol in the medium after the cells were incubated for specified periods of time. All experiments were performed in triplicate, in the presence of cells from one control subject and the cells from the study subjects to be examined. All results showing an efflux defect were confirmed at least three times.

Oligonucleotide synthesis

Eight phosphorothioate deoxyoligonucleotides complementary to various regions of the human *ABC1* cDNA sequence were obtained from GIBCO BRL. The oligonucleotides were purified by HPLC. The sequences of the antisense

25

oligonucleotides and their location are listed. One skilled in the art will recognize that other *ABC1* antisense sequences can also be produced and tested for their ability to decrease ABC1-mediated cholesterol regulation.

5	Name	<u>Sequence (5'- 3')</u>	mRNA target		
	control	-			
	AN-1	GCAGAGGCATGGCTTTATTTG (SEQ ID NO: 3)	AUG codon	46	
	AN-2	GTGTTCCTGCAGAGGGCATG (SEQ ID NO: 30)	AUG codon	50	
	AN-3	CACTTCCAGTAACAGCTGAC (SEQ ID NO: 31)	5'-Untranslated	79	
10	AN-4	CTTTGCGCATGTCCTTCATGC (SEQ ID NO: 32)	Coding	80	
	AN-5	GACATCAGCCCTCAGCATCTT (SEQ ID NO: 33)	Coding	120	
	AN-6:	CAACAAGCCATGTTCCCTC (SEQ ID NO: 34)	Coding		
	AN-7:	CATGTTCCCTCAGCCAGC (SEQ ID NO: 35)	Coding		
	AN-8:	CAGAGCTCACAGCAGGGA C (SEQ ID NO: 36)	Coding		
15					

Cell transfection with antisense oligonucleotides

Cells were grown in 35 mm culture dishes until 80 % confluent, then washed once with DMEM medium (serum and antibiotics free). One milliliter of DMEM (serum and antibiotics free) containing 500 nM antisense oligonucleotides and 5 μ g/ml or 7.5 μ g/ml of lipofectin (GIBCO BRL) were added to each well according to the manufacturer's protocol. The cells were incubated at 37°C for 4 hours, and then the medium was replaced by DMEM containing 10% FCS. Twenty-four hours after the transfection, the total cell RNA was isolated. Ten micrograms of total RNA was resolved on a 1% of agarose-formaldehyde gel and transferred to nylon membrane. The blot was hybridized with α -³²P dCTP labeled human *ABC1* cDNA overnight at 68°C. The membrane was subsequently exposed to x-ray film. The hybridizing bands were scanned by optical densitometry and standard to 28S ribosome RNA.

Cholesterol efflux with anti-ABC1 oligonucleotides

Human skin fibroblasts were plated in 6-well plates. The cells were labeled with 3 H-cholesterol (0.2 μ Ci /ml) in DMEM with 10% FBS for two days when the cell reached 50% confluence. The cells were then transfected with the antisense *ABC1* oligonucleotides at 500nM in DMEM (serum and antibiotic free) with 7.5 μ g/ml Lipofectin (GIBCO BRL) according to the manufacturer's protocol. Following the transfection, and the cells were loaded with nonlipoprotein (20 μ g/ml) for 12 hours in DMEM containing 2 mg/ml BSA without serum. The cellular cholesterol pools were then allowed to equilibrate for 6 hours in DMEM-BSA. The cholesterol efflux mediated by ApoAI (10 μ g /ml, in DMEM-BSA) were then carried out which is 48 hours after transfection.

Radiolabeled cholesterol released into the medium is expressed as a percentage of total ³H-cholesterol per well (medium + cell). Results are the mean +/- SD of triplicate dishes.

Determination of genomic structure of the ABC1 gene

Most splice junction sequences were determined from genomic sequence generated from BAC clones spanning the ABC1 gene. More than 160 kb of genomic sequence were generated. Genomic sequences were aligned with cDNA sequences to identify intron/exon boundaries. In some cases, long distance PCR between adjacent exons was used to amplify intron/exon boundary sequences using amplification primers designed according to the cDNA sequence.

25

20

Functionality of the newly-discovered 60 amino acids at the N-terminus

Antisense experiments

Phosphorothioate antisentisense oligonucleotides were designed to be complementary to the regions of the cDNA near newly discovered translation start site. AN-6 and AN-7 both overlap the initiator methionine codon; this site is in the middle of oligonucleotide AN-6. AN-8 is complementary to the very 5' end of the ABC1 cDNA. Antisense oligonucleotide AN-1 is complementary to the region of the ABC1 cDNA corresponding to the site identified as the ABC1 initiator methionine in AJ012376. Fig. 7C shows that antisense oligonucleotide AN-6 interferes with cellular cholesterol efflux in normal fibroblasts to the same extent as does antisense oligonucleotide AN-1. Transfection with either of these antisense oligonucleotides results in a decrease in cellular cholesterol efflux almost as severe as that seen in FHA cells. In general, antisense oligonucleotides complementary to coding sequences, especially near the 5' end of a gene's coding sequence, are expected to be more effective in decreasing the effective amount of transcript than are oligonucleotides directed to more 3' sequences or to non-coding sequences. The observation that AN-6 depresses cellular cholesterol efflux as effectively as AN-1 implies that both of these oligonucleotides are complementary to ABC1 coding sequences, and that the amino terminal 60 amino acids are likely to be contained in ABC1 protein. In contrast, the ineffectiveness of AN-8 shows that it is likely to be outside the protein coding region of the transcript, as predicted by presence of an in-frame stop codon between the initiator methionine and the region targeted by AN-8.

20

20

25

5

Antibody experiments

Polyclonal and monoclonal antibodies have been generated using peptides corresponding to discrete portions of the ABC1 amino acid sequence. One of these, 20-amino acid peptide #2 (Pep2: CSVRLSYPPYEQHECHFPNKA (SEQ ID NO: 37), in which the N-terminal cysteine was added to facilitate conjugation of the peptide) corresponds to a protein sequence within the 60 amino-terminal amino acids of the newly-discovered ABC1 protein sequence. The peptide was coupled to the KLH carrier protein and 300 µg injected at three intervals into two Balb/c mice over a four week period. The spleen was harvested from the mouse with the highest ELISA-determined immune response to free peptide, and the cells fused to NS-1 myeloma cells by standard monoclonal antibody generation methods. Positive hybridomas were selected first by ELISA and then further characterized by western blotting using cultured primary human fibroblasts. Monoclonal cell lines producing a high antibody titre and specifically recognizing the 245 kD human ABC1 protein were saved. The same size ABC1 protein product was detected by antibodies directed to four other discrete regions of the same protein. The 245 kD band could be eliminated in competition experiments with appropriate free peptide, indicating that it represents ABC1 protein (Fig. 13).

The foregoing experiments indicate that ABC1 protein is detected not only by antibodies corresponding to amino acid sequences within the previously-described ABC1 amino acid sequence, but also by the Pep2 monoclonal antibody that recognizes an epitope within the newly-discovered N-terminal 60 amino acids. The N-terminal 60 amino acid region is therefore coding, and is part of the ABC1 protein.

The epitope recognized by the Pep2 monoclonal antibody is also conserved among human, mouse, and chicken. Liver tissues from these three species

employed in a Western blot produced an ABC1 band of 245 kD when probed with the Pep2 monoclonal antibody. This indicates that the 60 amino acid N-terminal sequence is part of the ABC1 coding sequence in humans, mice, and chickens. Presence of this region is therefore evolutionarily conserved and likely to be of important functional significance for the ABC1 protein.

Bioinformatic analyses of ABC1 protein sequences

Transmembrane prediction programs indicate 13 transmembrane (TM) regions, the first one being between amino acids 26 and 42 (http://psort.nibb.ac.jp:8800/psort/helpwww2.html#ealom). The tentative number of TM regions for the threshold 0.5 is 13. (INTEGRAL Likelihood = -7.75 Transmembrane 26-42). The other 12 TM range in value between -0.64 and -12 (full results below). It is therefore very likely that the newly-discovered 60 amino acids contain a TM domain, and that the amino end of ABC1 may be on the opposite side of the membrane than originally thought.

```
ALOM: TM region allocation
           Init position for calculation: 1
           Tentative number of TMs for the threshold 0.5: 13
           INTEGRAL Likelihood = -7.75 Transmembrane 26 - 42
           INTEGRAL Likelihood = -3.98 Transmembrane 640 - 656
           INTEGRAL Likelihood = -8.70 Transmembrane 690 - 706
           INTEGRAL Likelihood = -9.61 Transmembrane 717 - 733
           INTEGRAL Likelihood = -1.44 Transmembrane 749 - 765
25
           INTEGRAL Likelihood = -0.64 Transmembrane 771 - 787
           INTEGRAL Likelihood = -1.28 Transmembrane 1041 -1057
           INTEGRAL Likelihood =-12.79 Transmembrane 1351 -1367
           INTEGRAL Likelihood = -8.60 Transmembrane 1661 -1677
           INTEGRAL Likelihood = -6.79 Transmembrane 1708 -1724
30
           INTEGRAL Likelihood = -3.40 Transmembrane 1737 -1753
           INTEGRAL Likelihood = -1.49 Transmembrane 1775 -1791
           INTEGRAL Likelihood = -8.39 Transmembrane 1854 -1870
           PERIPHERAL Likelihood = 0.69 (at 1643)
           ALOM score: -12.79 (number of TMSs: 13)
35
```

25

5

There does not appear to be an obvious cleaved peptide, so this first 60 amino acid residues are not likely to be cleaved, and are therefore not specifically a signal/targeting sequence. No other signals (e.g., for targeting to specific organelles) are apparent.

Agonists and Antagonists

Useful therapeutic compounds include those which modulate the expression, activity, or stability of ABC1. To isolate such compounds, ABC1 expression, biological activity, or regulated catabolism is measured following the addition of candidate compounds to a culture medium of ABC1-expressing cells. Alternatively, the candidate compounds may be directly administered to animals (for example mice, pigs, or chickens) and used to screen for their effects on ABC1 expression.

In addition its role in the regulation of cholesterol, ABC1 also participates in other biological processes for which the development of ABC1 modulators would be useful. In one example, ABC1 transports interleukin- 1β (IL- 1β) across the cell membrane and out of cells. IL- 1β is a precursor of the inflammatory response and, as such, inhibitors or antagonists of ABC1 expression or biological activity may be useful in the treatment of any inflammatory disorders, including but not limited to rheumatoid arthritis, systemic lupus erythematosis (SLE), hypoor hyper-thyroidism, inflammatory bowel disease, and diabetes mellitus. In another example, ABC1 expressed in macrophages has been shown to be engaged in the engulfment and clearance of dead cells. The ability of macrophages to ingest these apoptotic bodies is impaired after antibody-mediated blockade of ABC1. Accordingly, compounds that modulate ABC1 expression, stability, or biological activity would be useful for the treatment of these disorders.

25

5

ABC1 expression is measured, for example, by standard Northern blot analysis using an *ABC1* nucleic acid sequence (or fragment thereof) as a hybridization probe, or by Western blot using an anti-ABC1 antibody and standard techniques. The level of ABC1 expression in the presence of the candidate molecule is compared to the level measured for the same cells, in the same culture medium, or in a parallel set of test animals, but in the absence of the candidate molecule. ABC1 activity can also be measured using the cholesterol efflux assay.

<u>Transcriptional Regulation of ABC1 Expression</u>

ABC1 mRNA is increased approximately 8-fold upon cholesterol loading. This increase is likely controlled at the transcriptional level. Using the promoter sequence described herein, one can identify transcription factors that bind to the promoter by performing, for example, gel shift assays, DNAse protection assays, or *in vitro* or *in vivo* reporter gene-based assays. The identified transcription factors are themselves drug targets. In the case of ABC1, drug compounds that act through modulation of transcription of ABC1 could be used for HDL modulation, atherosclerosis prevention, and the treatment of cardiovascular disease. For example, using a compound to inhibit a transcription factor that represses ABC1 would be expected to result in up-regulation of ABC1 and, therefore, HDL levels. In another example, a compound that increases transcription factor expression or activity would also increase ABC1 expression and HDL levels.

Transcription factors known to regulate other genes in the regulation of apolipoprotein genes or other cholesterol- or lipid-regulating genes are of particular relevance. Such factors include, but are not limited to, the steroid response element binding proteins (SREBP-1 and SREBP-2), the PPAR (peroxisomal proliferation-activated receptor) transcription factors. Several

25

5

consensus sites for certain elements are present in the sequenced region 5' to the ABC1 gene (Fig. 16) and are likely to modulate ABC1 expression. For example, PPARs may alter transcription of ABC1 by mechanisms including heterodimerization with retinoid X receptors (RXRs) and then binding to specific proliferator response elements (PPREs). Examples of such PPARs include PPAR α , β , γ and δ . These distinct PPARs have been shown to have transcriptional regulatory effects on different genes. PPARa is expressed mainly in liver, whereas PPARy is expressed in predominantly in adipocytes. Both PPARα and PPARγ are found in coronary and carotid artery atherosclerotic plaques and in endothelial cells, smooth muscle cells, monocytes and monocyte-derived macrophages. Activation of PPARα results in altered lipoprotein metabolism through PPARa's effect on genes such as lipoprotein lipase (LPL), apolipoprotein CIII (apo CIII) and apolipoprotein AI (apo AI) and AII (apo AII). PPARα activation results in overexpression of LPL and apoA-I and apoA-II, but inhibits the expression of apo CIII. PPARα activation also inhibits inflammation, stimulates lipid oxidation and increases the hepatic uptake and esterification of free fatty acids (FFA's). PPARα and PPARγ activation may inhibit nitric oxide (NO) synthase in macrophages and prevent interleukin-1 (IL-1) induced expression of IL-6 and cyclo-oxygenase-2 (COX-2) and thrombin induced endothelin-1 expression secondary to negative transcriptional regulation of NF-KB and activation of protein-1 signaling pathway. It has also been shown that PPARa induces apoptosis in monocyte-derived macrophages through the inhibition of NF-KB activity.

Activation of PPARα can be achieved by compounds such as fibrates, β-estradiol, arachidonic acid derivatives, WY-14,643 and LTB4 or 8(s)HETE. PPARγ activation can be achieved through compounds such as thiozolidinedione

25

5

antidiabetic drugs, 9-HODE and 13-HODE. Additional compounds such as nicotinic acid or HMG CoA reductase inhibitors may also alter the activity of PPARs.

Compounds which alter activity of any of the PPARs (e.g., PPARα or PPARγ) may have an effect on ABC1 expression and thereby could affect HDL levels, atherosclerosis and risk of CAD. PPARs are also regulated by fatty acids (including modified fatty acids such as 3 thia fatty acids), leukotrienes such as leukotriene B4 and prostaglandin J2, which is a natural activator/ligand for PPARγ. Drugs that modulate PPARs may therefore have an important effect on modulating lipid levels (including HDL and triglyceride levels) and altering CAD risk. This effect could be achieved through the modulation of ABC1 gene expression. Drugs may also effect ABC1 gene expression and thereby HDL levels, by an indirect effect on PPARs via other transcriptional factors such as adipocyte differentiation and determination factor-1 (ADD-1) and sterol regulatory element binding protein-1 and 2 (SREBP-1 and 2). Drugs with combined PPARα and PPARγ agonist activity or PPARα and PPARγ agonists given in combination for example, may increase HDL levels even more.

A PPAR binding site (PPRE element) is found 5' to the ABC1 gene (nucleotides 2150 to 2169 of SEQ ID NO: 14). Like the PPRE elements found in the C-ACS, HD, CYP4A6 and ApoA-I genes, this PPRE site is a trimer related to the PPRE consensus sequence. Partly because of its similarity in the number and arrangement of repeats in this PPAR binding site, this element in particular is very likely to be of physiological relevance to the regulation of the ABC1 gene.

Additional transcription factors which may also have an effect in modulating ABC1 gene expression and thereby HDL levels, atherosclerosis and CAD risk include; REV-ERBα, SREBP-1 & 2, ADD-1, EBPα, CREB binding

25

5

protein, P300, HNF 4, RAR, LXR, and RORα. Additional degenerate binding sites for these factors can be found through examination of the sequence in SEQ ID NO: 14.

Additional utility of ABC1 polypeptides, nucleic acids, and modulators

ABC1 may act as a transporter of toxic proteins or protein fragments (e.g., APP) out of cells. Thus, ABC1 agonists/upregulators may be useful in the treatment of other disease areas, including Alzheimer's disease, Niemann-Pick disease, and Huntington's disease.

ABC transporters have been shown to increase the uptake of long chain fatty acids from the cytosol to peroxisomes and, moreover, to play a role in β -oxidation of very long chain fatty acids. Importantly, in x-linked adrenoleukodystrophy (ALD), fatty acid metabolism is abnormal, due to defects in the peroxisomal ABC transporter. Any agent that upregulates ABC transporter expression or biological activity may therefor be useful for the treatment of ALD or any other lipid disorder.

ABC1 is expressed in macrophages and is required for engulfment of cells undergoing programmed cell death. The apoptotic process itself, and its regulation, have important implications for disorders such as cancer, one mechanism of which is failure of cells to undergo cell death appropriately. ABC1 may facilitate apoptosis, and as such may represent an intervention point for cancer treatment. Increasing ABC1 expression or activity or otherwise upregulating ABC1 by any method may constitute a treatment for cancer by increasing apoptosis and thus potentially decreasing the aberrant cellular proliferation characterized by this disease. Conversely, down-regulation of ABC1 by any method may provide opportunity for decreasing apoptosis and allowing

25

5

increased proliferation of cells in conditions where cell growth is limited. Such disorders include but are not limited to neurodeficiencies and neurodegeneration, and growth disorders. ABC1 could, therefore, potentially be used as a method for identification of compounds for use in the treatment of cancer, or in the treatment of degenerative disorders.

Agents that have been shown to inhibit ABC1 include, for example, the anti-diabetic agents glibenclamide and glyburide, flufenamic acid, diphenylamine-2-carbonic acid, sulfobromophthalein, and DIDS.

Agents that upregulate ABC1 expression or biological activity include but are not limited to protein kinase A, protein kinase C, vanadate, okadaic acid, and IBMX1.

Those in the art will recognize that other compounds can also modulate ABC1 biological activity, and these compounds are also in the spirit of the invention.

Drug screens based on the ABC1 gene or protein

The ABC1 protein and gene can be used in screening assays for identification of compounds which modulate its activity and may be potential drugs to regulate cholesterol levels. Useful ABC1 proteins include wild-type and mutant ABC1 proteins or protein fragments, in a recombinant form or endogenously expressed. Drug screens to identify compounds acting on the ABC1 expression product may employ any functional feature of the protein. In one example, the phosphorylation state or other post-translational modification is monitored as a measure of ABC1 biological activity. ABC1 has ATP binding sites, and thus assays may wholly or in part test the ability of ABC1 to bind ATP or to exhibit ATPase activity. ABC1, by analogy to similar proteins, is thought to

25

5

be able to form a channel-like structure; drug screening assays could be based upon assaying for the ability of the protein to form a channel, or upon the ability to transport cholesterol or another molecule, or based upon the ability of other proteins bound by or regulated by ABC1 to form a channel. Alternatively, phospholipid or lipid transport can also be used as measures of ABC1 biological activity.

There is evidence that, in addition to its role as a regulator of cholesterol levels, ABC1 also transports anions. Functional assays could be based upon this property, and could employ drug screening technology such as (but not limited to) the ability of various dyes to change color in response to changes in specific ion concentrations in such assays can be performed in vesicles such as liposomes, or adapted to use whole cells.

Drug screening assays can also be based upon the ability of ABC1 or other ABC transporters to interact with other proteins. Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, co-purification, and yeast two-hybrid screening. Such interactions can be further assayed by means including but not limited to fluorescence polarization or scintillation proximity methods. Drug screens can also be based upon functions of the ABC1 protein deduced upon X-ray crystallography of the protein and comparison of its 3-D structure to that of proteins with known functions. Such a crystal structure has been determined for the prokaryotic ABC family member HisP, histidine permease. Drug screens can be based upon a function or feature apparent upon creation of a transgenic or knockout mouse, or upon overexpression of the protein or protein fragment in mammalian cells *in vitro*. Moreover, expression of mammalian (e.g., human) ABC1 in yeast or *C. elegans* allows for screening of

25

5

candidate compounds in wild-type and mutant backgrounds, as well as screens for mutations that enhance or suppress an ABC1-dependent phenotype. Modifier screens can also be performed in ABC1 transgenic or knock-out mice.

Additionally, drug screening assays can also be based upon ABC1 functions deduced upon antisense interference with the gene function. Intracellular localization of ABC1, or effects which occur upon a change in intracellular localization of the protein, can also be used as an assay for drug screening. Immunocytochemical methods will be used to determine the exact location of the ABC1 protein.

Human and rodent ABC1 protein can be used as an antigen to raise antibodies, including monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to functional studies and the development of drug screening assays and diagnostics. Monitoring the influence of agents (e.g., drugs, compounds) on the expression or biological activity of ABC1 can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trails of subjects exhibiting altered ABC1 gene expression, protein levels, or biological activity. Alternatively, the effectiveness of an agent determined by a screening assay to modulate ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trails of subjects exhibiting decreased altered gene expression, protein levels, or biological activity. In such clinical trials, the expression or activity of ABC1 and, preferably, other genes that have been implicated in, for example, cardiovascular disease can be used to ascertain the effectiveness of a particular drug.

For example, and not by way of limitation, genes, including ABC1, that are

modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates ABC1 biological activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cholesterol levels or cardiovascular disease, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of ABC1 and other genes implicated in the disorder. The levels of gene expression can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of ABC1 or other genes. In this way, the gene expression can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an ABC1 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the pre-administration sample with the ABC1 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent

25

5

to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of ABC1 to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of ABC1 to lower levels than detected.

The ABC1 gene or a fragment thereof can be used as a tool to express the protein in an appropriate cell *in vitro* or *in vivo* (gene therapy), or can be cloned into expression vectors which can be used to produce large enough amounts of ABC1 protein to use in *in vitro* assays for drug screening. Expression systems which may be employed include baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic systems such as CHO cells. Naked DNA and DNA-liposome complexes can also be used.

Assays of ABC1 activity includes binding to intracellular interacting proteins; interaction with a protein that up-regulates ABC1 activity; interaction with HDL particles or constituents; interaction with other proteins which facilitate interaction with HDL or its constituents; and measurement of cholesterol efflux. Furthermore, assays may be based upon the molecular dynamics of macromolecules, metabolites and ions by means of fluorescent-protein biosensors.

Alternatively, the effect of candidate modulators on expression or activity may be measured at the level of ABC1 protein production using the same general approach in combination with standard immunological detection techniques, such as Western blotting or immunoprecipitation with an ABC1-specific antibody. Again, useful cholesterol-regulating or anti-CVD therapeutic modulators are identified as those which produce an change in ABC1 polypeptide production. Agonists may also affect ABC1 activity without any effect on expression level.

Candidate modulators may be purified (or substantially purified) molecules

25

5

or may be one component of a mixture of compounds (e.g., an extract or supernatant obtained from cells). In a mixed compound assay, ABC1 expression is tested against progressively smaller subsets of the candidate compound pool (e.g., produced by standard purification techniques, e.g., HPLC or FPLC; Ausubel et al.) until a single compound or minimal compound mixture is demonstrated to modulate ABC1 expression.

Agonists, antagonists, or mimetics found to be effective at modulating the level of cellular ABC1 expression or activity may be confirmed as useful in animal models (for example, mice, pigs, rabbits, or chickens). For example, the compound may ameliorate the low HDL levels of mouse or chicken hypoalphalipoproteinemias.

A compound that promotes an increase in ABC1 expression or activity is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to increase the level or activity of native, cellular ABC1 and thereby treat a low HDL condition in an animal (for example, a human).

One method for increasing ABC biological activity is to increase the stabilization of the ABC protein or to prevent its degradation. Thus, it would be useful to identify mutations in an ABC polypeptide (e.g., ABC1) that lead to increased protein stability. These mutations can be incorporated into any protein therapy or gene therapy undertaken for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Similarly, compounds that increase the stability of a wild-type ABC polypeptide or decrease its catabolism may also be useful for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Such mutations and compounds can be identified using the methods described herein.

In one example, cells expressing an ABC polypeptide having a mutation are

25

5

transiently metabolically labeled during translation and the half-life of the ABC polypeptide is determined using standard techniques. Mutations that increase the half-life of an ABC polypeptide are ones that increase ABC protein stability. These mutations can then be assessed for ABC biological activity. They can also be used to identify proteins that affect the stability of ABC1 mRNA or protein. One can then assay for compounds that act on these factors or on the ability of these factors to bind ABC1.

In another example, cells expressing wild-type ABC polypeptide are transiently metabolically labeled during translation, contacted with a candidate compounds, and the half-life of the ABC polypeptide is determined using standard techniques. Compounds that increase the half-life of an ABC polypeptide are useful compounds in the present invention.

If desired, treatment with an agonist of the invention may be combined with any other HDL-raising or anti-CVD therapies.

It is understood that, while ABC1 is the preferred ABC transporter for the drug screens described herein, other ABC transporters can also be used. The replacement of ABC1 with another ABC transporter is possible because it is likely that ABC transporter family members, such as ABC2, ABCR, or ABC8 will have a similar mechanism of regulation.

Exemplary assays are described in greater detail below.

Protein-based assays

ABC1 polypeptide (purified or unpurified) can be used in an assay to determine its ability to bind another protein (including, but not limited to, proteins found to specifically interact with ABC1). The effect of a compound on that binding is then determined.

25

5

Protein Interaction Assays

ABC1 protein (or a polypeptide fragment thereof or an epitope-tagged form or fragment thereof) is harvested from a suitable source (e.g., from a prokaryotic expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation from ABC1-expressing cells). The ABC1 polypeptide is then bound to a suitable support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of, for example, a his-tagged form of ABC1). Binding to the support is preferably done under conditions that allow proteins associated with ABC1 polypeptide to remain associated with it. Such conditions may include use of buffers that minimize interference with protein-protein interactions. The binding step can be done in the presence and absence of compounds being tested for their ability to interfere with interactions between ABC1 and other molecules. If desired, other proteins (e.g., a cell lysate) are added, and allowed time to associate with the ABC polypeptide. The immobilized ABC1 polypeptide is then washed to remove proteins or other cell constituents that may be non-specifically associated with it the polypeptide or the support. The immobilized ABC1 polypeptide is then dissociated from its support, and so that proteins bound to it are released (for example, by heating), or, alternatively, associated proteins are released from ABC1 without releasing the ABC1 polypeptide from the support. The released proteins and other cell constituents can be analyzed, for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with specific antibodies. phosphoamino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of ABC1 can be employed in these assays to gain additional information about which part of ABC1 a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and muatant forms of the protein can be used to help distinguish true

25

5

binding proteins.

The foregoing assay can be performed using a purified or semipurified protein or other molecule that is known to interact with ABC1. This assay may include the following steps.

- 1. Harvest ABC1 protein and couple a suitable fluorescent label to it;
- 2. Label an interacting protein (or other molecule) with a second, different fluorescent label. Use dyes that will produce different quenching patterns when they are in close proximity to each other vs. when they are physically separate (i.e., dyes that quench each other when they are close together but fluoresce when they are not in close proximity);
- 3. Expose the interacting molecule to the immobilized ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
 - 4. Collect fluorescent readout data.

Another assay is includes Fluorescent Resonance Energy Transfer (FRET) assay. This assay can be performed as follows.

- 1. Provide ABC1 protein or a suitable polypeptide fragment thereof and couple a suitable FRET donor (e.g., nitro-benzoxadiazole (NBD)) to it;
- 2. Label an interacting protein (or other molecule) with a FRET acceptor (e.g., rhodamine);
- 3. Expose the acceptor-labeled interacting molecule to the donor-labeled ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
 - 4. Measure fluorescence resonance energy transfer.

25

5

Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.

Membrane permeability assay

The ABC1 protein can also be tested for its effects on membrane permeability. For example, beyond its putative ability to translocate lipids, ABC1 might affect the permeability of membranes to ions. Other related membrane proteins, most notably the cystic fibrosis transmembrane conductance regulator and the sulfonylurea receptor, are associated with and regulate ion channels.

ABC1 or a fragment of ABC1 is incorporated into a synthetic vesicle, or, alternatively, is expressed in a cell and vesicles or other cell sub-structures containing ABC1 are isolated. The ABC1-containing vesicles or cells are loaded with a reporter molecule (such as a fluorescent ion indicator whose fluorescent properties change when it binds a particular ion) that can detect ions (to observe outward movement), or alternatively, the external medium is loaded with such a molecule (to observe inward movement). A molecule which exhibits differential properties when it is inside the vesicle compared to when it is outside the vesicle is preferred. For example, a molecule that has quenching properties when it is at high concentration but not when it is at another low concentration would be suitable. The movement of the charged molecule (either its ability to move or the kinetics of its movement) in the presence or absence of a compound being tested for its ability to affect this process can be determined.

In another assay, membrane permeability is determined electrophysiologically by measuring ionic influx or efflux mediated by or modulated by ABC1 by standard electrophysiological techniques. A suitable control (e.g., TD cells or a cell line with very low endogenous ABC1 expression) can be used as a

25

5

control in the assay to determine if the effect observed is specific to cells expressing ABC1.

In still another assay, uptake of radioactive isotopes into or out of a vesicle can be measured. The vesicles are separated from the extravesicular medium and the radioactivity in the vesicles and in the medium is quantitated and compared.

Nucleic acid-based assays

ABC1 nucleic acid may be used in an assay based on the binding of factors necessary for ABC1 gene transcription. The association between the *ABC1* DNA and the binding factor may be assessed by means of any system that discriminates between protein-bound and non-protein-bound DNA (e.g., a gel retardation assay). The effect of a compound on the binding of a factor to *ABC1* DNA is assessed by means of such an assay. In addition to *in vitro* binding assays, *in vivo* assays in which the regulatory regions of the *ABC1* gene are linked to reporter genes can also be performed.

Assays measuring ABC1 stability

A cell-based or cell-free system can be used to screen for compounds based on their effect on the half-life of *ABC1* mRNA or ABC1 protein. The assay may employ labeled mRNA or protein. Alternatively, *ABC1* mRNA may be detected by means of specifically hybridizing probes or a quantitative PCR assay. Protein can be quantitated, for example, by fluorescent antibody-based methods.

In vitro mRNA stability assay

1. Isolate or produce, by *in vitro* transcription, a suitable quantity of ABC1 mRNA;

25

5

- 2. Label the ABC1 mRNA;
- 3. Expose aliquots of the mRNA to a cell lysate in the presence or absence of a compound being tested for its ability to modulate *ABC1* mRNA stability;
 - 4. Assess intactness of the remaining mRNA at suitable time points.

In vitro protein stability assay

- 1. Express a suitable amount of ABC1 protein;
- 2. Label the protein;
- 3. Expose aliquots of the labeled protein to a cell lysate in the presence or absence of a compound being tested for its ability to modulate ABC1 protein stability;
 - 4. Assess intactness of the remaining protein at suitable time points

In vivo mRNA or protein stability assay

- 1. Incubate cells expressing ABC1 mRNA or protein with a tracer (radiolabeled ribonucleotide or radiolabeled amino acid, respectively) for a very brief time period (e.g., five minutes) in the presence or absence of a compound being tested for its effect on mRNA or protein stability;
 - 2. Incubate with unlabeled ribonucleotide or amino acid; and
- 3. Quantitate the ABC1 mRNA or protein radioactivity at time intervals beginning with the start of step 2 and extending to the time when the radioactivity in ABC1 mRNA or protein has declined by approximately 80%. It is preferable to separate the intact or mostly intact mRNA or protein from its radioactive breakdown products by a means such as gel electrophoresis in order to quantitate the mRNA or protein.

5

Assays measuring inhibition of dominant negative activity

Mutant ABC1 polypeptides are likely to have dominant negative activity (i.e., activity that interferes with wild-type ABC1 function). An assay for a compound that can interfere with such a mutant may be based on any method of quantitating normal ABC1 activity in the presence of the mutant. For example, normal ABC1 facilitates cholesterol efflux, and a dominant negative mutant would interfere with this effect. The ability of a compound to counteract the effect of a dominant negative mutant may be based on cellular cholesterol efflux, or on any other normal activity of the wild-type ABC1 that was inhibitable by the mutant.

Assays measuring phosphorylation

The effect of a compound on ABC1 phosphorylation can be assayed by methods that quantitate phosphates on proteins or that assess the phosphorylation state of a specific residue of a ABC1. Such methods include but are not limited to ³²P labelling and immunoprecipitation, detection with antiphosphoamino acid antibodies (e.g., antiphosphoserine antibodies), phosphoamino acid analysis on 2-dimensional TLC plates, and protease digestion fingerprinting of proteins followed by detection of ³²P-labeled fragments.

Assays measuring other post-translational modifications

The effect of a compound on the post-translational modification of ABC1 is based on any method capable of quantitating that particular modification. For example, effects of compounds on glycosylation may be assayed by treating ABC1 with glycosylase and quantitating the amount and nature of carbohydrate released.

25

5

Assays measuring ATP binding

The ability of ABC1 to bind ATP provides another assay to screen for compounds that affect ABC1. ATP binding can be quantitated as follows.

- 1. Provide ABC1 protein at an appropriate level of purity and reconsititute it in a lipid vesicle;
- 2. Expose the vesicle to a labeled but non-hydrolyzable ATP analog (such as gamma ³⁵S-ATP) in the presence or absence of compounds being tested for their effect on ATP binding. Note that azido-ATP analogs can be used to allow covalent attachment of the azido-ATP to protein (by means of U.V. light), and permit easier quantitation of the amount of ATP bound to the protein.
 - 3. Quantitate the amount of ATP analog associated with ABC1

Assays measuring ATPase activity

Quantitation of the ATPase activity of ABC1 can also be assayed for the effect of compounds on ABC1. This is preferably performed in a cell-free assay so as to separate ABC1 from the many other ATPases in the cell. An ATPase assay may be performed in the presence or absence of membranes, and with or without integration of ABC1 protein into a membrane. If performed in a vesicle-based assay, the ATP hydrolysis products produced or the ATP hydrolyzed may be measured within or outside of the vesicles, or both. Such an assay may be based on disappearance of ATP or appearance of ATP hydrolysis products.

For high-throughput screening, a coupled ATPase assay is preferable. For example, a reaction mixture containing pyruvate kinase and lactate dehydrogenase can be used. The mixture includes phosphoenolpyruvate (PEP), nicotinamide adenine dinucleotide (NAD+), and ATP. The ATPase activity of ABC1 generates ADP from ATP. The ADP is then converted back to ATP as part of the pyruvate

25

5

kinase reaction. The product, pyruvate, is then converted to lactate. The latter reaction generates a colored quinone (NADH) from a colorless substrate (NAD+), and the entire reaction can be monitored by detection of the color change upon formation of NADH. Since ADP is limiting for the pyruvate kinase reaction, this coupled system precisely monitors the ATPase activity of ABC1.

Assays measuring cholesterol efflux

A transport-based assay can be performed *in vivo* or *in vitro*. For example, the assay may be based on any part of the reverse cholesterol transport process that is readily re-created in culture, such as cholesterol or phospholipid efflux. Alternatively, the assay may be based on net cholesterol transport in a whole organism, as assessed by means of a labeled substance (such as cholesterol).

For high throughput, fluorescent lipids can be used to measure ABC1-catalyzed lipid efflux. For phospholipids, a fluorescent precursor, C6-NBD-phosphatidic acid, can be used. This lipid is taken up by cells and dephosphorylated by phosphatidic acid phosphohydrolase. The product, NBD-diglyceride, is then a precursor for synthesis of glycerophospholipids like phosphatidylcholine. The efflux of NBD-phosphatidylcholine can be monitored by detecting fluorescence resonance energy transfer (FRET) of the NBD to a suitable acceptor in the cell culture medium. This acceptor can be rhodamine-labeled phosphatidylethanolamine, a phospholipid that is not readily taken up by cells. The use of short-chain precursors obviates the requirement for the phospholipid transfer protein in the media. For cholesterol, NBD-cholesterol ester can be reconstituted into LDL. The LDL can efficiently deliver this lipid to cells via the LDL receptor pathway. The NBD-cholesterol esters are hydrolyzed in the lysosomes, resulting in NBD-cholesterol that can now be transported back to

25

5

the plasma membrane and efflux from the cell. The efflux can be monitored by the aforementioned FRET assay in which NBD transfers its fluorescence resonance energy to the rhodamine-phosphatidylethanoline acceptor.

Animal Model Systems

Compounds identified as having activity in any of the above-described assays are subsequently screened in any available animal model system, including, but not limited to, pigs, rabbits, and WHAM chickens. Test compounds are administered to these animals according to standard methods. Test compounds may also be tested in mice bearing mutations in the *ABC1* gene. Additionally, compounds may be screened for their ability to enhance an interaction between ABC1 and any HDL particle constituent such as ApoAI, ApoAII, or ApoE.

The cholesterol efflux assay as a drug screen

The cholesterol efflux assay measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and is dependent on ABC1 function. In this procedure, cells are loaded with radiolabeled cholesterol by any of several biochemical pathways (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999). Cholesterol efflux is then measured after incubation for various times (typically 0 to 24 hours) in the presence of HDL3 or purified ApoAI. Cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation. ABC1 expression levels and/or biological activity are associated with increased efflux while decreased levels of ABC1 are associated with decreased cholesterol efflux.

This assay can be readily adapted to the format used for drug screening, which may consist of a multi-well (e.g., 96-well) format. Modification of the

assay to optimize it for drug screening would include scaling down and streamlining the procedure, modifying the labeling method, using a different cholesterol acceptor, altering the incubation time, and changing the method of calculating cholesterol efflux. In all these cases, the cholesterol efflux assay remains conceptually the same, though experimental modifications may be made. A transgenic mouse overexpressing ABC1 would be expected to have higher than normal HDL levels.

Knock-out mouse model

An animal, such as a mouse, that has had one or both ABC1 alleles inactivated (*e.g.*, by homologous recombination) is likely to have low HDL-C levels, and thus is a preferred animal model for screening for compounds that raise HDL-C levels. Such an animal can be produced using standard techniques. In addition to the initial screening of test compounds, the animals having mutant ABC1 genes are useful for further testing of efficacy and safety of drugs or agents first identified using one of the other screening methods described herein. Cells taken from the animal and placed in culture can also be exposed to test compounds. HDL-C levels can be measured using standard techniques, such as those described herein.

20

25

WHAM chickens: an animal model for low HDL cholesterol

Wisconsin Hypo-Alpha Mutant (WHAM) chickens arose by spontaneous mutation in a closed flock. Mutant chickens came to attention through their a Z-linked white shank and white beak phenotype referred to as 'recessive white skin' (McGibbon, 1981) and were subsequently found to have a profound deficiency of HDL (Poernama *et al.*, 1990).

25

5

This chicken low HDL locus (Y) is Z-linked, or sex-linked. (In birds, females are ZW and males are ZZ). Genetic mapping placed the Y locus on the long arm of the Z chromosome (Bitgood, 1985), proximal to the ID locus (Bitgood, 1988). Examination of current public mapping data for the chicken genome mapping project, ChickMap (maintained by the Roslin Institute; http://www.ri.bbsrc.ac.uk/ chickmap/ChickMapHomePage.html) showed that a region of synteny with human chromosome 9 lies on the long arm of the chicken Z chromosome (Zq) proximal to the ID locus. Evidence for this region of synteny is the location of the chicken aldolase B locus (ALDOB) within this region. The human ALDOB locus maps to chromosome 9q22.3 (The Genome Database, http://gdbwww.gdb.org/), not far from the location of human ABC1. This comparison of maps showed that the chicken Zq region near chicken ALDOB and the human 9q region near human ALDOB represent a region of synteny between human and chicken.

Since a low HDL locus maps to the 9q location in humans and to the Zq region in chickens, these low HDL loci are most probably located within the syntenic region. Thus we predicted that ABC1 is mutated in WHAM chickens. In support of this, we have identified an E=K mutation at a position that corresponds to amino acid 89 of human ABC1 (Figs. 14 and 15). This non-conservative substitution is at a position that is conserved among human, mouse, and chicken, indicating that it is in a region of the protein likely to be of functional importance.

Discovery of the WHAM mutation in the amino-terminal portion of the ABC1 protein also establishes the importance of the amino-terminal region. This region may be critical because of association with other proteins required to carry out cholesterol efflux or related tasks. It may be an important regulatory region (there is a phosphorylation site for casein kinase near the mutated residue), or it

25

5

may help to dictate a precise topological relationship with cellular membranes (the N-terminal 60 amino acid region contains a putative membrane-spanning or membrane-associated segment).

The amino-terminal region of the protein (up to the first 6-TM region at approximately amino acid 639) is an ideal tool for screening factors that affect ABC1 activity. It can be expressed as a truncated protein in ABC1 wild type cells in order to test for interference of the normal ABC1 function by the truncated protein. If the fragment acts in a dominant negative way, it could be used in immunoprecipitations to identify proteins that it may be competing away from the normal endogenous protein.

The C-terminus also lends itself to such experiments, as do the intracellular portions of the molecule, expressed as fragments or tagged or fusion proteins, in the absence of transmembrane regions.

Since it is possible that there are several genes in the human genome which affect cholesterol efflux, it is important to establish that any animal model to be used for a human genetic disease represents the homologous locus in that animal, and not a different locus with a similar function. The evidence above establishes that the chicken Y locus and the human chromosome 9 low HDL locus are homologous. WHAM chickens are therefore an important animal model for the identification of drugs that modulate cholesterol efflux.

The WHAM chickens' HDL deficiency syndrome is not, however, associated with an increased susceptibility to atherosclerosis in chickens. This probably reflects the shorter lifespan of the chicken rather than an inherent difference in the function of the chicken ABC1 gene compared to the human gene. We propose the WHAM chicken as a model for human low HDL for the development and testing of drugs to raise HDL in humans. Such a model could be

25

employed in several forms, through the use of cells or other derivatives of these chickens, or by the use of the chickens themselves in tests of drug effectiveness, toxicity, and other drug development purposes.

<u>Therapy</u>

5

Compounds of the invention, including but not limited to, ABC1 polypeptides, *ABC1* nucleic acids, other ABC transporters, and any therapeutic agent that modulates biological activity or expression of ABC1 identified using any of the methods disclosed herein, may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer such compositions to patients. Although intravenous administration is preferred, any appropriate route of administration may be employed, for example, perenteral, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspension; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations are found in, for example, Remington: The Science and Practice of Pharmacy, (19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer,

25

5

lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

Compounds

In general, novel drugs for the treatment of aberrant cholesterol levels and/or CVD are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field or drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant,

25

5

and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, *e.g.*, by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their HDL-raising and anti-CVD activities should be employed whenever possible.

When a crude extract is found to have cholesterol-modulating or anti-CVD activities or both, further fractionation of the positive lead extract is necessary to isolate chemical constituent responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having cholesterol-modulating or anti-CVD activities. The same *in vivo* and *in vitro* assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for the treatment of pathogenicity are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value are subsequently analyzed using any standard animal model of diabetes or obesity known in the art.

It is understood that compounds that modulate activity of proteins that

25

5

modulate or are modulated by ABC1 are useful compounds for modulating cholesterol levels. Exemplary compounds are provided herein; others are known in the art.

Compounds that are structurally related to cholesterol, or that mimic ApoAI or a related apolipoprotein, and increase ABC1 biological activity are particularly useful compounds in the invention. Other compounds, known to act on the MDR protein, can also be used or derivatized and assayed for their ability to increase ABC1 biological activity. Exemplary MDR modulators are PSC833, bromocriptine, and cyclosporin A.

Screening patients having low HDL-C

ABC1 expression, biological activity, and mutational analysis can each serve as a diagnostic tool for low HDL; thus determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of HDL increasing drugs (referred to herein as pharmacogenomics). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).

Agents, or modulators which have a stimulatory or inhibitory effect on ABC1 biological activity or gene expression can be administered to individuals to treat disorders (e.g., cardiovascular disease or low HDL cholesterol) associated with aberrant ABC1 activity. In conjunction with such treatment, the

25

5

pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in efficacy of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of ABC1 protein, expression of ABC1 nucleic acid, or mutation content of ABC1 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983-985, 1996; Linder, M. W., Clin. Chem., 43:254-266, 1997). In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). Altered drug action may occur in a patient having a polymorphism (e.g., an single nucleotide polymorphism or SNP) in promoter, intronic, or exonic sequences of ABC1. Thus by determining the presence and prevalence of polymorphisms allow for prediction of a patient's response to a particular therapeutic agent. In particular, polymorphisms in the promoter region may be critical in determining the risk of HDL deficiency and CVD.

25

5

In addition to the mutations in the *ABC1* gene described herein, we have detected polymorphisms in the human *ABC1* gene (Fig. 11). These polymorphisms are located in promoter, intronic, and exonic sequence of ABC1. Using standard methods, such as direct sequencing, PCR, SSCP, or any other polymorphism-detection system, one could easily ascertain whether these polymorphisms are present in a patient prior to the establishment of a drug treatment regimen for a patient having low HDL, cardiovascular disease, or any other ABC1-mediated condition. It is possible that some these polymorphisms are, in fact, weak mutations. Individuals harboring such mutations may have an increased risk for cardiovascular disease; thus, these polymorphisms may also be useful in diagnostic assays.

<u>Association Studies of ABC1 Gene Variants and HDL Levels or Cardiovascular</u> <u>Disease</u>

The following polymorphisms have been examined for their effect on cholesterol regulation and the predisposition for the development of cardiovascular disease.

Substitution of G for A at nucleotide -1045 [G(-1045)A]. This variant is in complete linkage disequilibrium with the variant at -738 in the individuals we have sequenced, and thus any potential phenotypic effects currently attributed to the variant at -738 may at least in part be due to changes at this site.

Substitution of G for A at nucleotide -738 [G(-738)A]. This variant has been found at very high frequencies in populations selected for low HDL cholesterol or premature coronary artery disease.

Insertion of a G nucleotide at position -4 [G ins (-4)]. This variant has been associated with less coronary artery disease in its carriers than in non-carriers.

25

5

Substitution of a C for G at nucleotide -57 [G(-57)C]. This variant is in complete linkage disequilibrium with the variant at -4 in the individuals we have sequenced, and thus the phenotypic effects currently attributed to the variant at -4 may at least in part be due to changes at this site.

Substitution of A for G at nucleotide 730 (R219K). We have found carriers to have significantly less cardiovascular disease.

Substitution of C for T at nucleotide 1270 (V399A). Within the French Canadian population, this variant has only been found in individuals from the low HDL population. It has also been seen in individuals with low HDL or premature coronary artery disease in individuals of Dutch ancestry.

Substitution of A for G at nucleotide 2385 (V771M). This variant has been found at an increased frequency in a Dutch population selected for low HDL and at an increased frequency in a population selected for premature coronary artery disease compared to a control Dutch population, indicating carriers of this variant may have reduced HDL and an increased susceptibility to coronary artery disease.

Substitution of C for A at nucleotide 2394 (T774P). This variant has been seen at lower frequencies in populations with coronary artery disease or low HDL than in individuals without.

Substitution of C for G at nucleotide 2402 (K776N). This variant has been found at a significantly lower frequency (0.56% vs. 2.91%, p=0.02) in a coronary artery disease population vs. a control population of similar Dutch background.

Substitution of C for G at nucleotide 3590 (E1172D). This variant is seen at lower frequencies in individuals with low HDL and in some populations with premature coronary artery disease.

Substitution of A for G at nucleotide 4384 (R1587K). This variant has been found at decreased frequencies in the 1/3 of individuals with the highest HDL

25

5

levels in our large Dutch coronary artery disease population (p=0.036), at increased frequencies in those with HDL cholesterol <0.9 mmol/L (p<0.0001) and at decreased frequencies in the cohorts with HDL cholesterol >1.4 mmol/L in both this population (p=0.02) and the Dutch control population (p=0.003).

Substitution of G for C at nucleotide 5266 (S1731C). Two FHA individuals who have this variant on the other allele have much lower HDL cholesterol (0.155±0.025) than the FHA individuals in the family who do not have this variant on the other allele (0.64±0.14, p=0.0009). This variant has also been found in one general population French Canadian control with HDL at the 8th percentile (0.92) and one French Canadian individual from a population selected for low HDL and coronary disease (0.72).

Substitution of G for A at nucleotide -1113 [A(-1113)G]. This variant has been seen at varying frequencies in populations distinguished by their HDL levels.

Additional polymorphisms that may be associated with altered risk for cardiovascular disease or altered cholesterol levels are as follows:

Substitution of G for A at nucleotide 2723 (1883M). This variant has been seen at a much higher frequency in individuals of Dutch ancestry with premature coronary artery disease.

Insertion of 4 nucleotides (CCCT) at position -1181.

Substitution of C for A at nucleotide -479 (linkage disequilibrium with -518).

Substitution of G for A at nucleotide -380.

Other Embodiments

All publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication was specifically

and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations following, in general, the principles of the invention and including such departures from the present disclosure within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

What we claim is:

25

- 1. A substantially pure ABC1 polypeptide having ABC1 biological activity.
- 2. The substantially pure ABC1 polypeptide of claim 1, wherein said ABC1 polypeptide is human ABC1.
 - 3. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.
 - 4. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 61 to 2261 of SEQ ID NO: 1.
 - 5. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 2261 of SEQ ID NO: 1.
 - 6. A substantially pure ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1.
 - 7. A substantially pure ABC1 polypeptide comprising amino acids 61 to 2261 of SEQ ID NO: 1.
 - 8. A substantially pure ABC1 polypeptide comprising amino acids 1 to 2261 of SEQ ID NO: 1.
 - 9. A substantially pure nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a

25

5

polypeptide having ABC1 biological activity.

- 10. A substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.
- 11. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 254 of SEQ ID NO: 2.
- 12. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 255 to 6857 of SEQ ID NO: 2.
- 13. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 6857 of SEQ ID NO: 2.
 - 14. An expression vector comprising the nucleic acid molecule of claim 9.
 - 15. A cell expressing the nucleic acid molecule of claim 9.
 - 16. A non-human mammal expressing the nucleic acid molecule of claim 9.
- 17. A substantially pure nucleic acid molecule comprising nucleotides 75 to 254 of SEQ ID NO: 2.
- 18. A substantially pure nucleic acid molecule comprising nucleotides 255 to 6857 of SEQ ID NO: 2.

25

- 19. A substantially pure nucleic acid molecule comprising nucleotides 75 to 6857 of SEQ ID NO: 2.
- 20. A substantially pure nucleic acid molecule comprising at least thirty consecutive nucleotides corresponding to nucleotides 7015-7860 of SEQ ID NO: 2.
- 21. The substantially pure nucleic acid molecule of claim 20, wherein said nucleic acid molecule comprises nucleotides 7015-7860 of SEQ ID NO: 2.
- 22. A substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.
- 23. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human an ABC1 polypeptide, or cholesterol-regulating fragment thereof.
- 24. The method of claim 23, wherein said ABC1 polypeptide has the sequence of SEQ ID NO: 1.
- 25. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its stability.
- 26. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.

27. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human a nucleic acid molecule encoding an ABC1 polypeptide or a cholesterol-regulating fragment thereof.

5

28. The method of claim 27, wherein said ABC1 polypeptide has the amino acid sequence of SEQ ID NO: 1.

- 29. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its stability.
- 30. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.
- 31. The method of claim 30, wherein said biological activity is regulation of cholesterol.

20

32. The method of claim 27, wherein said human has low HDL cholesterol levels relative to normal.

33. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity.

25

- 34. The method of claim 33, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.
- 35. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a compound that increases ABC1 biological activity.
- 36. The method of claim 35, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.
- 37. A method of preventing cardiovascular disease in a human, said method comprising administering to said human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter, said *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.
- 38. A method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene in a human, said method comprising introducing into said human an expression vector comprising a promoter operably linked to an *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.
- 39. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that

25

5

mimics the activity of wild-type ABC1.

- 40. The method of claim 39, wherein said animal is a human.
- 41. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that modulates the biological activity of ABC1.
 - 42. The method of claim 41, wherein said animal is a human.
 - 43. The method of claim 41, wherein said compound is selected from a group consisting of protein kinase A, protein kinase C, vanadate, okadaic acid, IBMX1, fibrates, β-estradiol, arachidonic acid derivatives, WY-14,643, LTB4, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.
 - 44. The method of claim 23, 27, 39, or 41, wherein said cardiovascular disease is coronary artery disease, cerebrovascular disease, coronary restenosis, or peripheral vascular disease.
 - 45. A method for determining whether a candidate compound is useful for modulating cholesterol levels, said method comprising the steps of:
 - (a) providing a chicken comprising a mutation in an ABC1 gene;
 - (b) administering said candidate compound to said chicken; and

25

- (c) measuring ABC1 biological activity in said chicken, wherein altered ABC1 biological activity, relative to a WHAM chicken not contacted with said compound, indicates that said candidate compound modulates cholesterol levels.
- 46. The method of claim 45, wherein said ABC1 biological activity is transport of cholesterol.
- 47. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:
- (a) providing a cell expressing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;
 - (b) contacting said cell with said candidate compound; and
- (c) measuring ABC1 biological activity of said cell, wherein altered ABC1 biological activity, relative to a cell not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.
- 48. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:
- (a) providing a cell expressing an *ABC1* gene comprising nucleotides 75 to 254 of SEQ ID NO: 2;
 - (b) contacting said cell with said candidate compound; and
 - (c) measuring ABC1 expression of said cell,
- wherein altered ABC1 expression, relative to a cell not contacted with said

25

5

compound, indicates that said candidate compound modulates ABC1 expression.

- 49. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:
- (a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene;
- (b) contacting said nucleic acid molecule with said candidate compound; and
- (c) measuring expression of said reporter gene,
 wherein altered reporter gene expression, relative to a control not contacted with
 said compound, indicates that said candidate compound modulates ABC1
 expression.
- 50. The method of claim 49, wherein said promoter comprises 50 consecutive nucleotides selected from nucleotides 1 to 8238 of SEQ ID NO: 14.
- 51. The method of claim 50, wherein said promoter comprises a binding site for a transcription factor selected from a group consisting of steroid response element binding proteins, peroxisomal proliferation-activated receptors, retinoid X receptors, and RAR-related orphan receptors.
- 52. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:
- (a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

- (b) contacting said polypeptide with said candidate compound; and
- (c) measuring ABC1 biological activity,

wherein a change in ABC1 biological activity, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.

- 53. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:
- (a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;
 - (b) contacting said polypeptide with said candidate compound; and
- (c) measuring expression of said ABC1 polypeptide, wherein a change in expression of said ABC1 polypeptide, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.
- 54. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:
- (a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;
 - (b) contacting said polypeptide with said candidate compound; and
- (c) measuring binding of said ABC1 polypeptide to said candidate compound, wherein binding of said ABC1 polypeptide to said compound indicates that said candidate compound modulates ABC1 biological activity.

25

25

- 55. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:
- (a) providing (i) an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1, and (ii) a second polypeptide that interacts with said ABC1 polypeptide;
 - (b) contacting said polypeptides with said candidate compound; and
- (c) measuring interaction of said ABC1 polypeptide with said second polypeptide, wherein an alteration in the interaction of said ABC1 polypeptide with said second polypeptide indicates that said candidate compound modulates ABC1 biological activity.
- 56. A method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide, said method comprising the steps of:
- (a) providing a cell comprising an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;
 - (b) contacting said cell with said candidate compound; and
- (c) measuring the half-life of said ABC1 polypeptide, wherein an increase in said half-life, relative to a control not contacted with said compound, indicates that said candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide.
- 57. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:
 - (a) providing an ABC1 polypeptide in a lipid membrane;

58. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1 polypeptide is in a cell-free system.

5

10

15

20

- 59. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1 polypeptide is in a cell.
 - 60. The method of claim 59, wherein said cell is from a WHAM chicken.
- 61. The method of claim 59, wherein said cell is in a human or in a non-human mammal.
 - 62. The method of claim 61, wherein said animal is a WHAM chicken.
- 63. The method of claim 52, wherein said biological activity is transport of lipid or interleukin-1.
 - 64. The method of claim 62, wherein said lipid is cholesterol.
 - 65. The method of claim 64, wherein said cholesterol is HDL-cholesterol.

25

- 66. The method of claim 52, wherein said biological activity is binding or hydrolysis of ATP by the ABC1 polypeptide.
- 67. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising determining whether an *ABC1* gene of said patient has a mutation, wherein a mutation indicates that said patient has an increased risk for cardiovascular disease.
- 68. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 biological activity in said patient or in a cell from said patient, wherein increased or decreased levels in said ABC1 biological activity, relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.
- 69. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 expression in said patient or in a cell from said patient, wherein decreased levels in said ABC1 expression relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.
- 70. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of ABC1 polypeptide.
- 71. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of *ABC1* RNA.

25

- 72. A non-human mammal comprising a transgene comprising a nucleic acid molecule encoding a dominant-negative ABC1 polypeptide.
- 73. A cell isolated from a non-human mammal comprising a transgene comprising a nucleic acid molecule encoding an ABC1 polypeptide having biological activity.
- 74. A method for determining whether a candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide, said method comprising the steps of:
 - (a) providing a cell expressing a dominant-negative ABC1 polypeptide;
 - (b) contacting said cell with said candidate compound; and
- (c) measuring ABC1 biological activity of said cell, wherein an increase in said ABC1 biological activity, relative to a cell not contacted with said compound, indicates that said candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.
- 75. A method for determining whether a person has an altered risk for developing cardiovascular disease, comprising examining the person's ABC1 gene for polymorphisms, wherein the presence of a polymorphism associated with cardiovascular disease indicates the person has an altered risk for developing cardiovascular disease.
- 76. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 gene that alters

25

5

the person's response to said drug.

- 77. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 promoter that alters the person's response to said drug.
- 78. A method for altering ABC1 expression in a cell, said method comprising contacting said cell with a compound selected from a group consisting of fibrates, β-estradiol, arachidonic acid derivatives, WY-14,643, LTB4, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.
- 79. A pharmaceutical composition comprising (i) a nucleic acid molecule that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity; and (ii) a pharmaceutically acceptable carrier.
- 80. A nucleic acid that hybridizes under high stringency conditions to nucleotides 1 to 8236 of SEQ ID NO: 14.
- 81. A nucleic acid comprising a region that is 80% identical to at least thirty contiguous nucleotides of nucleotides 1 to 8236 of SEQ ID NO: 14.
- 82. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

- (a) providing an ABC1 polypeptide;
- (b) contacting said polypeptide with cholesterol and said candidate compound; and
- (c) measuring binding of said cholesterol to said ABC1 polypeptide, wherein binding of said cholesterol to said ABC1 polypeptide indicates that said candidate compound modulates ABC1 biological activity.
 - 83. The method of claim 82, wherein said cholesterol is HDL cholesterol.
- 84. The method of claim 82, wherein said method is performed in a cell free assay.
- 85. The method of claim 82, wherein said ABC1 polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.
- 86. the method of claim 82, wherein said cholesterol or said ABC1 polypeptide is detectably labeled.

METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

Abstract of the Disclosure

The invention features ABC1 nucleic acids and polypeptides for the
diagnosis and treatment of abnormal cholesterol regulation. The invention also
features methods for identifying compounds for modulating cholesterol levels in
an animal (e.g., a human).

50110.002005 AmendedApplication.wpd




Fig. 1 4







Fig. 1B

Fig. 1C












Fig. 2C





Exon 30 mutation:





Fig. 4A



Fig. 4B






Fig. 4D

C A1864G (Q597R) Ö ე ე C . A Ö ල CCTACTT Family TD - 2, patient IV:10 Exon 13 mutation: ပ Control 1854 G

Fig. 5A

1867




Fig. 5B

Fig. 5C

Exon 14: FI-IA - 1, patient III:01




Fig. 6A




Fig. 6B




Fig. 6C

Exon 41: FHA - 3, patient III:01





Fig. 6D



Exon 48 mutation:







Fig. 6F



% Cholesterol Efflux



the live of the least term made the least the






Fig. 8

SEQ ID NO: 1

MACWPQLRLLLWKNLTFRRRQTCQLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKAMPSAGTLPWVQ GIICNANNPCFRYPTPGEAPGVVGNFNKSIVARLFSDARRLLLYSQKDTSMKDMRKVLRTLQQIKKSSSNL KLODFLVDNETFSGFLYHNLSLPKSTVDKMLRADVILHKVFLOGYOLHLTSLCNGSKSEEMIOLGDOEVSE LCGLPREKLAAAERVLRSNMDILKPILRTLNSTSPFPSKELAEATKTLLHSLGTLAQELFSMRSWSDMRQE VMFLTNVNSSSSSTQIYQAVSRIVCGHPEGGGLKIKSLNWYEDNNYKALFGGNGTEEDAETFYDNSTTPYC NDLMKNLESSPLSRIIWKALKPLLVGKILYTPDTPATRQVMAEVNKTFQELAVFHDLEGMWEELSPKIWTF MENSOEMDLVRMLLDSRDNDHFWEQQLDGLDWTAQDIVAFLAKHPEDVOSSNGSVYTWREAFNETNOAIRT ISRFMECVNLNKLEPIATEVWLINKSMELLDERKFWAGIVFTGITPGSIELPHHVKYKIRMDIDNVERTNK IKDGYWDPGPRADPFEDMRYVWGGFAYLQDVVEQAIIRVLTGTEKKTGVYMQQMPYPCYVDDIFLRVMSRS MPLFMTLAWIYSVAVIIKGIVYEKEARLKETMRIMGLDNSILWFSWFISSLIPLLVSAGLLVVILKLGNLL PYSDPSVVFVFLSVFAVVTILQCFLISTLFSRANLAAACGGIIYFTLYLPYVLCVAWQDYVGFTLKIFASL LSPVAFGFGCEYFALFEEQGIGVQWDNLFESPVEEDGFNLTTSVSMMLFDTFLYGVMTWYIEAVFPGQYGI PRPWYFPCTKSYWFGEESDEKSHPGSNOKRISEICMEEEPTHLKLGVSIONLVKVYRDGMKVAVDGLALNF YEGQITSFLGHNGAGKTTTMSILTGLFPPTSGTAYILGKDIRSEMSTIRONLGVCPOHNVLFDMLTVEEHI WFYARLKGLSEKHVKAEMEQMALDVGLPSSKLKSKTSQLSGGMQRKLSVALAFVGGSKVVILDEPTAGVDP YSRRGIWELLLKYRQGRTIILSTHHMDEADVLGDRIAIISHGKLCCVGSSLFLKNQLGTGYYLTLVKKDVE SSLSSCRNSSSTVSYLKKEDSVSQSSSDAGLGSDHESDTLTIDVSAISNLIRKHVSEARLVEDIGHELTYV LPYEAAKEGAFVELFHEIDDRLSDLGISSYGISETTLEEIFLKVAEESGVDAETSDGTLPARRNRRAFGDK OSCLRPFTEDDAADPNDSDIDPESRETDLLSGMDGKGSYQVKGWKLTQQQFVALLWKRLLIARRSRKGFFA OIVLPAVFVCIALVFSLIVPPFGKYPSLELQPWMYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCME GNPIPDTPCQAGEEEWTTAPVPQTIMDLFQNGNWTMQNPSPACQCSSDKIKKMLPVCPPGAGGLPPPORKO NTADILODLTGRNISDYLVKTYVQIIAKSLKNKIWVNEFRYGGFSLGVSNTQALPPSQEVNDAIKOMKKHL KLAKDSSADRFLNSLGRFMTGLDTRNNVKVWFNNKGWHAISSFLNVINNAILRANLOKGENPSHYGITAFN HPLNLTKQQLSEVALMTTSVDVLVSICVIFAMSFVPASFVVFLIQERVSKAKHLQFISGVKPVIYWLSNFV WDMCNYVVPATLVIIIFICFOOKSYVSSTNLPVLALLLLLYGWSITPLMYPASFVFKIPSTAYVVLTSVNL FIGINGSVATFVLELFTDNKLNNINDILKSVFLIFPHFCLGRGLIDMVKNQAMADALERFGENRFVSPLSW DLVGRNLFAMAVEGVVFFLITVLIQYRFFIRPRPVNAKLSPLNDEDEDVRRERQRILDGGGQNDILEIKEL TKIYRRKRKPAVDRICVGIPPGECFGLLGVNGAGKSSTFKMLTGDTTVTRGDAFLNKNSILSNIHEVHONM GYCPOFDAITELLTGREHVEFFALLRGVPEKEVGKVGEWAIRKLGLVKYGEKYAGNYSGGNKRKLSTAMAL IGGPPVVFLDEPTTGMDPKARRFLWNCALSVVKEGRSVVLTSHSMEECEALCTRMAIMVNGRFRCLGSVOH LKNRFGDGYTIVVRIAGSNPDLKPVQDFFGLAFPGSVLKEKHRNMLQYQLPSSLSSLARIFSILSQSKKRL HIEDYSVSOTTLDOVFVNFAKDOSDDDHLKDLSLHKNQTVVDVAVLTSFLODEKVKESYV*

Fig. 9A

SEQ ID NO: 2

GTCCCTGCTGTGAGCTCTGGCCGCTGCCTTCCAGGGCTCCCGAGCCACACGCTGGGGGTG CTGGCTGAGGGAACATGGCTTGTTGGCCTCAGCTGAGGTTGCTGCTGTGGAAGAACCTCA CTTTCAGAAGAAGACAACATGTCAGCTGTTACTGGAAGTGGCCTGGCCTCTATTTATCT TCCTGATCCTGATCTCTGTTCGGCTGAGCTACCCACCCTATGAACAACATGAATGCCATT TTCCAAATAAAGCCATGCCCTCTGCAGGAACACTTCCTTGGGTTCAGGGGATTATCTGTA ATGCCAACACCCCTGTTTCCGTTACCCGACTCCTGGGGAGGCTCCCGGAGTTGTTGGAA ACTTTAACAAATCCATTGTGGCTCGCCTGTTCTCAGATGCTCGGAGGCTTCTTTTATACA GCCAGAAAGACACCAGCATGAAGGACATGCGCAAAGTTCTGAGAACATTACAGCAGATCA AGAAATCCAGCTCAAACTTGAAGCTTCAAGATTTCCTGGTGGACAATGAAACCTTCTCTG GGTTCCTGTATCACAACCTCTCTCTCCCAAAGTCTACTGTGGACAAGATGCTGAGGGCTG ATGTCATTCTCCACAGGTATTTTTGCAAGGCTACCAGTTACATTTGACAAGTCTGTGCA ATGGATCAAAATCAGAAGAGATGATTCAACTTGGTGACCAAGAAGTTTCTGAGCTTTGTG GCCTACCAAGGGAGAAACTGGCTGCAGCAGAGCGAGTACTTCGTTCCAACATGGACATCC AAGCCACAAAAACATTGCTGCATAGTCTTGGGACTCTGGCCCAGGAGCTGTTCAGCATGA GAAGCTGGACTGCACAGGAGGTGATGTTTCTGACCAATGTGAACAGCTCCAGCT GGCTGAAGATCAAGTCTCTCAACTGGTATGAGGACAACAACTACAAAGCCCTCTTTGGAG GCAATGGCACTGAGGAAGATGCTGAAACCTTCTATGACAACTCTACAACTCCTTACTGCA ATGATTTGATGAAGAATTTGGAGTCTAGTCCTCTTTCCCGCATTATCTGGAAAGCTCTGA AGCCGCTGCTCGTTGGGAAGATCCTGTATACACCTGACACTCCAGCCACAAGGCAGGTCA TGGCTGAGGTGAACAAGACCTTCCAGGAACTGGCTGTGTTCCATGATCTGGAAGGCATGT GGGAGGAACTCAGCCCCAAGATCTGGACCTTCATGGAGAACAGCCAAGAAATGGACCTTG TCCGGATGCTGTTGGACAGCAGGGACAATGACCACTTTTGGGAACAGCAGTTGGATGGCT TAGATTGGACAGCCCAAGACATCGTGGCGTTTTTGGCCAAGCACCCAGAGGATGTCCAGT CCAGTAATGGTTCTGTGTACACCTGGAGAGAGCTTTCAACGAGACTAACCAGGCAATCC GGACCATATCTCGCTTCATGGAGTGTCTCAACCTGAACAAGCTAGAACCCATAGCAACAG AAGTCTGGCTCATCAACAAGTCCATGGAGCTGCTGGATGAGAGGAAGTTCTGGGCTGGTA TTGTGTTCACTGGAATTACTCCAGGCAGCATTGAGCTGCCCCATCATGTCAAGTACAAGA TCCGAATGGACATTGACAATGTGGAGAGGACAAATAAAATCAAGGATGGGTACTGGGACC TGCAGGATGTGGTGGAGCAGCAATCATCAGGGTGCTGACGGGCACCGAGAAGAAACTG GTGTCTATATGCAACAGATGCCCTATCCCTGTTACGTTGATGACATCTTTCTGCGGGTGA TGAGCCGGTCAATGCCCCTCTTCATGACGCTGGCCTGGATTTACTCAGTGGCTGTGATCA TCAAGGGCATCGTGTATGAGAAGGAGGCACGGCTGAAAGAGACCATGCGGATCATGGGCC TGGACAACAGCATCCTCTGGTTTAGCTGGTTCATTAGTAGCCTCATTCCTCTTCTTGTGA GCGCTGGCCTGCTAGTGGTCATCCTGAAGTTAGGAAACCTGCTGCCCTACAGTGATCCCA GCGTGGTGTTTGTCTTCCTGTCCGTGTTTGCTGTGGTGACAATCCTGCAGTGCTTCCTGA TTAGCACACTCTTCTCCAGAGCCAACCTGGCAGCCTGTGGGGGGCATCATCTACTTCA CGCTGTACCTGCCCTACGTCCTGTGTGTGGCATGGCAGGACTACGTGGGCTTCACACTCA AGATCTTCGCTAGCCTGCTGTCTCCTGTGGCTTTTGGGTTTGGCTGTGAGTACTTTGCCC TTTTTGAGGAGCAGGGCATTGGAGTGCAGTGGGACAACCTGTTTGAGAGTCCTGTGGAGG AAGATGGCTTCAATCTCACCACTTCGGTCTCCATGATGCTGTTTGACACCTTCCTCTATG GGGTGATGACCTGGTACATTGAGGCTGTCTTTCCAGGCCAGTACGGAATTCCCAGGCCCT GGTATTTTCCTTGCACCAAGTCCTACTGGTTTGGCGAGGAAAGTGATGAGAAGAGCCACC AGCTGGGCGTGTCCATTCAGAACCTGGTAAAAGTCTACCGAGATGGGATGAAGGTGGCTG GAGCGGGGAAGACGACCACGTGTCAATCCTGACCGGGTTGTTCCCCCCGACCTCGGGCA CCGCCTACATCCTGGGAAAAGACATTCGCTCTGAGATGAGCACCATCCGGCAGAACCTGG GGGTCTGTCCCCAGCATAACGTGCTGTTTGACATGCTGACTGTCGAAGAACACATCTGGT TCTATGCCCGCTTGAAAGGGCTCTCTGAGAAGCACGTGAAGGCGGAGATGGAGCAGATGG CCCTGGATGTTGGTTTGCCATCAAGCAAGCTGAAAAGCAAAACAAGCCAGCTGTCAGGTG GAATGCAGAGAAAGCTATCTGTGGCCTTTGTCGGGGGGATCTAAGGTTGTCATTC TGGATGAACCCACAGCTGGTGTGGACCCTTACTCCCGCAGGGGAATATGGGAGCTGCTGC TGAAATACCGACAAGGCCGCACCATTATTCTCTCTACACACCACATGGATGAAGCGGACG TCCTGGGGGACAGGATTGCCATCATCTCCCATGGGAAGCTGTGCTGTGTGGGCTCCTCCC AATCCTCCCTCAGTTCCTGCAGAAACAGTAGTAGCACTGTGTCATACCTGAAAAAGGAGG ACAGTGTTTCTCAGAGCAGTTCTGATGCTGGCCTGGGCAGCGACCATGAGAGTGACACGC TGACCATCGATGTCTCTGCTATCTCCAACCTCATCAGGAAGCATGTGTCTGAAGCCCGGC TGGTGGAAGACATAGGGCATGAGCTGACCTATGTGCTGCCATATGAAGCTGCTAAGGAGG GAGCCTTTGTGGAACTCTTTCATGAGATTGATGACCGGCTCTCAGACCTGGGCATTTCTA GTTATGGCATCTCAGAGACGACCCTGGAAGAAATATTCCTCAAGGTGGCCGAAGAGAGTG GGGTGGATGCTGAGACCTCAGATGGTACCTTGCCAGCAAGACGAAACAGGCGGGCCTTCG GGGACAAGCAGAGCTGTCTTCGCCCGTTCACTGAAGATGATGCTGCTGATCCAAATGATT

Fig. 9C

CCTACCAGGTGAAAGGCTGGAAACTTACACAGCAACAGTTTGTGGCCCTTTTGTGGAAGA GACTGCTAATTGCCAGACGGAGTCGGAAAGGATTTTTTGCTCAGATTGTCTTGCCAGCTG TGTTTGTCTGCATTGCCCTTGTGTTCAGCCTGATCGTGCCACCCTTTGGCAAGTACCCCA GCCTGGAACTTCAGCCCTGGATGTACAACGAACAGTACACATTTGTCAGCAATGATGCTC CTGAGGACACGGGAACCCTGGAACTCTTAAACGCCCTCACCAAAGACCCTGGCTTCGGGA GGACCACTGCCCCAGTTCCCCAGACCATCATGGACCTCTTCCAGAATGGGAACTGGACAATGCAGAACCCTTCACCTGCATGCCAGTGTAGCAGCGACAAAATCAAGAAGATGCTGCCTG TGTGTCCCCCAGGGGCAGGGGGGCTGCCTCCTCCACAAAGAAAACAAAACACTGCAGATA TCCTTCAGGACCTGACAGGAAGAACATTTCGGATTATCTGGTGAAGACGTATGTGCAGA TCATAGCCAAAAGCTTAAAGAACAAGATCTGGGTGAATGAGTTTAGGTATGGCGGCTTTT CCCTGGGTGTCAGTAATACTCAAGCACTTCCTCCGAGTCAAGAAGTTAATGATGCCATCA AACAAATGAAGAAACACCTAAAGCTGGCCAAGGACAGTTCTGCAGATCGATTTCTCAACA GCTTGGGAAGATTTATGACAGGACTGGACACCAGAAATAATGTCAAGGTGTGGTTCAATA ACAAGGGCTGGCATGCAATCAGCTCTTTCCTGAATGTCATCAACAATGCCATTCTCCGGG CCAACCTGCAAAAGGGAGAGAACCCTAGCCATTATGGAATTACTGCTTTCAATCATCCCC TGAATCTCACCAAGCAGCAGCTCTCAGAGGTGGCTCTGATGACCACATCAGTGGATGTCC TGATCCAGGAGCGGTCAGCAAAGCAAAACACCTGCAGTTCATCAGTGGAGTGAAGCCTG TCATCTACTGGCTCTCTAATTTTGTCTGGGATATGTGCAATTACGTTGTCCCTGCCACAC TGGTCATTATCATCTTCATCTGCTTCCAGCAGAGTCCTATGTGTCCTCCACCAATCTGC $\tt CTGTGCTAGCCCTTCTACTTTTGCTGTATGGGTGGTCAATCACACCTCTCATGTACCCAG$ CCTCCTTTGTGTTCAAGATCCCCAGCACAGCCTATGTGGTGCTCACCAGCGTGAACCTCT TCATTGGCATTAATGGCAGCGTGGCCACCTTTGTGCTGGAGCTGTTCACCGACAATAAGC TGAATAATATCAATGATATCCTGAAGTCCGTGTTCTTGATCTTCCCACATTTTTGCCTGG GACGAGGGCTCATCGACATGGTGAAAAACCAGGCAATGGCTGATGCCCTGGAAAGGTTTG GGGAGAATCGCTTTGTGTCACCATTATCTTGGGACTTGGTGGGACGAAACCTCTTCGCCA TGGCCGTGGAAGGGGTGTTCTTCCTCATTACTGTTCTGATCCAGTACAGATTCTTCA TCAGGCCCAGACCTGTAAATGCAAAGCTATCTCCTCTGAATGATGAAGATGAAGATGTGA GGCGGGAAAGACAGAATTCTTGATGGTGGAGGCCAGAATGACATCTTAGAAATCAAGG AGTTGACGAAGATATATAGAAGGAAGCGGAAGCCTGCTGTTGACAGGATTTGCGTGGGCA TTCCTCCTGGTGAGTGCTTTGGGCTCCTGGGAGTTAATGGGGCTGGAAAATCATCAACTT TCAAGATGTTAACAGGAGATACCACTGTTACCAGAGGAGATGCTTTCCTTAACAAAAATA

Fig. 9D

GTATCTTATCAAACATCCATGAAGTACATCAGAACATGGGCTACTGCCCTCAGTTTGATG CCATCACAGAGCTGTTGACTGGGAGAGAACACGTGGAGTTCTTTGCCCTTTTGAGAGGAG TCCCAGAGAAGAAGTTGGCAAGGTTGGTGAGTGGGCGATTCGGAAACTGGGCCTCGTGA AGTATGGAGAAAATATGCTGGTAACTATAGTGGAGGCAACAAACGCAAGCTCTCTACAG CCATGGCTTTGATCGGCGGCCTCCTGTGGTGTTTCTGGATGAACCCACCACAGGCATGG ATCCCAAAGCCCGGCGGTTCTTGTGGAATTGTGCCCTAAGTGTTGTCAAGGAGGGGAGAT CAGTAGTGCTTACATCTCATAGTATGGAAGAATGTGAAGCTCTTTGCACTAGGATGGCAA TCATGGTCAATGGAAGGTTCAGGTGCCTTGGCAGTGTCCAGCATCTAAAAAATAGGTTTG GAGATGGTTATACAATAGTTGTACGAATAGCAGGGTCCAACCCGGACCTGAAGCCTGTCC AGGATTTCTTTGGACTTGCATTTCCTGGAAGTGTTCTAAAAGAGAAACACCGGAACATGC TACAATACCAGCTTCCATCTTCATTATCTTCTCTGGCCAGGATATTCAGCATCCTCTCCC AGAGCAAAAAGCGACTCCACATAGAAGACTACTCTGTTTCTCAGACAACACTTGACCAAG TATTTGTGAACTTTGCCAAGGACCAAAGTGATGACCACTTAAAAGACCTCTCATTAC ACAAAAACCAGACAGTAGTGGACGTTGCAGTTCTCACATCTTTTCTACAGGATGAGAAAG TGAAAGAAGCTATGTATGAAGAATCCTGTTCATACGGGGTGGCTGAAAGTAAAGAGGAA CTAGACTTTCCTTTGCACCATGTGAAGTGTTGTGGAGAAAAAAAGAGCCAGAAGTTGATGTGG GAAGAAGTAAACTGGATACTGTACTGATACTATTCAATGCAATGCAATTCAATGCAATGA AAACAAAATTCCATTACAGGGGCAGTGCCTTTGTAGCCTATGTCTTGTATGGCTCTCAAG TGAAAGACTTGAATTTAGTTTTTTACCTATACCTATGTGAAACTCTATTATGGAACCCAA GGGGTTGCAACAATAATTCATCAAGTAATCATGGCCAGCGATTATTGATCAAAATCAAAA GGTAATGCACATCCTCATTCACTAAGCCATGCCATGCCCAGGAGACTGGTTTCCCGGTGA CACATCCATTGCTGGCAATGAGTGTGCCAGAGTTATTAGTGCCAAGTTTTTCAGAAAGTT TGAAGCACCATGGTGTCATGCTCACTTTTGTGAAAGCTGCTCTGCTCAGAGTCTATCA ACATTGAATATCAGTTGACAGAATGGTGCCATGCGTGGCTAACATCCTGCTTTGATTCCC TCTGATAAGCTGTTCTGGTGGCAGTAACATGCAACAAAAATGTGGGTGTCTCCAGGCACG GGAAACTTGGTTCCATTGTTATATTGTCCTATGCTTCGAGCCATGGGTCTACAGGGTCAT CCTTATGAGACTCTTAAATATACTTAGATCCTGGTAAGAGGCAAAGAATCAACAGCCAAA CTGCTGGGGCTGCAACTGCTGAAGCCAGGGCATGGGATTAAAGAGATTGTGCGTTCAAAC CTAGGGAAGCCTGTGCCCATTTGTCCTGACTGTCTGCTAACATGGTACACTGCATCTCAA GATGTTTATCTGACACAAGTGTATTATTTCTGGCTTTTTGAATTAATCTAGAAAATGAAA

Fig. 10

xorvintron	Nucleotide#	Amino acid		Parisana 4186 anno 12 anno 12	
-CIPHRION		Amino acid change		Sequence difference/context	SEQ ID NO:
2	T150C A152G		Public sequence Correct sequence:	TGTCAGCTGCTACTGGAAGTG3	168
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		concor ocquence.	in the second se	100
7	C839T	no change	Public sequence.	AGGAGCTGGCCGAAGCCACAA	170
			Correct sequence.	AGGAGCTGGCTGAAGCCACAA	171
22	0.700	+440F1			
33	C4738T		Public sequence:	AATGATGCCACCAAACAAATS	172
			Correct sequence.	AATGATGCCATCAAACAAAT3	:73
35	C5017T	P1588L	Public sequence:	GAGGTGGCTCCGATGACCACA	174
			Correct sequence:	GAGGTGGCTCTGATGACCACA	175
43	G5995A	R1914K	Public sequence:	TTCCTTAACAGAAATAGTATC	176
			Correct sequence:	TTCCTTAACAAAATAGTATC	177
48	C6577T	P2108L	Public sequence.	GGAAGTGTTCCAAAAGAGAAA	178
			Correct sequence.	GGAAGTGTTCTAAAAGAGAAA	179
			donical dequence.	32301011011011011011	
19	G6899A	not applicable	Public sequence:	AGTAAAGAGGGACTAGACTTT	180
			Correct sequence	AGTAAAGAGGAACTAGACTTT	: 181
tata a r					
tations:					SEQ ID NO:
:3	A1864G	Q597R	More common	GCCTACTTGCAGGATGTGGTS	182
			Less common	GCCTACTTGCGGGATGTGGTG	183
					100
14	delta CTT 2151-3	deltaL693	More common	CCTCATTCCTCTTCTGTGAGCG	184
			Less common	CCTCATTCCT/ CTTGTGAGC3	185
'5	G2385A	V771M	More common	GCAGGACTACGTGGGCTTCAC	186
			Less common	GCAGGACTACATGGGCTTCAC	187
18	C2799T	R909Stop	More common:	AAAAGTCTACCGAGATGGGAT	188
	027881	rtsosotop	Less common	AAAAGTCTACTGAGATGGGAT	189
			2000 GOMINGI		+
18	C2860T	T9291	More common	GGCCAGATCACCTCCTTCCTG	190
			Less common	GGCCAGATCATCTCCTTCCTC	191
_ ==	T3346C	M1091T	More common	ACACACCACATGGATGAAGCG	192
			Less common	ACACACCACGGATGAAGCG	193
Intron 24	(+1) G to C	Altered transcript	More common	CCTGGAAGAAGTAAGTTAAG.	194
	splice donor site	length	Less common	CCTGGAAGAACTAAGTTAAGT	195
30	T4503C	C1477R	More common	GCTGCCTGTGTCCCCCAGG	196
			Less common	GCTGCCTGTGCGTCCCCCAGG	197
35	00 1050 574- 0				
- 33	GG 4956-57 to C	Frameshift at aa1628	More common	TAGCCATTATGGAATTACTGCT TAGCCATTATCAATTACTGCT	198 199
		at aa 1028	Less common	TAGCCATTA.CAATTACTGC.	199
41	delta AAGATG 5752-7	delta(E D)1893-1894	More common	GATGAAGATGAAGATGTGAGGCGGGA	200
		DC.10(C.D)1000 1004	Less common	GATGAAGATG/TGAGGCGGGA	201
					1
48	C6504T	R2144Stop	More common	AATAGTTGTACGAATAGCAGG	202
			Less common:	AATAGTTGTATGAATAGCAGG	203
	1				
omoter Vari	iants: Position	Position	 		6FA IS 115
	Relative to	Relative to			SEQ ID NO:
	Xenon cDNA	SEQ ID NO: 14			5
	,	Containing			
		Exon 1			
			ļ. —		1
1	G57C	8216	More common	ACACGCTGGGGGTGCTGGCTG	204
		1	Less common	ACACGCTGGGCGTGCTGGCTG	205
5'	(-) 4 ins G	8158	More common	GACCAGCCACGGCGTCCCTG	206
	.,,	1	Less common	GACCAGCCACGGGCGTCCCTG	207
		T			1
5	A (-) 380 G	780	More common	CATTITCITAGAAAAGAGAGGT	208
		1	Less common	CATTITCT:AGAGAAGAGAGGT	209
5'	A / \ 430.0	7004	Mara as mara	CANAL TOTAL CONTRACTOR OF THE	
J	A (-) 479 C	7581	More common	GAAAATTAGTATGTAAGGAAG GAAAATTAGTCTGTAAGGAAG	210 211
******	·	1	Less common	ONMATING C. CINAGGANG	211
5,	A (-) 738 G	-422	More common	CCTCCGCCTGCCAGGTTCAGCGATT	212
	11,7,000		Less common	CCTCCGCCTGCCGGGTTCAGCGATT	213
					!
5'	A (-) 1045 G	115	More common	TATGTGCTGACCATGGGAGCTTGTT	214
	1	1	Less common	TATGTGCTGACCGTGGGAGCTTGTT	215
	A () *4*3 C	=047	Mara mar	GTGACACCCAACGGAGTAGGG	242
5	A (-) 1113 G	047	More common Less common	GTGACACCCAACGGAGTAGGG GTGACACCCAGCGGAGTAGGG	216
	1	1	pega cummityn	5-370/100000000000000000000000000000000000	211
5'	(-) 1181 ins CCCT	5979	More common	AGTATCCCT/TGTTCACGAGAA	218

Fig. 11

olymorphism: xon/Intron	Nucleotides	Amino acid change		Sequence difference/context	SEQ ID NO:
5	G548A	no change	More common	CTGGGTTCCTGTATCACAACC	220
			Less common.	CTGGGTTCCTATATCACAACC	221
6	G730A	R219K	More common.	GGCCTACCAAGGGAGAAACTG	222
		 	Less common	GGCCTACCAAAGGAGAAACTG	223
Intron 7	G (+) 2383 T	Not applicable	Allele 1		
	G (+) 2363 1	иот аррисавие	Allele 2	TTTAAAGGGGTGATTAGGA TTTAAAGGGGTTGATTAGGA	224
			PARCE Z	TTTAAAGGGGTTGATTAGGA	- 225
Intron 7	G (+) 3035 T	Not applicable	Allele 1	GAAGAAATTTGTTTTTTTGATT	226
			Allele 2	GAAGAAATTTTTTTTTTGA	227
					1
8	C1010T	no change	More common:	GCGGGCATCCCGAGGGAGGGG	228
			Less common	GCGGGCATCCTGAGGGAGGGG	229
8	G1022A	ing change			1
	GIUZZA	no change	More common Less common	AGGGAGGGGGCTGAAGATCA AGGGAGGGGACTGAAGATCA	230
			Less Common	AGGGGGGAC TGAAGA 1C4	231
Intron 9	(-) 42 ins G	Not applicable	More common	AGGAGCCAAACGCTCATTGT	232
			Less common	AGGAGCCAAAGCGCTCATTGT	233
Intron 13	T (+) 24 A	Not applicable	More common	AAGCCACTGTTTTTAACCACT	234
			Less common,	AAGCCACTGTATTTAACCAJT	235
15	A22040	T774P	Maria		
142	A2394C	11/45	More common.	CGTGGGCTTCACACTCAAGAT	236
·			Less common	CGTGGGCTTCCCACTCAAGAT	237
15	G2402C	K776N	More common	TCACACTCAAGATCTTCGCTG	238
			Less common	TCACACTCAACATCTTCGCTG	239
			32.38.001		,
Intron 14	C (+) 16 T	Not applicable	Allele 1	GCAGCCTCACCCGCTCTTCCC	240
			Altele 2	GCAGCCTCACTCGCTCTTCCC	241
17	402020	100214			
. 17	A2723G	1883M	Allele 1	AGAAGAGAATATCAGAAAT	242
			Allele 2	AGAAGAGAATGTCAGAAATCT	243
Intron 17	C (+) 2000 G	Not applicable	Allele 1	GCGCAGTGCCCTGTGTCCT73	244
	- 1 / 2000 5	107 400 0000	Allele 2	GCGCAGTGCGCTGTGTCCTTA	1 245
21	T3233G	по change	More common	GATCTAAGGTTGTCATTCTGG	246
			Less common	GATCTAAGGTGGTCATTCTGG	247
1-1					
Intron 21	G (+) 118 T	Not applicable	Allele 1	CTCTTCTGTTAGCACAGAACAGA	248
			Allele 2	CTCTTCTGTTATCACAGAACAGA	249
Intron 21	A (+) 563 G	Not apolicable	Allele 1	CATTCTAGGGATCATAGCCAT	250
			Allele 2	CATTCTAGGGGTCATAGCCAT	251
					20.
Intron 24	G (+) 321 T	Not applicable	Allele 1	AAGTACAGTGGGAGGAACAGCG	252
			Allele 2	AAGTACAGTGTGAGGAACAGCG	253
Intron 29	A () 824 C	Not opplestie	A 11-1- A		
II RIGITZS	A (-) 624 G	Not apolicable	Allele 1 Allele 2	ATTCCTAAAAAATAGAAATGCA ATTCCTAAAAAGTAGAAATCCA	254 255
			Allele 2	ATTCCTAMANGTAGAAA.CCA	255
Intron 31	T (+) 30 C	Not applicable	More common	GGCCCTGCCTTATTATTACT	256
			Less common	GGCCCTGCCGTATTATTACT	257
					1
Intron 33	A (+) 732 G	Not apolicable	Allele 1	TGAGAGAATTACTTGAACCCGG	258
		-	Allele 2	TGAGAGAATTGCTTGAACCCGG	259
intron 33	C (+) 898 T	Not acceptable	Allala 1	TTTGCTGAAACAATCACTGAC	
	C (+) dao 1	THE ALDRESON	Allele 1 Allele 2	TTTGCTGAAACAATCACTGAC	260 261
		- i			401
Intron 34	C (+) 234 T	Not acoucable	Allele 1	AACCTCAGTTCCCTCATCTGTG	262
			Allele 2	AACCTCAGTTTCCTCATCTGTG	263
34	G4834A	R1587K	More common	CTGGACACCAGAAATAATGTC	264
			Less common.	CTGGACACCAAAAATAATGTC	265
37	C5266G	S1731C	More commen	TCCTATGTGTCCTCCACCAT	
	~2000	<u> </u>	More common Less common	TCCTATGTGTCCTCCACCAAT	266 267
intron 43	T (+) 18 C	Not applicable	More common	AAGAAGTGGCTTGTATTTTGC	268
			Less common:	AAGAAGTGGCCTGTATTTTGC	269
ntmn 12	A (1) 1000 5	No.			
ntron 43	A (+) 1665 G	Not acoucable	Allele 1	AACTGATTTGATTGGTATAGCTC	270
			Allele 2	AACTGATTIGGTTGGTATAGCTC	271
	C6521T	no change	More common	CAGGGTCCAACCCGGACCTGA	272
48	200211		Less common	CAGGGTCCAATCCGGACCTGA	273
48		1			1
48				GCGTCAGGGATGGGGACAG	284
	(+) 14 ins T	Not applicable	More common		
	(+) 14 ins T		Mare common Less common	GCGTCAGGGATTGGGGACAG	285
Intron 10		1	Less common	GCGTCAGGGATTGGGGACAG	285
48 Intron 10	(+) 14 ins T		Less common More common	GCGTCAGGGATTGGGGACAG CCACTTCGGTCTCCATG	285
Intron 10		1	Less common	GCGTCAGGGATTGGGGACAG	285
exon 16	G2547A	V8251	Less common More common	GCGTCAGGGATTGGGGACAG CCACTTCGGTCTCCATG	285
Exon 16	G2547A	V8251	Less common More common Less common	GCGTCAGGGATTGGGGACAG CCACTTCGGTCTCCATG	285 286 287
Exon 16	G2547A	V8251	Less common More common Less common	GCGTCAGGGATTGGGGACAG CCACTTCGGTCTCCATG	285
Exon 16	G2547A	V8251	Less common More common Less common	GCGTCAGGGATTGGGGACAG CCACTTCGGTCTCCATG	285 286 287

Fig. 11
Page 2 of 2

Genomic contig containing ABC1 exon 1:

Underline = putitive promotor element

acctcttatagaatgatagaattcctctggaatgattggataacttcatttcatccttgacttttaccttggaggattt cttaccccttttggcttctcaaatttgactattaaaatgttgcctttaaaaataggaacacagtttcaggggggagtac cagcccatgacccttctgcaaggccccctaactcaaggtagtttccctggaactgtggtttatggaatgtttcaggagt gtgaggaggtataatttaaggctgtcctagcaaggatacccttaaggatagaggcccagtagcatctggaggccagaa aagttaaactgaggcagtcagattagcttcaggctcaattaagctgatgggtcagcctgggagaaattgcaggatgact ggtgtcttggccttcagtaaccttgttaggcttgtccctgaacgtggctaccgatccaaagacacatgatcagagaggc aattagagaacagaccttttccaaagcaagcatgttctgttgggcttagaagtttcatgtcctaatattataggaccct gtgcatctctctggagatgaggcacatgagtcatatctgtgattcttgcttttgtgtcaacatctcatgaataggcaat cagagetttggcaccaatgtattttcagttcatatctgatgtagttaaatccacctcctgctttgtagtttactggcaa gctgtttttgatataagacatctagaacactgtaaatatataacatttttatttgtctattatacctcaattacgaaaa agacatctagaagcaacctcatcaagagagatactgaggccgggcatggtagctcacacttgcaatcccattactttgg gaggetgaggeaggtagateacttgaggteaagagtttgaaaceagcetggeeaacatgttgaaaceetgtetetatta $\tt aaaatacaaaaaagttagctgggcttggtgggcacctgtaatcccagctactccggaggctgaggcaggagaatca$ $\verb|cttgaacctgggaggcagaggttgcagtgagctgagatcacaccactgcactccaacctgggcaccagagtgagattac||$ atctaaaaaataaaataaagtaataaaaaagagagatattgatagctgttgttggaaatttcaacttccatctcacttc ggtttaatgaaatagctgtcatataatcactgtttttgaaagaggagaattagttgctatctgtacattttgggtatgt gcatataagagttgttgaaaaagttatttcttgagaaaccagctctaatgctaggcaagtcacttgctttgggggaggc $\verb|ctcagettctctgtctataagattgcagcaggggtgtagtgggaatgagtcttcaacattccaagagattttatctact|$ aatacgacagtcaaatggagcatgactttgtggaagcctctcctctttccacccagaggggccaatttctctgtcccagt gagatgttgacacttgtatgatccctgcttggagacttccctcttctggaacctgccctggctcaggcatgagggctga agacagatttagtgctgtagaagagtagagggcagtcacgggaaggagttcctgtttttctttttggctatgccaaatgg ggaaaaatcctcctatcttgtctttttagtgtcatcctctctccccttttcttcttctttataattctcatctctatc tctcctggaaatgtgcatgtcaagttcaaaagggcacaatgttttggtgaggaagaggtgggagaacacgtgccaggtg agtaalagtaattttataatcccagctgtcatttaagccaccctttgtgggtagcatatggtccactctctcagttca ttgtcctaaagatgcttcatcagaaaggaataacttccaccccgttactctctgtccccttactctgctttattttct togtcaatcctaccaccaccactgtttgaacaacccactattatttgtctgtttcccatccctggtagaatagga $\verb|gccccatgaatgaaggaactttgcttctgttgttcaccactgaatctctaaggtatggaacacacctggcatgtgatag|$ taatgaatatttatctactattcctcttccaaggcgatcacacaataatcaggctttacactatccagttcttaggtct tccaagttatgacttgtgaggtatgttaattatgataatagaaggcagtttatttggttcagatttattgatgtgtaat ttaccacaqtaaqacttcccctttacaaaaqtatgatgagttttgacaaatggatacacatgtgtatctaccactgcca ${\tt tgctccttttcagtctgtcgtcccctccacccatgaccactggtcaccactgcagtgatttctgtccccttcatttcac}$ $\verb|ctttccagaatgtcatataaatggaatcatgcagtatgtagttttttgtgtctggcttatttttcttagcattaggct|\\$ tatatttatttatgaggaggtgtctcactctgtcacccaggctggagtgcggtagcgcgatctcagctcactgcaacct tttatattttttaqtaqaqatqqqqtttcaccatqttgqccaggctgatctcaaactcttgacctcaggtgatccgccca gtcttttcgacaactaattgtttccagtttttggctattctgtataaggcttctataaatattcacaaatacctaggat gggatgactgggtcatataatagtactgtataaccttagcagaaactgtcaaactattttccaaagtggctcttccatt ttacaattccacagtgtattgagtcccagtgtctccatacacatgctagcacttttaatatttaatttagtgggtatgt aatgatatctcattgtggttttaatttgcatttctctgcagctaatgatgagtgtttctgcttatttgggaaggtttta atttagcagtctgttgtattctgtagatattaataacttcaaaatatcagtggcatttgcagttaaaatttccttaaaa aattggccaaaggtttccagcagtcacttctgccatgcccaaactgtatgaaacaaggctgaggtgtggagattgtcac attttggcaaggagtgatccacttgggtgactgatgagacccagagagcgtacgcctcgggcttgagggtgaggacggg cgggaagtcgactgcatggccttgctggccttgggaggctgcccagtccttagctaaagctggcagttatgggaaacag act tagattc tattac gttttt caggat gtcccaggagtcacctgggaagctcagcagtcctttgtgactttcaagcatatggtagaagctgctgaacacagagctccctctttggggataattttgcccaaatcatttaatcaggcttgagaaatgag gacatccccaagtgcttacgacaagccaggacccttttgcatactaaggaaaacaggatgaaggaaacagaaatggtc tctgctctgactcagaaggtagaaatcctctttcccagccaagtcttcctagggaagcacgtaggaagggctctgaaccc acgtgtcagttgcaggggaggatatcaggaaaggacattgaagaagtggagacctaagtttgagacctaggcattagccaggctagcagtgcttgaaaaagtgtcttaggacaagagaactcaccagtgaagtcccagtggtaggagagcgtgcagca tattctgagcctgtatacacatctccagggcattgcttagcaggtggggagtggcaagagagtaggctggagtcacaga agggaggccaggtagaccttggtgagcactggactctatgttcaggtgctgaggagctggcaaaaggttttaagtcggg gagaggcatgttcagatatttggtctagctgagtaactttgggtgctctgtgacaaatggttgggagaccagtgaggtg taactggaaatgtgtatgagggcagaagtgagtgtactgcatttgaaaacattgagaaatctagtacatagtactgtctc ttggcttcagttacctgagcagaaggggccgggcattgccaaactctcctcttaggacagaattgctcccagtattgat aagcttgcctaagtgtgcccagcaaagccacggtagaactttctactgtggctctatgctacttcttagcaaccttctc catgtgcttcctggagagtccttggagtcagaacctttttcttgaaacccagacactttacttccaagaaaatgctgtc caagaaaactcatccttcccttcttctcatgaacgttgtgtagaggtgtgtcttctctttccttttgagctttttccactca gggtttaggggaggtgatattctatatttgggtttggctctgggtactgcaacactaggctattaagatttcatcctta ctgctttgcccctcctatctttccagaaacccacaatggatttgctagaaataatggaacgtcctgtttggacaggata $\verb|ttaaattaagccatgtactgtgttgggaaattatttatattatctcgttgaatccacagtagaacacagttgaacacca|$ tacaaggtaagtattgtcatccttattttaccatgaggaaattgatgcttagagagcataaagccttggccaggggcac atagttgggaagccggggctaattcatgcctgggctctttctgatagttttccttttttaattgtcccctcctcattgt taccttggggatttcaagagattcatgtagcttctaaatcaacgaactgattcctggagagcagcttctgtatgagaaa aatctagctaattatttatttcagtgtctctggaatgcaagctctgtcctgagccacttagaaaacaatttgggatgac aagcatgtgtctcacaatgctgctctggttgccagtgctgtgctgccagttgtcatctttgaacaaactgatgcagtgc tggtttaactottcctctttttggagtaagaaactttqqaqqcctgtgtccttctagaagtttgctgagcaaatggtaa ggaaaagaaataggtcctaaggcttgactatttcagagaatttcttgatttattggactgtcaatgaattgaattggaat acatagtggtaggctgtcttttcttctcagacactgcaatttcctccaatctcttgacttttctagaagttttaatcca agtccttgttgggtggtagataaaagggtattgttctactagagactgaccttggcatggagatctcatttggactcac agatttctagtctagcgtttggttttgtatccatacctcgctactgcattcttagttccttcttgctccttgttcctcat $\tt gcccagtgtcccacccttacccttagccctactcctctagaggccacagtgattcactgagccatttcataagcacagct$ aggagagttcatggctaccaagtgccagcagggccgaattttcacctgtgtgtcctcccttccatttttcatcttctgc $\verb|cccctccccagctttaactttaatataactacttgggactattccagcattaaataagggtaactgctggatggc|\\$ tgggatacacagaatgtagtatcccttgttcacgagaagaccttcttgccctagcatggcaaacagtcctccaaggagg $\verb|cacctgtgacacccaacggagtaggggggggtgtgttcaggtgcaggtggaacaaggccagaagtgtgcatatgtgct| \\$ gaccatgggagcttgtttgtcggtttcacagttgatgccctgagcctgccatagcagacttgtttctccatgggatgct gttttctttccagagacacagcgctagggttgtcctcattacctgagagccaggtgtcggtagcattttcttggtgttt tgagacagagtctcgctctgtcgccatgctggagtgtagtggcacaatcttggctcactgcacctccgcctgccaggtt caaagtgctgggattataggcttgagccaccacgcctggccgatggtgctttttatcatttgaaggactcagt<u>tgtata</u> <u>ac</u>ccactgaaaattagtatgtaaggaagttcagggaatagtataagtcactccaggcttgaggcaaaatttacaaatgc $\verb|cctcagtgtttttggccacctgagagaggtctattttcagaaatgcattcttcattcccagatgataacatctatagaa|\\$ ctaaaatgattaggaccataacacgtagctcctagcctgctgtcggaacacctcccgagtccctctttgtgggtgaacc cagaggctgggagctggtgactcatgatccattgagaagcagtcatgatgcagagctgtgtgttgggaggtctcagctga gagggctggattagcagtcctcattggtgtatggctttgcagcaataactgatggctgtttcccctcctgctttatctt tcagttaatgaccagccacggcGTCCCTGCTGTGAGCTCTGGCCGCTGCCTTCCAGGGCTCCCGAGCCACACGCTGGGG $\tt GTGCTGGCTGAGGGAACATGGCTTGTTGGCCTCAGCTGAGGTTGCTGTGGAAGAACCTCACTTTCAGAAGAAGACA$ AACAgtaagcttgggtttttcagcagcggggggttctctctcattttttctttgtggttttgagttggggattggaggagg gagggagggaaggaagctgtgtttggttttcacacagggattgatggaatctggctcttatggacacagaactgtgtgt ccggatatggcatgtggcttatcatagagggcagatttgcagccaggtagaaatagtagctttggtttgtgctactgcc $\verb|caggcatgag| to tgatccctaggacctggctccgaatcgcccctgagcaccccactttttccttttgctgcagccctg|$ qqaccacctqqctctccaaaagcccctaatgggcccctgtatttctggaagctgtgggtgaagtgagttagtggcccca ctcttagagatcaatactgggtatcttggtgtcaatctggattctttccttcaggcctggaggaatataataactgaga

cttgttttatttctgcagagggttctaagccattcacttcccagatgggccaataatgctttgagtaatctggagatca tetttaatgegeaggtgaatggaactetteeaeagagggatgtgagggetgtagageaggtgaacteectgaaactea aatgtagcttaacatgtctgtaatcaaaatgatcatctttctgagattcaaagggctataagggactttggagagaatt ctaaatttccttttttattatagtgttacttaaatattaggaagttaaaagtaggtataaacttcttataggctgttat tatacaactatatgacccatacatatttacaaattaagtgcagccaaaattgcaaaatcaataccattcaaattaatac cttaaatgtggtgaggcagctgttgttcaactgaaaccaaattataagttgcatggcagtaaatgctatcatgctgatc attttgagtttggccagtctatattatcatgtgctaatgattgaattctccacccatttttctacttgtatgaccttaa tttgatggcacctgttccatcctcatgagtttgctacaattatactggtgccaacacaatcataaacacaaatataaac ttgggctttgaaatcttgtgccagaacttggctttaaagtaagcatttaaaaatccatatgtgtttattagactttgt ttagatgactgttgaaatgaaaacaaagtgtttaaaatcctcttagagaacttaaatataatccctcagcaatatgtat acagatcttcctttgagaaaaactgattgtgttcagcctctcatgttacaaatggggaacctgaattctgaggtctcta aaaaagagagnnnnnnacacttagaatgagcttccatgtgtgaggcactaactgattaggcattattaactagatttat teettttaaggeeeegegatgtaetgttattteeacatgttgtagetggggaaegtgetaeteeagagaggttaagtaae ttgtctgaggtccacaccactaacaaggagcacaggtagggttcaaatccagataatctgactttggagctggcactct aactcaatgtgcctaatcgcttttcagtggtgtcattatttttgcctattctccatctgagaatattgaagtttctgact tatteetttgetaeagtgtgateeagggeteetgeeettettateetggtagagggggeeeaettgetgggaaattgte tccgccatggtttatccatgttgtgtccattagtgagtagtgggaagaatcatatcatgttggcaatgaaagggggg ctatggctctggggtagtctagtctgaactcttatttt

Genomic contig containing ABC1 exon 2:

ctttttttttttttttttttttgaggtgaagtctcactctgttgcccaggctggagtgcaatggagcgatc ttggctcaccccaacctctgtctcctgggttcaaacagttctcctgcctcagcctcccgagtagctgggattacaggctc $\verb|ccgccaccatgcccagctattttttttttttcagtagagatggggtttcacccttttgaccaggctggtcttgaactc|\\$ ctgacctcatgatcaacccacctcagcctccaaagtgctgggattacaggtgtgagccaccacgcccggcctcataagt attttctaaatttatttacagtcatgccatttaaaaggaaagttgtattcctgtctttgttaatatttataagtgatttt attcagctacaagcttggaatggcatataattttgtattctgcttttttcacttaatattacatggctaatgatttctgt gtttcataaacattattctgatgatggcatgatatattgttgagtacatgtaccataattgaatcatttccctattgcta cttaagttcagtttcctaggatgaatttccaggaatagtaattgggcaaatgggataaacatgactcttgaatacgtatt gttaacattgctttcccaaagggctcaactgatttatatttccqtgttcattatcttttaaaccagctcatttactcacc ggtccctggtgtaccaagtgctgatacagacacaaagtacctggggaaattgagatgagggagtcctggctcagctggga $\verb|gagtatgttgcctctttgggattatttacagaaatattagcaagaccagccccatctttggtcttgagtactccactgtc|\\$ agcatgctttcttccagagagggatccatttgcctttatttttcattctgttgtgccgtctatgcaaactattcttgata gttttatggtaacagtgtttttttgttccatgagataaatttatacatgctcattgtggaaaatttagaaaagacaggaa ggagtgcagtggcgtgatctcagctcacagcaacctccgcttcccaggtttaagtgattctcctgcctcagcctcccaag tagctgggagtacaggcatgcaccaccacgcccggctaatttttgtatttttagtagagatggggtttcaccatgttggcc tgcgccagccacacctacgttcttatcatcctagtacatccactgtcattatcttgctgtatttccttctgcccagtctc actotgateatgeagtggcgtgateatgeagtgateteggeteactgeaacetaggcettetgggttegagtgattetee tgccttaqcctcctgggttcaagtgattctcttgccttgqcctcccaagtagctgggattacaggcatacacccccatgc ccatctaatttttgtatttttagtagacacagcgtttcactaaaattttgtatttttagtagagatggggtttcaccatg ctgcatccatcgccaaaaagattttttaaaagagtttaatgtagaaccatatcaaaggtctttggaaataaaaaacagtt cagaaaggttcaattatgatctattcatagagtggaatatcaagtagacattacaggacatgttttaagattatatttta tgtcatgggaaatgctctcccagtatgatgttaaatgaaaaaacagaatacaaaagtatatatgctgcatagtctcaata ttgtagagaaaaaatattatttatgtatgcatgaaaaaagacaaaagatgttaacagagatccattgttacttcagttta $\verb|ctagggattgtctctgggaggtaggattaaggtgatttatatttacctttttaaacttttctgtatttttattttcaa|\\$ attttccataaaaatataaggacttgaagatcaagaaaaatttctgctttggctcagtgcagtcgtcacgcctgtaatc ccaqcaqtttggqagccctaggggagaggatcacttgaacccaagagtttgacgttccagtgagctatgatctccggatc agtototototgttgocccagotggagtacagtggcacaatotcagotcacogcaacototgcctoctgggttcaagoga gagacagggtttcaccatgttggccaggctggtctcgaattcctgacctcagctgatccaccggccttggcctcccaaag tgctgggattacaggcatgagccactgtgcccagcccaatcttttgctttttttaaaaaaagaagacaaaaagggatttt ataccagtattatcttggctgtgtgactctgaagccacagttgtaagttataattactctgaaacacaaggccctgtgac tettttgggetetttggtgtttatettgattacaacgttggaatatagaaatgaaaggaatgggagaggtgatagaette aggcagtgtaactagttgtctgaacactactggctcaattatattgtgtctagtgatttccatcttgtccgtctgctaat ttatcgcctggtaactcactgaggcagggttttcctttggagaaacctcattgttttaaccagtgtatcatgcttgttta gaagttcaatgatctttttaactcatcggagaagatgatgaccagacctggacagatggggaaggactttgcactctctc tttacagtcctgagtgcacacaggtcaatatggaactatgtgtgaattttcattgtctttgagagccctcttctctgccc catagggagcagctttgtgtgcaattagaggagcaagggttgtgtgtatttagcacagcaggttggcctggtcctctcct atgtgctgaggaagccagcaacagaacagatgatttcaggagctccaggaaaatgctacaggaggagtgtgcctgggtt actggagtagcacaggaggagggcttctagctcaggctgagatttttagtaaaggaaattatgccacgatgaatcctgaag aatgaatagaagtgaaccagataaagcacgataggaagcatcttcccttacctaagggaagacacagaggtatatggaat $\verb|ggtatgttaaaaggttgggactccaaacagttctgttaaagcttagagagtggtgggagagactggagaagttgattaat|\\$ ${\tt tagtaaatgaagttgtctgtggatttcccagatcccagtggcattggatatccatattattttaaaatttacagtgttct}$ atcttatttcccactcagTGTCAGCTGCTGCAAGTGGCCTGGCCTCTATTTATCTTCCTGATCCTGATCTCTGTTCG GCTGAGCTACCCACCCTATGAACAACATGAATgtaagtaactgtggatgttgcctgagactcaccaatggcagggaaaat

ccaggcaattaacgtgggctaaattggacttttccaaagatgctgtctttgggaaacatcacacatgctttggatcagaa aacctaggcttctaatttgttgataaggcatgaactcaggagactgttttcagtcctagtgaatggtgataattgtaatt ataacagtagacaacatctctttttacacattttaaatcatgaaaatagaataaccttactgataattttagaaagtggtg attaaaagcacatttaagataatgccttaacacctagtcttttccatatgcatgatgtcttaatcacacattgcaaatca tggaacacagaatttt

Genomic contig containing ABC1 exon 3:

caacatttacgtagctgggaaatgtagctgggacttcagtttcactgccctagtgatttttcctaccactaagcagctca gtccatacccctacgagacccacaagcttatgagatactgttcttccaggaaagcagtggggccagggccaccttttaat tgtgtttcttggcctggtcccatctttctcacaatatatagcaacagttatttacttgctgattttctaatgcacatcac aaaccagcctggccaacacggtggaacctcgtctctactaaaaatacaaaaattagccaggcgtggtggcgcacacctgt aatcccagctactggggaggctgaggcaggagaattgcttcaacctgcgaggctgaggttgcagtgagccgagattgcgc acattttagattttatttaagcattatgccaagcaccactgaagtataagtttcaagggcaaactcagttttttcatcta ctagacgaatgattttctggaatgattacaagcaggcaagatggtgtagtggaaatagcaaatgtcttcggcatcagaca agttggggtttgtttgtatectgeetetgeeetteaeegaggttgtgatettgggeagattgttgagttttaaeetagat tcctctgactccagatcataaattttcagaaaagttctgaaattcttgtatatactgatggtaaatgagacttttcctta catctatgcacttctttgtttgttttgttttgagatggtcttgctctgttgcccagactggagtgcagtagtgcaatctcc gctcactacaatgtctgcctccaggttccagtgagcctcctgcctcagcctcccaaatagctgagactacaggcatgtg ccaccacgtccggctaatttttgtatttttagtagagacagggttttgccatgttgaccacactggtctcgaactcctgg cctcaggtgattcgcccgcctcagcctccaaagtgctgggattacaggcatgagccaccatgcccggccatatccatgc acttcttgcaaccttaccttcttttctcatcaccctccagggacctagttggaagagcagagttaaaagttaaggtgaaa cttggagaggtgtcttgtccctaggaacaaaggactggtttgaaattctctgtaaatcttccccagttcaaaccagagtt gcaaggggccttgttttgttttccttgaactattaacaggaagatagggagattaactgtgtaaatgttcaataggccag agtccctgcagagggtggccacagtgatcagatcttatcacatccttgctttgggtgttgcctctctggttggagtatgg $\verb|atagaaaagaaagaaccctatattgaaatgcaaagtgcagcaagtcctgactttggattaacttctcagcccatttg|$ ctgggcaacagcagagtaagtgctggggtagattcactcccacagtgcctggaaaatcctcataggctcatttgttgagt ctttgtcctacaccaggcactctgcaaaacgctttgcctgcaaggtctcatgcgatgctcaccacagctctgtgaagtt aattgtacttttatcaccattttacagatgagaaaactgagggtatggggtcaatgacttggctaaagtcactgcttagc aagctgcagggactggatgtgaattccaattggtttgactccaaagcctgtgaagctacttgttcttcaccacctagagc tgtggttcttgataactgtgaactcttttggggtcacaaatagccctgagaatatgatagaagcaggagctctggccttt ctgtccatacctgaacaggtccttgggttaagagcccctcgtccagggcctattaatcttgatcctcataagcagcatcc atgtattacggccgcaaaccaaactgtgccagaccgaatcctaggaccaagcccaaatatgtcccatcatccttttggta agaagctcattgtaagaaagaaagagagagagcaagaggatgacctagtgcatggggcctcattgttttaattagtgacaa $\tt aacaacaataataacaacaacaacaccccgaagcttcacagatgacatcagaccccaagcctgtgtttttcaggtgccct$ tgaggagctttgtagctggcagaggaggtgaaactgacaaatgtttggcagatggaggagagtaccagaggggtttgaga tgagctaaattccaatctaaccgcagtgttgaggaagaggcttggattgggaccatggagatgggggttctactcccagt tegetettgtegeeeaggetggagtgaaatggegegatettggeteactgeaacetececetectgagtteaagegatte tcctgcctcagcctccagagtacctgggattacaggcgcctgccaccaagcccatcgaattttttgtatgcttagtagaga cagggtttcgccatgttggccagggtggtcttgaactcctgacctcaggtgatccgccaccttggcctcccaaagtgct gggattacaggcgcgagccactgtgcccagcccacttcatcttaccgtagttacctccttagagtatgaaaaaataggct tagggcatccccaagtcccctctatgtctgagagctgaggctgtcaaagaggaactaaggatgccagggactttct gettaggacccctctcatcacttetccaacgetggtatcatgaaccccattetacagatgatgtccactagattaagaat ggcatgtgaggccaagtttccacctgagagtcagttttattcagaagagacaggtctctggggatgtggggaatgggacgg acagacttggcatgaagcattgtataaatggagcctcaaaatcgcttcagggaattaatgtttctccctgtgtttttcta ctcctcqatttcaacagGCCATTTCCAAATAAAGCCATGCCCTCTGCAGGAACACTTCCTTGGGTTCAGGGGATTATCT GTAATGCCAACACCCCTGTTTCCGTTACCCGACTCCTGGGGAGGCTCCCGGAGTTGTTGGAAACTTTAACAAATCCATg tggctggatttaagtgaagttgtttttgtaaatgcttgtgtgatagagtctgcagaatgagggaagggagaattttggag aatttggggtatttggggtatccatcacctcgagtatttatcatttctgtatgttgtgaacatttcaagtcctgtctgct gagggtaggggttggcacaaagatgcatgctggaagggtccttgcccataagaagcttacagccaaggctaggggagttc

tgtcttctctgcatcaggtcacctctctcacctctgtcactgccccatcagactacaatgtctgcaggtctttctcccct gagtgtgagctccctgagcaaagcaggatgctgccccttccctttgtattccttgctccttgctcttcagtgcctgtacata agtatgggcataataagtgtcccccaaatgagacattgaggattcttcaaatgcacaggaccgtgatgtgagttaggacg gagtaaggacgatgggatgtggctcatgacaatcctgaggaagctgcagctgcggcacgcagggccacactgtcatgttcatggaccctagacctagactggctttgtagcctccatgggccccttccatacac

Genomic contig containing ABC1 exon 4:

tcatgactgccattggtataaagatgaatataatccagaccagattcatgattattcatacatttttagtgtattaactt ttaattctgcttttaaaataaattaaaacattctaatatgcccttaagagtatcccagcccaggccactgagcctactgt tgaatggagctgggtgtggggagccatgggagtgggttagggccagcctgtggaggacctgggagccaggctgagttcta tgcacttggcagtcacttctgtaaagcagcagaggcagttggcctagctaaagcctttcgccttttcttgcaccctttac agtgtggctcgcctgttctcagatgctcggaggcttcttttatacagccagaaagacaccagcatgaaggacatgcgcaa ${\tt AGTTCTGAGAACATTACAGCAGATCAAGAAATCCAGCTCAAg} taagtaaaaaaccttctctgcatccgtttataattggaa$ attgacctgcaccagggaaagagtagcccaggtgtctggggcttgttcccattagatcttccccaaggggtttttctc gtactaatcttctctgggaagacagaagaaagtccccagggaagaatactacagacttggccttagggacagctagggg tgcagattgctgccaactgcattttttctgaagttggccatatggttgcagtgaatggatttatagacagagtatttctg tgcatataagagcaattacagttgtaagttgatatggataagtgaaagttaagcacttcttctaaaaaagagaatgcaat tcattttcccctaatcatttcaattagtctgatgggcatttgaacttgttgtctttaaaaagtgaaatctttacctctga gccagtaatggcatgt

Genomic contig containing ABC1 exon 5:

agetetecaggtgattetgatgeataettaagtttgagaaeeattgettgttttgeattaaaeaggagattagtetetge agettgtgggaataaagetttaaateteteeaattttagetetgtgaaaaggeagtggggagaeaggaatgaaeggaeta gtgccacaaagctcaggtggggtgggtgagatcatttagaagagaaagaccggggcatggtggctcacgcctgtactgtca tgtactaaagataaaaaaaaaaatttgccagtcatggtgatgcatacctgtaatcccagctactcgggaggctgaggc aggagaatotottgaaccogggaggogggggttgcagtqaqotqaqattocaccattgcactccaacctaggtgacaggg $\verb|gtgtgtgtaacagcaccatcacactgtttgagttgaggagcacatgctgagttgtggctcaacatgttaccagaaagcaat|\\$ acactatttctcaatagACTTGAAGCTTCAAGATTTCCTGGTGGACAATGAAACCTTCTCTGGGTTCCTGTATCACAACC TCTCTCTCCCAAAGTCTACTGTGGACAAGATGCTGAGGGCTGATGTCATTCTCCACAAGGtaagctgatgcctccagctt tggaatatgcaacctggcgtcatgggccagctggttaaaataaaattgatttctggcttatcacttggcatttgtgatga tttcctcctacaagggatacattttaagttgagttaaacttaaaaatattcacagttctgaggcaataaccgtggttaa gggttattgatctggaggagctctgtctaaaaaattgaggacaggagactttagacaagggtgtatttggagacttttaa ccctgcagcttgtgggaataaggctttaaatctctccaattttagctctgtgagatggcactggggaaacagaaatgaac ggactagtgtcacaaagctcaggtgggatggacgagatcacttcaaaggtctgtaatcccacgtctataatcccagcact ttgggaggccaaggcgggaaaatcacttgaggtcaggagttcgagaccatcctggccaacaatgcaaagcctgtctctac taaaaatatgaaaattagctcagcgtggtggcatgctcctgtagtcccagctactcgtgaggctgagacaggagaatcgt ttgaacctgggaggcggaggttgcagtgagccaatatcacgccattgcactccagcctggctgacagagtgagactccat ctcaaaaaaaaaaaaaaaaaaaaaattttataaaatcaggaaataattagtgtttatgttgaattttaactttagaat catagaaaacttcctctggcatcattattagacagctcttqtqcaqtgggtagcaccagacccagcttgcatggttattg atttttcagagacactttttgagcttattctctggcagaaaggggaactgcttcctcccctatctcgtgtctgcatacta gcttgtctttacaagaagcagaagtagtggaaatgtttattcttgaaaataagctttttgcttcacatgatctagaattt ttaaaattagaaaaatgtgcttactgcg

Genomic contig containing ABC1 exon 6:

Genomic exon containing ABC1 exon 7 and 8:

ccgtttggcaaatgctcagtaaaagaaaagggttagaaggggagaaasgcattttatcccaagccttcaggaatcaggat gaggatgtcttcaccttgtggtggggagtaattatacaattagagacagcacattggagtgtggctgatatgctgtga tgatagctctagctctctgcctagcagaggaaggacatttcaatagaagaaaaagtttaagaccttgccgagaaacagag aaaggatgtttgtctttttaagaagttgaaaaccctgtttgcagacaaaagccctccagttttggcagtaaactttcatg caagggaagaaaaaggcaggggatgacattgttgacaattgtgaggaattaccatgtgccaggcactgtgcgaggggctt tgtacatatcctctagtttttagtgcttataaaaactctgtgatatgtgcacagcattttaaactttgctgcatagtcgag $\tt aaaatggaaggattggggaatttgagtcatttgcccagggttctatagctaccccaggttcccatgactggagaattgggg$ cacagggtggcgqqqqqagagtgagtgacaagaatcctaacaatcttatttccattgagtccttataaaaagaagtggatta tttgctatgctgtcttgaacatctgtcatcttgtaggcctaacggtaaacacaaaaacactttacctcctatagctttca attaagatctctcagtttgtgtttgtaatagttttccaggcaagttctccctaggttcggcttctagtgtgttaaccttt agttataaagtgaacccaaagagagaaagtagaaacaaaacacctcacctgtttttgctcatgaattactctctatggaa $\tt ggaacaatcatgaacacctctgcgtatcacagaggcctatctgagtctgacgtttaagggagaccgcgtaggtccctttg$ atagaacctttaggcaggttttcttagaaatgcacattgaggattatgcttggatattgtgatgatcagaatgatactca atcccttctgcatttggaattctctttgaaagaaaacatcccaggcagctatttctcagagatagtgagtcccagccact tctagacattttcttgtgtagtctacattataatttcacagcagtctctgatatgacaaatgtcaaaatagcccaacctt $\verb|ctctaaacttcagagatgtctgatatgatattgaataaaacaatgctcatagaaacatcaagaaaggtggattttccctg|$ $\tt gatacttttttcctgcttgacaaataacagtgaagaaactgatctcacgtctttttctcttttggaagcctgaacactcag$ tgctttctgccctaatttatcttttccctgttctaatgaattattgtcctatatctgctgtgcagttaggtgacatataa cagcaattaaatatatgaattggtacatataaagatttgactaaaactcgatgtaaaaataagtgttctacattcaattt ccagtgttagaaacagtgctgacttgaacagagtgacagaattccatctttccctatttttgacagctttaaactttata ttttcttcctttcttgtgagccgtcattaacttgtttctcaaagccattcccgtattacccatcttgcagacgcagacag atttgggaatttgcggtcagagttgtattggacacatccccccagcccacatgagatccttttaatctattgcatattaa ctagttttaagtacaatattcctacttcatttaaaaccattaatcaaagaatgagtttgaaaaatgaacaaaatgcaaact GAGAACACTAAACTCTACATCTCCCTTCCCGAGCAAGGAGCTGGCCGAAGCCACAAAAACATTGCTGCATAGTCTTGGGA ctggcaagaggtccttttgagttgaatatcacatgggatgtaatatcaattttcaaagtataagtgatgtaaacaataat gttttgatttccttattttagaaatgaagaaacctaaaactcatagatgtctcagagctaattggttagtggctaacagc ${\tt tggatatctagtttagaaccttctccattttttctttttgcccctaggtaatcatacatttgtaaagaggagaattatct}$ ctgccactgcccatgcactgcttttgtctgaccagcaatttctccatattgcttcttcagtagcaaggccaatcatttta ccaacacacatgcttgctaactaacaggaataacgtggtacccctaattcagccctttcccttgaaagcatctggcttct gaggttcaactatgggaatatggtctcttaatgaacattaagttgagtttgccttttaggtccacatgttgacaaatgta actccacctttctgactcccagccttgtctcaaattaggcttggaagcgaggaactgtctggtgtcccccagcataggaa $\verb"gctgagccaggggcagtgctcacaaacaatacagactttaacgtgtaggatattggaaaataataatttgtggggaaat$ tgtctcagacttggtccacccttatttttagctgcttctctaatccgtttttctttttttggtgcttgtatctaacctac ccattttttqqtqcttgcatcattttttcaaatatcaaaaacgaactttatgttttctaacaatgaaagtattgcatgtt cattgtggaaaatgctgaagacttggaaaatacaaaaatgctgagatcaaacactattgatacgttagtgtatttcttcc gaggagaagccttctttcagcttgccatttgttaccctggttatgaaggctggtaaccttttttactaggtagagaagct ggaccaactggggttcttccagggggagaatgagaaagagaaactgttttgcaagtccgtagctatttctctagggccct gttagctgacattgacatgccttgcattgctctgcagatcccctcgcagccctctgtcccttgttcatttctggccttag agaaagcaaagcagggtctgtaacaggggaggctgcctctaaactcagggtttggttacagctgttttcacttacatcac gaccatctgcctctttcaatagaacacctccagatccctttgatcaaaagttactcattgtctgacttgctatttctgtg agataaatgggagaagatcaataaatgcacttgtttgtccagtcagcgtgtggaaagttgataattttgaccaaagcaca ${\tt accctgaaaggaaaagaaaaagggagtgaatgtcttctgagaagctgcctaggttcagacagtgtcacccatttccctgt}$ ttttccagtcacccaatgagttaattgacaaaactgggattcaaacccagaactgttggattccaaagcctgtgttgttg

ggaggacagggaggcagcatctcagatgtccacccagcaccgaccagctgcctggcattgctaggtgttgaggactcagc acaggagggatatatgcagtgaagaaaaagcagggtaaggggcatagagcatgagaaggtgctttttttaaagggggktga caggaagaatggcagatacaaagacattgatgctagagcatgcctaaggaatgtgtttaaggaccagggaaagtgagcaa gtggtggggggaggaggaggtcagagcaggaggaggtgagtgccatacaggcctggcaagactttggattcctgctgg tgggttgagaagagactgggatgggggaaagggacaaaggacattgtgctggattgagaaagcagtaagtcagtttc tcaggaagcacttcccagataaagtttggagtgtgagctgaggtgtaggagaaagagtaagagtttacccctgaaacggg tgctgggaagagtcaatagtttggaataactcaataatttatggtgcttctttagaaagatttgctggctttatgtggga ctgttatttaaaaatctctagggctgttccaataagcaacaaaaggcaaaatggcctggttctctgtcccctttctgtct gtatgcctcgtacaggttatgaaaagaaaagttgggaaaagctgtccacctcacctaattgtgttcttgtggagtgtgc tagatgccccctctctggagaaaaaaaatccttgtggcctctgacccacctctggagagcctagttcccttctggaggca gaaggcaaagcttaggacctagagagtgctggaccacgccactcacaggaaccagcaggctgtgaggttgaaagctaggc atatggagctttccaggctgggtgcagggcctcgtggcccttccccttccctttgtgctctatagctcagtcttcccagg cggtgtgaacacgcagtgacatttccaggaatacagggatttattaatgatttcttgtgaaatgtttggaaatacaaagt actctataaatatttcataatagcattggggctgagaactccacaaagtgccggaatacatttgcatgtaagacagaacg ctgcctgggtcattgatgcctgttgagtggcagtcacagacactgcctagggtttctgactcacgctgttgggactgttc tatgeagggcaccetettgtgtggcataggatttgtgceteaceacactgttgtagetttgetgtettgatgatgagt agagggcagtgtccaggccatggtataagcatctactgccccccagggttaccaaaaccaagccaagttgtgtctcagcg agctccgtgaagcatggagaagttgagtactcagagacatgacgtgacttttcaaaggctgtaagctgacgagggacata ggctggattgcagtggtgcttggctcactgcaacctctgcctcccgggttcaagcaattctcctgcctcagcctccccag tagctqqqattacaggcacctgccaccatgcctqgccaacattttttgtatttttttagtagagatqgggtttcaccatqt tggccaggctggtcttgaactcctgacctcaggtgatccacccgcctcgacctcccaaagtactgggattacaggtgtga gccactgcacccggcccagactcgagtttttcatcttaatgctttttcattgcctgacactttactgagaccaagatagg gaacttcacatacagtaccttttctcccaaggcggaagagggctgttcaatttctacactagagttcggggagttttaga aatgagtcagttatcgaggatgagagcagttcctgataggctcaaccacaatgagatgtagctgttcagagaaagcattc ttttatctataaactggaagataatcccggtgaaacgaagcccagccccaggggcttcactaactccaggctgtgcttct caaactttagtgagcataggaatcacctgggcatcttgtgaagctgtagattttgaattctgcaggtcggcagaggggtct cagaatccgcatttccaacaatgtctccagtaatgctgatgctcgtccctggaccacagattgggtagccaggttct ggcaagctcatcccaaggctttgagatgacatcagacaaaatatgttctgggacatggcttttgagaggtcaagaaaata agatgtttctttctctctctcatccccaacccttgcactgcccttttctccccttcccctaccctcctttctgtccccatcc $\verb|ctgacgccagCTGTTCAGCATGAGAAGCTGGAGTGACATGCGACAGGAGGTGATGTTTCTGACCAATGTGAACAGCTCCA||$ CTCAACTGGTATGAGGACAACAACTACAAAGCCCTCTTTGGAGGCAATGGCACTGAGGAAGATGCTGAAACCTTCTATGA CAACTCTACAAqtgagtgtccatgcagaccccagccctgtccccaaccccatcccttagttctggccttggcctgt gtcatctcctcctctgtagcagcgttagatgtctacatgcccatttgcccaccagactgagctcttcctagaggagaga ggettetettgaatagetacetgteeccagttetetgaatgeageetggeacateteaggtgeacagtagtgtttateaa tggaatgaatgattgacagccaaccttctggttttctgggggatgtggaagggtggcttccagggtgatcaagaatgaga taatggcagaaggacaaatcctgcaagatctcacttatatatggaatatatgtaaggtagaaagtgtcagtttcacatga gagagtagatccgaagtgttcacactacacaaaaaaggcaactatgaggtgatggatttattaacagcttgattgtggtg atccttttacaaagtatacatattaaaacatcacattgtataccttaaatatatacaatttttatttgtcagttgtaa ctcaaaaaagctagaaaagcatttttaaaaaggatgatgtactggtcttaatattaccattgagataagctttataataa cataaaaagaaataacagtaatgataatagcaacaacaacaacaacaagaactaacatttaagtagaatttcttgtgca ctgtgcattctgtttaagttatctcattttaccctcatgataacctgcagggaagattctttaaccccacatttcatagg ctcagagaggttaagtgccttggttagagccacatcagagttaatccacaagagccaggattcaagcccaaatctgcctg attettagetgeaaggeagtgttaaagaaceetgtgteteeatateeacteeceacacttaageacttttgtgggeeegt gtgccgtatgcctcgtggcagcagggatccaatgtcacagttttaggcagtggcatccttttccttgaaaacttgatgca aagaaccttttcttctctggagtaaagcactccagacattcgcaagttgctttacaagccttaaaaaggatggtattgtag

 $\tt gcaactttaattaaatcccatctcctcctcccccagcttgcaagttgacccaaggaagccttcatttccatgacagacttaattgtgagggcatcctca$

Genomic contig containing ABC1 exons 9 through 22:

actgtgttagcaaggatggtctcgatctcctgacctcgtgatccgcctgtatcggcctcccaaagtgctgggattacagg tgcagtgacacaatctcggctcactgcaacctctgcctcctgggttcaagcaattctcctgcctcagcctcatgcgtcac cacgcccagctaatttttttttagtagagacagggtttctccatgttggtcaggctggtctcgaactcccaacctca ggtggttcgcccgccttggcctcccaaagtgctgggattgcaggcatgagccactgcgcccagccccaaattttggtttt tgcttgaaaactgaggtctgaattcagccttctggttgcccctcaagagtcagtttaaatgttggtcatgttagttgtca gtgaaaacaatggtgaggctggcatgagagtgtgaatctggatgggagggcttgtgcttcatgaaaacatttttccagat cagtttaatctgagataatcttctccacatctctccacatagatgttatgaattttacttttacagaggagccaactgag gctcagataagttacttattatatgactagtagtggtagagctggggtttcaactaagaactctctggctccaaagccct tgtaagtttctatcagtatatgaccatgcatatgagcatttgtctctcttcttcttcatagCTCCTTACTGCAATGATTT GATGAAGAATTTGGAGTCTAGTCCTCTTTCCCGCATTATCTGGAAAGCTCTGAAGCCGCTGCTCGTTGGGAAGATCCTGT ATACACCTGACACCCAGCCACAAGGCAGGTCATGGCTGAGgtaagctgccccaaggcccaagactcccccagaatct ccccagaactgggggcaaaaactcaaggtagcttcagaggtgtgcgctaagtatactcacggctcttctggaattccca gagtgaaaacctcaagtctgatgcagaccagagctgggccagctccccagtcgtgggtatagaatcatagttacaagcag geatttettggggatgggaggactggcacagggetgetgtgatggggtatetttteagggaggagccaaacgetcattg tetgtgetteteeteetttttetgeggteeetggeteeceacetgaeteeagGTGAACAAGACCTTCCAGGAACTGGCTG TGTTCCATGATCTGGAAGGCATGTGGGAGGAACTCAGCCCCAAGATCTGGACCTTCATGGAGAACAGCCAAGAAATGGAC CTTGTCCGGgtgagtgtccctcccattattaccatgtgcctgcttgatactggagaggtgagtttctggtcactttccca ggtgtgagtgaggtgagaattctttcagtttatctagctgggggaatgtagtgagcatagctaaagtcacagggcaccac ctctccagaagtacaggccatggtgcagagataacgctgtgcatatcagcatccatgccactcacggtcaaatagcagtt ttctgcaaaacttagtgagggctggtgtttggaagtggagttgagtaattgcagtaccctattttcctttttgctgcagc ctctcagccagccacagcatctccctgtgtcttggtaggttttggaaagaagtgtgggagcaaaagcatgatgttacatg tagactggcctgagatactcattctcagggcactgtgtgaatgatgagctgctgttactgtgtggaggggaaatgcactt agtgcttcagagccacttgaaagggataagtgctctagagacaattgggttcaaatgtggagcaggctgagcaagaacag aatgtctcctttgcctgagcctgagtgctgttaatcacatcttcctgccttgggctgagttagagaatcattagactatt tectgtttccatggtgagggaggcctcttccttttgtctctgctccccttaagaagcaggtgaggattttgccaggtttc ggactattccctgatccgctgggaggcaggttactgaggaagtccctttaaaaaacaaaggagtttatactgagaaaagca taaacagtgatttgtatggattcacactgactaatatagctcatgccattaaagtggggtctcttctctaaaggagggtt atatgatctagccccgtagacctaagtgtggtttcagacctgttcttcctggtcctctccttggaatccatatttctact agttggactttttctgtttgtctggctctcagaggattataggaggccctgtgaagtgactcagtgaattttgatttgtg ggcaagtagatggttccctagtctgaaattgactttgccttaggtgcttcaattcttcataagctcccagttcttaaagg acaagatccttgtaaacatggcaatggcattcattaggaatctagctgggaaaatccagtgtgtatgcttggaaatgagg gatctggggctggagagaaaggcatgggcatgccttggagggacttgtgtgtcaagctgaggacctttactttaagctct aggggaccaggcaaggggagatgtagatacgttactctgatggggtggatgaattgaagaaggatgaggcaagaatgaag geagagaccagggaggaggetetecaagtggccaaggcataaagcaagaaatgaggcctggtgactgcttagtggcagag cacccaggctgaaatgcagtggcatgatcttggctcaccacagcctccgcctcctgggttcaagcaattctcctgtctca gcctccagagtagctgggattacaggcacatatcactgtgcccggctaatttttgtattttcagtggagatgggatttca ccatgttggtcgggctggaatgaactcctgacctcaagtgatccacctgcctcagcctcccaaagtgttgggattacagg tgtagcctggcatctcctacacgaggtgatggctgaggcttctgcttctgcttggggtagctctgatctttctgctttctc tggcactgtctacccatgttgcctcaccccacaggtcccagggcacctctctcgggcaagtcttggaaccctctgacact tettaggteteetgeeeeteaegageaeeeeagagaggeeaegtgeteagtgateteagtgggegeatetttetagtett gctattctttttggccatgttgttcagaaaccatactgggcagggccgacttcaccctaaaggctgcgtctcttcactct gcttttgtttgttccaaataaagtggcttcagaattgctaaccctagcctctgtgaacttgtgaggtacaattttgtgtc tgttatgttaacaaaaatacatacataccttcctggtgatggtataaattgctattctctattggaaagcaatttggaat ataattttaaagaagtcaccatatgagagaaaatgttattgctatattgttattgtgagaaattggaaatagactaaatg

agactecaatteggtagaaccagagetteatettetetgtegaagetgtgacaggagttgcaaatgcetetetttttge ${\tt tgagtttgcagctgctgtttttccggcagcacatctgtgcaggcctctgcctcggcccctctggatctgctgattgagca}$ gcggattgatctgtccttctctttcgtgttgacccatgtgaggaaccaactggcaagggaacaagaaatggaaataggcc tcctttgcatcatgacctgtacatcctgcaattggaaaagattgtactttagttggtttaaccagcagcattatttttct $\tt aaactaagcagtaagaaggaattaggttttatgtgggatcaacagactgggtctcaaaagaggaaggtgatagaacacag$ tggggagggggaggtgcactagaaacagagggcctatgctttcattctggcttttgctacttaatagctgtgtgacccaat cttagagacttaacctctctgaacttccattttctcatgtataaaatgggaaatattaaaaggatactcactgggctggtg gcttgtgcctgtaatcccagcacttggggaggttgaggtgggaggatcacttgagcccaggtgttcaagaccagcccagg caacatggcaagactctgtctctatgaaaaaattaaaaattagccaggtgtggtggtgtgcacctgtagtcttagctact tggtaggctgagatgggaggatcacttgggcttgggaggtcaaggctgcggtgagctgtgattccatcactgcactccag cccgggcggcagagcgagacaCtgaatccaaacgacaacaacaacaacaaaaggcaaaaaataaaagtgccctctttatgga gttgtgtaaggtgaagcatatacactattcaacatagtaactatataaaggaagtattgttgttgttactgtagttaata ccattaagtgagatgtttcgtatagtggaaagcacatggactctgaattcagactggtctgactttgagtctcagctcca gggacactgtcatttacctcagttttctgtgaggataaaacaacgacagtgtatatgcaagtattttgtaaattttgtag tgctcctcaagatttagttggtgtttactacttgtactttctcactggaatggcagATGCTGTTGGACAGCAGGACAAT GACCACTTTTGGGAACAGCAGTTGGATGGCTTAGATTGGACAGCCCAAGACATCGTGGCGTTTTTTGGCCAAGCACCCAGA GGATGTCCAGTCCAGTAATGGTTCTGTGTACACCTGGAGAGAGCTTTCAACGAGACTAACCAGGCAATCCGGACCATAT ggttcaggcaggaggcaagtttagaaataatgtatagtctcatttacaaaactatccctcaagcctaacacaggatttga tattctatataggctcaagagaatatttctacccattttcttctaggttttcctatctcagtgactaatggtagcaaagc attocottaaaaaggoattatttgtgaaaottayotaaaatogaattogggtocaattaaatttttgaaattttatatta cttagaatttctcttaaattgcagtgaaaaaccaaaatccttcattcttggttgaaggttggaaaactacgttagagagg attagagagaggatgagcaatcgtgtagtcagcccttgcctcctagtgtaggatttgtctcagccactgcttgttgtc TCTGGCTCATCAACAAGTCCATGGAGCTGCTGGATGAGAGGAAGTTCTGGGCTGGTATTGTGTTCACTGGAATTACTCCM RGCAGCATTGAGCTGCCCCATCATGTCAAGTACAAGATCCGAATGGACATTGACAATGTGGAGAGGACAAATAAAATCAA GGATGGgtaagtggaatcccatcacaccagcctggtcttggggaggtccagagcacctattatattaggacaagaggtac tttattttaactaaaaatttggtagaaatttcaacaacaacaaaaaactcaacttggtgtcatgatttttggtgaaattg gtacatgacttgctggaaggtttttcataggtcataaaataacagtatcttttgatttagcatttctactcaagggaatt aattccaggaattttggtggcaggcacctgtaatcccagctactcgggaggctgaggcaggagaattgcttgaacccagg aggcagaggttgcagtgagctaagatcgcatcattgcactcccgcctgggcaataagagtgaaactccatctcaaaaaa attgtatggttctaaaggaatggttgattacctgtggtttggttttagGTACTGGGACCCTGGTCCTCGAGCTGACCCCT ttgaggacatgcggtacgtctggggggcttcgcctacttgcaggatgtggtggagcaggcaatcatcagggtgctgacg GGCACCGAGAAGAAAACTGGTGTCTATATGCAACAGATGCCCTATCCCTGTTACGTTGATGACATgtaagttacctqcaa egeceaggetggagtgcagtggctcgateteggetcaetgcaacetttgcctcccgggttcaagctattctcctgcctca gcctccacagtagctgggactacaggctcatgctgccacgcccggctgacttttttgtattttagtagagacgaggtttca ccatgttacccaggctagacttcaactcctgagctcaggcaatccaccetccttggcctcccaaagtgctgggattacag gtgtgagccactgcacccagcccaccactttaatttttacactctacccttttggtcaaaatttgctcaatctgcaagc ttaaaatgtgtcatgacaaacacatgcaagcacatactcacacatagatgcagaaacagcgtctaaaacttataaaagcac agtttatgtaaatgtgtgcacttcttctccctaggtggtaaaccacatttcaaaaccacacaataaaactgaacaaagc ttetteetettagaetttttagaaaatettteagtgetgagteactaagetgeeaagtteteattgtgggaactatgeet ttggatgtaatgatttcttctaagacaatgggcggaggtgtagttattgcagacatctgaaatatgtaatgtttcttcca gtgtgtagggatcaggatgcgggaggagctgggttctgcttgtattggttctctgttttgcattgaatagtgtttcct tgtatggctatctatagcttttcaaggtcaccagaaattatcctgtttttcaccttctaaacaattagctggaatttttc aaaggaagacttttacaaagacccctaagctaaggtttactctagaaaggatgtcttaagacagggcacaggagttcaga ggcattaagagctggtgcctgttgtcatgtagtgagtatgtgcctacatggtaaagctttgacgtgaacctcaagttcag ggtccaaaatctgtgtgcctttttactttgcacatctgcattttctattctagcttggaatctgaaacattgacaagagc tgcctgaaatgtatgtctgtggtgtgattagagttacgataagcaagtcaatagtgagatgaccttggagatgttgaact

tttgtgagagaatgagttgtttttttttttgtttttagtttttagtactttaacataatctacctttagtttaagtatcgctcac agttacctagttactgaagcaagcccccaaagaaatttggtttggcaacactttgttagcctcgtttttctctctacatt gcattgctcgtgaagcattggatcatacgtacatttcagagtctagagggcctgtccttctgtggcccagatgtggtgct ggggctccagCTTTCTGCGGGTGATGAGCCGGTCAATGCCCCTCTTCATGACGCTGGCCTGGATTTACTCAGTGGCTGT GATCATCAAGGGCATCGTGTATGAGAAGGAGGCACGGCTGAAAGAGACCATGCGGATCATGGGCCTGGACAACAGCATCC TCTGGTTTAGCTGGTTCATTAGTAGCCTCATTCCTCTTCTTGTGAGCGCTGGCCTAGTGGTCATCCTGAAGgtaagg caagcctctggtagagaaggggtcatacctgtcatttcctgcaatttcatccatttatagttggggaaagtgaggcccag agaggggcagtgacttgcccaaggtcaacccagccgggtagcagctaagtaggatgagagtgcagggttcatgctttcca ggaagcagaggctgaaatagagtttgatgtatgggtatttatgagggctcaatacctatggaagagatatggaagatgca ggattgggcagagggaggagttgaactgtgatatagggccaaccccgtggggcactctagagaatatgcagcttgttgga ctcaatcaatcactggatgtgggctgccctgggaaggtcgtgccccagggcctacatggctctctgctgctgtgacaaac ccagagttgctgatgcctgaggccgtctactgacagctgggcaacaaggcttccctgaatgggactctgggcagtgcag aaatagttcctactgattgccaaggactgtttaaacacatcacatgggcttcttcttctatcctcactaacccttttaac agacaaggaaatgaggctcaggaaggtcaaggactttattgaggttccacagtaggatacagttcttgctaaaagcaacc tgetetgagacaactgcatgetggtgggteetgcagacatgtacecatcageeggagataggetcaaaatatecacaaga gtttggatgattgtgggaatgcagaatccatggtgatcaagagggaaagtcaagttgcctggccattttccttggctttt agacagaaaagttacgtgggatattatctcccacagctcttctgtggtgccaccagtcatagtccttatataaggagaaa ccagttgaaattacctattgaagaaacaaagagcaaactcgcccactgaaatgcgtagaaagccctggactctgttgtat tcataactctgccattattttttctgcgtagtttttgggtaagtcacttatcttctttaggatggtaatgatcagttgcctc atcagaaagatgaacagcattacgcctctgcattgtctctaacatgagtaggaataaaccctgtctttttttctgtagatc ${\tt CAGTGATCCCAGCGTGGTTTTGTCTTCCTGTCCGTGTTTGCTGTGACAATCCTGCAGTGCTTCCTGATTAGCACAC}$ GCATGGCAGGACTACGTGGGCTTCACACTCAAGATCTTCGCTgtgagtacctctggcctttcttcagtggctgtaggcat ttgaccttcctttggagtccctgaataaaagcagcaagttgagaacagaagatgattgtcttttccaatgggacatgaac cttagctctagattctaagctctttaagggtaagggcaagcattgtgttttattaaattgtttacctttagtcttctcag tgaatcctggttgaattgaattgaatggaatttttccgagagccagactgcatcttgaactgggctggggataaatggca ttgaggaatggcttcaggcaacagatgccatctctgccctttatctcccagctctgttggctatgttaagctcatgacaa accaaggccacaaatagaactgaaaactcttgatgtcagagatgacctctcttgtcttccttgtgtccagtatggtgttt tgcttgagtaatgttttctgaactaagcacaactgaggagcaggtgcctcatcccacaaattcctgacttggacacttcc ttccctcgtacaqagcagggggatatcttqqagaqtqtqtqaqcccctacaagtqcaagttgtcagatgtccccaggtca cttatcaggaaagctaagagtgactcataggatgctcctgttgcctcagtctgggcttcataggcatcagcagccccaaa acaggattgctgagccttggggcatctttggaaacataaagttttaaaagttttatgcttcactgtatatgcatttctga aatgtttgtatataatgagtggttacaaatggaatcattttatatgttacttggtagcccaccactccctaaagggactc tataggtaaatactacttctgcaccttatgattgatccattttgcaaattcaaatttctccaggtataatttacactaga agagatagaaaaatgagactgaccaggaaatggataggtgactttgcctgtttctcacag**AGCCTGCTGTCTCCTGTGGC** TTTTGGGTTTGGCTGTGAGTACTTTGCCCCTTTTTGAGGAGCAGGGCATTGGAGTGCAGTGGGACAACCTGTTTGAGAGTC CTGTGGAGGAAGATGGCTTCAATCTCACCACTTCGGTCTCCATGATGCTGTTTGACACCTTCCTCTATGGGGTGATGACC TGGTACATTGAGGCTGTCTTTCCAGgtacactgctttgggcatctgtttggaaaatatgacttctagctgatgtcctttc tttgtgctagaatctctgcagtgcatgggcttccctgggaagtggtttgggctatagatctatagtaaacagatagtcca aggacaggcagctgatgctgaaagtacaattgtcactacttgtacagcacttgtttcttgaaaactgtgtgccaggcagc atgcaaaatgttttatacacattgcttcatttaattctcacaaggctactctgaagtagttactataataaccagcaatt ttcaaatgagagaactgtgactcaaagacgttaagtaaccagctttggtcacacaactgttaaatgttggtacgtggagg tgaatccacttcggttacactgggtcaataagcccaggcgaatcctcccaatgctcacccaattctgtatttctgtgtcc tcagagggggtacaactaggagaggttctgtttcctgagtacaggttgttaataattaaatatactagctctaaggcctg tgaccaagtccaagaggaacctgcgttggacagttttcatatgagatcaaattctgagagagcaagatttaacccttttt

caattttgcagcatgcagattctggatttaaattctgagtcttaacttactggctgagggaccttgggataggctccttat ccctcagtttcctcatctctaaaatggggatggcacctgcccgtgggttgttggaaggacttacagaggtgcagaatgt acgttgtacatagcaggtttcagcaaatgttagctccctctttccccacatccattcaaatctgttccttctccaaagga tgtgtcaaggaggaaatggacctggctgggaaaccctcagaatactgggatgatgctgagcttggctcatacctgtgctt $\verb|tgcttcaggccagtacggaattcccaggccctggtatttccttgcaccaagtcctactggtttggcgaggaaagtgat|\\$ GAGAAGAGCCACCCTGGTTCCAACCAGAAGAGAATGTCAGAAAgtaagtgctgttgacctcctgctctttctttaaccta gtgetgetgeetetgetaactgttgggggeaagegatgteteetgeetttetaaaagactgtgaaaccactccaggggca gagaaatcacatgcagtgtccctttccaaatcctcccatgccatttatgtccaatgctgttgacctattgggagttcacg gtotogatocotgagggacattttotttgttgtottggottotagaagagtatottttaottgoococtoccaaacacac tgacatggtgacctgtgtatcagcctgtgtgggctgagaccaagtggctaccacagagctcagcctatgcttcataatgt ctgggttctttgtgcttagagtggcttcctaaatatttaataggtcccttttctgccagtctcttctgtgcccatcccct gattgcccttggtaaaagtatgatgccccttagtgtagcacgcttgcctgctgttcctaatcatcttctcctacctcctc tttacacctagctcctgtttcagtcacctagaaatgctcacagtcgctggaatatgtcatgttcttccacacctccatgc ctttgtaggtactgtttgctctcacaggagaactttctctctaacttgcctatcttctctaactcctcctttctccaag gcacgtgaaagaaaatcttttttattttaaaacaattacagactcacaagaagtaatacaaattacatgagggggttccct taaacctttcatccagtttccccaatggtagcagcatgtgtaactgtagaatagtatcaaaaccatgaaattgacatagg caattttatcatgtgtgaattcatgtaattactagctcagtcaagctgcagaaatatctcattgtcacaaagctccttca tgctaccccttaatggccacagccacctcccttcttcctcagttcctgacacctgtcaaccactaatgcgttcctcgttt ccctgggagggtgtatcacagttccatggcatttttagatgtatttttaaaacagctttcagcatcctctattttaatt gtteatcaagteettttteeeaatagaetetgaatgeteetttateategtatteeeatea<mark>ceaceaceateagtaeeeaaa</mark>t ${\tt aggccctaaataaacatttatagcctcctgcctgagaaaccagggtggacatggagagaaggcacttctgaaagtt}$ caagcgcagtgcsctgtgtccttacactccactcctcagtgctttctgtgggttcatttctgtcttctctctgtcacag TCTGCATGGAGGAGGAACCCACCCACTTGAAGCTGGGCGTGTCCATTCAGAACCTGGTAAAAGTCTACCGAGATGGGATG GACGACCACCATgtaagaagagggtgtggttcccgcagaatcagccacaggagggttctgcagtagagttagaaatttat accttaggaaaccatgctgatccctgggccaagggaaggagcacatgaggagttgccgaatgtgaacatgttatctaatc atgagtgtctttccacgtgctagtttgctagatgttatttcttcagcctaaaacaagctggggcctcagatgacctttcc taattcccaggaactctgtctctaagcagatgtgagaagcacctgtgagacgcaatcaagctgggcagctggcttgattg ccttccctgcgacctcaaggaccttacagtgggtagtatcaggaggggtcaggggctgtaaagcaccagcgttagcctca gtggcttccagcacgattcctcaaccattctaaccattccaaagggtatatctttggggggtgacattcttttcctgttt tctttttaatcttttttaaaacatagaattaatatattatgagcttttcagaagatttttaaaaggcagtcagaaatcc atacaaaatacattttttaaagaatactttcattgcaaattggaaacttcgtttaaaaaaatgctcatactaaaattggca tttctaacccataggcccacttgtagttatttaccgaagcaaaaggacagctttgctttgtgtgggtctggtagggttca ggtcaaccctgacttctgtacttctaaatttttgtcctcagGTCAATCCTGACCGGGTTGTTCCCCCCGGACCTCGGGCAC CGCCTACATCCTGGGAAAAGACATTCGCTCTGAGATGAGCACCATCCGGCAGAACCTGGGGGTCTGTCCCCAGCATAACG $\verb|ctctgtagccaggctggactgtagtggcgcgatctcggctcactgcaaccttggcctcccaggttcaagcgattctcctg|$ cctcagcctcccgagtagctgggactctaggcacaccaccatgcccagctaatttttgtgttttttagtagagacgggg $\verb|tttcaccatgttggccaggatggtctcaatgtcttgacctcgtgatccgcccacctcggtctcccaaagtgctgggaaca| \\$ gcttgggaaacattgcttcccattattgtcatgctggagggccctttagcccatcctctcccccccgccaccctccttatt gaggeetggageagaetteeeagaeetggtagtgetteagggeeetggtatgatggaeetatatttgetgettaagaeat taaagtgaacacatggggctcatgtgcagggtcctccccgctttcagagcctgaggtcccctgaggctcaggaaggctgc tecaggtgagtgecgagetgaettettggtggaegtgetgtggggaeageecattaaagaecaeatettggggeeetgaa

attgaaagttgtaactgcctggtgcatggtggccaggcctgctggaaacaggttggaagcgatctgtcacctttcacttt gatttcctgagcagctcatgtggttgctcactgttgttctaccttgaatcttgaagattatttttcagaaattgataaag ttattttaaaaagcacggggagagaaaaatatgcccattctcatctgttctgggccaggggacactgtattctggggtat ccagtagggcccagagctgacctgcctccctgtccccaggCTGACTGTCGAAGAACACATCTGGTTCTATGCCCGCTTGA AGCAAAACAAGCCAGCTGTCAGgtgcggcccagagctaccttccctatccctctcccctcctccggctacacacatg cggaggaaaatcagcactgccccagggtcccaggctgggtgcggttggtaacagaaacttgtccctggctgtgcccctag gtoototgoottoactoactgtotggggotggtootggagtttgtottgototgtttttttgtagGTGGAATGCAGAGAA AGCTATCTGTGGCCTTGGCCTTTGTCGGGGGATCTAAGGTTGTCATTCTGGATGAACCCACAGCTGGTGTGGACCCTTAC TCCCGCAGGGGAATATGGGAGCTGCTGAAATACCGACAAGgtgcctgatgtgtatttattctgagtaaatggactga gagagagoggggggcttttgagaagtgtggctgtatctcatggctaggcttctgtgaagccatgggatactcttctgtta kcacagaagagataaagggcattgagactgagattcctgagaggagatgctgtgtctttattcatctttttgtccccaac cattgggaaagtcacaacttgcctcaccttctttgccgataataatagtggtgcgttacctcatagaggattaaattaaa tgagaatgcacacaaaccacctagcacaatgcctggcatatagcaagttcccaaataaaatgcgtactgttcttacctct gtgaggatgtggtacctatatatacaaagctttgccattctaggggtcatagccatacagggtgaaaggtggcttccagg tctcttccagtgcttacccctgctaatatctctctagtccctgtcactgtgacaaatcagaactgagaggcctcacctgt cccacatccttgtgttttgtgcctggcagGCCGCACCATTATTCTCTCTACACACCACATGGATGAAGCGGACGTCCTGGG GGACAGGATTGCCATCATCTCCCATGGGAAGCTGTGCTGTGTGGGCTCCTCCCTGTTTCTGAAGAACCAGCTGGGAACAG ctccatctccacccttttgccatgttgaaaccaccatctccctgctctgttgcccctttgaaatcatatcatacttaag gcatggaaagctaaggggccctctgctcccattgtgctagttctgttgaatcccgttttccttttcctatgaggcacana gagtgatggagaaggtccttagaggacattattatgtcaaagaaaagagacttgtcaagaggtaagagccttggctacaa atttcaaccttttttttttttaacctctatcatctcaattaaag

Genomic contig containging ABC1 exons 23 to 28:

gtgaacacacattaaagcatgagaagcatgaactagacatgtagccaggtaaaggccttgctgagatggttggcaaaggc ctcattgcagcattcattggcaggccacagttcttttggcagctctgcttcctgacctttcaccctcaggaagcgaggct ettcacacggcacacacatgccagacagggtcctctgaagccacggctgccagtgcatgtgtcccagggaaagctttttc ctttagttctcacacaacagagcttcttggaagccctccccggcgaaggtgctggtggctctgccttgcttccgtccctga $\verb|cccgttctcacctccttctttgccatcaggaggaCAGTGTTTCTCAGAGCAGTTCTGATGCTGGCCTGGGCAGCGACCAT| \\$ GAGAGTGACACGCTGACCATCGgtaaggactctggggtttcttattcaggtggtgcctgagcttcccccagctgggcaga gtggaggcagaggaggaggtgcagaggctggtggcgctgactcaaggtttgctgctgggctggggctgggtggctgcg tgtcccagagagctgagatgattgggggtttggggaatcccttaggggagtggacactgaataccagggatgaggatga gggccaagccaggagggtgggatttgagcttagtacataagaagagtgagagcccaggagatgaggaacagccttccaga $\verb|ttttcttgggtagcgtgttaggaggccagtgtcaccagtagcatatgtggaacagaagtcttgacccttgctatctct| \\$ $\verb|gagggaacctactttataagcataggaaagggtgaagaatcttttaagattcctttactcaagttttcttttgaagaatc|\\$ $\verb|catcctcccatcccatccacccatccacccatccacccatccacccattctacactgagtacctataatgtgcctgg|$ $\verb|ctttggtgatacaaaggtgaataagacatagtcctttcctttgcccccaaccctcagaccagagatgaacatgtggaatgaaccagagatgaacatgttggaatgaaccagagatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgttggaatgaacatgaacatgttggaatgaacataacatgaacataacataacatgaacatacataacataacataacataacataacataacataacataacatacata$ acctaaacacctggaacaggtgtggtgtatgagcggcaggcctctgatgagagggtgggggatggccagccctcactccg aagcccctctgagttgattgagccatctttgcattctggtcctgcagATGTCTCTGCTATCTCCAACCTCATCAGGAAGC ATGTGTCTGAAGCCCGGCTGGTGGAAGACATAGGGCATGAGCTGACCTATGTGCCCATATGAAGCTGCTAAGGAGGGA GCCTTTGTGGAACTCTTTCATGAGATTGATGACCGGCTCTCAGACCTGGGCATTTCTAGTTATGGCATCTCAGAGACGAC CCTGGAAGAAgtaagttaagtggctgactgtcggaatatatagcaaggccaaatgtcctaaggccagaccagtagcctgc attgggagcaggattatcatggagttagtcattgagtttttaggtcatcgacatctgattaatgttggccccagtgagcc atttaagatqqtaqtqqqaqataqcaqqaaaqaqtqttttcctctqtaccacaqtacatqcctqaqatttqtqttqt $\tt aaccagtggtacctaacacatttacatcccaaccttaaactcctatgcacttatttaccctttaatgagcctctttactt$ ${\tt aagtacagtgkgaggaacagcggcatcaggatcacttgggaacttgttagaaattcagcaacttgggcccagctcagacc}$ ctgtgacctcatttaattctcaaaaaaagatgaaaaatgaacactcaggaatgctgacatgagattcagaatcaggggt $\verb|ttggggcttcaaagtccatcctctttatccatgtaatgcctccccttagagatacaacatcacagaccttgaaggctg|$ aaggggatataaaagctgtctggccaagtggtctccaaqcttgacagtgcagcagaatcacctggggatattattaaaaa taaacatactaaqgtttggcttcagggcctgtgaatcagaatttctggaggtgaggccttgaagtctgtatttctattgc ctgccatcatatttctagtgctctatttcctcctgctcattctgtcttggataacttatcatagtactagcctactcaaa $\tt gatttagagccacagtcctgaaagaagccacttgactcattccctgtaggttcagaataaatttcttctgcgcagtgtct$ gtcatagctttttttaaatttttttttttttgatgagactggagttttgctcttattgcccaagctggagtgcagtgg tgcgatttttggctcactgcaacctccacctcccaggttcaagcgattctcctgcctcagcctcccaagtagctgagatta caagcatgtgctaccacgcccagctaattttgtatttttagtagagatgggttttatccatgttggtcaggctggtctcg agetecagaceteaggtgatetgecegeeteggeeteceaaagtgetgggattataggeetgageeacagegeteageea taactttaatttgaaaatgattgtctagcttgatagctctcaccactgaggaaatgttctctggcaaaaacggcttctct cccaggtaactctgagaaagtgttattaagaaatgtggcttctactttctctgtcttacggggctaacatgccactcagt TTCCTCAAGGTGGCCGAAGAGAGTGGGGTGGATGCTGAGACCTCAGgtaactgccttgagggagaatggcacacttaaga tagtgccttctgctggctttctcagtgcacgagtattgttccttttccctttgaattgttctattgcattctcatttgtag gatggtaccttgccagcaagacgaaacaggcgggccttcggggacaagcagagctgtcttcgcccgttcactgaagatga TGCTGCTGATCCAAATGATTCTGACATAGACCCAGgtctgttagggcaagatcaaacagtgtcctactgtttgaatgtga aatteteteteatgeteteacetgttttetttggatqqcetttagecaaggtgatagatecetacagagtccaaagagaa $\tt gtgaggaaatggtaaaagccacttgttctttgcagcatcgtgcatgtgatcaaacctgaaagagcctatccatatcactt$ tata cattaggtgtttaattgttgaacaaatattcattcgagtagatgagtgattttgaaagagtcagaaaggggaatttgctgttagagttaattgtaccctaagacttagatatttgaggctgggcatggtggctcatgccagtaatcccagcgcttt gagaggctgaggtgggtagatcacctgaggtcaggagtttgagaccagtctgaccaacaaggtgaaaccccgtctctact aaatacaaaaattagccgagtgtggtggcacatgcctgtcatcccagctacttgggaggctgaggcaggagaatcgctt gaacccaggaggcagaggttgcagtcagccacggttgcgccattgcactccagactgggcaacaagagtgaaaactccat ctcaaaaaagaaaaaaaaagaattagatattttggatgagtgtgtctttgtgtgttttaactgagatggagaggaggagcta

agacatcaaacaaatattgttaagatgtaaaagcacatcagttaggtatcattagtttaggacaaggatttctagaaaaat cttcatacagtatcagtacttagatcatttgaaatgtgtccacgttttaccaaaatataatagggtgagaagctgagatg ctaattgccattgtgtattctcaaatatgtcaagctacgtacatggcctgtttcatagagtagtctataagaaattgatg acttgattcatccgaatggctggctgtaacacctggttacgcatgaacacctcttttcagttgtctcaagacacctttct tttctgtacttatcagacaaggactgaaaggcagagactgctactgttagacattttgagtcaagcttttccttggacat agctttgtcatgaaagccctttacttctgagaaacttctagcttcagacacatgccttcaagatagttgttgaagacacc agaagaaggagcatggcaatgccgaaaacacctaagataataggtgaccttcagtgttggcttcttgcagAATCCAGAGA GACAGACTTGCTCAGTGGGATGGCAAAGGGTCCTACCAGGTGAAAGGCTGGAAACTTACACAGCAACAGTTTGTGG CCCTTTTGTGGAAGAGACTGCTAATTGCCAGACGGAGTCGGAAAGGATTTTTTGCTCAGgtgagacgtgctgttttcgcc ${\tt agagactctggcttcatgggttgggctgcaggctctgtgaccagtgaaggcaggatagcatcctggtcaagatatggatgc}$ cggagccagatttatctgtatttcaatcccagttctattccttgccagttgtgtgtatccgctggcaagttacttctctatg cctcaatctcctcatctgtaaaatggggataataatattacctgcaatacagggttgttacgaaaataaaaatgaatagg aaaggacaaagtgtagaaaaactggttgggtgtattcagctgtcataacatgagagttgttatgcccagatgcacttgac atgtgaatttattagaaacatgatttttctctgagttgatgtttaactcaaactgatagaaaagataggtcagaatatag ttggccaacagagaagacttgttagactattgtctgcatqtcagtgtttgcatgctaacttgcttagttagaaaggttaa attttttcactctataaaatcaagaaatatagagaaaaggtctgcagagagtctttcatttgatgatgtggatattgtta agagegggagtttggageataeagageteaagttgaateetgaetttgetaettattggetatatgaeetttgggeaaget gettagtetetetgateetcagttacetttgtttgttgatgatgaceattgataacacacaccataaataatgacaacata gagatagttctcattatagtagttgttatacagaattattcactcaatgttaattttctgcattgaaatcccagaacatt agaattgggggcattatttgaatctttaaggttataaggaatacatttctcagcaataaatggaaggagttttgggttaa cttataaagtatacccaagtcattttttttcagagaagatatggtagaaagtcttaggaggttgaagaaggaattggata tttattctttctgagactatcatgggagataatgactatggttgtccatgattggagccgttgctgtagagttggtttta ttatagtgtaggatttgaatgggccatgtgttctcagacctcagaataaaaagagaaaactgaggccagtggggagcgtg acttcacatgggtacacttgtgctagagacagaaccaggattcaggacttctggctcctggtcctgggttcatggcccaa tgtagtctttctcagtcttcaggaggaggaaggcaggacccagtgttctgagtcaccctgaatgtgagcactatttact tegtgaacttettggettagtgeetetgeeaggtggeeataacetetggeettgtgttgeeagagaaaaggtttagtttt caggctccattgcttcccagctgccaagaatgccttggtgcagcacagtcataggccctgcattcctcattgccgtgctg gttggtcggggaggtgggctggactcgtagggatttgccccttggccttgtttctaacacttgccgtttcctgctgtccc cctgcccctccactgcctgggtaaagATTGTCTTGCCAGCTGTGTTTTGTCTGCATTGCCCTTGTGTTCAGCCTGATCGT GCCACCCTTTGGCAAGTACCCCAGCCTGGAACTTCAGCCCTGGATGTACAACGAACAGTACACATTTGTCAGgtatgttt gtcttctacatcccaggaggggtaagattcgagcagaccaaagatgtttacgagggccaagggaatggacttcagaatt acacggtggaat

Genomic contig containg ABC1 exon 29:

gcccacattttcttcttacatagttcaggtttactttattttttcctttccggctgctgaccctgtattgcccgtagttg ttgccctttcttggaaaatcctgcttgtctgtgccaaagggataattgtgaaagcacttttgaaatacttaatgagttga cccatttaaaacaagctccactttggagtgctctacgtcaccctgatgccgaatacagggccagagtctgagatccttct gggtggtttctgtgttttgttcatttctgttttaagagcctgtcacagagaaatgcttcctaaaatgtttaatttataaa ${ t CAATCCC}$ gtgagtgccactttagccataagcagggcttcttgtgcttgttgcctggtttgatttctaatatgctgcattt gtaaccgaactaaattatctaggaacaaacgtttggagagtcttctaacaccgyscaaagcacgtcattacagacatttg tttactgatttagaaccttaatatttaatttaaatacgcactttacacttactgatgaaatgcttttcctttctct $\verb"cccagcccctgtacttaagtgcttcaataggctctcattatatatgatttttaggttttgcttatcagcttcttcgcttt$ tataatctgaaaagatggcatatgaatttttataaaaagggacactttcttcttctcaaattgtatatttttattgtact taggggaagggaggtcaccagatcactgtgagtgaagatggtgagaggtgaggatcttatgaggccgtgctcaaggctg gtagaggtgggttagtgtttccaggtttaggcagaatctcagctgaggtcatgaaacaacagtgatctctgaaaaattat ggcaaggtgggaaggtgctggagaattggagagggggcaaacttgactttcaagtttcaatgggaagataggtgactctg cacaccacagaacagtgagcatgataacctgtttatacaaggttctagagcagatttctaaatggatagctactgtgtgc ttgtttgttcttaattagtattggatagttactaaatacttgttagtacttagtacataatgggtggtaaatcctagcag ctaatattggttcccaaataaccagatgacaaggatagagaaggacacagacacggcctatctggatttcatggtgcctt tgattttccacatgaaggttgtgtagggaagatagaagcatgagatgagatgataatatagttatctggattcatcactg gccagctgaaccatatgaactcatggattgatgctagcttaggaaggctctgtaggagccagaactgggctgagagccag cccatagagacaaaagaggcccggccctgacatcagagggttcaaacatgatgtctgagccccacctacagtctgccgga ggtggttggaaggaagagcctttatccttacaattcttactgaaattcaaatttttaggttttgcaaaaaaatggtggac ctgaaggaaatttgacaggagcatgtctcagctgtatttaaatttgtctcagccaatccccttttgaatgttcagagtgt aagcttcaggagggcagcgcgtcttagtgtgacttttctggtcagttcaggtgctttaaggagacaattagagatcaatc ctctgttgcccaggctggagtgcagtggctcaatcttggctcactgccacctctgcctcccaggttcaagtgattctcct acctcagcctcctgagtagctgggattacaagcatgtgccaccacactggctaa

Genomic contiq containing ABC1 exons 30 and 31:

tettgecagtetetacteatttttcageacategageataagatecagaetettteecaggeeteteteatetggeteet ctcctcctcttatcattactcttcttcgtagcttatcctactccagccatgctgtcttcctattattcctaaaaarta gaaatgcatttetteetagggeetttgtacetgeacttgeeategettttgeteagaatgttetttttgeeaagettttg $\verb|cccagcttgttctccatcattgttatgttttggctgaaatgtcttctctttagtaggttcattctccccagtcactgtctt|\\$ tttatttttqctttattttgggccatctaaggttatcttattaqtqtatttgttgttcgtctcctccatgggcatacacct ccatgaaggcaggtattttcaccttaggccctcgaatatactggacagcatctggcacgtagtagatgctcaacgaatgt ttgttgtgtgagcaaatggttggttgattggattgaactgagttcagtatgtaaatatttagggcctcttttgcattctat tttacttatqtataaaatgatacataatgatgatataaatqatqtcacagtgtacaaggctgttgtgggatcaagcaatc $a a atgagat catg \verb|ctt| titcc| catagtg agggaat agatg catgtttg tg tg ttacggaatg atcctg tg ctc|$ ctgaggcaacagaaaggccaggccatctctggtaatcctactcttgctgtcttccctttgcagAGACACGCCCTGCCAGG CAGGGGAGGAAGAGTGGACCACTGCCCCAGTTCCCCAGACCATCATGGACCTCTTCCAGAATGGGAACTGGACAATGCAG AACCCTTCACCTGCATGCCAGTGTAGCAGCGACAAAATCAAGAAGATGCTGCCTGTGTGTCCCCCAGGGGCAGGGGGGCT GCCTCCTCCACAAgtgagtcactttcagggggtgattgggcagaaggggtgcaggatgggctggtagcttccgcttggaa ttgctctqtcqcccaqqctggagtgctgtggcatgatcttqcctcactgcaacctccacctcccaggttcaagcgattct agggtttcgccgtgttggctaggctggtctggaattcctgacctcaggtgatccacccgcctcggcctcccaaagtgctg ggattacaggcgtgagccactacgcccagccctgtttcagtctttaactcgcttcttgtcataagaaaaagcatgtgagt tttgaggggagaaggtttggaccacactgtgcccatgcctgtcccacagcagtaaagtcacaggacagactgtggcaggc ctggcttccaatcttggctctgcaacaaatgagctggtagcctttgacaggcctgggcctgtttcttcacctctgaatta gggaggctggaccagaaaactcctgtggatcttgtcaactctggtattcttagagactctgtttgggaaggagtcctgag ccattttttttttttcttgagaatttcaggaagaggagtgcttatgatagctctctgctgcttttatcagcaaccaaattgc aggatgaggacaagcaattctaaatgagtacaggaactaaaagaaggcttggttaccactcttgaaaataatagctagtc caggtgcggggtggctcacacctgtaatctcagtattttgggatgccgaggtggactgatcacctaaggtcaggagttcg aaaccagcttggccaatgtggcgaaaccctgtctctactaaaaattcaaaaattagccaggcatggtggcacatgcctgt aatcccagttacttgggaggctgaagcaggagaattgcttgaacctgggaggtggaggtcgcagggagccaaaattgcgc cactgtactccaqcctgagcaacacagcaaaactccatatcaaaaaataaaatgaataaaataacagctaatctagtcat cagtataactccagtgaacagaagatttattaggcatagtgaatgatggtgcttcctaaaaaatctcttgactacaaagaa tctcatttcaatgtttattgtttagatgttcagaataaattcttgggaaagaccttggcttggtgtaagtgaattaccag tgccgagggcagggtgaaccaagtctcagtgctggttgactgagggcagtgtctgggacctgtagtcaggtttccggtca cactgtggacatggtcactgttgtccttgatttgttttctgtttcaattcttgtctataaagacccgtatgcttggtttt catgtgatgacagAGAAAACAAAACACTGCAGATATCCTTCAGGACCTGACAGGAAGAAACATTTCGGATTATCTGGTGA AGACGTATGTGCAGATCATAGCCAAAAGGtgactttttactaaacttggcccctgccttattattactaattagaggaat taaagacctacaaataacagactgaaacagtgggggaaatgccagattatggcctgattctgtctattggaagtttagga tattatcccaaactagaaaagatgacgagagggactgtgaacattcagttgtcagcttcaaggctgaggcagcctggtct agaatgaaaatagaaatggattcaacgtcaaattttgccac

Genomic contig containing ABC1 exon 32:

Genomic contig containing ABC1 exons 33 to 36:

gctttatagagtttctgcctagagcatcatggctcagtgcccagcagcccctccagaggcctctgaatatttgatatact ttgtactttcccccaaaccagattcccgaggcttcttaaggactcaaggacaatttctaggcatttagcacgggactaa aaaggtettagaggaaataagaagegecaaaaceatetetttgeaetgtattteaacecatttgteettetgggttttga aggaacaggtgggactggggacagaagagttcttgaagccagtttgtccatcatggaaaatgagataggtgatgtggcta tetetgggcagagcagacgcaggcccctataatagccctcatgctagaaaggagccggagcctgtgtataaggccagcgc agoctactctggacagtgcagggttcccactctcccaactccccatctgcttgcctccagacccacattcacacacgagc cactgggttggaggagcatctgtgagatgaaacaccattctttcctcaatgtctcagctatctaactgtgtgtaatca ggccaggtcctccctgctgggcagaaaccatgggagttaagagattgccaacatttattagaggaagctgacgtgtaact tctgaggcaaaatttagccctcctttgaacaggaatttgactcagtgaaccttgtacacactcgcactgagtctgct gatgatactgtgcaccccactgtctgggttttaatgtcaggctgttcttttagGTATGGCGGCTTTTCCCTGGGTGTCAG taaaatatctatcgtaagatgtatcagaaaaatgggcatgtagctgctgggatataggagtagttggcaggttaaacgga $\verb|tcacctggcagctcattgttctgaatatgttggcatacagagccgtctttggcatttagcgatttgagccagacaaaact|$ gaattacttaqttqtacgtttaaaagtgtaggtcaaaaacaaatccagaggccaggagctgtggctcatgcctgtaatcc tagcactttgggaggetgaagegggtggateaettgaggteaggagttegagaeeageetggeetacatgaeaaaeeee gtatctactaaaaatacaaaaaattagctgggcttggtggcacacctgtaatcccagctacttgggaggctgaggca ggagaattgcttgaaccctgtaggaagaggttgtagtgagccaagatcgcaccgttgcactccagcctgggcaacaagag caaaactccatctcaaaaaacaaattaaatccagagatttaaaagctctcagaggctgggcgcgggtggcttacacctgtt atcccagcattttgggatgccgaggcgggcaaagcacaaggtcaggagtttgagaccagcctggccaacatagtgaaacc tgagagaattrettgaacccgggaggcggaggttgcagtgageccagattgcaccactgcactccagcctgggcgacaga taggacctgataagtactcacttcatttctctgtgtctcaggtttcccatttttaggtgagaattaaggggctctgataa aacagaccctaggattgtggacagcagtgatagtcctagagtccacaagtctgcttttgagtgatgggcccatgtatctg gcacatctgcaggcagagcgtggttctggctcttcagatgatgccggtggagcactttgaggagtcctcaccccaccgtg ataaccagacattaaaatcttggggctttgcatcccaggatttctctgtgattccttctagacttgtggcatcatggcag ggtagtggcattgctcttcacagggccgtcctgttgtccacaggttccagattgactgttgccccttatctatgtgaaca gtcacaactgaggcaggtttctgttttacagGACAGTTCTGCAGATCGATTTCTCAACAGCTTGGGAAGATTTATGAC AGGACTGGACACCAGAAATAATGTCAAGgtaaaccgctgtctttgttctagtagctttttgatgaacaataatccttatg tttcctggagtactttcaactcatggtaaagttggcaggggcattcacaacagaaaagagcaaactattaactttaccag tgaggcagtacggtgtagtgtagtgattcagagaatttgctttgccaccagacataccaggtaaccttgactaagttact taacctatctaaacctcagttycctcatctgtgaaatggagacagtaatcatagctatttccaaactgttgtgagaattc aatgagttaaaggtataaggtcctcaccacagegcctgcccacatagtcagtgatcactatgtcctgaacactgtaatta TAACAAGGGCTGGCATGCAATCAGCTCTTTCCTGAATGTCATCAACAATGCCATTCTCCGGGCCAACCTGCAAAAGGGAG AGAACCCTAGCCATTATGGAATTACTGCTTTCAATCATCCCCTGAATCTCACCAAGCAGCAGCTCTCAGAGGTGGCTCTq taagtgtggctgtgtctgtatagatggagtggggcaagggagagggttatggagaaggggagaaaaatgtgaatctcatt gtaggggaacagctgcagagaccgttatattatgataaatctggattgatccaggctctgggcagaagtgataagtttac gaattggctggttgggcttcttgaactgcagaagagaaaatgacactgatatgtaaaaatcgtaacatttagtgaattca tataaagtgagttcaaaaattgttaattaaattataatttaattataagtgtttaatcagtttgatttgtttaaaaacca gtgtgtgtgtgtgtgtgtgtgtgtgtgtgaagtttaaagccaggatgagctagtttaaagtatgcagcctttggagtc atacagatctgggtttgaatctggtctctaaactttatagatgtatgatattaaatgaggcagttcatgtaaattgccaa gcccagcactcagcacagagttgatatttcacacacattagatacctttcctgtatgtggagcatggcagttcctgtttc tgctttactcctacaggatactaatataggacactaggatctttataccaagaccccatgtaatgggcttatgagaccat tettettataaaaatetgaeagaatttttgtatgtgttagateaataggetgeataetgttattttcaagttgatttaca gccagaaatattaatttatttgagtagttacagagtaatatttctgctctcatttagttttcaagccccactagtccttt gtgtgtgaaaatttacaacttactgctcttacaaggtcatgaacagtggaccaaagtgaatgccattaaccactctgact tectteattaqttttattgtgacagtggactettttgaceteagtaataceagtttggcatttacattgtcatattttta gacttaaaaatgatcatcttaaccctgaataaaatgtgtctggtgaacagatgtttttccttggctgtgcctcagatatc

totgtgtgtgtgttacgtgtgttttgtctgtgtgtccatgtcctcactgattgagccctaactgcatcaaagacccctca gattttcacacgctttttctctccagGATGACCACATCAGTGGATGTCCTTGTGTCCATCTGTGTCATCTTTTGCAATGTC CTTCGTCCCAGCCAGCTTTGTCGTATTCCTGATCCAGGAGCGGGTCAGCAAAGCAAAACACCTGCAGTTCATCAGTGGAG TGAAGCCTGTCATCTACTGGCTCTCTAATTTTGTCTGGGATATGgtaaggacacaggcctgctgtatctttctgatgtct gtcagggccatggattgatatggataagaaagaagatcttggctatcatcaggaaatgttccagctactctaaagatg tatgaaaaagaaatagccagaggcaggtgatcactttcatgacaccaaacacagcattgggtaccagagttcatgtcaca $\verb|ccagagggaaaattctgtacacaatgatgaaaattaataccactaccacttaagttcctatgtgacaactttcccaagaa|\\$ tcagagagatacaagtcaaaactccaagtcaatgcctctaacttctctgatgggttttaacctccagagtcagaatgttc tgtttttgtgccasccacaatattgcttctatttggaccaatatgggggatttgaaggaattctgaagttctaattat ctaattcttctcccaccgaacaagtccctggatatttaaaaataactctcatactctcatttaacctgagtattacccag ataagatgatatatgagaatacaccttgtaacctccgaagcactgtacaaatgtgagcaatgatggtggagatgatgatg agatetttgetgtttataccaageceettagaetgtgteaetettetgateeggttgteettgtatggeeatgetgtata ttgtgaatgtcccgttttcaaaagcaaagccaagaattaaccttgtgttcaggctgtggtctgaatggttatgggtccag agggagttgatctttagctcacacttctattactgcagcacaaagattttgcattttggaaggagcaccgtcttactggc aacttagtggtaaaccaaaacctccatttcacacaaatgattgtgaaattcgggtctccttcattctatacaaattcatt tgattttttttgaaactaaactttatatttatccatattaaattacatgggttttatttttgttttatcttgattcagtaa ttactcctttcagtaaacacagactgagtgctgtgtctgacttatgccaggcataggtgattcagagatgaaaggtca tgtcttcatctaagttgttgataaacacatcaagtaggattggactgaggcagagccctgtagtctgaagctgcagttct tetageggetgaeaagecceactateacttecetgetggtgetttgetetgeeagetgtgaatteteataattgteetat cgtcaagtctttatttctgcattttactgcttgatacactgtcaggacagactttaaaattattctcagtgcgatgaaac aattotgacattoatgttatgagcagttacctcataaatagattacatg

Genomic contig containing ABC1 exons 37 to 41:

aaattactctgactgggaatccatcgttcagtaagtttactgagtgtgacaccttggcttgactgttggaaagacagaaa $\verb|gggcatgtagttataaaatcagccaaggggaaaatgcttgtcaaaatgtattgtcgggtattttgattaatagtttatg|$ tggcttcattaattcagagttactctccaatatgtttatctgccctttcttqtctgataatggtgaaaacttgtgtgtgtg cattgtatatttgatttaggggtgaactggatgtctttgttttcacttttagTGCAATTACGTTGTCCCTGCCACACTGG TCATTATCATCTTCATCTGCTTCCAGCAGAAGTCCTATGTGTCCTCCACCAATCTGCCTGTGCTAGCCCTTCTACTTTTG CTGTATGGctaagtcacctctgagtgagggagctgcacagtggataaggcatttggtgcccagtgtcagaaggagggcag ggactctcagtagacacttatctttttgtgtctcaacagGTGGTCAATCACACCTCTCATGTACCCAGCCTCCTTTGTGT TCAAGATCCCCAGCACAGCCTATGTGGTGCTCACCAGCGTGAACCTCTTCATTGGCATTAATGGCAGCGTGGCCACCTTT GTGCTGGAGCTGTTCACCGACAATgtgagtcatgcagagagaacactcctgctgggatgagcatctctgggagccagagg acagtgtttaattgtgatcttattccacttgtcagtggtattgacactgctgactgccttgtcctgtcttcagagtctgt cttccctgagaaggcaaagcactttctttcttgctgtgccttacattttgctggtcaagcctttcagtttcttttgaca gttttttttacttcttttttttcaatgttgctcttaccaagagtagctcctctgccttccactttacacatgagagct gggcgacgcattcagtcctaaggcttttaccatcacctctcttggtgttttttattgtcatctctaagatcaatgccttta gccttgatcataaccttgaactctaatctcaaattctcacttgcctagtggattgctccatttagatagtatatagatac cccaacctggatatgtcctagttttctttccccttggaacttaatgcttttcttgccatccctgtcacactcagtggcac actggttatgttgtcagttcttccaggtatggacctctaaaataaggcttcctctccattccggttgtcattgcctttgt ccaaacacagcacacaaggccttttacagttqcacaactcttcctgtccatacccaccacaccctttcccagctgtaagc ttcagatgagttgcctccaaccaccatgctcctqtaqqcctggcttgaaatgcccttcttctgtcacagggtctggtagt atatecettgeeetteaagatttagetaaaatgtgaagettteettaeetgetgggaggtgttetetettttetetgtge totcagagtcottagtcoatgcotcoagtacaacgtacatcoacttacatggtaatttcotgtttacatacttttcotac teggagtggagtetgtttettaataattttgeeteteeeatgeeetageaeagtgeateeagegtatageeeettattea gttggtagatatttggccactgttgccttgtgqgatcataagttctgatgtatttgagaagaatttctaaaaattctgaca aaatcctgaaactcaaatattgacccagacatgagcaatttgcttttcaaatgctaagggatttttaatggatttgcttt aattaaatctagcctgtttctaagctttattcattatttctccatactcagagcatttctccagattttctaaagaatag aattttattgctacatatcatcagctatgcctgctgctatttaattggtatctgaattaaaaggtctggtttgtccctag CGTGTTCTTGATCTTCCCACATTTTTGCCTGGGACGAGGGCTCATCGACATGGTGAAAAACCAGGCAATGGCTGATGCCC TGGAAAGGTTTGgtgagtgaagcagtggctgtaggatgctttaatggagatggcactctgcataggccttggtaccctga actttgttttggaaagaagcaggtgactaagcacaggatgttccccccacccccatgcccagtgacagggctcatgccaac acagctggttgtggcatgggttttgtgacacaaccatttgtctgtgtctctgtatagcattgagaaaagtgaaagggcagt aagtcaaaccataactttgagaattaggtgatcagggaatcagaaggaaagatgcaaactttggctcttttaggcgaatc atgtgcctgcagatgaggtcatttattatcttttacacagtctataaaattataatgtattacatctttttctaccttta gaatggttaaaaatatttctccggtagccatatgattattattcatccattagataatatagtcaaatgggccatgttat ttactgttcatagaagagggctttttgcaacttgggctacaaaggagatatgtaaggaatttaaggaatggttacatgg a acta gattta att gaatct ag t gg t t ta att gattcact ag gata t at gc t act ga a ag gg ga at c t gc t ta a ag t gc taaaaggatttttggcatgtctcattaaaaaaagaaatactagatatcttcagtgaagttacaaatcgaatacacattggc tctgaaattctgattgatactgggtcataaaaaagttttcccaaatcagacttggaaagtgatcactctcttgttactctt ttttccttgtcatgggtgatagccatttgtgtttattggaagatcggtgaattttaaggaacataggcccaaatttgagg aagggccatggtttttgatccctccattctgaccggatctctgcattgtgtctactagGGGAGAATCGCTTTGTGTCACC ATTATCTTGGGACTTGGTGGGACGAAACCTCTTCGCCATGGCCGTGGAAGGGGTGGTGTTCTTCCTCATTACTGTTCTGA TCCAGTACAGATTCTTCATCAGGCCCAGgtgagctttttcttagaacccgtggagcacctggttgagggtcacagaggag gcgcacagggaaacactcaccaatgggggttgcattgaactgaactcaaaatatgtgataaaactgattttcctgatgtg ggcatcccgcagccccctccctgcccatcctggagactgtggcaagtaggttttataatactacgttagagactgaatct $\verb|ttgtcctgaaaaatagtttgaaaggttcatttttcttgttttttcccccaage \verb|ACCTGTAAATGCAAAGCTATCTCCTCTG||$ AATGATGAAGATGAAGATGTGAGGCGGGAAAGACAGAGATTCTTGATGGTGGAGGCCAGAATGACATCTTAGAAATCAA gtttgctgacttgcttaataaaagggcatgtgttcccaaaatgtacatctataccaaggttctgtcaattttattttaaa aacaccatggagacttcttaaagaattcttactgagaattcttttgtgatatgaattcccattctcgaatactttggttt tatatgcttacatttatgtgttagttattaaaacatactaatattgtatatctagtcaaactgagtagagagataatggt gatt

Genomic contig containing exons 42 through 45:

ttttaaaatacctgcaatacatatatgttgaatagatgaaaaattatgtagatgataatgaatgatacggttctaaaa agacaggttaaaaagtaagttcacttttattttgagcttcagaatcattcagaagccagtcgccacaaacgcagaccaag gctcttggcacatcaaatatgcctatggcttagggttattgacaagtcttatgttgcagtgtatgtggtttatagtcctg GGAAGCGGAAGCCTGCTGTTGACAGGATTTGCGTGGGCATTCCTCCTGGTGAGgtaaagacactttgtctatattgcgtt tgtccctattagttcagactatctctacccaatcaagcaacgatgctcgttaagaggtaaaagtggattttaaaggcttc tgtatttatgccaggatggagcaattagtcatcgagaagagagggaccctgtatgtcaagagaatgatttcagagaatcc aatacaatttaagaaaaagcatggggctgggcgcagtgattcactcctgtaatcccagcactttgggaggccgaggtggg cggactcacgaggtcaggagattgagaccatcctggccaacatggtgaaaccccatctctactataaatacaaaaattag ctgggcatagtagtgcattcctgtagtcccagctactcgggaggctgaggcaggagaattgcttgaacctaggagggga ggttgcccagattgcgctgctgcactccagcctggtgacagagtgagactcatgtcaacaacaacaacagaaaaagcacg cacatctaaaacatgcttttgtgatccatttgggatggtgatgacattcaaatagttttttaaaaaatagattttccctt tctggtttccgtttgtgttcttttatgcccttttgccagagtaggtggtgcaatttggctagctggctttcattactgtt tttcacacattaactttggcctcaacttgacaactcaaataatattataaatacagccacacttaaaatggtcccatta tgaaatacatatttaaatatctatacgatgtgttaaaaccaagaaaatatttgattcttctctgatatttaagaattgaa ggtttgaggtagttacgtgttaggggcatttatattcatgtttttagagtttgcttatacaacttaatctttccttttca gtgctttgggctcctgggagttaatggggctggaaaatcatcaactttcaagatgttaacaggagataccactgttacca GAGGAGATGCTTTCCTTAACAAAAATAGgtgagaaaagaagtggcttgtattttgctgcaaagactttgtttttaattta tttaaagaaataggttgttatttttgattacagtggtatttttagagttcataaaaatgttgaaatatagtaaagggtaa agaagcacataaaatcatccatgatttcaatatctagagataatcacaatttacatttcctttcagtctcattcttct tttaacagotttattoaggtataatttacatacaatataatttgottgtttttaagagtataatttagtgatttttggt aaattgagagttttgcaaccatcaccacaatccagttttagaacttttccatcaccccacatctgtcttatatacacata tttcccagtgggttacatttcctaagatgtggaattttacattgctacataaaatccccctatgtacatgtacctataat ttatttaataaattccttataaatgttggacacattagtttccatttttcactatgtaaatatgtccctgtatacatctt ttattatttcctcaggaacaattcctacaaagtaaattgccctctctaaagagcatacaaattgactgagccaccgttag gccattttctgagactgcacaggtcacaaagcaatctgatctttgggaatacagctacattttataggcttcttagataa ggctggagagcaatggcgcgaccttggctcactgcaacctccgcctcccaggttcaagcgattctcctgcctcagcctcc gttggccagactggtctcgagctcctgacctcaggtgatccacctgcctcagcctcccaaagttctgggattacaggcat gagccactgcgcccggcttctctggacttattatgtggagagatagtacaaggcagtggctttcagagtttttttgaccat gaccgttgtgggaaatacattttatatctcaacctagtatgtacacacagacatgtagacacatgtataacctaaagttt cataaagcagtacctactgttactaattgtagtgcactctgctatttcttattctaccttatactgcgtcattaaaaaag tgctggtcatgacccactaaatttatttcccaaaccactaatgaacaatgactcacaatttgaacacactggacaggggg atagccaataaaattgaaaagagcaaggaaattaatgtattcatgatctcctctcctgtctcttacattttttgcagtagc aatgtaaaggaatcctaagagaacagacattctgggaatagcaggcctagcgctgcacaactgctttcctaggcttgctc ctagtaccaagctcctgacgcatatagcagtggcagtaataaccagcccatagtaaggtttgtcacagggactggttgta agaactgatttgrttggtatagctgtgagggcctggcacggtgtccacgtgtgcctcaatcctaattctgaaaaaggctg ccaaagccacccaccaccacataaattgtgtctctaggttctgtgttgctcacactcaaaatttctgggccttctcatt tggtgcatgtgaatggtgcatatgagtgaagtctaggatggggccttagcgttaaagccctggggtagtgtgactgagat tgttggtaaagaatgtgcagtggttggcatgacctcagaaattctgaaatgggactgcacctgcagactgaagtgttcag agagecagggaggtgcaaggactgggggagggtagaggeaggaaccetgeetgecaggaagagetagcateetgggggeag aaaggctgtgctttcaagtagcagcagatgtattggtatctttgtaatggagaagcatactttacaggaacattaggcca gattgtctaaccagagtatctctacctgcttaaaatctaagtagttttcttgtcctttgcagTATCTTATCAAACATCCA $\tt TGAAGTACATCAGAACATGGGCTACTGCCCTCAGTTTGATGCCATCACAGAGCTGTTGACTGGGAGAGAACACGTGGAGT$ TCTTTGCCCTTTTGAGAGGAGTCCCAGAGAAAGAAGTTGGCAAGgtactgtgggcacctgaaagccagcctgtctccttt ggcatcctgacaatatataccttatggcttttccacacgcattgacttcaggctgtttttcctcatgaatgcagcagcac gtgctgctcccaccacgagtcccttctccctgctttggctcctcaccagttgtcaggttatgattatagaatctagtc ctactcagtgaaagaactttcatacatgtatgtgtaggacagcatgataaaattcccaagccagaccaaagtcaaggtgc tttttatcactgtagGTTGGTGAGTGGGCGATTCGGAAACTGGGCCTCGTGAAGTATGGAGAAAAATATGCTGGTAACTA TAGTGGAGGCAACAAACGCAAGCTCTCTACAGCCATGGCTTTGATCGGCGGGCCTCCTGTGGTGTTTCTGgtgagtataa

Genomic contig containing ABC1 exons 46 to 49:

ngccnnqttnaaaanqaaaatttnnnnnaaattnaannttannggngnnntttcccccagaaaaaacnaaaangatttccn cccnggggggncccccnantcnaaaaggccccncttntttgnggngagggaaagnttttttggaatttttaatttttgg tcccccaaaacctattattgagaatttaattacataaaaaagtactcagaatatttgagtttcctgcatcaataagacat ttataataatqaccttgtttacaaatgaatttgaaagttactctaattctttgattcatcaagaaataactagaatggca aagacttattttattctaattacagGATGAACCCACCACAGGCATGGATCCCAAAGCCCGGCGGTTCTTGTGGAATTGTG CCCTAAGTGTTGTCAAGGAGGGGAGATCAGTAGTGCTTACATCTCATAGgtccgtagtaaagtcttgggttcctcactgt gggatgttttaactttccaagtagaatatgcgatcattttgtaaaaattagaaaatacagaaaagcaaagagtaaaacaa ttattacctgaaattatatatgcatattcttacaaaaatgcaagcccagtataaatactgctctttttcacttaatatat tgtaaacattattccaagtcagtgcatttaggtgtcatttcttatagctggatagtattccattaggatatactcttatt taactattcccccttttgtagacatttggattatttccaacttqttcacaattqtaaacaccactacactgaacagcatc atccctatatccacatgtacttgtaacagaatacaattccctaggaagctggaatgctggaagtcatggtgatgttctca tggttacagagaatctctctaaaactaaaacctctttctgttttaccgcagTATGGAAGAATGTGAAGCTCTTTGCACTA GGATGGCAATCATGGTCAATGGAAGGTTCAGGTGCCTTGGCAGTGTCCAGCATCTAAAAAATAGgtaataaagataattt ctttgggatagtgcctagtgagaaggcttgatatttattcttttgtgagtatataaaatggtgcctctaaaataaagggaa ataaaactgagcaaaacagtatagtggaaagaatgagggctttgaagtccgaactgcattcaaattctgtctttaccatt tgctatagatgaaatgaaaaaaatttacatgtgccagtactggtgagagcgcaagctttggagtcaaacacaaatgggtt tgcatcctggccctaccaattatgagctctgagccatgggcaagtgactaactccctgggcctcagtttctctgtaacat ctgtcagacttcatqggtccaggtgaggattaaaggagatcatgtatttacagcacatggcatggtgcttcacataaaat aagtatttagtaaatgataactggttccttctctcagaaacttatttctgggcctgccaggggccgccctttttcatggc acaagttggqttcccagggttcagtattcttttaaatagttttctggagatcctccatttgggtatttttcctgctttc aggtttggagatggttatacaatagttgtacgaatagcagggtccaacccggacctgaagcCtgtcCaggatttctttgg ACTTGCATTTCCTGGAAGTGTTCYAAAAGAGAAACACCGGAACATGCTACAATACCAGCTTCCATCTTCATTATCTTCTC TGGCCAGGATATTCAGCATCCTCTCCCAGAGCAAAAAGCGACTCCACATAGAAGACTACTCTGTTTCTCAGACAACACTT GACCAAgtaagctttgagtgtcaaaacagatttacttctcagggtgtggattcctgccccgacactcccgcccataggtc caagagcagtttgtatcttgaattggtgcttgaattcctgatctactattcctagctatgctttttactaaacctctctg aacctgaaaagggagatgatgcctatgtactctataggattattgtgagaatttactgtaataataaccataaaaactac catttagtgagcacctaccatgggccaggcattttacttggtgcctaatcctatttaaattagataaaaaagtaccaaat aggtcctgacacttaagaagtactcagtaaatattttcttccctcttccctttaatcaagaccgtatgtgccaaagtaaa tggatgactgagcagttggtgatgtagggggtgggggggatatagaaagtcagtttttggccggggcgtggtggctcatgc ctgtaatcccagcactttgggaggctgaggagcaggcagatcatgaggtcaggagatccagataatcctggccaacaggg tgaaaccccgtctctactaaaaatacaaaattagctgggcatggtggtgcgcacttgtagtcccagctacttgcgaggc tgaggcaggagaattgctcgaacccaggaggtggaggttacagtgagccaaggtctcgccactgcactccagcctgggga cagagcaagaccccatttcaaggggggaaaaaagtctattttaagttgttattgctttttcaagtattcttccctcc ttcacacacagttttctagttaatccatttatgtaattctgtatgctcctacttgacctaatttcaacatctggaaaaaat agaactagaataaagaatgagcaagttgagtggtatttataaaggtccatcttaatcttt**taacagGTATTTGTGAACTT** TGCCAAGGACCAAAGTGATGATGACCACTTAAAAGACCTCTCATTACACAAAAACCAGACAGTAGTGGACGTTGCAGTTC AGAGGAACTAGACTTTCCTTTGCACCATGTGAAGTGTTGTGGAGAAAAGAGCCAGAAGTT**GATGTGGGAAGAAGTAAAC**T GGATACTGTACTGATACTATTCAATGCAATGCAATTCAATGcaatgaaaacaaaattccattacaggggcagtgcctttg tagcctatgtcttgtatggctctcaagtgaaagacttgaatttagttttttacctatacctatgtgaaactctattatgg ${\tt taattcatcaagtaatcatggccagcgattattgatcaaaatcaaaaggtaatgcacatcctcattcactaagccatgcc}$ atgcccaggagactggtttcccggtgacacatccattgctggcaatgagtgtgccagagttattagtgccaagtttttca gaaagtttgaagcaccatggtgtctcatgctcacttttgtgaaagctgctctgctcagagtctatcaacattgaatatca gttgacagaatggtgccatgcgtggctaacatcctgctttgattccctctgataagctgttctggtggcagtaacatgca acaaaaatgtgggtgtctccaggcacgggaaacttggttccattgttatattgtcctatgcttcgagccatgggtctaca gggtcatccttatgagactcttaaatatacttagatcctggtaagaggcaaagaatcaacagccaaactgctggggctgc aactgctgaagccagggcatgggattaaagagattgtgcgttcaaacctagggaagcctgtgcccatttgtcctgactgt $\verb|ctgctaacatggtacactgcatctcaagatgtttatctgacacaagtgtattatttctggctttttgaattaatctagaa|\\$ aatgaaaagatggagttgtattttgacaaaaatgtttgtactttttaatgttatttggaattttaagttctatcagtgac $\verb|ttctgaatccttagaatggcctctttgtagaaccctgtggtatagaggagtatggccactgcccactattttatttct|$ tatqtaaqtttqcatatcagtcatgactagtgcctagaaagcaatgtgatggtcaggatctcatgacattatatttgagt





Fig. 13



7ig. 14

Fig. 15

No.	Name	Location in SEQ ID No. 14	Sequence	Sequence Strand
	DODE	50 60	ACCTALLACTCA	Length
	PPRE	58-69	AGGTAAAAGTCA	12 Complement
	PPRE	1997-2009	AGAGTAGAGGGCA	13 Lead
	PPRE	2150-2161	ATGTCAAGTTCA	12 Lead
	PPRE	2156-2169	AGTTCAAAAGGGCA	14 Lead
	PPRE		AGGCCAGCAGGCC	14 Complement
6	PPRE	5075-5087	AGGGCAGAAGTGA	13 Lead
7	PPRE	6604-6615	ATGCCAAGGTCA	12 Complement
8	PPRE	6731-6743	GGGGCAAGGGTA	13 Complement
9	PPRE	7220-7233	AGGTAATGAGGACA	14 Complement
10	PPRE	7554-7568	GGATCACGAGGTCA	15 Complement
1	SRE	159-166	CAGCCCAT	8 Lead
2	SRE	1133-1140	CAGCTCAC	8 Complement
3	SRE	1145-1152	CACACCAC	8 Lead
4	SRE	1809-1816	CAGCCCTC	8 Complement
5	SRE	1894-1901	CAGCCCAT	8 Lead
	SRE	2563-2570	CAACCCAC	8 Lead
	SRE	3303-3310	CAGCTCAC	8 Lead
	SRE	3470-3477	CCGCCCAC	8 Lead
	SRE	4784-4791	CTCCCCAC	8 Complement
	SRE	4802-4809	CAGCCTAC	8 Complement
	SRE	4970-4977	CACCTCAC	8 Complement
	SRE	6487-6494	CAGCCTAC	8 Complement
	SRE	6565-6572	CACCCAAC	· ·
	SRE	6727-6734	CACCCTAC	
	SRE	7041-7048	CACCCAAC	
	SRE	8059-8066	CAGCCCTC	
10	SKE	6039-6066	CAGCCCIC	o Complement
4	POP/retipole and reporter related	166-172	AGGGTCA	7 Complement
	ROR(retinoic acid receptor related)			•
	ROR(retinoic acid receptor related)		AAGGGTCA	•
	ROR(retinoic acid receptor related)		ATGGGTCA	
	ROR(retinoic acid receptor related)		TGGGTCA	
	ROR(retinoic acid receptor related)		TAGGGTCA	
	ROR(retinoic acid receptor related)		AGGGTCA	
7	ROR(retinoic acid receptor related)		TGGGTCA	
8	ROR(retinoic acid receptor related)	6604-6610	AAGGTCA	7 Complement
1	SREBP-1 or "E box"	473-479	ACACCTG	7 Complement
2	! SREBP-1 or "E pox"	536-541	ACACATG	7 Lead
3	SREBP-1 or "E box"	537-543	TCATGTG	7 Complement
4	SREBP-1 or "E box"	655-661	TCATGTG	7 Complement
5	SREBP-1 or "E box"	925-931	ACACTTO	7 Lead
6	SREBP-1 or "E box"	967-973	TCACTTG	7 Lead
7	SREBP-1 or "E box"	968-974	TCAAGTG	7 Complement
8	S SREBP-1 or "E pox"	1063-1069	ACAGGTG	7 Complement
9	SREBP-1 or "E box"	1104-1110	TCACTTO	7 Lead
10	SREBP-1 or "E box"	1105-1111	TCAAGTG	7 Complement
11	SREBP-1 or "E box"	1561-1567	TCACTTO	5 7 Lead
12	SREBP-1 or "E box"	1670-1676	TCAAATG	7 Lead
13	SREBP-1 or "E box"	1748-1754	ACACTTO	7 Lead
14	SREBP-1 or "E box"	1749-1755	ACAAGTO	G 7 Complement
	SREBP-1 or "E box"	1852-1858	TCATGTO	7 Lead
16	S SREBP-1 or *E box"	1853-1859	ACACATO	7 Complement
	SREBP-1 or "E box"	1899-1905		
	S SREBP-1 or "E box"	2199-2205		,
	SREBP-1 or "E box"	2393-2399		7 Complement
	SREBP-1 or "E box"	2659-27005		•
	SREBP-1 or "E box"	2677-2683		
	2 SREBP-1 or "E box"	2740-2746		
	3 SREBP-1 or "E box"	2969-297		•
	SREBP-1 or "E box"	2979-298		
	5 SREBP-1 or "E box"	2981-298		
	6 SREBP-1 or "E box"	2980-2980		
	7 SREBP-1 or "E box"	2982-298		•
	B SREBP-1 or "E box"	3461-346		
	9 SREBP-1 or "E box"	3462-346		
	0 SREBP-1 or "E box"	3547-355		
	1 SREBP-1 or "E box"	3752-375		•
	2 SREBP-1 or "E box"	4226-423		
	3 SREBP-1 or "E box"	4582-458		
	4 SREBP-1 or "E box"	4582-456 4588-459		· ·
	5 SREBP-1 or "E box"	4588-459 4861-486		
		4951-495		
	6 SREBP-1 or "E box"			
	7 SREBP-1 or "E box"	5096-510		
	8 SREBP-1 or "E box"	5912-591		
	9 SREBP-1 or "E box"	5913-591		•
	0 SREBP-1 or "E box"	6245-625		
	1 SREBP-1 or "E box"	6288-629		·
	2 SREBP-1 or "E box"	6623-662		
	3 SREBP-1 or "E box"	6836-684		
	4 SREBP-1 or "E box"	6837-684		·
4	5 SREBP-1 or "E box"	7032-703	8 ACAGGT	G 7 Complement

Fig. 16

46 SREBP-1 or "E box"	7069-7075	TCAGGTG	7 Lead
47 SREBP-1 or "E box"	7101-7107	ACATATG	7 Complement
48 SREBP-1 or "E box"	7138-7144	ACAGTTG	7 Lead
49 SREBP-1 or "E box"	7139-7145	TCAACTG	7 Complement
50 SREBP-1 or "E box"	7240-7246	ACACCTG	7 Complement
51 SREBP-1 or "E box"	7467-7473	ACAGGTG	7 Lead
52 SREBP-1 or "E box"	7640-7646	TCATTTG	7 Lead
53 SREBP-1 or "E box"	7641-7647	TCAAATG	7 Complement
54 SREBP-1 or "E box"	7653-7659	TCAGTTG	7 Lead
55 SREBP-1 or "E box"	7654-7660	ACAACTG	7 Complement
56 SREBP-1 or "E box"	7735-7741	ACAAATG	7 Lead
57 SREBP-1 or "E box"	7838-7844	TCAGGTG	7 Complement
58 SREBP-1 or "E box"	7880-7886	TCATCTG	7 Complement
59 SREBP-1 or "E box"	8051-8057	TCAGCTG	7 Lead
60 SREBP-1 or "E box"	8052-8058	TCAGCTG	7 Complement

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS, the specification of which

is attached hereto.	
☐ was filed on	as Application Serial No
and was amended on	
☐ was described and claim	ned in PCT International Application No
filed on	and as amended under PCT Article 19 on
•	and understand the contents of the above-identified specification, by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

FOREIGN PRIORITY RIGHTS: I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?		
			Yes/No		

PROVISIONAL PRIORITY RIGHTS: I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status	
60/124,702	March 15, 1999	Pending	
60/138,048	June 8, 1999	Pending	
60/139,600	June 17, 1999	Pending	
60/151,977	September 1, 1999	Pending	

COMBINED DECLARATION AND POWER OF ATTORNEY

NON-PROVISIONAL PRIORITY RIGHTS: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status				

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No.36,268, James D. DeCamp, Ph.D., Reg. No. 43,580.

Address all telephone calls to: Paul T. Clark at 617/428-0200.

Address all correspondence to: Paul T. Clark at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship	
Michael R. Hayden Vancouver, British Columbia CANADA		4484 West 7 th Avenue Vancouver, British Columbia V6R 1W9 CANADA	USA and CANADIAN	
Signature:	Date:			

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship		
Angela R. Wilson Richmond, British Columbia CANADA		7100 Langton Road Richmond, British Columbia V7C 4B2 CANADA	CANADIAN		
Signature:	Date:				

		Post Office Address (Street, City, State, Country)	Citizenship		
Simon N. Pimstone Vancouver, British Columbia CANADA		4746 West 6 th Avenue Vancouver, British Columbia V6T 1C5 CANADA	CANADIAN		
Signature:			Date:		

SEQUENCE LISTING

- <110> Hayden, Michael R. Wilson, Angela R. Pimstone, Simon N.
- <120> METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
- <130> 50110/002005
- <150> 60/124,702
- <151> 1999-03-15
- <150> 60/138,048
- <151> 1999-06-08
- <150> 60/139,600
- <151> 1999-06-17
- <150> 60/151,977
- <151> 1999-09-01
- <160> 287
- <170> FastSEQ for Windows Version 4.0
- <210> 1
- <211> 2261
- <212> PRT
- <213> Homo sapiens
- <400> 1
- Met Ala Cys Trp Pro Gln Leu Arg Leu Leu Trp Lys Asn Leu Thr 1 5 10 15
- Phe Arg Arg Gln Thr Cys Gln Leu Leu Glu Val Ala Trp Pro 20 25 30
- Leu Phe Ile Phe Leu Ile Leu Ile Ser Val Arg Leu Ser Tyr Pro Pro 35 40 45
- Tyr Glu Gln His Glu Cys His Phe Pro Asn Lys Ala Met Pro Ser Ala 50 55 60
- Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn Ala Asn Asn Pro 65 70 75 80
- Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn
 85 90 95
- Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp Ala Arg Leu 100 105 110
- Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp Met Arg Lys Val
- Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser Asn Leu Lys Leu

	130					135					140				
Gln		Dhe	Leu	Val.	Λαn		GI 11	Thr	Dhe	Cor		Dho	T 011	TT 770	пia
145	тър	FIIC	пец	vai	150	Abii	GIU	TIIT	PIIC	155	СТУ	PHE	ьеи	туг	160
	T. 211	Ser	Leu	Dro		Car	Thr	17a l	Λαn		Mot	T 021	7 200	ח ד ת	
Abii	цец	DET	пец	165	пуъ	per	TIIL	vaı	170	пув	Mec	шеu	AIG		Asp
1727	T10	T 021	His		۲ <i>۲</i> - 1	Dho	T 011	01 n		TT- 120	<i>a</i> 1	Т олг	TT-1 -	175	mla sa
vaı	TTE	цец	180	пуъ	vai	PIIE	цец	185	GIY	туг	GIII	ьеи		ьеи	1111
G07	Τ 011	Cara	Asn	~1	0.22	Trra	Core		a1	M	T1.	a1	190	a3	7\
per	пеп	195	ASII	GIY	ser	пув	200	GIU	GIU	Met	тте		ьец	GTA	Asp
Cl.	<i>α</i> 3		C	a1	T	C		T	D	70	~ 7	205	T	- T -	7 7 -
GIII		vaı	Ser	GIU	ьeu		GIY	ьeu	Pro	arg		ьуѕ	ьeu	Ala	Ala
7.7.~	210	7\ ~~~	77a 7	т от	7) 200	215	7	16 - L	7	-7 -	220	T	D	-1	T
225	GIU	Arg	Val	ьец	230	ser	ASII	мет	Asp		ьеи	ьуѕ	Pro	ile	
	The se	Τ 011	7. 0. 20	Com		C	D	Dl	D	235	T	a 1	T	7 . 7	240
ALG	1111	пеп	Asn	245	TIIT	ser	PLO	Pne		ser	ьys	GIU	ьеu		GIU
7/10	Thr	Tara	Thr		T 011	TI i a	Cox	T 011	250	⊞b so	T 011	7. 7. ~	<u>ما ت</u>	255	T
Ата	1111	пуъ	260	пец	цец	птр	ser	265	СТУ	TILL	ьеи	Ата		GLU	ьeu
Dhe	Cor	Mο+	Arg	Car	Trn	Cor	7 an		7.20	Cln	C7.11	7727	270	Dho	T 011
FIIC	DCI	275	Arg	SCI	ттЪ	SET	280	Mec	AIG	GIII	GIU	285	Mec	PHE	ьеи
Thr	Agn		Asn	Car	Car	cor		Car	Thr	Cln	T10		Cln	7.7.0	7707
1111	290	vai	ADII	DCI	DCI	295	DET	DCI	1111	GIII	300	тут	GIII	ALA	vai
Ser		T1e	Val	Czza	G] 37		Dro	<i>(</i> 2] 11	G137	@lsz		T.011	Tard	T10	Laza
305	H19	110	vai	СуЗ	310	1112	FIO	GIU	Сту	315	Gry	пец	пуъ	TTC	320
	Len	Agn	Trp	Tvr		Asn	Δan	Δαn	Туг		Δla	T.e.11	Dhe	G157	
				325	014	TIDE	21011	11011	330	Lyb	1114	пси	1110	335	O _T y
Asn	Glv	Thr	Glu		Asp	Ala	Glu	Thr		Tvr	Asp	Asn	Ser		Thr
	1		340		<u>-</u> -			345	1110	-7-	пър	11011	350		****
Pro	Tyr	Cvs	Asn	Asp	Leu	Met	Lvs		Leu	Glu	Ser	Ser		Leu	Ser
	1	355		L			360					365			
Arq	Ile	Ile	Trp	Lvs	Ala	Leu		Pro	Leu	Leu	Val		Lvs	Tle	Leu
,	370					375	-1				380	<u>1</u>	1		
Tyr	Thr	Pro	Asp	Thr	Pro	Ala	Thr	Arq	Gln	Val		Ala	Glu	Val	Asn
385			_		390			_		395					400
Lys	Thr	Phe	Gln	Glu	Leu	Ala	Val	Phe	His	Asp	Leu	Glu	Gly	Met	Trp
				405					410	_			-	415	-
Glu	Glu	Leu	Ser	Pro	Lys	Ile	Trp	Thr	Phe	Met	Glu	Asn	Ser	Gln	Glu
			420					425					430		
Met	Asp	Leu	Val	Arg	Met	Leu	Leu	Asp	Ser	Arg	Asp	Asn	Asp	His	Phe
		435					440					445			
Trp	Glu	${\tt Gln}$	${\tt Gln}$	Leu	Asp	Gly	Leu	Asp	Trp	Thr	Ala	Gln	Asp	Ile	Val
	450					455					460				
Ala	Phe	Leu	Ala	Lys	His	Pro	Glu	Asp	Val	Gln	Ser	Ser	Asn	Gly	Ser
465					470					475					480
Val	Tyr	Thr	${\tt Trp}$	Arg	Glu	Ala	Phe	Asn	Glu	Thr	Asn	Gln	Ala	Ile	Arg
				485					490					495	
Thr	Ile	Ser	Arg	Phe	Met	Glu	Cys	Val	Asn	Leu	Asn	Lys	Leu	Glu	Pro
			500					505					510		
Ile	Ala	Thr	Glu	Val	Trp	Leu	Ile	Asn	Lys	Ser	Met	Glu	Leu	Leu	Asp
		515					520					525			
Glu		Lys	Phe	Trp	Ala		Ile	Val	Phe	Thr	Gly	Ile	Thr	Pro	Gly
	530					535					540				

Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile 550 555 Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro 570 565 Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly 580 585 Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu 600 Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr 615 Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met 630 635 Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile 650 645 Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg 665 Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser 680 Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu 695 Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val 710 715 Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile 725 730 Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Cys Gly Gly Ile 740 745 Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala Trp Gln 760 Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro 775 780 Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Gln 790 795 Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu 805 810 Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr 820 825 830 Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly 840 Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr 855 860 Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln 870 875 Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met 905 Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile 920 Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Met Ser 935 940 Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu

945					950					955					960
Gly	Lys	Asp	Ile	Arg 965	Ser	Glu	Met	Ser	Thr 970	Ile	Arg	Gln	Asn	Leu 975	Gly
Val	Cys	Pro	Gln 980	His	Asn	Val	Leu	Phe 985	Asp	Met	Leu	Thr	Val 990	Glu	Glu
His	Ile	Trp 995	Phe	Tyr	Ala	Arg	Leu 1000	Lys	Gly	Leu	Ser	Glu 1005	Lys	His	Val
Lys	Ala 1010	Glu	Met	Glu	Gln	Met 1015	Ala		Asp	Val	Gly 1020	Leu		Ser	Ser
Lvs	Leu	_	Ser	Lvs	Thr			Leu	Ser	Glv			Gln	Ara	Lvs
1025		•		-	1030					1035	_			_	1040
Leu	Ser	Val	Ala	Leu	Ala	Phe	Val	Gly	Gly	Ser	Lys	Val	Val	Ile	Leu
				1045				-	1050		-			1055	
Asp	Glu	Pro	Thr 1060		Gly	Val	Asp	Pro 1065	-	Ser	Arg	Arg	Gly 1070		Trp
Glu	Leu		Leu		Tyr	Arg		Gly		Thr	Ile		Leu		Thr
ui a	TT i a	1075		α1.,	77.	7	1080		71.	7 ~~	7 ~~~	1085		т1.	Tlo
	His 1090)	_			1095	5		_	_	1100)			
		Gly	Lys	Leu	_	_	Val	Gly	Ser			Phe	Leu	Lys	Asn
110		_	_		1110			_		1119				_	1120
Gln	Leu	Gly	Thr	Gly 112!	_	Tyr	Leu	Thr	Leu 1130		Lys	Lys	Asp	Val 1135	
Ser	Ser	Leu	Ser 1140	Ser		Arg	Asn	Ser 1145	Ser		Thr	Val	Ser 1150		Leu
Larc	Taza	G3.11			v. l	Car	Gln.			Cor	7 an	7.7.5			Gly
цур	цуз	1155	_	Ser	vai	DCI	1160		DCI	DEL	Азр	1165	_	пец	GIY
Ser	Asp			Ser	Agn	Thr			Tle	Δsn	Val			Tle	Ser
501	1170		Ciu	501	тър	1179		1111		тър	1180		1114	110	DCI
Asn			Ara	Lvs	His			Glu	Ala	Ara			Glu	Asp	Ile
1185			ے	4	1190					119				I-	1200
		Glu	Leu	Thr			Leu	Pro	Tyr			Ala	Lys	Glu	Gly
*				120	_				1210				1	1215	_
Ala	Phe	Val	Glu	Leu	Phe	His	Glu	Ile	Asp	Asp	Arg	Leu	Ser	Asp	Leu
			1220	С				1225	5				1230)	
Gly	Ile	Ser	Ser	Tyr	Gly	Ile	Ser	Glu	Thr	Thr	Leu	Glu	Glu	Ile	Phe
		1235	5				1240)				1245	5		
Leu	Lys	Val	Ala	Glu	Glu	Ser	Gly	Val	Asp	Ala	Glu	Thr	Ser	Asp	${ t Gly}$
	1250)				125	5				1260)			
Thr	Leu	Pro	Ala	Arg	Arg	Asn	Arg	Arg	Ala	Phe	Gly	Asp	Lys	Gln	Ser
126	5				1270)				1275	5				1280
Cys	Leu	Arg	Pro	Phe 1289		Glu	Asp	Asp	Ala 129		Asp	Pro	Asn	Asp 1295	
Asp	Ile	Asp	Pro	Glu	Ser	Arg	Glu	Thr	Asp	Leu	Leu	Ser	Gly	Met	Asp
			1300					1309					1310		
Gly									_	_	-		~ 7		_
	Lys			Tyr	Gln	Val			Trp	Lys	ьeu			Gln	Gln
Dho		1315	5				1320	C				1325	5		
	Val	1319 Ala O	5 Leu	Leu	Trp	Lys 1335	1320 Arg 5) Leu	Leu	Ile	Ala 1340	132! Arg)	ā Arg	Ser	Arg
	Val	1319 Ala O	5 Leu	Leu	Trp	Lys 1335	1320 Arg 5) Leu	Leu	Ile	Ala 1340	132! Arg)	ā Arg	Ser	Arg

Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser 1365 1370 Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser 1380 1385 Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu 1400 Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile 1415 1420 Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro 1430 1435 Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met 1445 1450 Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys 1465 1460 Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Gln 1480 1485 1475 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn 1490 1500 1495 Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser 1510 1515 1520 Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser 1530 1525 Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser Gln Glu Val Asn 1540 1545 Asp Ala Ile Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser 1560 1565 Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu 1575 1580 Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His 1590 1595 Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala 1610 1605 1615 Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe 1625 1630 Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Leu 1635 1640 1645 Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala 1655 1660 Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg 1670 1675 Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val 1690 1695 1685 Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val 1700 1705 1710 Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser 1720 1725 Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu 1735 1740 Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe 1750 1755

Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe

				1765	5				1770)				1775	5
Ile	Gly	Ile	Asn 1780	_	Ser	Val	Ala	Thr 1785		Val	Leu	Glu	Leu 1790		Thr
Asp	Asn	Lys 1795	Leu	Asn	Asn	Ile	Asn 1800	-	Ile	Leu	Lys	Ser 1805		Phe	Leu
Ile	Phe 1810		His	Phe	Cys	Leu 1815	-	Arg	Gly	Leu	Ile 1820	_	Met	Val	Lys
Asn 1825		Ala	Met	Ala	Asp 1830		Leu	Glu	Arg	Phe 1835		Glu	Asn	Arg	Phe 1840
Val	Ser	Pro	Leu	Ser 1845		Asp	Leu	Val	Gly 1850		Asn	Leu	Phe	Ala 1855	
Ala	Val	Glu	Gly		Val	Phe	Phe			Thr	Val	Leu			Tyr
			1860					1865		_			1870		_
Arg	Phe	Phe 1875	Ile	Arg	Pro	Arg	Pro 1880		Asn	Ala	Lys	Leu 1885		Pro	Leu
Δqn	Δan		Asp	Glu	Agn	Val			Glu	Δra	Gln			T.em	Agn
ASII	1890		тър	Giu	дър	1895		Arg	Gru	Arg	1900	_	110	пси	nap
Gly	Gly	Gly	Gln	Asn	Asp	Ile	Leu	Glu	Ile	Lys	Glu	Leu	Thr	Lys	Ile
1905	5				1910)				1915	5				1920
Tyr	Arg	Arg	Lys	Arg 1925		Pro	Ala	Val	Asp 1930		Ile	Cys	Val	Gly 1935	
Dro	Dro	C1	~1.,			C1	T 011	T 033			7. a.m	C1.	7.7.		
PIO	PIO	GIY	Glu 1940		PHE	GIY	neu	1945		vai	ASII	GIY	1950		пуъ
Ser	Ser	Thr	Phe	Lys	Met	Leu	Thr	Gly	Asp	Thr	Thr	Val	Thr	Arq	Gly
		1955		-			1960		-			1965			•
Asp	Ala	Phe	Leu	Asn	Lys	Asn	Ser	Ile	Leu	Ser	Asn	Ile	His	Glu	Val
-	1970				•	1975					1980				
His	Gln	Asn	Met	Gly	Tyr	Cys	Pro	Gln	Phe	Asp	Ala	Ile	Thr	Glu	Leu
1985				2	1990					1995					2000
Leu	Thr	Gly	Arg	Glu	His	Val	Glu	Phe	Phe	Ala	Leu	Leu	Arg	Gly	Val
				2005					2010					2015	
Pro	Glu	Lys	Glu		Gly	Lys				Trp	Ala	Ile			Leu
Glv	T. - 211	7727	2020	-	G] v	Glu		2025		G] w	λan	ጥ ኒ ፖንዮ	2030	-	Gly
Оту	пси	2035		тут	Сту	GIU	2040		Ата	оту	VÖII	2045		Сту	Сту
Δen	Taze		Lys	T.e.11	Ser	Thr			Zla	T.011	Tle			Dro	Dro
ADII	2050		пув	пси	DCI	2055		ricc	AIG	пси	2060		ОТУ	110	FIO
Val			T.e11	Δan	G111			Thr	Glv	Met			Taze	Δla	Arg
2065		FIIC	пец	Asp	2070		T 11T	TIIL	GIY	2075		FIO	пуъ	ΑΙα	2080
		T. 🗕 21	Trp	Δen			T. - 11	Ser	TeV			Glu	Glv	7\ ra	
Arg	FIIC	пец	ттр	2085	-	ALG	пец	Det	2090		цуъ	GIU	Сту	2095	
Va I	77 = 77	T.e.ii	Thr			Ser	Met	Glu			Glu	Δla	T. - 31		
val	vai	шси	2100		111.13	DCI	FICE	2105		Cys	Giu	лти	2110	-	T 11T
Δra	Met	Δla	Ile		Val	Δan	Glv			Δra	Cvs	T.e.11			Val
****9	1100	2115		1100	vai	11011	2120		1110	Arg	Cyb	2125		DCL	Val
Gln			Lys	Asn	Arg		_	Asp	Gly	Tyr			Val	Val	Arg
_~	2130		_	_	_	2135		_	_		2140		_,	_,	
		Gly	Ser	Asn		_	Leu	Lys	Pro			Asp	Phe	Phe	_
2145			_	a -	2150			-	~ 7	2155		_	_		2160
Leu	Ala	Phe	Pro			Val	Leu	ГЛS			His	Arg	Asn		
				2165	>				2170	J				2175)

```
Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
                                2185
Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
        2195
                            2200
                                               2205
Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
                        2215
Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
2225
                    2230
                                       2235
Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
                2245
                                    2250
Lys Glu Ser Tyr Val
            2260
<210> 2
<211> 7864
<212> DNA
<213> Homo sapiens
<400> 2
qtccctqctq tqaqctctqq ccqctqcctt ccaqqqctcc cqaqccacac qctqqqqqtq
                                                                      60
ctggctgagg gaacatggct tgttggcctc agctgaggtt gctgctgtgg aagaacctca
                                                                     120
                                                                     180
tcctgatcct gatctctgtt cggctgagct acccacccta tgaacaacat gaatgccatt
                                                                     240
ttccaaataa agccatgccc tctgcaggaa cacttccttg ggttcagggg attatctgta
                                                                     300
atgecaacaa ceeetgttte egttaceega eteetgggga ggeteeegga gttgttggaa
                                                                     360
actitaacaa atccattgtg gctcgcctgt tctcagatgc tcggaggctt cttttataca
                                                                     420
gccagaaaga caccagcatg aaggacatgc gcaaagttct gagaacatta cagcagatca
                                                                     480
agaaatccag ctcaaacttg aagcttcaag atttcctggt ggacaatgaa accttctctg
                                                                     540
ggttcctgta tcacaacctc tctctcccaa agtctactgt ggacaagatg ctgagggctg
                                                                     600
atgtcattct ccacaaggta tttttgcaag gctaccagtt acatttgaca agtctgtgca
                                                                     660
atggatcaaa atcagaagag atgattcaac ttgqtgacca agaagtttct qagctttgtq
                                                                     720
                                                                     780
gcctaccaag ggagaaactg gctgcagcag agcqagtact tcqttccaac atggacatcc
tgaagccaat cctgagaaca ctaaactcta catctccctt cccgagcaag gagctggctg
                                                                     840
aagccacaaa aacattgctg catagtcttg ggactctggc ccaggagctg ttcagcatga
                                                                     900
gaagctggag tgacatgcga caggaggtga tgtttctgac caatgtgaac agctccagct
                                                                     960
cctccaccca aatctaccag gctgtgtctc gtattgtctg cgqgcatccc gaggqagggg
                                                                    1020
ggctgaagat caagtctctc aactggtatg aggacaacaa ctacaaagcc ctctttggag
                                                                    1080
gcaatggcac tgaggaagat gctgaaacct tctatgacaa ctctacaact ccttactgca
                                                                    1140
atgatttgat gaagaatttg gagtctagtc ctctttcccg cattatctgg aaagctctga
                                                                    1200
agccgctgct cgttgggaag atcctgtata cacctgacac tccagccaca aggcaggtca
                                                                    1260
tggctgaggt gaacaagacc ttccaggaac tggctgtgtt ccatgatctg gaaqgcatgt
                                                                    1320
gggaggaact cagccccaag atctggacct tcatggagaa cagccaagaa atggaccttg
                                                                    1380
tccggatgct gttggacagc agggacaatg accacttttg ggaacagcag ttggatqgct
                                                                    1440
tagattggac agcccaagac atcgtggcgt ttttggccaa gcacccagag gatgtccagt
                                                                    1500
ccagtaatgg ttctgtgtac acctggagag aagctttcaa cgagactaac caggcaatcc
                                                                    1560
ggaccatatc tegetteatg gagtgtgtea acctgaacaa getagaacce atagcaacag
                                                                    1620
aagtetgget catcaacaag tecatggage tgetggatga gaggaagtte tgggetggta
                                                                    1680
ttgtgttcac tggaattact ccaggcagca ttgagctqcc ccatcatqtc aaqtacaaqa
                                                                    1740
tccgaatgga cattgacaat gtggagagga caaataaaat caaggatggg tactgggacc
                                                                    1800
etggteeteg agetgaeeee tttgaggaea tgeggtaegt etggggggge ttegeetaet
                                                                    1860
```

tgcaggatgt ggtggagcag gcaatcatca gggtgctgac gggcaccgag aagaaaactg

gdgtgtctat	atgcaacaga	tgccctatcc	ctgttacgtt	gatgacatct	ttctgcgggt	1980
	tcaatgcccc					2040
	atcgtgtatg					2100
	agcatcctct					2160
	ctgctagtgg					2220
	tttgtcttcc					2280
	ctcttctcca					2340
	ctgccctacg					2400
	gctagcctgc					2460
	gagcagggca					2520
	ttcaatctca					2580
	acctggtaca					2640
	ccttgcacca					2700
	aaccagaaga					2760
	gtgtccattc					2820
	ctggcactga					2880
	aagacgacca					2940
	atcctgggaa					3000
	ccccagcata					3060
	cgcttgaaag					3120
	gttggtttgc					3180
	agaaagctat					3240
	cccacagctg					3300
	cgacaaggcc					3360
	gacaggattg					3420
	aagaaccagc					3480
	ctcagttcct					3540
	tctcagagca					3600
	gatgtctctg					3660
	gacatagggc					3720
	gtggaactct					3780
	atctcagaga					3840
	gctgagacct					3900
	cagagetgte					3960
	agacccagaa					4020
	ggtgaaaggc					4080
	aattgccaga					4140
	ctgcattgcc					4200
	acttcagccc			-		4260
	cacgggaacc					4320
	tatggaagga					4380
	tgccccagtt					4440
	cccttcacct					4500
	cccaggggca					4560
	ggacctgaca					4620
	caaaagctta					4680
	tgtcagtaat					4740
	gaagaaacac					4800
	aagatttatg					4860
	ctggcatgca					4920
	gcaaaaggga					4980
333	5	3 3	3 99			

```
5040
ccctgaatct caccaagcag cagctctcag aggtggctct gatgaccaca tcagtggatg
teettgtgte catetgtgte atetttgeaa tgteettegt eecageeage tttgtegtat
                                                                 5100
tcctgatcca ggagcgggtc agcaaagcaa aacacctgca gttcatcagt ggagtgaagc
                                                                 5160
                                                                 5220
ctgtcatcta ctggctctct aattttgtct gggatatgtg caattacgtt gtccctgcca
                                                                 5280
cactggtcat tatcatcttc atctgcttcc agcagaagtc ctatgtgtcc tccaccaatc
tqcctqtqct aqcccttcta cttttqctqt atqqqtqqtc aatcacacct ctcatqtacc
                                                                 5340
                                                                 5400
cagoctcott tgtgttcaag atcoccagca cagoctatgt ggtgctcacc agogtgaacc
tetteattgg cattaatgge agegtggeea cetttgtget ggagetgtte acegacaata
                                                                 5460
                                                                 5520
agctgaataa tatcaatgat atcctgaagt ccgtgttctt gatcttccca catttttgcc
tgggacgagg gctcatcgac atggtgaaaa accaggcaat ggctgatgcc ctggaaaggt
                                                                 5580
                                                                 5640
ttggggagaa tcgctttgtg tcaccattat cttgggactt ggtgggacga aacctcttcg
ccatggccgt ggaaggggtg gtgttcttcc tcattactgt tctgatccag tacagattct
                                                                 5700
tcatcaggcc cagacctgta aatgcaaagc tatctcctct gaatgatgaa gatgaagatg
                                                                 5760
tgaggcggga aagacagaga attcttgatg gtggaggcca gaatgacatc ttagaaatca
                                                                 5820
aggagttgac gaagatatat agaaggaagc ggaagcctgc tgttgacagg atttgcgtgg
                                                                 5880
gcattcctcc tggtgagtgc tttgggctcc tgggagttaa tggggctgga aaatcatcaa
                                                                 5940
ctttcaagat gttaacagga gataccactg ttaccagagg agatgctttc cttaacaaaa
                                                                 6000
                                                                 6060
ataggtatct tatcaaacat ccatgaagta catcagaaca tgggctactg ccctcagttt
                                                                 6120
gatgccatca cagagctgtt gactgggaga gaacacgtgg agttctttgc ccttttgaga
ggagtcccag agaaagaagt tggcaaggtt ggtgagtggg cgattcggaa actgggcctc
                                                                 6180
gtgaagtatg gagaaaaata tgctggtaac tatagtggag gcaacaaacg caagctctct
                                                                 6240
acagecatgg ctttgatcgg cgggcctcct gtggtgtttc tggatgaacc caccacaggc
                                                                 6300
atggatccca aagcccggcg gttcttgtgg aattgtgccc taagtgttgt caaggagggg
                                                                 6360
agatcagtag tgcttacatc tcatagtatg gaagaatgtg aagctctttg cactaggatg
                                                                 6420
gcaatcatgg tcaatggaag gttcaggtgc cttggcagtg tccagcatct aaaaaatagg
                                                                 6480
tttggagatg gttatacaat agttgtacga atagcagggt ccaacccgga cctgaagcct
                                                                 6540
gtccaggatt tctttggact tgcatttcct ggaagtgttc taaaagagaa acaccggaac
                                                                 6600
atgctacaat accagettee atetteatta tettetetgg ceaggatatt cageateete
                                                                  6660
toccagagoa aaaagogact ccacatagaa gactactotg tttotcagac aacacttgac
                                                                 6720
caagtatttg tgaactttgc caaggaccaa agtgatgatg accacttaaa agacctctca
                                                                 6780
ttacacaaaa accagacagt agtggacgtt gcagttctca catcttttct acaggatgag
                                                                 6840
aaagtgaaag aaagctatgt atgaagaatc ctgttcatac ggggtggctg aaagtaaaga
                                                                 6900
ggaactagac tttcctttgc accatgtgaa gtgttgtgga gaaaagagcc agaagttgat
                                                                 6960
7020
atgaaaacaa aattccatta caggggcagt gcctttgtag cctatgtctt gtatggctct
                                                                 7080
caagtgaaag acttgaattt agttttttac ctatacctat gtgaaactct attatggaac
                                                                 7140
7200
cattggggtt gcaacaataa ttcatcaagt aatcatggcc agcgattatt gatcaaaatc
                                                                 7260
7320
gtgacacatc cattgctggc aatgagtgtg ccagagttat tagtgccaag tttttcagaa
                                                                 7380
agtttgaagc accatggtgt gtcatgctca cttttgtgaa agctgctctg ctcagagtct
                                                                 7440
atcaacattg aatatcagtt gacagaatgg tgccatgcgt ggctaacatc ctgctttgat
                                                                 7500
tccctctgat aagctgttct ggtggcagta acatgcaaca aaaatgtggg tgtctccagg
                                                                 7560
cacgggaaac ttggttccat tgttatattg tcctatgctt cgagccatgg gtctacaggg
                                                                 7620
                                                                 7680
tcatccttat gagactctta aatatactta gatcctggta agaggcaaag aatcaacagc
caaactgctg gggctgcaac tgctgaagcc agggcatggg attaaagaga ttgtgcqttc
                                                                 7740
aaacctaggg aagcctgtgc ccatttgtcc tgactgtctg ctaacatggt acactgcatc
                                                                 7800
tcaagatgtt tatctgacac aagtgtatta tttctggctt tttgaattaa tctagaaaat
                                                                 7860
gaaa
                                                                 7864
```

<210> 3 <211> 22 <212> DNA		
<212> DNA <213> Homo	sapiens	
<400> 3 gcagagggca	tggctttatt tg	22
<210> 4 <211> 24 <212> DNA		
<213> Homo	sapiens	
<400> 4 ctgccaggca	ggggaggaag agtg	24
<210> 5 <211> 23 <212> DNA		
<213> Homo	sapiens	
<400> 5 gaaagtgact	cacttgtgga gga	23
<210> 6 <211> 20 <212> DNA		
<213> Homo	sapiens	
<400> 6 aaaggggctt	ggtaagggta	20
<210> 7 <211> 20		
<212> DNA <213> Homo	sapiens	
<400> 7 catgcacatg	cacacata	20
<210> 8 <211> 27		
<212> DNA <213> Homo	sapiens	
<400> 8 ctttctgcgg	gtgatgagcc ggtcaat	27
<210> 9 <211> 20 <212> DNA		

<213> Homo sapiens					
<400> 9					
ccttagcccg tgttgagcta					20
<210> 10					
<211> 26					
<212> DNA					
<213> Homo sapiens					
<400> 10					
cctgtaaatg caaagctatc	tcctct				26
3 3 3					
<210> 11					
<211> 26					
<212> DNA					
<213> Homo sapiens					
F					
<400> 11					
cgtcaactcc ttgatttcta	agatgt				26
<210> 12					
<211> 20					
<212> DNA					
<213> Homo sapiens					
-					
<400> 12					
gggttcccag ggttcagtat					20
<210> 13					
<211> 21					
<212> DNA					
<213> Homo sapiens					
<400> 13					
gatcaggaat tcaagcacca	a				21
<210> 14					
<211> 10545					
<212> DNA					
<213> Homo sapiens					
<220>					
<221> misc_feature					
<222> (1)(10545)					
<223> n = a, t, c, or	g				
<400> 14					_
acctcttata gaatgataga					60
cttttacctt ggaggatttc					120
gcctttaaaa ataggaacac	agtttcaggg	gggagtacca	gcccatgacc	cttctgcaag	180

240 gccccctaac tcaaggtagt ttccctggaa ctgtggttta tggaatgttt caggagtgtg aggaggtata atttaaggct gtcctagcaa ggataccctt aaggatagag ggcccagtag 300 catctggagg ccagaaaagt taaactgagg cagtcagatt agcttcaggc tcaattaagc 360 420 tgatgggtca gcctgggaga aattgcagga tgactctcaa tatcccctcc caccccaca 480 gcagccacga tctgtctgtc tttaatcatg ggtgcagtga acctgttctt tccaggtgtc 540 ttggccttca gtaaccttgt taggcttgtc cctgaacgtg gctaccgatc caaagacaca tgatcagaga ggcaattaga gaacagacct tttccaaagc aagcatgttc tgttgggctt 600 agaagtttca tgtcctaata ttataggacc ctgtgcatct ctctggagat gaggcacatg 660 720 agtcatatct gtgattcttg cttttgtgtc aacatctcat gaataggcaa tcagagcttt 780 ggcaccaatg tattttcagt tcatatctga tgtagttaaa tccacctcct gctttgtagt 840 ttactggcaa gctgtttttg atataagaca tctagaacac tgtaaatata taacattttt 900 atttgtctat tatacctcaa ttacgaaaaa gacatctaga agcaacctca tcaagagaga tactgaggcc gggcatggta gctcacactt gcaatcccat tactttggga ggctgaggca 960 1020 ggtagatcac ttgaggtcaa gagtttgaaa ccagcctggc caacatgttg aaaccctgtc tctattaaaa atacaaaaaa gttagctggg cttggtggtg ggcacctgta atcccagcta 1080 1140 ctccggaggc tgaggcagga gaatcacttg aacctgggag gcagaggttg cagtgagctg 1200 agatcacacc actgcactcc aacctgggca ccagagtgag attacatcta aaaaataaaa taaagtaata aaaaagagag atattgatag ctgttgttgg aaatttcaac ttccatctca 1260 cttctggtaa ctttttggaa gtttgttgaa caaagtggaa tacacgcaca tacacacaca 1320 1380 cacatactct cttgtttgtt taaggtttaa tgaaatagct gtcatataat cactgttttt 1440 gaaagaggag aattagttgc tatctgtaca ttttgggtat gtgaactatt tggatagaac tctgagaaat gcattcagaa caacaaacaa aatcatagga gaaatagcta agtgggaagg 1500 ggcatataag agttgttgaa aaagttattt cttgagaaac cagctctaat gctaggcaag 1560 tcacttgctt tgggggaggc ctcagcttct ctgtctataa gattgcagca ggggtgtagt 1620 gggaatgagt cttcaacatt ccaagagatt ttatctacta atacgacagt caaatggagc 1680 atgactttgt ggaagcetet cetetteeac ecagagggge caatttetet gteecagtga 1740 gatgttgaca cttgtatgat ccctgcttgg agacttccct cttctggaac ctgccctggc 1800 tcaggcatga gggctgactg tcaccettcg ataggagece ageactaaag etcatgtgtt 1860 ggcagtgttc ttgcgggaag gaaaaagacc agccagccca tttgttactg cacaagcaaa 1920 cagcttctgg tagctgtaca gatacatgca ctttctttcc tcactgtgtt tccatagaca 1980 gatttagtgc tgtagaagag tagagggcag tcacgggaag gagttcctgt ttttcttttg 2040 2100 gctatgccaa atggggaaaa atcctcctat cttgtctttt tagtgtcatc ctctctcccc ttttcttctt ctttataatt ctcatctctc atctctcctg gaaatgtgca tgtcaagttc 2160 aaaagggcac aatgttttgg tgaggaagag gtgggagaac acgtgccagg tgctaactag 2220 2280 ggtcatcatt tcccccttca cagccagctt cctgtgaatg tgtgtgtgt tgtgtgtgtg tgtgtgtgtg tgtgtgtgt tgtgtatttc ttttgccagc atcactgaat ctgtctgctg 2340 tctggtattc caggttttgg tttagggaaa agtaaaagta attttataat cccagctgtc 2400 atttaagcca cccctttgtg ggtagcatat ggtccactct ctcagttcat tgtcctaaag 2460 atgetteate agaaaggaat aactteeace cegttaetet etgteeeett aetetgettt 2520 atttttcttc gtcaatccta ccaccaccac ccactgtttg aacaacccac tattatttgt 2580 2640 ctgtttccca tccctggtag aataggagcc ccatgaatga aggaactttg cttctgttgt tcaccactga atctctaagg tatggaacac acctggcatg tgataggcac tcgataaata 2700 tttgttgtgg ctcatgggca ccttgcagag ttaaggctgc agttgtttgt ggaatttata 2760 2820 agtggtaatg aatatttatc tactattcct cttccaaggc gatcacacaa taatcaggct ttacactatc cagttcttag gtcttccaag ttatgacttg tgaggtatgt taattatgat 2880 aatagaaggc agtttatttg gttcagattt attgatgtgt aatttaccac agtaagactt 2940 cccctttaca aaagtatgat gagttttgac aaatggatac acatgtgtat ctaccactgc 3000 catgeteett tteagtetgt egteecetee acceatgace actggteace actgeagtga 3060 tttctgtccc cttcatttca ccttttccag aatgtcatat aaatggaatc atgcagtatg 3120 tagttttttg tgtctggctt atttttctta gcattaggct tttgggattc atccaggttg 3180 togoatgtaa cagtagotta ttoottttta tggotgagta agtgtoocag ttttatttat 3240

atatttattt atgaggaggt gtctcactct gtcacccagg ctggagtgcg gtagcgcgat 3300 ctcagctcac tgcaacctcc gcctcccagg ttcaagcaat tctcctgcct cctgagtagc 3360 tgggattaca ggcacccacc gccacgccca actaattttt atatttttag tagagatggg 3420 gtttcaccat gttggccagg ctgatctcaa actcttgacc tcaggtgatc cgcccacctc 3480 tggctcccaa agtgctagga ttacaggcat gagccactgt gcccagcccc agttttattt 3540 attcaccagt tgatggtctt ttcgacaact aattgtttcc agtttttggc tattctgtat 3600 aaggetteta taaatattea caaataeeta ggatgggatg aetgggteat ataatagtae 3660 tgtataacct tagcagaaac tgtcaaacta ttttccaaag tggctcttcc attttacaat 3720 tccacagtgt attgagtccc agtgtctcca tacacatgct agcactttta atatttaatt 3780 tagtgggtat gtaatgatat ctcattgtgg ttttaatttg catttctctg cagctaatga 3840 tgagtgtttc tgcttatttg ggaaggtttt aatttagcag tctgttgtat tctgtagata 3900 ttaataactt caaaatatca gtggcatttg cagttaaaat ttccttaaaa aattggccaa 3960 aggtttccag cagtcacttc tgccatgccc aaactgtatg aaacaaggct gaggtgtgga 4020 gattgtcaca ttttggcaag gagtgatcca cttgggtgac tgatgagacc cagagagcgt 4080 acgcctcggg cttgagggtg aggacgggcg ggaagtcgac tgcatggccc tgctggcctt 4140 gggaggctgc ccagtcctta gctaaagctg gcagttatgg gaaacagact tagattctat 4200 tacgtttttc aggatgtccc aggagtcacc tgggaagctc agcagtcctt tgtgactttc 4260 aagcatatgg tagaagctgc tgaacacaga gctccctctt tggggataat ttgcccaaat 4320 catttaatca ggcttgagaa atgagttacc acaggtccag gagtgctgcc acccttgaat 4380 tetgacacce tattteteet atcegtetet taattaatta ageagacate eecaagtget 4440 tacgacaagc caggaccctt ttgcatacta aggaaaacag ggatgaagga aacagaaatg 4500 gtctctgctc tgactcagaa ggtagaaatc ctctttccca gccaagtctt cctagggagc 4560 acgtaggaag ggctctgaac ccacgtgtca gttgcagggg aggatatcag gaaaggacat 4620 tgaagaagtg gagacctaag tttgagacct aggcattagc caggctagca gtgcttgaaa 4680 aagtgtetta ggacaagaga acteaceagt gaagteecag tggtaggaga gegtgeagea 4740 tattctgagc ctgtatacac atctccaggg cattgcttag caggtgggga gtggcaagag 4800 agtaggetgg agteaeagaa gggaggeeag gtagaeettg gtgageaetg gaetetatgt 4860 traggtgrtg aggagrtggr aaaaggtttt aagtrgggga gaggratgtt ragatatttg 4920 gtctagctga gtaactttgg gtgctctgtg acaaatggtt gggagaccag tgaggtggca 4980 gttgcggtca tctaggagca ggatcagagt ggcctattga ctgggatgac tgtgaagtgg 5040 gatcctttcc agccagtaac tggaaatgtg tatgagggca gaagtgagtg tactgcattt 5100 gaaacattga gaaatctagt acatagtact gtctctttta tatcttttt tttttttt 5160 ttgattttgg tttgtttgtt cactaacttg gaaaactgat gtggaaatgt ccctttggct 5220 tcagttacct gagcagaagg ggccgggcat tgccaaactc tcctcttagg acagaattgc 5280 tcccagtatt gatcattgtg ttctgagttg ggggagcaaa ttgtqcaqqa qqccaqqtca 5340 gtgccaaggt gggtgggagg aattggagca ggaagcttgc ctaagtgtgc ccagcaaagc 5400 cacggtagaa ctttctactg tggctctatg ctacttctta gcaaccttct ccatgtgctt 5460 cctggagagt ccttggagtc agaacctttt tcttgaaacc cagacacttt acttccaaga 5520 aaatgctgtc caagaaaact catccttccc ttcttctcat gaacgttgtg tagaggtgtg 5580 tettetette etttgagett ttecaeteag ggtttagggg aggtgatatt etatatttgg 5640 gtttggctct gggtactgca acactaggct attaagattt catccttact gctttgcccc 5700 tcctatcttt ccagaaaccc acaatggatt tgctagaaat aatggaacgt cctgtttgga 5760 caggatataa ccatttctca gctagaggat attgttggaa tgaagaaaga taaatgggga 5820 gaagggaact cacattgctt tggcacttaa attaagccat gtactgtgtt gggaaattat 5880 ttatattatc tcgttgaatc cacagtagaa cacagttgaa caccatacaa ggtaagtatt 5940 gtcatcctta ttttaccatg aggaaattga tgcttagaga gcataaagcc ttggccaggg 6000 gcacatagtt gggaagccgg ggctaattca tgcctgggct ctttctgata gttttccttt 6060 tttaattgtc ccctcctcat tgttaccttg gggatttcaa gagattcatg tagcttctaa 6120 atcaacgaac tgattcctgg agagcagctt ctgtatgaga aaaatctagc taattattta 6180 tttcagtgtc tctggaatgc aagctctgtc ctgagccact tagaaaacaa tttgggatga 6240 caagcatgtg tctcacaatg ctgctctggt tgccagtgct gtgctgccag ttqtcatctt 6300

```
6360
tgaacaaact gatgcagtgc tggtttaact cttcctcttt ttggagtaag aaactttgga
                                                                    6420
ggcctgtgtc cttctagaag tttgctgagc aaatggtaag gaaaagaaat aggtcctaag
gcttgactat ttcagagaat ttcttgattt attggactgt caatgaatga attggaatac
                                                                    6480
atagtggtag gctgtctttt cttctcagac actgcaattt cctccaatct cttgactttt
                                                                    6540
                                                                    6600
ctagaagttt taatccaagt ccttgttggg tggtagataa aagggtattg ttctactaga
                                                                    6660
gactgacctt ggcatggaga tctcatttgg actcacagat ttctagtcta gcgcttggtt
ttgtatccat acctegetac tgcattetta gtteettetg eteettgtte eteatgeeca
                                                                    6720
gtgtcccacc ctacccttgc ccctactcct ctagaggcca cagtgattca ctgagccatt
                                                                    6780
tcataagcac agctaggaga gttcatggct accaagtgcc agcagggccg aattttcacc
                                                                    6840
                                                                    6900
tgtgtgtcct cccttccatt tttcatcttc tgccccctcc ccagctttaa ctttaatata
                                                                    6960
actacttggg actattccag cattaaataa gggtaactgc tggatgggtg gctgggatac
                                                                    7020
acagaatgta gtatcccttg ttcacgagaa gaccttcttg ccctagcatg gcaaacagtc
                                                                    7080
ctccaaggag gcacctgtga cacccaacgg agtagggggg cggtgtgttc aggtgcaggt
ggaacaaggc cagaagtgtg catatgtgct gaccatggga gcttgtttgt cggtttcaca
                                                                    7140
                                                                    7200
gttgatgccc tgagcctgcc atagcagact tgtttctcca tgggatgctg ttttctttcc
agagacacag cgctagggtt gtcctcatta cctgagagcc aggtgtcggt agcattttct
                                                                    7260
                                                                    7320
tggtgtttac tcacactcat ctaaggcacg ttgtggtttt ccagattagg aaactgcttt
attgatggtg cttttttttt ttttttttga gacagagtct cgctctgtcg ccatgctgga
                                                                    7380
gtgtagtggc acaatcttgg ctcactgcac ctccgcctgc caggttcagc gattctcctg
                                                                    7440
ceteageete ceaagtaget gggactaeag gtgeetgeea ceatgeecag etaatttttg
                                                                    7500
tatttttagt agagacgggg tttcaccgta ttggctagga tggtctcgat ttcttgacct
                                                                    7560
cgtgatccgc ctgcctcggc ctcccaaagt gctgggatta taggcttgag ccaccacgcc
                                                                    7620
tggccgatgg tgctttttat catttgaagg actcagttgt ataacccact gaaaattagt
                                                                    7680
atgtaaggaa gttcagggaa tagtataagt cactccaggc ttgaggcaaa atttacaaat
                                                                    7740
gctgctgact ttgtatgtaa ggggaggcat tttcttagaa aagagaggta ggtctctggg
                                                                    7800
                                                                    7860
attccagtat gccatttcca tcctcagtgt ttttggccac ctgagagagg tctattttca
gaaatgcatt cttcattccc agatgataac atctatagaa ctaaaatgat taggaccata
                                                                    7920
                                                                    7980
acacgtaget cetageetge tgteggaaca ceteeegagt eeetetttgt gggtgaacee
agaggctggg agctggtgac tcatgatcca ttgagaagca gtcatgatgc agagctgtgt
                                                                    8040
                                                                    8100
gttggaggte teagetgaga gggetggatt ageagteete attggtgtat ggetttgeag
caataactga tggctgtttc ccctcctgct ttatctttca gttaatgacc agccacggcg
                                                                    8160
                                                                    8220
tecetgetgt gagetetgge egetgeette eagggeteee gageeacaeg etgggggtge
tggctgaggg aacatggctt gttggcctca gctgaggttg ctgctgtgga agaacctcac
                                                                    8280
tttcagaaga agacaaacag taagcttggg tttttcagca gcggggggtt ctctcatttt
                                                                    8340
8400
tttcacacag ggattgatgg aatctggctc ttatggacac agaactgtgt ggtccggata
                                                                    8460
tggcatgtgg cttatcatag agggcagatt tgcagccagg tagaaatagt agctttggtt
                                                                    8520
tgtgctactg cccaggcatg agttctgatc cctaggacct ggctccgaat cgcccctgag
                                                                    8580
                                                                    8640
caccccactt tttccttttg ctgcagccct gggaccacct ggctctccaa aagcccctaa
                                                                    8700
tgggcccctg tatttctgga agctgtgggt gaagtgagtt agtggcccca ctcttagaga
tcaatactgg gtatcttggt gtcaatctgg attctttcct tcaggcctgg aggaatataa
                                                                    8760
taactgagac ttgttttatt tctgcagagg gttctaagcc attcacttcc cagatgggcc
                                                                    8820
                                                                    8880
aataatgett tgagtaatet ggagateate tttaatgege aggtgaatgg aactetteea
cagagggatg tgagggctgt agagcagagt gaactccctg aaactcagac gtcagctctt
                                                                    8940
tgtctctcta tctctgaaca cccttcctta gagatcccat ctctaggatg catttctctg
                                                                    9000
tagttagttt ctaaqtctct tgttcctqtt ctqcctttat ttttttttcc tqqattctaa
                                                                    9060
gccagtatcc ccacttggct gtcttaatgt agcttaacat gtctgtaatc aaaatgatca
                                                                    9120
tetttetgag atteaaaggg etataaggga etttggagag aattteatte agtttteete
                                                                    9180
aaactagaat aatgettgea etgtetgtaa aagaacaaaa gtgteaaage ateettttgt
                                                                    9240
tcactaaatt tcctttttta ttatagtgtt acttaaatat taggaagtta aaagtaggta
                                                                    9300
taaacttctt ataggctgtt attatacaac tatatgaccc atacatattt acaaattaag
                                                                    9360
```

```
9420
tgcagccaaa attgcaaaat caataccatt caaattaata ccttaaatgt ggtgaggcag
                                                                     9480
ctgttgttca actgaaacca aattataagt tgcatggcag taaatgctat catgctgatc
attttgagtt tggccagtct atattatcat gtgctaatga ttgaattctc cacccatttt
                                                                     9540
                                                                     9600
tctacttgta tgaccttaat ttgatggcac ctgttccatc ctcatgagtt tgctacaatt
atactggtgc caacacaatc ataaacacaa atataaactt gggctttgaa atcttgtgcc
                                                                     9660
                                                                     9720
agaacttggc tttaaagtaa gcatttaaaa aatccatatg tgtttattag actttgttta
gatgactgtt gaaatgaaaa caaagtgttt aaaatcctct tagagaactt aaatataatc
                                                                     9780
cctcagcaat atgtatacag atcttccttt gagaaaaact gattgtgttc agcctctcat
                                                                     9840
                                                                     9900
gttacaaatg gggaacctga attctgaggt ctctagtgag agaacaggga ctggaatctg
                                                                     9960
tggatcctat ctgttttaat aataattgta aagtataata gataatatta tattaaaaaag
agagnnnnnn acacttagaa tgagcttcca tgtgtgaggc actaactgat taggcattat
                                                                    10020
taactagatt tattcctttt aaggccccgc gatgtactgt tatttccaca tgttgtagct
                                                                    10080
ggggaacgtg ctactcagag aggttaagta acttgtctga ggtccacacc actaacaagg
                                                                    10140
agcacaggta gggttcaaat ccagataatc tgactttgga gctggcactc taactcaatg
                                                                    10200
tgcctaatcg cttttcagtg gtgtcattat tttgcctatt ctccatctga gaatattgaa
                                                                    10260
                                                                    10320
gtttctgact ccttccttgc ctttctccct gcctcccqtg qttatcccca ggtcttgqtg
ttccagtcct ctatgtccgt ccttactctt attcctttgc tacagtgtga tccagggctc
                                                                    10380
etgecettet tateetggta gaggggeee acttgetggg aaattgtete egecatggtt
                                                                    10440
tatccatgtt gtgtgtccat tagtgagtag tgggaagaat catatcatgt tggcaatgaa
                                                                    10500
aggggggcta tggctctggg gtagtctagt ctgaactctt atttt
                                                                    10545
<210> 15
<211> 4736
<212> DNA
<213> Homo sapiens
```

<400> 15 cttttttttt tttttttt ttttttttt tgaggtgaag tctcactctg ttgcccaggc 60 tggagtgcaa tggagcgatc ttggctcacc ccaacctctg tctcctgggt tcaaacagtt 120 ctcctgcctc agcctcccga gtagctggga ttacaggctc ccgccaccat gcccagctat 180 ttttttgtat tttcagtaga gatggggttt caccettttg accaggetgg tettgaacte 240 ctgacctcat gatcaaccca cctcagcctc ccaaagtgct gggattacag gtgtgagcca 300 ccacgcccgg cctcataagt attttctaaa tttatttaca gtcatgccat ttaaaaggaa 360 agttgtattc ctgtctttgt taatatttat aagtgatttt attcagctac aagcttggaa 420 tggcatataa ttttgtattc tgcttttttc acttaatatt acatggctaa tgatttctgt 480 gtttcataaa cattattctg atgatggcat gatatattgt tgagtacatg taccataatt 540 gaatcatttc cctattgcta tgcaattaag ttgtttccaa tattttgcaa ttataatgtt 600 tcaatgaatg aataacttta tgcatatagc tttttgatat cttaagttca gtttcctagg 660 atgaatttcc aggaatagta attgggcaaa tgggataaac atgactcttg aatacgtatt 720 gttaacattg ctttcccaaa gggctcaact gatttatatt tccgtgttca ttatctttta 780 aaccagetea tttaeteace aaacattttt aaageeatta teatgtggta ggettagtaa 840 gaagaaagtg accctaaggg agaagcttat atataaatag ggtccctggt gtaccaagtg 900 ctgatacaga cacaaagtac ctggggaaat tgagatgagg gagtcctggc tcagctggga 960 gaaaagttca ttttcataga gtcatggttt tgttctttgg cagaaagaaa attgctttct 1020 tccccacccc caccccage tttattgagg tataattgac aaataaaaat tgtatatett 1080 taagatatgc aatgtgatat atatgtatat ctcaacttaa aaaataagct acagaataaa 1140

aaggtgtttg ctattaaaaa aaaagaaaag gctgaatgtc attcccaagc ttggaaattt

gagtatgttg cctctttggg attatttaca gaaatattag caagaccagc cccatctttg

gtcttgagta ctccactgtc agcatgcttt cttccagaga gggatccatt tgcctttatt

1200

1260

1320

```
1380
tttcattctg ttgtgccgtc tatgcaaact attcttgata gttttatggt aacagtgttt
ttttgttcca tgagataaat ttatacatgc tcattgtgga aaatttagaa aagacaggaa
                                                                     1440
                                                                     1500
agtattaaaa acatcmcytt ttttttttt ttttttttt tttttttamg cagacagagt
cttgctctgt cgcccaggcc ggagtgcagt ggcgtgatct cagctcacag caacctccgc
                                                                     1560
                                                                     1620
ttcccaggtt taagtgattc tcctgcctca gcctcccaag tagctgggag tacaggcatg
                                                                     1680
caccaccacg cccggctaat tttgtatttt tagtagagat ggggtttcac catgttggcc
aggotggtct caaactcctg acctcaggtg atccgcctgc cttggcctcg caaagttctg
                                                                     1740
                                                                     1800
ggattatagg caggagccac tgcgccagcc acacctacgt tcttatcatc ctagtacatc
cactgtcatt atcttgctgt atttccttct gcccagtctc actctgatca tgcagtggcg
                                                                     1860
                                                                     1920
tgatcatgca gtgatctcgg ctcactgcaa cctaggcctt ctgggttcga gtgattctcc
tgccttagcc tcctgggttc aagtgattct cttgccttgg cctcccaagt agctgggatt
                                                                     1980
                                                                     2040
acaggcatac acccccatgc ccatctaatt tttgtatttt tagtagacac agcgtttcac
                                                                     2100
taaaattttg tatttttagt agagatgggg tttcaccatg ttggccaggc tggtctccaa
ctcctgacct caggtgatcc gcctgccttg gcctcacaaa gtgattacag gcatgagcca
                                                                     2160
                                                                     2220
ctgcatccat cgccaaaaag attttttaaa agagtttaat gtagaaccat atcaaaggtc
tttggaaata aaaaacagtt ttttaaaaaat atcagaaata aaacaacaaa taaataaata
                                                                     2280
                                                                     2340
aataaaaaca cccaaaacaa tctgaagcac gagcacctag cagaaaggtt caattatgat
                                                                     2400
ctattcatag agtggaatat caagtagaca ttacaggaca tgttttaaga ttatatttta
tgtcatggga aatgctctcc cagtatgatg ttaaatgaaa aaacagaata caaaagtata
                                                                     2460
tatgctgcat agtctcaata ttgtagagaa aaaatattat ttatgtatgc atgaaaaaaag
                                                                     2520
                                                                     2580
acaaaagatg ttaacagaga tccattgtta cttcagttta ctagggattg tctctgggag
gtaggattaa ggtgatttat atttaccttt ttaaactttt ctgtattttt ttattttcaa
                                                                     2640
                                                                     2700
attttccata aaaatataag gacttgaaga tcaagaaaaa atttctgctt tggctcagtg
cagtogtcac gcctgtaatc ccagcagttt gggagcccta ggggagagga tcacttgaac
                                                                     2760
ccaagagttt gacgttccag tgagctatga tctccggatc gtaccgcctg gacgatggag
                                                                     2820
caagaccctg tctcaaaaaa aaaaatcttt gctttttttt tttgtttgtt tttgagacgg
                                                                     2880
agtetetete tgttgeecea getggagtae agtggeacaa teteagetea eegeaacete
                                                                     2940
tgcctcctgg gttcaagcga ttctcttgcc tcagcctccc aagtacctgg gattccatgc
                                                                     3000
acceaceact atgeceaget aettttttgt atttteagta gagacagggt tteaceatgt
                                                                     3060
                                                                     3120
tggccaggct ggtctcgaat tcctgacctc agctgatcca ccggccttgg cctcccaaag
tgctgggatt acaggcatga gccactgtgc ccagcccaat cttttgcttt ttttaaaaaa
                                                                     3180
agaagacaaa aagggatttt ataccagtat tatcttggct gtgtgactct gaagccacag
                                                                     3240
ttgtaagtta taattactct gaaacacaag gccctgtgac tcttttgggc tctttggtgt
                                                                     3300
ttatcttgat tacaacgttg gaatatagaa atgaaaggaa tgggagaggt gatagacttc
                                                                     3360
                                                                     3420
aggcagtgta actagttgtc tgaacactac tggctcaatt atattgtgtc tagtgatttc
catcttgtcc gtctgctaat ttatcgcctg gtaactcact gaggcagggt tttcctttgg
                                                                     3480
agaaacctca ttgttttaac cagtgtatca tgcttgttta gaagttcaat gatcttttta
                                                                     3540
actcatcgga gaagatgatg accagacctg gacagatggg gaaggacttt gcactctctc
                                                                     3600
tttacagtcc tgagtgcaca caggtcaata tggaactatg tgtgaatttt cattgtcttt
                                                                     3660
gagageeete ttetetgeee catagggage agetttgtgt geaattagag gageaagggt
                                                                     3720
tgtgtgtatt tagcacagca ggttggcctg gtcctctcct ctcaacatag tcaccacata
                                                                     3780
cctggcacta tgctaaggct gggaatgcag acagatgggt gcctgctttc agagtgctca
                                                                     3840
atgtgctgag gaagccagca acagaaacag atgatttcag gagctccagg aaaatgctac
                                                                     3900
aggaggagtg tgcctgggtt actggagtag cacaggagga gggcttctag ctcaggctga
                                                                     3960
gattttagta aaggaaatta tgccacgatg aatcctgaag aatgaataga agtgaaccag
                                                                     4020
ataaagcacg ataggaagca tetteeetta eetaagggaa gacacagagg tatatggaat
                                                                     4080
ggtatgttaa aaggttggga ctccaaacag ttctgttaaa gcttagagag tggtgggaga
                                                                     4140
gactggagaa gttgattaat tagtaaatga agttgtctgt ggatttccca gatcccagtg
                                                                     4200
gcattggata tccatattat ttttaaattt acagtgttct atcttatttc ccactcagtg
                                                                     4260
tcagctgctg ctggaagtgg cctggcctct atttatcttc ctgatcctga tctctgttcg
                                                                     4320
gctgagctac ccaccctatg aacaacatga atgtaagtaa ctgtggatgt tgcctgagac
                                                                     4380
```

tgctgtcttt tgataaggca ataacagtag gataatttta	cagggaaaat gggaaacatc tgaactcagg acaacatctc gaaagtggtg catgatgtct	acacatgctt agactgtttt ttttacacat attaaaagca	tggatcagaa cagtcctagt tttaaatcat catttaagat	aacctaggct gaatggtgat gaaaatagaa aatgccttaa	tctaatttgt aattgtaatt taaccttact cacctagtct	4440 4500 4560 4620 4680 4736
<210> 16 <211> 4768 <212> DNA <213> Homo	sapiens					
<400> 16						
	cacagtcttt	ctcttagggc	tagactcaat	gagtagatta	acactgcaga	60
	tctaaaggat					120
	tagtgatttt					180
	tgagatactg					240
	ggcctggtcc					300
	tgcacatcac					360
	tcaagaaaca					420
	aggcacagtg					480
	ggccaacacg					540
	gcacacctgt					600
	ggctgaggtt					660
	gactctgtct					720
	atatgcctgt					780
	atgagcaaat					840
	tttcaagggc					900
	agcaggcaag					960
	tgtttgtatc					1020
	taacctagat					1080
	tatactgatg					1140
	gagatggtct					1200
	atgtctgcct					1260
	caggcatgtg					1320
	atgttgacca					1380
tcagcctccc	aaagtgctgg	gattacaggc	atgagccacc	atgcccggcc	atatccatgc	1440
acttcttgca	accttacctt	cttttctcat	caccctccag	ggacctagtt	ggaagagcag	1500
agttaaaagt	taaggtgaaa	cttggagagg	tgtcttgtcc	ctaggaacaa	aggactggtt	1560
tgaaattctc	tgtaaatctt	ccccagttca	aaccagagtt	atcaaggtct	taaaaacttc	1620
cctgggtcct	gagagcccat	tatattattt	acttgtcttc	ctgtacaccc	actgcctagt	1680
cctgatccta	cttttgtttg	caaataggat	ggggcacaac	gtacaaggaa	gggcctttgc	1740
cacccctgct	aagggataac	ctgaaatacc	ttcaccatca	ctgccctgtg	ctgcttttca	1800
cctatgccag	tctgtctaca	gtgccagtgt	ctcctggcat	tgaaagggga	gaatcttttg	1860
	tatttggttg					1920
	ttgtttggtt					1980
	aataggccag					2040
	ttgggtgttg					2100
	atgcaaagtg					2160
	aaaagatgaa					2220
agatggaagg	agtgttcctg	ctgggcaaca	gcagagtaag	tgctggggta	gattcactcc	2280

```
cacagtgcct ggaaaatcct cataggctca tttgttgagt ctttgtccta caccaggcac
                                                                     2340
tetgcaaaaa egetttgeet geaaggtete atgegatget caccacaget etgtgaagtt
                                                                     2400
aattgtactt ttatcaccat tttacagatg agaaaactga gggtatgggg tcaatgactt
                                                                     2460
ggctaaagtc actgcttagc aagctgcagg gactggatgt gaattccaat tggtttgact
                                                                     2520
ccaaagcctg tgaagctact tgttcttcac cacctagagc tgtggttctt gataactgtg
                                                                     2580
aactcttttg gggtcacaaa tagccctgag aatatgatag aagcaggagc tctggccttt
                                                                     2640
ctgtccatac ctgaacaggt ccttgggtta agagccctc gtccagggcc tattaatctt
                                                                     2700
gatecteata ageageatee atgtattaeg geegeaaace aaactgtgee agacegaate
                                                                     2760
ctaggaccaa gcccaaatat gtcccatcat ccttttggta agaagctcat tgtaagaaag
                                                                     2820
aaagaggaga gcaagaggat gacctagtgc atggggcctc attqttttaa ttaqtqacaa
                                                                     2880
aacaacaata ataacaacaa aacccccgaa gcttcacaga tgacatcaga ccccaagcct
                                                                     2940
gtgtgttttt caggtgccct tgaggagctt tgtagctggc agaggaggtg aaactgacaa
                                                                     3000
atgtttggca gatggaggag agtaccagag gggtttgaga tgagctaaat tccaatctaa
                                                                     3060
ccgcagtgtt gaggaagagg cttggattgg gaccatggag atgggggttc tactcccagt
                                                                     3120
cacgccaget gactttgcga gtgttctttg tcagtcactt tatcttattt tatttatttt
                                                                     3180
tatttttttg aaatggagtt tcgctcttgt cgcccaggct ggagtgaaat ggcgcgatct
                                                                     3240
tggctcactg caacctcccc ctcctgagtt caagcgattc tcctgcctca gcctccagag
                                                                     3300
tacctgggat tacaggcgcc tgccaccaag cccatcgaat ttttgtatgc ttagtagaga
                                                                     3360
cagggtttcg ccatgttggc cagggtggtc ttgaactcct gacctcaggt gatccgccca
                                                                     3420
ccttggcctc ccaaagtgct gggattacag gcgcgagcca ctgtgcccag cccacttcat
                                                                     3480
cttaccgtag ttacctcctt agagtatgaa aaaataggct tagggcatcc ccaagtcccc
                                                                      3540
tctatgtctg agagctgagg ctggctgtca aagaggaact aaggatgcca gggactttct
                                                                     3600
gcttaggacc cctctcatca cttctccaac gctggtatca tgaaccccat tctacagatg
                                                                     3660
atgtccacta gattaagaat ggcatgtgag gccaagtttc cacctgagag tcagttttat
                                                                     3720
tcagaagaga caggtctctg ggatgtgggg aatgggacgg acagacttgg catgaagcat
                                                                     3780
tgtataaatg gagcctcaaa atcgcttcag ggaattaatg tttctccctq tqtttttcta
                                                                     3840
ctcctcgatt tcaacaggcc attttccaaa taaagccatg ccctctgcag gaacacttcc
                                                                     3900
ttgggttcag gggattatct gtaatgccaa caaccectgt ttccgttacc cgactcctgg
                                                                      3960
ggaggctccc ggagttgttg gaaactttaa caaatccatg taagtatcag atcaggtttt
                                                                     4020
ctttccaaac ttgtcagtta atccttttcc ttcctttctt gtcctctgga gaattttgaa
                                                                     4080
tggctggatt taagtgaagt tgtttttgta aatgcttgtg tgatagagtc tgcagaatga
                                                                     4140
gggaagggag aattttggag aattttggggt atttggggta tccatcacct cgagtattta
                                                                     4200
tcatttctgt atgttgtgaa catttcaagt cctgtctgct agctattttg gaatatacta
                                                                     4260
tatgttgtta atgatatcat gcagcagacg tgcatctgaa tgggctggct ctaggagcta
                                                                     4320
gagggtaggg gctggcacaa agatgcatgc tggaaqqqtc cttqcccata aqaaqcttac
                                                                     4380
agccaaggct aggggagttc tgtcttctct gcatcaggtc acctctctca cctctgtcac
                                                                     4440
tgccccatca gactacaatg tctgcaggtc tttctcccct gagtgtgagc tccctgagca
                                                                     4500
aagcaggatg ctgccccttc cctttgtatt ccttgctcct tgcttcagtg cctgtacata
                                                                     4560
agtatgggca taataagtgt cccccaaatg agacattgag gattcttcaa atgcacagga
                                                                     4620
ccgtgatgtg agttaggacg gagtaaggac gatgggatgt ggctcatgac aatcctgagg
                                                                     4680
aagetgeage tgeggeaege agggeeaeae tgteatgtte atggaeeeta gaetggettt
                                                                     4740
gtagcctcca tgggcccctt ccatacac
                                                                     4768
<210> 17
<211> 1295
<212> DNA
<213> Homo sapiens
<400> 17
tcatgactgc cattggtata aagatgaata taatccagac cagattcatg attattcata
                                                                       60
```

cattittagt gtattaactt ttaattctgc tittaaaaata aattaaaaca tictaatatq

```
cccttaagag tatcccagcc caggccactg agcctactgt ggttcatgga taagtttgcc
                                                                       180
cctgggggca tgtgtgtgca tgcatgtgtg tgcacatgca tgatgagccg ggccttgaag
                                                                       240
ggtggtaaga tttgggtgtg tagaccaatg gagaaaggca tttggggcag tgatgatggg
                                                                       300
tgggggaggg aacatggtga tgaatggagc tgggtgtggg gagccatggg agtgggttag
                                                                       360
ggccagcctg tggaggacct gggagccagg ctgagttcta tgcacttggc agtcacttct
                                                                       420
gtaaagcagc agaggcagtt ggcctagcta aagcctttcg ccttttcttg caccctttac
                                                                       480
agtgtggctc gcctgttctc agatgctcgg aggcttcttt tatacagcca gaaagacacc
                                                                       540
agcatgaagg acatgcgcaa agttctgaga acattacagc agatcaagaa atccagctca
                                                                       600
agtaagtaaa aaccttctct gcatccgttt ataattggaa attgacctgc accagggaaa
                                                                       660
agagtagece aggtgtetgg ggettgttee cattagatet teeceaaggg gtttttetee
                                                                       720
ttggtggctg gcctgtgggg cccctctcca ggaggcattg gtgaagaaac taggggagct
                                                                       780
ggttgccaca gacagtgatg tactaatctt ctctgggaag acagaagaaa agtccccagg
                                                                       840
gaagaatact acagacttgg ccttagggac agctaggggt gcagattgct gccaactgca
                                                                       900
ttttttctga agttggccat atggttgcag tgaatggatt tatagacaga gtatttctgt
                                                                       960
gcatataaga gcaattacag ttgtaagttg atatggataa gtgaaagtta agcacttctt
                                                                      1020
tctaaaaaga gaatgcaatt cattttcccc taatcatttc aattagtctg atgggcattt
                                                                      1080
gaacttgttg tctttaaaaa gtgaaatctt tacctctgat ctggtaagta tccaggcaat
                                                                      1140
ttcttgtgtg ccacccagga ggtatctggg gagtgggcat tttctgactg aggcattggc
                                                                      1200
tgccatagca tcagagcagc cttccaggca gtggcctggc aaggggacag aggctggtgg
                                                                      1260
gagcagctgg ctgagtgcag ccagtaatgg catgt
                                                                      1295
<210> 18
<211> 2188
<212> DNA
<213> Homo sapiens
<400> 18
agctctccag gtgattctga tgcatactta agtttgagaa ccattgcttg ttttgcatta
                                                                        60
aacaggagat tagtetetge agettgtggg aataaagett taaatetete caattttage
                                                                       120
tctgtgaaaa ggcagtgggg agacaggaat gaacggacta gtgccacaaa gctcaggtgg
                                                                       180
ggtgggtgag atcatttaga agagaaagac cgggcatggt ggctcacgcc tgtactgtca
                                                                       240
gcactttggg aggccaaggc aggttggatc acaaggtcag gagtttgaga ccagcctgcc
                                                                       300
tatcatggtg aaaccctgtc tgtactaaag ataaaaaaaa aaaaatttgc cagtcatggt
                                                                       360
gatgcatacc tgtaatccca gctactcggg aggctgaggc aggagaatct cttgaacccg
                                                                       420
ggaggcgggg gttgcagtga gctgagattc caccattgca ctccaaccta ggtgacaggg
                                                                       480
tgagactccg tctcaaaata aaaaaaaaaa aagaaaagga aaggctgtgt gtgtgtgtat
                                                                       540
gtgtgtgtgt gtgtgtgt gtgtgtgtaa cagcaccatc acactgtttg agttgaggag
                                                                       600
cacatgctga gtgtggctca acatgttacc agaaagcaat attttcatgc ctctcctgat
                                                                       660
atggcgatgc tcccctatct cattcctgtg tgtgtttagc caggcaactg ttgatcatca
                                                                       720
atattatgat aacgtttctc cactgtccca ttgtgcccac ttttttttt tttttgagtt
                                                                       780
acttactaaa taaaaataaa acactatttc tcaatagact tgaagcttca agatttcctg
                                                                       840
gtggacaatg aaaccttctc tgggttcctg tatcacaacc tctctctccc aaagtctact
                                                                       900
gtggacaaga tgctgagggc tgatgtcatt ctccacaagg taagctgatg cctccagctt
                                                                      960
cctcagtagg gctgatggca attacgttgt gcagctactg gaaagaaatg aataaaccct
                                                                      1020
tgtccttgta atggtggtga aggggaggga ggtagtttga atacaacttc acttaatttt
                                                                     1080
acttecetat teaggeagga attgeeaaac cateeaggag tggaatatge aacetggegt
                                                                     1140
catgggccag ctggttaaaa taaaattgat ttctggctta tcacttggca tttgtgatga
                                                                     1200
tttcctccta caagggatac attttaagtt gagttaaact taaaaaatat tcacagttct
                                                                     1260
gaggcaataa ccgtggttaa gggttattga tctggaggag ctctgtctaa aaaattgagg
                                                                     1320
acaggagact ttagacaagg gtgtatttgg agacttttaa gaattttata aaataagggc
                                                                     1380
tggacgcagt ggcactgagt tgagaactgt tgcttgcttt gcattaaata ggagatcagt
                                                                      1440
```

```
ccctgcagct tgtgggaata aggctttaaa tctctccaat tttagctctg tgagatggca
                                                                    1500
ctggggaaac agaaatgaac ggactagtgt cacaaagctc aggtgggatg gacgagatca
                                                                    1560
cttcaaaggt ctgtaatccc acgtctataa tcccagcact ttgggaggcc aaggcgggaa
                                                                    1620
aatcacttga ggtcaggagt tcgagaccat cctggccaac aatgcaaagc ctgtctctac
                                                                    1680
taaaaatatg aaaattagct cagcgtggtg gcatgctcct gtagtcccag ctactcgtga
                                                                    1740
ggctgagaca ggagaatcgt ttgaacctgg gaggcggagg ttgcagtgag ccaatatcac
                                                                    1800
1860
aagaatttta taaaatcagg aaataatatt agtgtttatg ttgaatttta actttaqaat
                                                                    1920
catagaaaac ttcctctggc atcattatta gacagctctt gtgcagtggg tagcaccaga
                                                                    1980
cccagcttgc atggttattg atttttcaga gacacttttt gagcttattc tctqqcaqaa
                                                                    2040
aggggaactg cttcctcccc tatctcgtgt ctgcatacta gcttqtcttt acaaqaaqca
                                                                    2100
gaagtagtgg aaatgtttat tottgaaaat aagotttttq ottcacatqa totaqaattt
                                                                    2160
ttaaaattag aaaaatgtgc ttactgcg
                                                                    2188
<210> 19
<211> 1183
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(1183)
<223> n = a, t, c, or g
<400> 19
agtaaaatgg agaattccaa attctgaaat tgttagaaca tagttctgtg tcttagttaa
                                                                      60
atatogacao ttacagataa atagcataaa tgotttotoo coatatttoa goocagtoot
                                                                     120
acttaaagac aacataaatt gcaaaatagt gaggatgttg ttcatctaat aaaagtggtt
                                                                     180
ccaggaattc agactctgga ttcctgtttg ccaaatcatg tgtcccactc ttaagaaaac
                                                                     240
gagttggact ntggattttt ctttgcaaga gggacaagag tgtgggagat actgaqttaa
                                                                     300
tgcaacttgc aggttttaag tgtcctgtca ttgtgccttg tgctttqata cattctqaqt
                                                                     360
ttcagtaaag agacctgatg cattggactg ttgcaatgga acctgtttta agatcttcaa
                                                                     420
agctgtattg atatgaagtt ctccaaaaga cttcaaggac ccagcttcca atcttcataa
                                                                     480
tectettgtg ettgtetete tttgcatgaa atgetteeag gtatttttge aaggetaeca
                                                                     540
gttacatttg acaagtctgt gcaatggatc aaaatcaqaa qaqatqattc aacttqqtqa
                                                                     600
ccaagaagtt tetgagettt gtggeetaec aagggagaaa etggetgeag cagagegagt
                                                                     660
acttegttee aacatggaca teetgaagee aateetggtg agtagaettg eteactggag
                                                                     720
aaacttcaag cactaatgct ttcggaatgt gaggcttttc cttggacagc atgactttgt
                                                                     780
tttgtagaaa agtacggctg gctgggagtt tgtgatataa tttagttcag tggtattcta
                                                                     840
agtgttctta gtgttctttc agacttttgg gccatctccc aaagggtgaa tgggaagaat
                                                                     900
aagctgggtg tggctgagtt taagccaaaa gttttttgtg cttgtttcaa tcagagaaga
                                                                     960
cctgcttttt catgttttta ctattataat actaaqcaaq aqctcatttq aaaacaqaqt
                                                                    1020
tcttcatatt taaaaaaaaa aagtcttgaa accattgatg ggaagatgga tatctattta
                                                                    1080
tgtttaaaaa cccatcataa agatgacatt gtgggctgtc acagttggaa ggccctggaa
                                                                    1140
ttagatgaga ccacactatt tagcttactt agtaataaca ttg
                                                                    1183
<210> 20
<211> 8981
<212> DNA
<213> Homo sapiens
```

<400> 20						
	aatgctcagt	аааадаааад	gattagaagg	ggagaaaggc	attttatccc	60
	gaatcaggat					120
	acattggagt					180
	aaggacattt					240
	tgtcttttta					300
	aactttcatg					360
	accatgtgcc					420
						480
	aaaactctgt					540
	gatggggaat					600
	agaattgagg					660
	ccattgagtc					720
	taggttatgt					
	tgtcttgaac					780
	atagctttca					840
	ctaggttcgg					900
	agaaacaaaa					960
	tgaacacctc					1020
	ggtccctttg					1080
	aagagatgaa					1140
	tgcacattga					1200
	catttggaat					1260
	cccagccact					1320
	atatgacaaa					1380
	ttgaataaaa					1440
	tcctgcttga					1500
	gaacactcag					1560
	aaattattgt					1620
	ttctaatgaa					1680
	atatatgaat					1740
	cattcaattt					1800
	tccctatttt					1860
	cttgtttctc					1920
	ttgcggtcag					1980
	tgcatattaa					2040
	atgagtttga					2100
	ttttggttag					2160
	cttgtttatt					2220
	tctcattaca					2280
	ccacaaaaac					2340
	cagtaccagg					2400
	gtccttttga					2460
	aaacaataat					2520
	ctcagagcta					2580
	tttctttttg					2640
	ccatgcactg					2700
	aatcattta					2760
	agccctttcc					2820
	atgaacatta					2880
	ctctgtccta					2940
ctgactccca	gccagtgcac	actccacctt	tctgactccc	agccttgtct	caaattaggc	3000

ttggaagcga ggaactgtct ggtgtccccc agcataggaa gctgagccag ggggcagtgc 3060 tcacaaacaa tacagacttt aacgtgtagg atattggaaa ataataattt gtggggaaat 3120 tgtctcagac ttggtccacc cttattttta gctgcttctc taatccgttt ttctttttt 3180 ggtgcttgta tctaacctac ccattttttg gtgcttgcat cattttttca aatatcaaaa 3240 acgaacttta tgttttctaa caatgaaagt attgcatgtt cattgtggaa aatgctgaag 3300 acttggaaaa tacaaaaatg ctgagatcaa acactattga tacgttagtg tatttcttcc 3360 tgtcctgttc tactttcttt ctttgaattc tgctcacgtg tttctgactg atgaggtctg 3420 acttttgggt tccttttcca gaggagaagc cttctttcag cttgccattt gttaccctgg 3480 ttatgaaggc tggtaacctt ttttactagg tagagaagct ggaccaactg gggttcttcc 3540 agggggagaa tgagaaagag aaactgtttt gcaagtccgt agctatttct ctagggccct 3600 gttagetgae attgaeatge ettgeattge tetgeagate ceetegeage cetetgteee 3660 ttgttcattt ctggccttag agaaagcaaa gcagggtctg taacagggga ggctgcctct 3720 3780 tttctggcat taaaaaaaaa aattggaagc aggtgatgtt cccattgctg atgtggtgga 3840 aactctccaa gtgaacaata tacgtttttc ttggcagctg tttcttgtgc cctgcttgct 3900 cctggtccag gacaagcaag gaccatctgc ctctttcaat agaacacctc cagatccctt 3960 tgatcaaaag ttactcattg tctgacttgc tatttctgtg agataaatgg gagaagatca 4020 ataaatgcac ttgtttgtcc agtcagcgtg tggaaagttg ataattttga ccaaagcaca 4080 accetgaaag gaaaagaaaa agggagtgaa tgtettetga gaagetgeet aggtteagae 4140 agtgtcaccc atttccctgt atgctccaca tgacaaacct gagtgggtct catcatgtcc 4200 attttgcaga tggcaccaag gctcagaaag gttaggcaac ttttccagtc acccaatgag 4260 ttaattgaca aaactgggat tcaaacccag aactgttgga ttccaaagcc tgtgttgttg 4320 cctgcttcgt gaaaaactcc agtagcgact ggaatagaaa ggagaacctt ccaagaaaga 4380 aaatacgcac tagcagaacc tggaaattgg gaggaaatga ggacttgagg aataagatga 4440 atgaaagctg acctgagttt cacatctggg tgatgggaag ggaggacagg gaggcagcat 4500 ctcagatgtc cacccagcac cgaccagctg cctggcattg ctaggtgttg aggactcagc 4560 agtgaacacg ctaacttctc tgctttcttg gggcacgtat agggtgagag acagaaacaa 4620 acaggtcagt gtacaatgcc acaggaggga tatatgcagt gaagaaaaag cagggtaagg 4680 ggcatagagc atgagaaggt gcttttttta aaggggktga ttaggaaagc tctctctaag 4740 gtgacagttg gacctgaagg agatgatagc atgtctgtgg tgagggaagg aaactccgaa 4800 caggaagaat ggcagataca aagacattga tgctagagca tgcctaagga atgtgtttaa 4860 4920 agtgccatac aggcctggca agactttgga ttcctgctgg gtgagatgag aatccagcgg 4980 agggettgag ggaggggaca tgatgtgate tagagtttag aetgtttaea etetggttgt 5040 tgggttgaga agagactggg atgggggaaa gggaggacaa aggacattgt gctggattga 5100 gaaagcagta agtcagtttc attcattcac tcaaccgatg atgttcaaat accaccatca 5160 tccgtgggct aaaggatgaa gagccatccc tccctgagag tcaggaagca cttcccagat 5220 aaagttttgga gtgtgagctg aggtgtagga gaaagagtaa gagtttaccc ctgaaacggg 5280 tgctgggaag agtcaatagt ttggaataac tcaataattt atggtgcttc tttagaaaga 5340 tttgctggct ttatgtggga agaaatttkt ttttttgatt ggggagtggt gggttggtgg 5400 tgaggctgcc tgtggaaaga gaagtgagtg ttttgactca ctgttattta aaaatctcta 5460 gggctgttcc aataagcaac aaaaggcaaa atggcctggt tctctgtccc ctttctgtct 5520 gtatgcctcg tacaggttat gaaaagaaaa agttgggaaa agctgtccac ctcacctaat 5580 tgtgttcttg tggagtgtgc tagatgcccc ctctctggag aaaaaaaatc cttgtggcct 5640 ctgacccacc tctggagagc ctagttccct tctggaggca gaaggcaaag cttaggacct 5700 agagagtgct ggaccacgcc actcacagga accagcaggc tgtgaggttg aaagctaggc 5760 atatggaget ttecaggetg ggtgeaggge etegtggeee tteceeteee etetgtgete 5820 tatageteag tetteeeagg eggtgtgaae aegeagtgae attteeagga atacagggat 5880 ttattaatga tttcttgtga aatgtttgga aatacaaagt actctataaa tatttcataa 5940 tagcattggg gctgagaact ccacaaagtg ccggaataca tttgcatgta agacaqaacq 6000 ctgcctgggt cattgatgcc tgttgagtgg cagtcacaga cactgcctag ggtttctgac 6060

teaegetgtt gggaetgtte tatgeaggge accetettgt gtggeatagg atttgtgeet 6120 caccacacac tgttgtagct ttgctgtctt gatgatgagt agagggcagt gtccaggcca 6180 tggtataagc atctactgcc ccccagggtt accaaaacca agccaagttg tgtctcagcg 6240 agctccgtga agcatggaga agttgagtac tcagagacat gacgtgactt ttcaaaggct 6300 gtaagctgac gagggacata gctagggttc agacttgagt ttttctttt cttttcttt 6360 ttetttttt tttaagactg agtettgett ttgtegeeca ggetggattg cagtggtget 6420 tggctcactg caacctctgc ctcccgggtt caagcaattc tcctgcctca gcctccccag 6480 tagctgggat tacaggcacc tgccaccatg cctggccaac atttttgtat ttttttagta 6540 gagatggggt ttcaccatgt tggccaggct ggtcttgaac tcctgacctc aggtgatcca 6600 cccgcctcga cctcccaaag tactgggatt acaggtgtga gccactgcac ccggcccaga 6660 ctcgagtttt tcatcttaat gctttttcat tgcctgacac tttactgaga ccaagatagg 6720 gaacttcaca tacagtacct tttctcccaa ggcggaagag ggctgttcaa tttctacact 6780 agagttcggg gagttttaga aatgagtcag ttatcgagga tgagagcagt tcctgatagg 6840 ctcaaccaca atgagatgta gctgttcaga gaaagcattc ttttatctat aaactggaag 6900 ataatcccgg tgaaacgaag cccagcccca ggggcttcac taactccagg ctgtgcttct 6960 caaactttag tgagcatagg aatcacctgg gcatcttgtg aagctgtaga tttgaattct 7020 gcaggtcggc agaggggtct cagaatccgc atttccaaca atgtctccag taatgctgat 7080 getgetegte cetggaceae agattgggta gecaggttet ggeaagetea teceaagget 7140 ttgagatgac atcagacaaa atatgttctg ggacatggct tttgagaggt caagaaaata 7200 agatgtttet ttetettete atececaaee ettgeaetge eettttetee etteeeetae 7260 cctcctttct gtccccatcc ctgacgccag ctgttcagca tgagaagctg gagtgacatg 7320 cgacaggagg tgatgtttct gaccaatgtg aacagctcca gctcctccac ccaaatctac 7380 caggetgtgt etegtattgt etgegggeat eeegagggag gggggetgaa gateaagtet 7440 ctcaactggt atgaggacaa caactacaaa gccctctttg gaggcaatgg cactgaggaa 7500 gatgctgaaa ccttctatga caactctaca agtgagtgtc catgcagacc ccagccctgt 7560 ecceaacee atecetecet tagttetgge ettggeetgt gteateteet eectetgtag 7620 cagegttaga tgtetacatg cecatttgee caceagactg agetetteet agaggagaga 7680 ggcttctctt gaatagctac ctgtccccag ttctctgaat gcagcctggc acatctcagg 7740 tgcacagtag tgtttatcaa tggaatgaat gattgacagc caaccttctg gttttctggg 7800 ggatgtggaa gggtggcttc cagggtgatc aagaatgaga taatggcaga aggacaaatc 7860 ctgcaagatc tcacttatat atggaatata tgtaaggtag aaagtgtcag tttcacatga 7920 tgaataagtt cctgggatct tgatgtacat cgtgatgact atagttagta acactgtata 7980 gtatacttga aatttgctaa gagagtagat ccgaagtgtt cacactacac aaaaaaggca 8040 actatgaggt gatggattta ttaacagctt gattgtggtg atccttttac aaagtataca 8100 tatattaaaa catcacattg tataccttaa atatatacaa tttttatttg tcagttgtaa 8160 ctcaaaaaag ctagaaaagc atttttaaaa aggatgatgt actggtctta atattaccat 8220 tgagataagc tttataataa cataaaaaga aataacagta atgataatag caacaacaac 8280 aacaacaaag aactaacatt taagtagaat ttcttgtgca ctgtgcattc tgtttaagtt 8340 atctcatttt accctcatga taacctgcag ggaagattct ttaaccccac atttcatagg 8400 ctcagagagg ttaagtgcct tggttagagc cacatcagag ttaatccaca agagccagga 8460 ttcaagccca aatctgcctg gatctgtgct ctctaagata actgttagtg gtggcgtgtg 8520 tgttctcaca ctcagacatt tgatctgccc tttgtttccc attcttagct gcaaggcagt 8580 gttaaagaac cetgtgtete catateeact ceccacaett aageaetttt gtgggeeegt 8640 gtgccgtatg cctcgtggca gcagggatcc aatgtcacag ttttaggcag tggcatcctt 8700 ttccttgaaa acttgatgca ggggaacctt tctccatttc caaccacagg tgtgtctttc 8760 agacactgag tgaggcaggt tttgtacttt attgtaacac aagaaccttt tcttctctgg 8820 agtaaagcac tccagacatt cgcaagttgc tttacaagcc ttaaaaggat ggtattgtag 8880 gcaactttaa ttaaatccca tctcctcctc tcccccagct tgcaagttga cccaaggaag 8940 ccttcatttc catgacagac ttaattgtga gggcatcctc a 8981

<210> 21

```
<211> 20284
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(20284)
<223> n = a, t, c, or g
<400> 21
actgtgttag caaggatggt ctcgatctcc tgacctcgtg atccgcctgt atcggcctcc
                                                                        60
caaagtgctg ggattacagg cgtgaaccac tgcgccctgt tgagaatttt tttttttt
                                                                       120
tttgggagaa agagtttcgc tcttgttgcc cgggctagag tgcagtgaca caatctcggc
                                                                       180
teactgeaac etetgeetee tgggtteaag caatteteet geeteageet catgegteae
                                                                       240
cacgcccagc taattttgta tttttagtag agacagggtt tctccatgtt qqtcaqqctq
                                                                       300
gtctcgaact cccaacctca ggtggttcgc ccgccttggc ctcccaaagt gctgggattg
                                                                       360
caggcatgag ccactgcgcc cagccccaaa ttttggtttt tgcttgaaaa ctgaggtctg
                                                                       420
aattcageet tetggttgee eetcaagagt cagtttaaat gttggteatg ttagttgtea
                                                                       480
gtgaaaacaa tggtgaggct ggcatgagag tgtgaatctg gatgggaggg cttgtgcttc
                                                                       540
atgaaaacat ttttccagat cagctcagtc gtgagttatc cgtcattgac gttataataa
                                                                       600
gctctgatta tttatcaagc atcattcttt atagatatct cagtttaatc tqaqataatc
                                                                       660
ttctccacat ctctccacat agatgttatg aattttactt ttacagagga gccaactgag
                                                                       720
gctcagataa gttacttatt atatgactag tagtggtaga gctggggttt caactaagaa
                                                                       780
ctctctggct ccaaagccct tgtaagtttc tatcagtata tgaccatgca tatgagcatt
                                                                       840
tgtctctcct cttcttcata gctccttact gcaatgattt gatgaagaat ttggagtcta
                                                                       900
gtcctctttc ccgcattatc tggaaagctc tgaagccgct gctcgttggg aagatcctgt
                                                                       960
atacacetga caetecagee acaaggeagg teatggetga ggtaagetge ceccageeca
                                                                      1020
agactecete eccagaatet ecceagaaet gggggeaaaa aacteaaggt agetteagag
                                                                     1080
gtgtgcgcta agtatactca cggctcttct ggaattccca gagtgaaaac ctcaagtctg
                                                                     1140
atgcagacca gagctgggcc agctccccag tcgtgggtat agaatcatag ttacaaqcaq
                                                                     1200
gcatttcttg gggatgggga ggactggcac agggctgctg tgatggggta tcttttcaqq
                                                                     1260
gaggagccaa acgctcattg tctgtgcttc tcctcctttt tctgcggtcc ctggctcccc
                                                                     1320
acctgactcc aggtgaacaa gaccttccag gaactggctg tgttccatga tctggaaggc
                                                                     1380
atgtgggagg aactcagece caagatetgg acettcatgg agaacageca agaaatggae
                                                                     1440
cttgtccggg tgagtgtccc tcccattatt accatgtgcc tgcttgatac tggagaggtg
                                                                     1500
agtttctggt cactttccca ggtgtgagtg aggtgagaat tctttcagtt tatctagctg
                                                                     1560
ggggaatgta gtgagcatag ctaaagtcac agggcaccac ctctccagaa gtacaggcca
                                                                     1620
tggtgcagag ataacgctgt gcatatcagc atccatgcca ctcacggtca aatagcagtt
                                                                     1680
ttctgcaaaa cttagtgagg gctggtgttt ggaagtggag ttgagtaatt gcagtaccct
                                                                     1740
attttccttt ttgctgcagc ctctcagcca gccacagcat ctccctgtgt cttggtaggt
                                                                     1800
tttggaaaga agtgtgggag caaaagcatg atgttacatg tagactggcc tgagatactc
                                                                     1860
attctcaggg cactgtgtga atgatgagct gctgttactg tgtggagggg aaatgcactt
                                                                     1920
agtgcttcag agccacttga aagggataag tgctctagag acaattgggt tcaaatgtgg
                                                                     1980
agcaggetga gcaagaacag aatgteteet ttgeetgage etgagtgetg ttaateacat
                                                                     2040
cttcctgcct tgggctgagt tagagaatca ttagactatt tcctgtttcc atggtgaggg
                                                                     2100
aggestetts stittgtets tgetseestt aagaagsagg tgaggatttt gesaggttts
                                                                     2160
ttgttttgaa ccttattgac tttaagggcg gctgggtttt agagactgta cctacctagg
                                                                     2220
gggaacactt ccgaagttta ggactattcc ctgatccgct gggaggcagg ttactgagga
                                                                     2280
agtcccttta aaaacaaagg agtttatact gagaaaagca taaacagtga tttgtatgga
                                                                     2340
ttcacactga ctaatatagc tcatgccatt aaagtggggt ctcttctcta aaggagggtt
                                                                     2400
```

atatgatcta gccccgtaga cctaagtgtg gtttcagacc tgttcttcct ggtcctctcc 2460 ttggaatcca tatttctact agttggactt tttctgtttg tctggctctc agaggattat 2520 aggaggccct gtgaagtgac tcagtgaatt ttgatttgtg ggcaagtaga tggttcccta 2580 gtctgaaatt gactttgcct taggtgcttc aattcttcat aagctcccag ttcttaaagg 2640 acaagatcct tgtaaacatg gcaatggcat tcattaggaa tctagctggg aaaatccagt 2700 gtgtatgctt ggaaatgagg gatctggggc tggagagaaa ggcatgggca tgccttggag 2760 ggacttgtgt gtcaagctga ggacctttac tttaagctct aggggaccag gcaaggggag 2820 atgtagatac gttactctga tggggtggat gaattgaaga aggatgaggc aagaatgaag 2880 gcagagacca gggaggaggc tctccaagtg gccaaggcat aaagcaagaa atgaggcctg 2940 gtgactgctt agtggcagag cagtgaaaga gagggaggca tcaaagtgag tctcgatttc 3000 tagctgggtg ggtggtagcg atgtccagta ggccagtggc tactgaggtc tgcagtggag 3060 gagggtggtt gggctggaga cagatgatga gggagtcatc agcctgtggg tggaagaaaa 3120 3180 tggacagagt cttgctctgt cacccaggct gaaatgcagt ggcatgatct tggctcacca 3240 cagecteege etectgggtt caageaatte teetgtetea geetecagag tagetgggat 3300 tacaggcaca tatcactgtg cccggctaat ttttgtattt tcagtggaga tgggatttca 3360 ccatgttggt cgggctggaa tgaactcctg acctcaagtg atccacctgc ctcagcctcc 3420 caaagtgttg ggattacagg catgagccac cgcgcccggc ctttcttccc tctcttaaag 3480 agtgtttatt taattccaca aacatgagct tgtcaccccc tgtagcctgg catctcctac 3540 acgaggtgat ggctgaggct tetgcttctg ctggggtagc tetgatettt ctgctttctc 3600 tggcactgtc tacccatgtt gcctcacccc acaggtccca gggcacctct ctcgggcaag 3660 tottggaacc ctctgacact gatttgctct cttttctgag ctgcttttag ccacccatcc 3720 tegggacetg ttttetetet geetecaeee etgegggeag tettaggtet eetgeeeete 3780 acgagcaccc cagagaggcc acgtgctcag tgatctcagt gggcgcatct ttctagtctt 3840 gctattcttt ttggccatgt tgttcagaaa ccatactggg cagggccgac ttcaccctaa 3900 aggetgegte tetteactet gettttgttt gttecaaata aagtggette agaattgeta 3960 accctageet etgtgaactt gtgaggtaca attttgtgte tgttatgtta acaaaaatae 4020 atacatacct tcctggtgat ggtataaatt gctattctct attggaaagc aatttggaat 4080 gaaaatttaa agaaccattt taaaatatgc tatcctgcgt acctccattc cacccacccc 4140 cagggatgta gcctactgaa ataattttaa agaagtcacc atatgagaga aaatgttatt 4200 gctatattgt tattgtgaga aattggaaat agactaaatg ttcagcacta taggaataat 4260 taatgaaatt acatatactc tatacaatca ttatgctgcc attgaaataa taaatacaaa 4320 ggcgcaaggg gggaaaagct tataatgtta gtgaaactaa gactgatttt tttataaagc 4380 agcagttttc agacccttgg agactccaat tcggtagaac cagagcttca tcttctctgt 4440 cgaagctgtg acaggagttg caaatgcctc tcctttttgc tgagtttgca gctgctgttt 4500 ttccggcagc acatctgtgc aggcctctgc ctcggcccct ctggatctgc tgattgagca 4560 gcggattgat ctgtccttct ctttcgtgtt gacccatgtg aggaaccaac tggcaaggga 4620 acaagaaatg gaaataggcc tcctttgcat catgacctgt acatcctgca attggaaaag 4680 attgtacttt agttggttta accagcagca ttatttttct aaactaagca gtaagaagga 4740 attaggtttt atgtgggatc aacagactgg gtctcaaaag aggaaggtga tagaacacag 4800 tggggagggg gaggtgcact agaaacagag ggcctatgct ttcattctgg ctttgctact 4860 taatagctgt gtgacccaat cttagagact taacctctct gaacttccat tttctcatgt 4920 ataaaatggg aaatattaaa ggatactcac tgggctggtg gcttgtgcct gtaatcccag 4980 cacttgggga ggttgaggtg ggaggatcac ttgagcccag gtgttcaaga ccagcccagg 5040 caacatggca agactctgtc tctatgaaaa aattaaaaat tagccaggtg tggtggtgt 5100 cacctgtagt cttagctact tggtaggctg agatgggagg atcacttggg cttgggaggt 5160 caaggctgcg gtgagctgtg attccatcac tgcactccag cccgggcggc agagcgagac 5220 actgaatcca aacgacaaca acaacaaaag gcaaaaaaat aaaagtgccc tctttatgga 5280 gttgtgtaag gtgaagcata tacactattc aacatagtaa ctatataaag gaagtattgt 5340 tgttgttact gtagttaata ccattaagtg agatgtttcg tatagtggaa agcacatgga 5400 ctctgaattc agactggtct gactttgagt ctcagctcca catctagtaa tactatgacc 5460

aagccctggt taaaatcatg tttttttttc ttcagcctca gtcttctcac atataaaata 5520 gggacactgt catttacctc agttttctgt gaggataaaa caacgacagt gtatatgcaa 5580 gtattttgta aattttgtag tgctcctcaa gatttagttg gtgtttacta cttgtacttt 5640 ctcactggaa tggcagatgc tgttggacag cagggacaat gaccactttt gggaacagca 5700 gttggatggc ttagattgga cagcccaaga catcgtggcg tttttggcca agcacccaga 5760 ggatgtccag tccagtaatg gttctgtgta cacctggaga gaagctttca acgagactaa 5820 ccaggcaatc cggaccatat ctcgcttcat ggaggtgaat ctgttgctgg gatcatttag 5880 aaaagactta acggettett tetetgagae gttacaataa ggtteaggea ggaggeaagt 5940 ttagaaataa tgtatagtct catttacaaa actatccctc aagcctaaca caggatttga 6000 taacaaaagg cacttaataa atgttagttg agtggttgaa tgagtaaata aactctaqct 6060 ttagtaaatt aactctagct tattctatat aggctcaaga gaatatttct acccattttc 6120 ttctaggttt tcctatctca gtgactaatg gtagcaaagc attcccttaa aaaggcatta 6180 tttgtgaaac ttayctaaaa tcgaattcgg gtccaattaa atttttgaaa ttttatatta 6240 aaaattatat tagtagggat gggtaagagg tgttttggtc tggttggttg gttagttgct 6300 atgactcaga attgctaaga aaacagaaaa gtaagataag atcattgttt taacctcttt 6360 tcctccacaa aatcaataaa taacatatcc ctaaattact cttagaattt ctcttaaatt 6420 gcagtgaaaa accaaaatcc ttcattcttg gttgaaggtt ggaaaactac gttagagagg 6480 attagagaga gaggatgagc aatcgtgtag tcagcccttg cctcctagtg taggatttgt 6540 ctcagccact gcttgttgtc ctggctgcca acgttctcat gaaggctgtt cttctatcag 6600 tgtgtcaacc tgaacaagct agaacccata gcaacagaag tctggctcat caacaagtcc 6660 atggagctgc tggatgagag gaagttctgg gctggtattg tgttcactgg aattactccm 6720 rgcagcattg agctgcccca tcatgtcaag tacaagatcc gaatggacat tgacaatgtg 6780 gagaggacaa ataaaatcaa ggatgggtaa gtggaatccc atcacaccag cctggtcttg 6840 gggaggtcca gagcacctat tatattagga caagaggtac tttattttaa ctaaaaattt 6900 ggtagaaatt tcaacaacaa caaaaaaact caacttggtg tcatgatttt ggtgaaattg 6960 gtacatgact tgctggaagg tttttcatag gtcataaaat aacagtatct tttgatttag 7020 catttctact caagggaatt aattccagga attttggtgg caggcacctg taatcccagc 7080 tactcgggag gctgaggcag gagaattgct tgaacccagg aggcagaggt tgcagtgagc 7140 taagategea teattgeact eeegeetggg caataagagt gaaacteeat etcaaaaaaa 7200 aaaaagatac aaaaatagaa aaaggggctt ggtaagggta gtagggtttt gggcaatttt 7260 ttttttttt ttttttta ttgtatggtt ctaaaggaat ggttgattac ctgtggtttg 7320 gttttaggta ctgggaccct ggtcctcgag ctgacccctt tgaggacatg cggtacgtct 7380 gggggggctt cgcctacttg caggatgtgg tggagcaggc aatcatcagg gtgctgacgg 7440 gcaccgagaa gaaaactggt gtctatatgc aacagatgcc ctatccctgt tacgttgatg 7500 acatgtaagt tacctgcaag ccactgtttt taaccagttt atactgtgcc agatgggggt 7560 gtatatatgt gtgtgcatgt gcatgcatgt gtgaatgatc tggaaataag atgccagatg 7620 taagttgtca acagttgcag ccacatgaca gacatagata tatgtgcaca cactagtaaa 7680 cctctttcct tctcatccat ggttgccact tttatctttt tatttttatt tttttttg 7740 agatggagtc tcgctctgac gcccaggctg gagtgcagtg gctcgatctc ggctcactgc 7800 aacctttgcc tcccgggttc aagctattct cctgcctcag cctccacagt agctgggact 7860 acaggeteat getgeeaege eeggetgaet tittgtatti tagtagagae gaggtiteae 7920 catgttaccc aggctagact tcaactcctg agctcaggca atccaccctc cttggcctcc 7980 caaagtgctg ggattacagg tgtgagccac tgcacccagc ccaccacttt aatttttac 8040 actctaccct tttggtcaaa atttgctcaa tctgcaagct taaaatgtgt catgacaaac 8100 acatgcaagc acatactcac acatagatgc agaaacagcg tctaaactta taaaagcaca 8160 gtttatgtaa atgtgtgcac ttcttctccc taggtggtaa accacatttc aaaacaaccc 8220 aaataaaact gaacaaagct tcttcctctt agacttttta gaaaatcttt cagtgctgag 8280 tcactaagct gccaagttct cattgtggga actatgcctt tggatgtaat gatttcttct 8340 aagacaatgg gcggaggtgt agttattgca gacatctgaa atatgtaatg tttcttccag 8400 attctggaaa ttctcttatt ctctgtggtt ggtggtggtg gtgggatgtg tgtgtgtg 8460 tgtgtgtgtg tgtgtgtg tgtgtaggga tcaggatgcg ggaggagctg ggttctgctt 8520

```
8580
gtattggttc tctgttttgc attgaatagt gtgtttcctt gtatggctat ctatagcttt
                                                                    8640
tcaaggtcac cagaaattat cctgtttttc accttctaaa caattagctg gaatttttca
aaggaagact tttacaaaga cccctaagct aaggtttact ctagaaagga tgtcttaaga
                                                                    8700
                                                                    8760
cagggcacag gagttcagag gcattaagag ctggtgcctg ttgtcatgta gtgagtatgt
                                                                    8820
gcctacatgg taaagctttg acgtgaacct caagttcagg gtccaaaatc tgtgtgcctt
                                                                    8880
tttactttgc acatctgcat tttctattct agcttggaat ctgaaacatt gacaagagct
                                                                    8940
gcctgaaatg tatgtctgtg gtgtgattag agttacgata agcaagtcaa tagtgagatg
accttggaga tgttgaactt ttgtgagaga atgagttgtt tttttgtttt ggtttttagt
                                                                    9000
                                                                    9060
actttaacat aatctacctt tagtttaagt atcgctcaca gttacctagt tactgaagca
                                                                    9120
agcccccaaa gaaatttggt ttggcaacac tttgttagcc tcgtttttct ctctacattg
                                                                    9180
cattgctcgt gaagcattgg atcatacgta catttcagag tctagagggc ctgtccttct
                                                                    9240
gtggcccaga tgtggtgctc cctctagcat gcaggctcag aggccttggc ccatcaccct
ggctcacgtg tgtctttctt tctccccttg tccttccttg gggcctccag ctttctgcgg
                                                                    9300
                                                                    9360
gtgatgagcc ggtcaatgcc cctcttcatg acgctggcct ggatttactc agtggctgtg
atcatcaagg gcatcgtgta tgagaaggag gcacggctga aagagaccat gcggatcatg
                                                                    9420
                                                                    9480
ggcctggaca acagcatcct ctggtttagc tggttcatta gtagcctcat tcctcttctt
                                                                    9540
gtgagcgctg gcctgctagt ggtcatcctg aaggtaaggc agcctcactc gctcttccct
gccaggaaac tccgaaatag ctcaacacgg gctaagggag gagaagaaga aaaaaaatcc
                                                                    9600
aagcctctgg tagagaaggg gtcatacctg tcatttcctg caatttcatc catttatagt
                                                                    9660
                                                                    9720
tggggaaagt gaggcccaga gaggggcagt gacttgccca aggtcaaccc agccgggtag
                                                                    9780
cagctaagta ggatgagagt gcagggttca tgctttccag ataaccacat gctcaactgt
gccatgctgt ctcattggta gtggttcatg gcagcatctg aaagctattt attttcttag
                                                                    9840
atatattggg tggcgattct tcctaagttt ctaagaacaa taatcagaag gatatatatt
                                                                    9900
                                                                    9960
gttgcaggtt agactgtctg gaagcagagg ctgaaataga gtttgatgta tgggtattta
                                                                   10020
tgagggctca atacctatgg aagagatatg gaagatgcag gattgggcag agggaggagt
                                                                   10080
tgaactgtga tatagggcca accccgtggg gcactctaga gaatatgcag cttgttggag
ttgttcttca tcgagctgaa acatccagcc ctttgtgctc ccccaaggcc tccctcctga
                                                                   10140
caccacctac ctcagccctc tcaatcaatc actggatgtg ggctgccctg ggaaggtcgt
                                                                   10200
                                                                   10260
gccccagggc ctacatggct ctctgctgct gtgacaaacc cagagttgct gatgcctgag
10320
                                                                   10380
tttgtgtctg aaccatacat taatatattt atatccgaat tttctttctc tgcaagcatt
tcatataaag acacatcagg taaaaataaa tgtttttgaa gcaaaaggag tacaaagaga
                                                                   10440
taagaactaa ctaatttaat actagttacc atctgttaca aatagttcct actgattgcc
                                                                   10500
aaggactgtt taaacacatc acatgggctt cttcttctat cctcactaac ccttttaaca
                                                                   10560
gacaaggaaa tgaggctcag gaaggtcaag gactttattg aggttccaca gtaggataca
                                                                   10620
                                                                   10680
gttcttgcta aaagcaaccc ctccctcatg ctctgttatc taactgcaag gggaaggtca
gtggcagagg tagtggtccc atggttggtg cataagagct gctctgagac aactgcatgc
                                                                   10740
                                                                   10800
tggtgggtcc tgcagacatg tacccatcag ccggagatag gctcaaaata tccacaagag
                                                                   10860
tttggatgat tgtgggaatg cagaatccat ggtgatcaag agggaaagtc aagttgcctg
                                                                   10920
gccattttcc ttqqctttta qacaqaaaag ttacqtqqqa tattatctcc cacaqctctt
ctgtggtgcc accagtcata gtccttatat aaggagaaac cagttgaaat tacctattga
                                                                   10980
agaaacaaag agcaaactcg cccactgaaa tgcgtagaaa gccctggact ctgttgtatt
                                                                   11040
cataactctg ccattatttt tctgcgtagt tttgggtaag tcacttatct tctttaggat
                                                                   11100
                                                                   11160
ggtaatgate agttgeetea teagaaagat gaacageatt aegeetetge attgteteta
                                                                   11220
acatgagtag gaataaaccc tgtctttttt ctgtagatca tacaagtgag tgcttgggat
tgttgaggca gcacatttga tgtgtctctt ccttcccagt taggaaacct gctgccctac
                                                                   11280
                                                                   11340
agtgatecea gegtggtgtt tgtetteetg teegtgtttg etgtggtgae aateetgeag
tgcttcctga ttagcacact cttctccaga gccaacctgg cagcagcctg tgggggcatc
                                                                   11400
atctacttca cgctgtacct gccctacgtc ctgtgtgtgg catggcagga ctacgtgggc
                                                                   11460
                                                                   11520
ttcacactca agatcttcgc tgtgagtacc tctggccttt cttcagtggc tgtaggcatt
tgaccttcct ttggagtccc tgaataaaag cagcaagttg agaacagaag atgattgtct
                                                                   11580
```

tttccaatgg gacatgaacc ttagctctag attctaagct ctttaagggt aagggcaagc 11640 11700 tgaatggaat ttttccgaga gccagactgc atcttgaact gggctgggga taaatggcat 11760 tgaggaatgg cttcaggcaa cagatgccat ctctgccctt tatctcccag ctctgttggc 11820 tatgttaagc tcatgacaaa ccaaggccac aaatagaact gaaaactctt gatgtcagag 11880 atgacetete ttgtetteet tgtgteeagt atggtgtttt gettgagtaa tgttttetga 11940 actaagcaca actgaggagc aggtgcctca tcccacaaat tcctgacttg gacacttcct 12000 tccctcgtac agagcagggg gatatcttgg agagtgtgtg agcccctaca agtgcaagtt 12060 gtcagatgtc cccaggtcac ttatcaggaa agctaagagt gactcatagg atgctcctgt 12120 tgcctcagtc tgggcttcat aggcatcagc agccccaaac aggcacctct gatcctgagc 12180 catccttggc tgagcaggga gcctcagaag actgtgggta tgcgcatgtg tgtgggggaa 12240 caggattgct gagccttggg gcatctttgg aaacataaag ttttaaaagt tttatgcttc 12300 actgtatatg catttctgaa atgtttgtat ataatgagtg gttacaaatg gaatcatttt 12360 atatgttact tggtagccca ccactcccta aagggactct ataggtaaat actacttctg 12420 caccttatga ttgatccatt ttgcaaattc aaatttctcc aggtataatt tacactagaa 12480 gagatagaaa aatgagactg accaggaaat ggataggtga ctttgcctgt ttctcacaga 12540 gcctgctgtc tcctgtggct tttgggtttg gctgtgagta ctttgccctt tttgaggagc 12600 agggcattgg agtgcagtgg gacaacctgt ttgagagtcc tgtggaggaa gatqqcttca 12660 atctcaccac ttcggtctcc atgatgctgt ttgacacctt cctctatggg gtgatgacct 12720 ggtacattga ggctgtcttt ccaggtacac tgctttgggc atctgtttgg aaaatatgac 12780 ttctagctga tgtcctttct ttgtgctaga atctctgcag tgcatgggct tccctgggaa 12840 gtggtttggg ctatagatct atagtaaaca gatagtccaa ggacaggcag ctgatgctga 12900 aagtacaatt gtcactactt gtacagcact tgtttcttga aaactgtgtg ccaggcagca 12960 tgcaaaatgt tttatacaca ttgcttcatt taattctcac aaggctactc tgaagtagtt 13020 actataataa ccagcaattt tcaaatgaga gaactgtgac tcaaagacgt taagtaacca 13080 gctttggtca cacaactgtt aaatgttggt acgtggaggt gaatccactt cggttacact 13140 gggtcaataa gcccaggcga atcctcccaa tgctcaccca attctgtatt tctgtgtcct 13200 cagagggggt acaactagga gaggttctgt ttcctgagta caggttgtta ataattaaat 13260 atactagete taaggeetge etgtgattta attageatte aataaaaatt catgttgaat 13320 ttttctttag tacttctttc ttaatataat acatcttctt gaccaagtcc aagaggaacc 13380 tgcgttggac agttttcata tgagatcaaa ttctgagaga gcaagattta accctttttg 13440 gttcaccttc tgatcctccc ctaaggaggt atacatgaaa tatttattac tcctgcctga 13500 acttetttea ttgaatatge aattttgeag catgeagatt etggatttaa attetgagte 13560 ttaacttact ggctgaggga ccttggatag gctccttatc cctcagtttc ctcatctcta 13620 aaatggggat ggcacctgcc ccgtgggttg ttggaaggac ttacagaggt gcagaatgta 13680 cgttgtacat agcaggtttc agcaaatgtt agctccctct ttccccacat ccattcaaat 13740 ctgttccttc tccaaaggat gtgtcaagga ggaaatggac ctggctggga aaccctcaga 13800 atactgggat gatgctgagc ttggctcata cctgtgcttt gctttcaggc cagtacggaa 13860 ttcccaggcc ctggtatttt ccttgcacca agtcctactg gtttggcgag gaaagtgatg 13920 agaagagcca ccctggttcc aaccagaaga gaatgtcaga aagtaagtgc tgttgacctc 13980 ctgctctttc tttaacctag tgctgctgcc tctgctaact gttgggggca agcgatgtct 14040 cctgcctttc taaaagactg tgaaaccact ccaggggcag agaaatcaca tgcagtgtcc 14100 ctttccaaat cctcccatgc catttatgtc caatgctgtt gacctattgg gagttcacgg 14160 tctcgatccc tgagggacat tttctttgtt gtcttggctt ctagaagagt atcttttact 14220 tgccccctcc caaacacaca tttcatggtc tcctaacaag ctagaagaaa gaggtaaaga 14280 caagcgtgat tgtggaacca tagcctcgct gcctgcctgt gacatggtga cctgtgtatc 14340 agcctgtgtg ggctgagacc aagtggctac cacagagctc agcctatgct tcataatgta 14400 atcattaccc agatccctaa tcctctcttg gctcttaact gcagacagag atgtccacag 14460 ctcatcaaag gctctgcttc tgggttcttt gtgcttagag tggcttccta aatatttaat 14520 aggtcccttt tctgccagtc tcttctgtgc ccatcccctg attgcccttg gtaaaagtat 14580 gatgcccctt agtgtagcac gcttgcctgc tgttcctaat catcttctcc tacctcctct 14640

```
14700
ttacacctag ctcctgtttc agtcacctag aaatgctcac agtcgctgga atatgtcatg
                                                                   14760
ttcttccaca cctccatqcc tttqtagqta ctgtttgctc tcacaggaga actttctctc
                                                                   14820
taacttgcct atcttctcaa ctcctccttt ctctccaaga tctagttccg gatcccctcc
cctgagcatc cctccttggt tctcaggtag tcagtcactc tctgccctga acttccatgg
                                                                   14880
                                                                   14940
cacgtgaaag aaaatctttt tattttaaaa caattacaga ctcacaagaa gtaatacaaa
                                                                   15000
ttacatgagg gggttccctt aaacctttca tccagtttcc ccaatggtag cagcatgtgt
                                                                   15060
aactgtagaa tagtatcaaa accatgaaat tgacataggt acaattcaca aaccttcttc
                                                                   15120
agatttcact agctttatgt gcgctcattt gtgtgtgtgt gtgcgtattt agttctatgc
aattttatca tgtgtgaatt catgtaatta ctagctcagt caagctgcag aaatatctca
                                                                   15180
                                                                   15240
ttgtcacaaa gctccttcat gctacccctt aatggccaca gccacctccc ttcttcctca
gttcctgaca cctgtcaacc actaatgcgt tcctcgtttt tacagtttta ttatttctag
                                                                   15300
15360
                                                                   15420
ttcactcagc agtattccct tagatctatc caagttgtgt gtgtcaacag ttcattcctc
                                                                   15480
ttcactgctg agtagtgttc cctgggaggg gtgtatcaca gttccatggc atttttagat
                                                                   15540
gtatttttta aacagctttc agcatcctct attttaattg ttcatcaagt cctttttccc
aatagactct gaatgctcct ttatcatcgt attcccatca ccaacatcag tacccaaata
                                                                   15600
                                                                   15660
ggccctaaat aaacatttat agcctcctgc ctgcctgaga aaccagggtg gacatggaga
gaaggcactt ctgaaagttc aagcgcagtg csctgtgtcc ttacactcca ctcctcagtg
                                                                   15720
ctttctgtgg gttcatttct gtcttctctc ctgtcacagt ctgcatggag gaggaaccca
                                                                   15780
                                                                   15840
cccacttgaa gctgggcgtg tccattcaga acctggtaaa agtctaccga gatgggatga
aggtggctgt cgatggcctg gcactgaatt tttatgaggg ccagatcacc tccttcctgg
                                                                   15900
gccacaatgg agcggggaag acgaccacca tgtaagaaga gggtgtggtt cccgcagaat
                                                                   15960
                                                                   16020
cagccacagg agggttctgc agtagagtta gaaatttata ccttaggaaa ccatgctgat
                                                                   16080
ccctgggcca agggaaggag cacatgagga gttgccgaat gtgaacatgt tatctaatca
tgagtgtctt tccacgtgct agtttgctag atgttatttc ttcagcctaa aacaagctgg
                                                                   16140
                                                                   16200
ggcctcagat gacctttccc atgtagttca cagaattctg cagtggtctt ggaacctgca
                                                                   16260
gccacgaaaa gatagattac atatgttgga gggagttggt aattcccagg aactctgtct
ctaagcagat gtgagaagca cctgtgagac gcaatcaagc tgggcagctg gcttgattgc
                                                                   16320
cttccctgcg acctcaagga ccttacagtg ggtagtatca ggaggggtca ggggctgtaa
                                                                   16380
agcaccagcg ttagcctcag tggcttccag cacgattcct caaccattct aaccattcca
                                                                   16440
aagggtatat ctttgggggg tgacattctt ttcctgtttt ctttttaatc ttttttaaa
                                                                   16500
acatagaatt aatattat gagettttea gaagattttt aaaaggeagt cagaaateet
                                                                   16560
actacctaac acaaaaattg tttttatctt tgaataatat gttcttgttt gtccattttc
                                                                   16620
catgcatgcg atgttaggca tacaaaatac attttttaaa gaatactttc attgcaaatt
                                                                   16680
ggaaacttcg tttaaaaaat gctcatacta aaattggcat ttctaaccca taggcccact
                                                                   16740
tgtagttatt taccgaagca aaaggacagc tttgctttgt gtgggtctgg tagggttcat
                                                                   16800
                                                                   16860
tagaaaggaa tgggggcggt gggagggttg gtgttctgtt ctctctgcag actgaatgga
gcatctagag ttaagggtag gtcaaccctg acttctgtac ttctaaattt ttgtcctcag
                                                                   16920
gtcaatcctg accgggttgt tccccccgac ctcgggcacc gcctacatcc tgggaaaaga
                                                                   16980
                                                                   17040
cattegetet gagatgagea ceateeggea gaacetgggg gtetgteece ageataaegt
                                                                   17100
gctgtttgac atgtgagtac cagcagcacg ttaagaatag gccttttctg gatgtgtgtg
tgtcatgcca tcatgggagg agtgggactt aagcatttta ctttgctgtg tttttgtttt
                                                                   17160
ttcttttttt ctttttatt tttttgagat ggagtctcgc tctgtagcca ggctggactg
                                                                   17220
tagtggcgcg atctcggctc actgcaacct tggcctccca ggttcaagcg attctcctgc
                                                                   17280
ctcagcctcc cgagtagctg ggactctagg cacacaccac catgcccagc taatttttgt
                                                                   17340
gtttttagta gagacggggt ttcaccatgt tggccaggat ggtctcaatg tcttgacctc
                                                                   17400
                                                                   17460
gtgatccgcc cacctcggtc tcccaaagtg ctgggaacac aggcatgagc cactgtgtct
ggccacattt tactttcttt gaatatggca ggctcacctc cgtgaacacc ttgagaccta
                                                                   17520
gttgttcttt gattttagga gaagtgggag gtgaatggtt gagctgtaga ggtgacatca
                                                                   17580
                                                                   17640
gcccagccag tggatgggg cttgggaaac attgcttccc attattgtca tgctggaggg
ccctttagcc catcctctcc ccccgccacc ctccttattg aggcctggag cagacttccc
                                                                   17700
```

	gtgcttcagg					17760
	caggttgtcc					17820
agagagagac	ctgagctctg	caatcttggg	caaggctttt	cccttatgtt	tcttcttatc	17880
taaagtgaac	agctggggct	catgtgctcc	ctcctcatct	aaagtgaaca	catggggctc	17940
atgtgcaggg	tcctccccgc	tttcagagcc	tgaggtcccc	tgaggctcag	gaaggctgct	18000
ccaggtgagt	gccgagctga	cttcttggtg	gacgtgctgt	ggggacagcc	cattaaagac	18060
cacatcttgg	ggccctgaaa	ttgaaagttg	taactgcctg	gtgcatggtg	gccaggcctg	18120
ctggaaacag	gttggaagcg	atctgtcacc	tttcactttg	atttcctgag	cagctcatgt	18180
ggttgctcac	tgttgttcta	ccttgaatct	tgaagattat	ttttcagaaa	ttgataaagt	18240
	agcacgggga					18300
	ctggggtatc					18360
	agaacacatc					18420
	gatggagcag					18480
	ccagctgtca					18540
	acacacatgc					18600
	cagaaacttg					18660
	gtcctggagt					18720
	gccttggcct					18780
	gacccttact					18840
	tgtgtattta					18900
	tgtatctcat					18960
	ataaagggca					19020
	gtccccaaca					19080
	gaagcggaga					19140
	tatgaggagc					19200
	tcacaacttg					19260
						19320
	taaattaaat					19320
	caaataaaat					19440
	ttgccattct					19500
	gcttacccct					
	ctcacctgtc					19560
	caccacatgg					19620
	ctgtgctgtg					19680
	accttggtca					19740
	gtgtcatacc					19800
	agccaggact					19860
	ccaccatctc					19920
	taaggggccc					19980
	aggcacanag					20040
	ttgtcaagag					20100
	aatctcattg					20160
	catgccagag					20220
tttatatago	gttgttacca	tttcaacctt	tttttttt	taacctctat	catctcaatt	20280
aaag						20284

<210> 22

<211> 7052

<212> DNA

<213> Homo sapiens

<400> 22						
	attaaagcat	gagaagcatg	aactagacat	gtagccaggt	aaaggccttg	60
	tggcaaaggc					120
	cctgaccttt					180
	tcctctgaag					240
	cacacaacag					300
	ccgtccctga					360
	agttctgatg					420
	tctggggttt					480
	aggaggagag					540
	ggtggctgcg					600
	tggggctcgg					660
	ggggaatccc					720
	aggagggtgg					780
	gccttccaga					840
	ggaacagaag					900
	aaggcttctg					960
	actttataag					1020
	ttgaagaatc					1080
	cccatccacc					1140
	cccatccagc					1200
	acaaaggtga					1260
	atgtggaatg					1320
	gagggtgggg					1380
	gcattctggt					1440
	agcccggctg					1500
	taaggaggga					1560
	catttctagt					1620
	tcggaatata					1680
	ggattatcat					1740
	ccagtgagcc					1800
	cacagtacat					1860
	aaccttaaac					1920
	kgaggaacag					1980
	agctcagacc					2040
	ggtatcaact					2100
	tgtgccaggt					2160
	atttaattct					2220
	aatcaggggt					2280
	gagatacaac					2340
	gtctccaagc					2400
	aaggtttggc					2460
	tttctattgc					2520
	cattcagatt					2580
	tcctgctcat					2640
	cacagtcctg					2700
	cgcagtgtct					2760
	gctcttattg					2820
	cccaggttca					2880
	ctaccacgcc					2940
	gctggtctcg					3000
-		-		-		

```
3060
aagtgctggg attataggcc tgagccacag cgctcagcca taactttaat ttgaaaatga
ttgtctagct tgatagctct caccactgag gaaatgttct ctggcaaaaa cggcttctct
                                                                     3120
cccaggtaac tctgagaaag tgttattaag aaatgtggct tctactttct ctgtcttacg
                                                                     3180
gggctaacat gccactcagt aatataataa tcgtggcagt ggtgactact ctcgtaatgt
                                                                     3240
                                                                     3300
tggtgcttat aatgttctca tctctctcat tttccagata ttcctcaagg tggccgaaga
                                                                     3360
gagtggggtg gatgctgaga cctcaggtaa ctgccttgag ggagaatggc acacttaaga
tagtgccttc tgctggcttt ctcagtgcac gagtattgtt cctttccctt tgaattgttc
                                                                     3420
                                                                     3480
tattgcattc tcatttgtag agtgtaggtt tgttgcagat ggggaaggtt tgttttgttg
taaataaaat aaagtatggg attettteet tgtgeettea gatggtaeet tgeeageaag
                                                                     3540
                                                                     3600
acgaaacagg cgggccttcg gggacaagca gagctgtctt cgcccgttca ctgaagatga
                                                                     3660
tgctgctgat ccaaatgatt ctgacataga cccaggtctg ttagggcaag atcaaacagt
                                                                     3720
gtcctactgt ttgaatgtga aattctctct catgctctca cctgttttct ttggatggcc
                                                                     3780
tttagccaag gtgatagatc cctacagagt ccaaagagaa gtgaggaaat ggtaaaagcc
                                                                     3840
acttgttctt tgcagcatcg tgcatgtgat caaacctgaa agagcctatc catatcactt
                                                                     3900
cctttaaaga cataaagatg gtgcctcaat cctctgaacc catgtattta ttatcttttc
                                                                     3960
tgcggggtcc tagtttcttg tatacattag gtgtttaatt gttgaacaaa tattcattcg
                                                                     4020
agtagatgag tgattttgaa agagtcagaa aggggaattt gctgttagag ttaattgtac
                                                                     4080
cctaagactt agatatttga ggctgggcat ggtggctcat gccagtaatc ccagcgcttt
                                                                     4140
gagaggctga ggtgggtaga tcacctgagg tcaggagttt gagaccagtc tgaccaacaa
qqtqaaaccc cqtctctact aaatacaaaa aattaqccga gtgtggtggc acatgcctgt
                                                                     4200
                                                                     4260
catcccagct acttgggagg ctgaggcagg agaatcgctt gaacccagga ggcagaggtt
                                                                     4320
gcagtcagcc acggttgcgc cattgcactc cagactgggc aacaagagtg aaaactccat
                                                                     4380
ctcaaaaaag aaaaaaaaag aattagatat tttggatgag tgtgtctttg tgtgtttaac
                                                                     4440
tgagatggag aggagagcta agacatcaaa caaatattgt taagatgtaa aagcacatca
                                                                     4500
gttaggtatc attagtttag gacaaggatt tctagaaaat ttttaggaac agaaaacttt
                                                                     4560
ccagttctct cacccctgct caaagagtgt atggctctta cattatatat aactgcctga
cttcatacag tatcagtact tagatcattt gaaatgtgtc cacgttttac caaaatataa
                                                                     4620
                                                                     4680
tagggtgaga agctgagatg ctaattgcca ttgtgtattc tcaaatatgt caagctacgt
acatggcctg tttcatagag tagtctataa gaaattgatg acttgattca tccgaatggc
                                                                      4740
                                                                      4800
tggctgtaac acctggttac gcatgaacac ctcttttcag ttgtctcaag acacctttct
tttctgtact tatcagacaa ggactgaaag gcagagactg ctactgttag acattttgag
                                                                     4860
                                                                     4920
tcaaqctttt ccttqqacat aqctttqtca tqaaaqccct ttacttctga gaaacttcta
gcttcagaca catgccttca agatagttgt tgaagacacc agaagaagga gcatggcaat
                                                                     4980
gccgaaaaca cctaagataa taggtgacct tcagtgttgg cttcttgcag aatccagaga
                                                                     5040
                                                                     5100
gacagacttg ctcagtggga tggatggcaa agggtcctac caggtgaaag gctggaaact
                                                                      5160
tacacagcaa cagtttgtgg cccttttgtg gaagagactg ctaattgcca gacggagtcg
                                                                      5220
gaaaggattt tttgctcagg tgagacgtgc tgttttcgcc agagactctg gcttcatggg
tgggctgcag gctctgtgac cagtgaaggc aggatagcat cctggtcaag atatggatgc
                                                                      5280
                                                                      5340
cggagccaga tttatctgta tttcaatccc agttctattc cttgccagtt gtgtatccgc
                                                                      5400
tggcaagtta cttctctatg cctcaatctc ctcatctgta aaatggggat aataatatta
cctgcaatac agggttgtta cgaaaataaa aatgaatagg tgcttagaat ggggcctgac
                                                                      5460
                                                                      5520
attagtaagt gcttagtttt gtgtgtgtat atgttatttt tattttggag gagaacataa
                                                                      5580
aaaggacaaa gtgtagaaaa actggttggg tgtattcagc tgtcataaca tgagagttgt
                                                                      5640
tatgcccaga tgcacttgac atgtgaattt attagaaaca tgatttttct ctgagttgat
gtttaactca aactgataga aaagataggt cagaatatag ttggccaaca gagaagactt
                                                                      5700
gttagactat tgtctgcatg tcagtgtttg catgctaact tgcttagtta gaaaggttaa
                                                                      5760
attttttcac tctataaaat caagaaatat agagaaaagg tctgcagaga gtctttcatt
                                                                      5820
tgatgatgtg gatattgtta agagcgggag tttggagcat acagagctca agttgaatcc
                                                                      5880
                                                                      5940
tgactttgct acttattggc tatatgacct tgggcaagct gcttagtctc tctgatcctc
                                                                      6000
agttaccttt gtttgttgat gatgaccatt gataacacaa ccataaataa tgacaacata
                                                                      6060
gagatagttc tcattatagt agttgttata cagaattatt cactcaatgt taattttctg
```

cattgaaatc	ccagaacatt	agaattgggg	gcattatttg	aatctttaag	gttataagga	6120
atacatttct	cagcaataaa	tggaaggagt	tttgggttaa	cttataaagt	atacccaagt	6180
cattttttt	cagagaagat	atggtagaaa	gtcttaggag	gttgaagaag	gaattggata	6240
tttattcttt	ctgagactat	catgggagat	aatgactatg	gttgtccatg	attggagccg	6300
ttgctgtaga	gttggtttta	ttatagtgta	ggatttgaat	gggccatgtg	ttctcagacc	6360
tcagaataaa	aagagaaaac	tgaggccagt	ggggagcgtg	acttcacatg	ggtacacttg	6420
tgctagagac	agaaccagga	ttcaggactt	ctggctcctg	gtcctgggtt	catggcccaa	6480
tgtagtcttt	ctcagtcttc	aggaggagga	agggcaggac	ccagtgttct	gagtcaccct	6540
gaatgtgagc	actatttact	tcgtgaactt	cttggcttag	tgcctctgcc	aggtggccat	6600
aacctctggc	cttgtgttgc	cagagaaaag	gtttagtttt	caggctccat	tgcttcccag	6660
ctgccaagaa	tgccttggtg	cagcacagtc	ataggccctg	cattcctcat	tgccgtgctg	6720
gttggtcggg	gaggtgggct	ggactcgtag	ggatttgccc	cttggccttg	tttctaacac	6780
ttgccgtttc	ctgctgtccc	cctgccccct	ccactgcctg	ggtaaagatt	gtcttgccag	6840
ctgtgtttgt	ctgcattgcc	cttgtgttca	gcctgatcgt	gccacccttt	ggcaagtacc	6900
ccagcctgga	acttcagccc	tggatgtaca	acgaacagta	cacatttgtc	aggtatgttt	6960
gtcttctaca	tcccaggagg	gggtaagatt	cgagcagacc	aaagatgttt	acgagggcca	7020
agggaatgga	cttcagaatt	acacggtgga	at			7052

<210> 23 <211> 2534 <212> DNA <213> Homo sapiens

<400> 23

60 attggcctct ttttctctaa gcccacattt tcttcttaca tagttcaggt ttactttatt 120 180 ttttcctttc cggctgctga ccctgtattg cccgtagttg tggaacatag catgtgtttg tgacctgtgc ctgttatttt tgtgctttct agttgtgcat gcaaagagta caaagttttc 240 ttgccctttc ttggaaaatc ctgcttgtct gtgccaaagg gataattgtg aaagcacttt 300 tgaaatactt aatgagttga ttttcttcaa attaaaaaaa atatataaat gtatatgtgt 360 atgtacatgt gtgtacacat acacaccttt atacatacag cccatttaaa acaagctcca 420 480 ctttggagtg ctctacgtca ccctgatgcc gaatacaggg ccagagtctg agatccttct 540 gggtggtttc tgtgttttgt tcatttctgt tttaagagcc tgtcacagag aaatgcttcc taaaatgttt aatttataaa aacattttta tototogatt actggtttta atgaattact 600 aagctggctg cctctcatgt acccacagca atgatgctcc tgaggacacg ggaaccctgg 660 720 aactettaaa egeeeteace aaagaceetg gettegggae eegetgtatg gaaggaaace caatcccgtg agtgccactt tagccataag cagggcttct tgtgcttgtt gcctggtttg 780 atttctaata tgctgcattt atcaactgca tgccacattg tgaccgccag catttgccct 840 ttgaattatt attatgtttt atttacaaaa agcgaaggta gtaaccgaac taaattatct 900 aggaacaaac gtttggagag tcttctaaca ccgyscaaag cacgtcatta cagacatttg 960 1020 tttactgatt tagaacctta atatttaatt taaatacgca ctttacactt actgatgaaa tgcttttcct ttctttctct cccagcccct gtacttaagt gcttcaatag gctctcatta 1080 tatatgattt ttaggttttg cttatcagct tcttcgcttt tataatctga aaagatggca 1140 1200 tatgaatttt tataaaaagg gacactttct tcttctcaaa ttgtatattt ttattgtact ttccttcaaa accccctttt aaaaagtaag cagtggataa ataaattcag tgaagcatcc 1260 1320 atatgaccct taagtgagtg taggggaagg gaggtcacca gatcactgtg agtgaagatg 1380 gtggagaggt gaggatetta tgaggeegtg etcaaggetg gtagaggtgg gttagtgttt ccaggtttag gcagaatctc agctgaggtc atgaaacaac agtgatctct gaaaaattat 1440 ggcaaggtgg gaaggtgctg gagaattgga gagggggcaa acttgacttt caagtttcaa 1500

```
tgggaagata ggtgactctg cacaccacag aacagtgagc atgataacct gtttatacaa
                                                                   1560
ggttctagag cagatttcta aatggatagc tactgtgtgc ttgtttgttc ttaattagta
                                                                   1620
ttggatagtt actaaatact tgttagtact tagtacataa tgggtggtaa atcctagcag
                                                                   1680
                                                                  1740
ctaatattgg ttcccaaata accagatgac aaggatagag aaggacacag acacggccta
                                                                   1800
tctggatttc atggtgcctt tgattttcca catgaaggtt gtgtagggaa gatagaagca
tgagatgaga tgataatata gttatctgga ttcatcactg gccagctgaa ccatatgaac
                                                                   1860
tcatggattg atgctagett aggaaggete tgtaggagee agaactggge tgagageeag
                                                                   1920
cccatagaga caaaagaggc ccggccctga catcagaggg ttcaaacatg atgtctgagc
                                                                   1980
cccacctaca gtctgccgga ggtggttgga aggaagagcc tttatcctta caattcttac
                                                                   2040
                                                                   2100
tgaaattcaa atttttaggt tttgcaaaaa aatggtggac ctgaaggaaa tttgacagga
gcatgtctca gctgtattta aatttgtctc agccaatccc cttttgaatg ttcagagtgt
                                                                   2160
aagetteagg agggeagege gtettagtgt gaettttetg gteagtteag gtgetttaag
                                                                   2220
gagacaatta gagatcaatc tggaaaactt catttgaatt tttaatacat aagaaaacaa
                                                                   2280
2340
2400
ctctgttgcc caggctggag tgcagtggct caatcttggc tcactgccac ctctgcctcc
                                                                   2460
caggttcaag tgattctcct acctcagcct cctgagtagc tgggattaca agcatgtgcc
                                                                  2520
accacactgg ctaa
                                                                   2534
<210> 24
<211> 2841
<212> DNA
<213> Homo sapiens
<400> 24
tcttgccagt ctctactcat ttttcagcac atcgagcata agatccagac tctttcccag
                                                                     60
gcctctctca tctggctcct ctcctcctcc tttatcatta ctcttcttcg tagcttatcc
                                                                    120
tactccagcc atgctgtctt cctattattc ctaaaaarta gaaatgcatt tcttcctagg
                                                                    180
gcctttgtac ctgcacttgc catcgctttt gctcagaatg ttctttttgc caagcttttg
                                                                    240
cccagcttgt tctccatcat tgttatgttt tggctgaaat gtcttctctt agtaggttca
                                                                    300
ttctccccag tcactgtctt tttattttgc tttattttgg gccatctaag gttatcttat
                                                                    360
tagtgtattt gttgttcgtc tcctccatgg gcatacacct ccatgaaggc aggtattttc
                                                                    420
accttaggcc ctcgaatata ctggacagca tctggcacgt agtagatgct caacgaatgt
                                                                    480
ttgttgtgtg agcaaatggt tggttgattg gattgaactg agttcagtat gtaaatattt
                                                                    540
                                                                    600
agggcctctt tgcattctat tttacttatg tataaaatga tacataatga tgatataaat
                                                                    660
gatgtcacag tgtacaaggc tgttgtggga tcaagcaatc aaatgagatc atgcttgtct
tttccaaatg gtgagggaat agatgcatgt ttgtggttgt tacggaatga tcctgtgctc
                                                                    720
ctgaggcaac agaaaggcca ggccatctct ggtaatccta ctcttgctgt cttccctttg
                                                                    780
cagagacacg ccctgccagg caggggagga agagtggacc actgccccag ttccccagac
                                                                    840
catcatggac ctcttccaga atgggaactg gacaatgcag aacccttcac ctgcatgcca
                                                                    900
gtgtagcagc gacaaaatca agaagatgct gcctgtgtgt cccccagggg cagggggct
                                                                   960
gcctcctcca caagtgagtc actttcaggg ggtgattggg cagaaggggt gcaggatggg
                                                                   1020
ctggtagctt ccgcttggaa gcaggaatga gtgagatatc atgttgggag ggtctgtttc
                                                                   1080
agtetttttt gttttttgtt tttttttetg aggeggagte ttgetetgte geceaggetg
                                                                   1140
gagtgctgtg gcatgatctt gcctcactgc aacctccacc tcccaggttc aagcgattct
                                                                  1200
cctgcctcag cctcctgagt agctgggatt acaggcacgc accaccatgt ctggctaatt
                                                                  1260
tttgtgtttt tagtagagat agggtttege egtgttgget aggetggtet ggaatteetg
                                                                   1320
acctcaggtg atccacccgc ctcggcctcc caaagtgctg ggattacagg cgtgagccac
                                                                   1380
tacgcccage cetgtttcag tetttaacte gettettgte ataagaaaaa geatgtgagt
                                                                   1440
tttgagggga gaaggtttgg accacactgt gcccatgcct gtcccacagc agtaaagtca
                                                                   1500
```

caggacagac tgtggcaggc ctggcttcca atcttggctc tgcaacaaat gagctgqtag

<400> 26

```
1620
cctttqacaq qcctqqqcct qtttcttcac ctctqaatta qqqaqqctqq accagaaaac
                                                                     1680
tcctgtggat cttgtcaact ctggtattct tagagactct gtttgggaag gagtcctgag
ccattttttt tttcttgaga atttcaggaa gaggagtgct tatgatagct ctctgctgct
                                                                     1740
                                                                     1800
tttatcagca accaaattgc aggatgagga caagcaattc taaatgagta caggaactaa
aagaaggctt ggttaccact cttgaaaata atagctagtc caggtgcggg gtggctcaca
                                                                     1860
                                                                     1920
cctqtaatct caqtattttq qqatqccqaq qtgqactqat cacctaagqt caggagttcg
aaaccagctt ggccaatgtg gcgaaaccct gtctctacta aaaattcaaa aattagccag
                                                                     1980
gcatggtggc acatgcctgt aatcccagtt acttgggagg ctgaagcagg agaattgctt
                                                                      2040
                                                                      2100
gaacctggga ggtggaggtc gcagggagcc aaaattgcgc cactgtactc cagcctgagc
                                                                      2160
aacacagcaa aactccatat caaaaaataa aatgaataaa ataacagcta atctagtcat
                                                                      2220
cagtataact ccagtgaaca gaagatttat taggcatagt gaatgatggt gcttcctaaa
aatctcttga ctacaaagaa tctcatttca atgtttattg tttagatgtt cagaataaat
                                                                      2280
tcttgggaaa gaccttggct tggtgtaagt gaattaccag tgccgagggc agggtgaacc
                                                                      2340
                                                                      2400
aagtotoagt gotggttgac tgagggoagt gtotgggaco tgtagtoagg tttooggtoa
cactqtqqac atqqtcactq ttqtccttqa tttqttttct qtttcaattc ttqtctataa
                                                                      2460
                                                                      2520
agacccgtat qcttqqtttt catqtqatqa cagaqaaaac aaaacactqc agatatcctt
caggacctga caggaagaaa catttcggat tatctggtga agacgtatgt gcagatcata
                                                                      2580
gccaaaaggt gactttttac taaacttggc ccctgcctta ttattactaa ttagaggaat
                                                                      2640
                                                                      2700
taaagaccta caaataacag actgaaacag tgggggaaat gccagattat ggcctgattc
                                                                      2760
tgtctattgg aagtttagga tattatccca aactagaaaa gatgacgaga gggactgtga
acattcagtt gtcagcttca aggctgaggc agcctggtct agaatgaaaa tagaaatgga
                                                                      2820
ttcaacgtca aattttgcca c
                                                                      2841
<210> 25
<211> 852
<212> DNA
<213> Homo sapiens
<400> 25
                                                                        60
gcatgctgga gtgatagtga ccatgagttt ctaagaaaga agcataattt ctccatatgt
                                                                       120
catccacaat tgaaatatta ttgttaattg aaaaagcttc taggccaggc acggtggctc
atgcctgtaa tcccagcact ttaggagcca aggcgggtgg atcacttgag gtcaggagtt
                                                                       180
tgagaccagc ctggccaaca tggggaaacc ctgtctctac taaaaaataca aaataagctg
                                                                       240
                                                                       300
ggcgtggtgg tgcgtgcctg taatcccagc tacttgggag gctgaggcag gagaactgct
                                                                       360
tgaatctggg aggcggaggt tgcagtgagc tgagttcatg ccattgcatt ccagcctggg
caacaagagc gaaaccatct cccaaaagaa aaaaaaaaga aagaaaaagc ttctagtttg
                                                                       420
gttacatctt ggtctataag gtggtttgta aattggttta acccaaggcc tggttctcat
                                                                       480
ataagtaata gggtatttat gatggagaga aggctggaag aggcctgaac acaggcttct
                                                                       540
                                                                       600
tttctctagc acaaccctac aaggccagct gattctaggg ttatttctgt ccgttcctta
                                                                       660
tatcctcagg tggatattta ctccttttgc atcattagga ataggctcag tgctttcttt
qaactqattt tttqtttctt tqtctctqca qcttaaaqaa caaqatctqq qtqaatqaqt
                                                                       720
ttaggtaagt tgctgtcttt ctggcacgtt tagctcaggg ggaggatggt gttgtaggtg
                                                                       780
tgcttggatt gaagaaagcc ttggggattg tttgtcactc acacacttgt gggtgccatc
                                                                       840
                                                                       852
tcactgtgag ga
<210> 26
<211> 6289
<212> DNA
<213> Homo sapiens
```

	gtttctgcct					60
	ttgatatact					120
	agtaagtagt					180
	ggcttcttaa					240
	gaggaaataa					300
	tgggttttga					360
	tcatggaaaa					420
	gatttccgtc					480
	gagcagacgc					540
cctgtgtata	aggccagcgc	agcctactct	ggacagtgca	gggttcccac	tctcccaact	600
	ttgcctccag					660
tgtgagatga	aacaccattc	tttcctcaat	gtctcagcta	tctaactgtg	tgtgtaatca	720
ggccaggtcc	tccctgctgg	gcagaaacca	tgggagttaa	gagattgcca	acatttatta	780
gaggaagctg	acgtgtaact	tctgaggcaa	aatttagccc	tcctttgaac	aggaatttga	840
ctcagtgaac	cttgtacaca	ctcgcactga	gtctgctgct	gatgatactg	tgcaccccac	900
tgtctgggtt	ttaatgtcag	gctgttcttt	taggtatggc	ggcttttccc	tgggtgtcag	960
taatactcaa	gcacttcctc	cgagtcaaga	agttaatgat	gccatcaaac	aaatgaagaa	1020
acacctaaag	ctggccaagg	taaaatatct	atcgtaagat	gtatcagaaa	aatgggcatg	1080
tagctgctgg	gatataggag	tagttggcag	gttaaacgga	tcacctggca	gctcattgtt	1140
ctgaatatgt	tggcatacag	agccgtcttt	ggcatttagc	gatttgagcc	agacaaaact	1200
gaattactta	gttgtacgtt	taaaagtgta	ggtcaaaaac	aaatccagag	gccaggagct	1260
gtggctcatg	cctgtaatcc	tagcactttg	ggaggctgaa	gcgggtggat	cacttgaggt	1320
caggagttcg	agaccagcct	ggcctacatg	acaaaacccc	gtatctacta	aaaatacaaa	1380
	gggcttggtg					1440
	ttgaaccctg					1500
	gcaacaagag					1560
	agaggctggg					1620
	aaagcacaag					1680
	taaaaacata					1740
	gaggctgagg					1800
	gcaccactgc					1860
	aacaaccagg					1920
	ctgaaayaat					1980
	agctggtctg					2040
	ttttaggtga					2100
	tagtcctaga					2160
	aggcagagcg					2220
	ccccaccgtg					2280
	attccttcta					2340
	ttctcaggag					2400
	ttgctcttca					2460
	tatgtgaaca					2520
	atttctcaac					2580
	aaaccgctgt					2640
	tactttcaac					2700
	actttaccag					2760
	gacataccag					2820
	gtgaaatgga					2880
	aggtataagg					2940
	actgtaatta					3000
	tttctttctg					3060
	5	55 55		333 3	3 1 3 1 3	

```
3120
ggagcccggt ttgggggcat taccttgtac ctggtatgtt ttctttcagg tgtggttcaa
taacaagggc tggcatgcaa tcagctcttt cctgaatgtc atcaacaatg ccattctccg
                                                                    3180
                                                                    3240
ggccaacctg caaaagggag agaaccctag ccattatgga attactgctt tcaatcatcc
                                                                    3300
cctgaatctc accaagcage agctctcaga ggtggctctg taagtgtggc tgtgtctgta
tagatggagt ggggcaaggg agagggttat ggagaagggg agaaaaatgt gaatctcatt
                                                                    3360
gtaggggaac agctgcagag accgttatat tatgataaat ctggattgat ccaggctctg
                                                                    3420
ggcagaagtg ataagtttac gaattggctg gttgggcttc ttgaactgca gaagagaaaa
                                                                    3480
                                                                    3540
tgacactgat atgtaaaaat cgtaacattt agtgaattca tataaagtga gttcaaaaat
                                                                    3600
tgttaattaa attataattt aattataagt gtttaatcag tttgatttgt ttaaaaacca
ctgttttaaa tttggtggaa tatgttttta ttagcttgta tctttaattc ctaaattaag
                                                                    3660
3720
gccaggatga gctagtttaa agtatgcagc ctttggagtc atacagatct gggtttgaat
                                                                    3780
                                                                    3840
ctggtctcta aactttatag atgtatgata ttaaatgagg cagttcatgt aaattgccaa
gcccagcact cagcacagag ttgatatttc acacacatta gatacctttc ctgtatgtgg
                                                                    3900
agcatggcag ttcctgtttc tgctttactc ctacaggata ctaatatagg acactaggat
                                                                    3960
ctttatacca agaccccatg taatgggctt atgagaccat tcttcttata aaaatctgac
                                                                    4020
agaatttttg tatgtgttag atcaataggc tgcatactgt tattttcaag ttgatttaca
                                                                    4080
gccagaaata ttaatttatt tgagtagtta cagagtaata tttctgctct catttagttt
                                                                    4140
                                                                    4200
tcaagcccca ctagtccttt gtgtgtgaaa atttacaact tactgctctt acaaggtcat
                                                                    4260
gaacagtgga ccaaagtgaa tgccattaac cactctgact tccttcatta gttttattgt
gacagtggac tcttttgacc tcagtaatac cagtttggca tttacattgt catattttta
                                                                    4320
                                                                    4380
gacttaaaaa tgatcatctt aaccctgaat aaaatgtgtc tggtgaacag atgtttttcc
ttggctgtgc ctcagatatc tctgtgtgtg tgtacgtgtg tgtttgtctg tgtgtccatg
                                                                    4440
                                                                    4500
tecteactga ttgageecta actgeateaa agaceectea gatttteaca egetttttet
ctccaggatg accacatcag tggatgtcct tgtgtccatc tgtgtcatct ttgcaatgtc
                                                                    4560
cttcgtccca gccagctttg tcgtattcct gatccaggag cgggtcagca aagcaaaaca
                                                                    4620
cctgcagttc atcagtggag tgaagcctgt catctactgg ctctctaatt ttgtctggga
                                                                    4680
tatggtaagg acacaggcct gctgtatctt tctgatgtct gtcagggcca tggattgata
                                                                    4740
                                                                    4800
tggataagaa agaaagagct ctggctatca tcaggaaatg ttccagctac tctaaagatg
tatgaaaaag aaatagccag aggcaggtga tcactttcat gacaccaaac acagcattgg
                                                                    4860
gtaccagagt tcatgtcaca ccagagggaa aattctgtac acaatgatga aaattaatac
                                                                    4920
cactaccact taagttccta tgtgacaact ttcccaagaa tcagagagat acaagtcaaa
                                                                    4980
                                                                    5040
actocaagto aatgootota acttototga tgggttttaa cotocagagt cagaatgtto
tttgccttac taggaaagcc atctgtcatt tagaaaactc tgtacatttt atcagcagct
                                                                    5100
tatccatcca ttgcaaatat tgtttttgtg ccasccacaa tatattgctt ctatttggac
                                                                    5160
caatatgggg gatttgaagg aattctgaag ttctaattat atttcaactc tactttacaa
                                                                    5220
tatctccctg aaatatatct ccctgtaact tctattaatt ataagctaca cagagcaaat
                                                                    5280
ctaattette teecacegaa caagteeetg gatatttaaa aataaetete ataeteteat
                                                                    5340
ttaacctgag tattacccag ataagatgat atatgagaat acaccttgta acctccgaag
                                                                    5400
cactgtacaa atgtgagcaa tgatggtgga qatgatgatg agatctttgc tgtttatacc
                                                                    5460
aagcccctta gactgtgtca ctcttctgat ccggttgtcc ttgtatggcc atgctgtata
                                                                    5520
ttgtgaatgt cccgttttca aaagcaaagc caagaattaa ccttgtgttc aggctgtggt
                                                                    5580
                                                                    5640
ctgaatggtt atgggtccag agggagttga tctttagctc acacttctat tactgcagca
caaagatttt gcattttgga aggagcaccg tcttactggc aacttagtgg taaaccaaaa
                                                                    5700
                                                                    5760
cctccatttc acacaaatga ttgtgaaatt cgggtctcct tcattctata caaattcatt
tgattttttt gaaactaaac tttatattta tccatattaa attacatggg ttttattttt
                                                                    5820
gttttatctt gattcagtaa ttactccttt cagtaaacac agactgagtg ctgtgtgtct
                                                                    5880
gacttatgcc aggcataggt gattcagaga tgaaaggtca agtccctgaa cccatctctt
                                                                    5940
gtcttcctgg gtattatctg tccctccctg ctttagagct cctgaaattt gctagaagca
                                                                    6000
                                                                    6060
tgtcttcatc taagttgttg ataaacacat caagtaggat tggactgagg cagagccctg
tagtctgaag ctgcagttct tctagcggct gacaagcccc actatcactt ccctgctggt
                                                                    6120
```

gctttgctct	gccagctgtg	aattctcata	attqtcctat	cqtcaaqtct	ttatttctqc	6180
	: ttgatacact		-			6240
_	ttcatgttat			_		6289
•	_			-		
<210> 27						
<211> 4244	:					
<212> DNA						
<213> Homo	sapiens					
<400> 27						
aaattactct	gactgggaat	ccatcgttca	gtaagtttac	tgagtgtgac	accttggctt	60
gactgttgga	aagacagaaa	gggcatgtag	tttataaaat	cagccaaggg	gaaaatgctt	120
gtcaaaatgt	attgtcgggt	attttgatta	atagtttatg	tggcttcatt	aattcagagt	180
tactctccaa	tatgtttatc	tgccctttct	tgtctgataa	tggtgaaaac	ttgtgtgatg	240
cattgtatat	ttgatttagg	ggtgaactgg	atgtctttgt	tttcactttt	agtgcaatta	300
cgttgtccct	gccacactgg	tcattatcat	cttcatctgc	ttccagcaga	agtcctatgt	360
gtcctccacc	: aatctgcctg	tgctagccct	tctacttttg	ctgtatgggt	aagtcacctc	420
tgagtgaggg	agctgcacag	tggataaggc	atttggtgcc	cagtgtcaga	aggagggcag	480
ggactctcag	tagacactta	tctttttgtg	tctcaacagg	tggtcaatca	cacctctcat	540
gtacccagcc	: tcctttgtgt	tcaagatccc	cagcacagcc	tatgtggtgc	tcaccagcgt	600
gaacctcttc	: attggcatta	atggcagcgt	ggccaccttt	gtgctggagc	tgttcaccga	660
caatgtgagt	: catgcagaga	gaacactcct	gctgggatga	gcatctctgg	gagccagagg	720
acagtgttta	attgtgatct	tattccactt	gtcagtggta	ttgacactgc	tgactgcctt	780
gtcctgtctt	cagagtctgt	cttccctgag	aaggcaaagc	acctttcttt	cttgctgtgc	840
cttacatttt	gctggtcaag	cctttcagtt	tcttttgaca	gttttttta	cttctttctt	900
ttttcaatgt	tgctcttacc	aagagtagct	cctctgcctt	ccactttaca	catgagagct	960
gggcgacgca	ı ttcagtccta	aggcttttac	catcacctct	cttggtgttt	ttattgtcat	1020
ctctaagatc	: aatgccttta	gccttgatca	taaccttgaa	ctctaatctc	aaattctcac	1080
	gattgctcca		_		_	1140
	: cccttggaac					1200
	: tcggttgccc					1260
	cccacattca					1320
	cctctccatt			_		1380
	tgcacaactc	-				1440
	, ttgcctccaa	_			_	1500
	gtctggtagt	-	_	_		1560
	gctgggaggt	-			_	1620
-	caacgtacat			_		1680
	gtctgtttct		_	-		1740
	cccttattca					1800
	, tatttgagaa					1860
	atgagcaatt			_		1920
	agcctgtttc	_				1980
	taaagaatag					2040
	tctgaattaa					2100
	tcagaacttg				_	2160
	c ctcccttccc			_		2220

2340

atcaatgata tootgaagto ogtgttottg atottoccac atttttgcot gggacgaggg

ctcatcgaca tggtgaaaaa ccaggcaatg gctgatgccc tggaaaggtt tggtgagtga

```
agcagtggct gtaggatgct ttaatggaga tggcactctg cataggcctt ggtaccctga
                                                                     2400
actitigtitit ggaaagaagc aggitgactaa gcacaggatg ticccccacc cccatgccca
                                                                     2460
gtgacagggc tcatgccaac acagctggtt gtggcatggg ttttgtgaca caaccatttg
                                                                     2520
tctgtgtctc tgatagcatt gagaaaagtg aaagggcagt tttgaaggta aggaaaatag
                                                                     2580
tgttatttgc ttggatccac tggctcatgc cactgtctgg gttggttaga agcactggaa
                                                                     2640
                                                                     2700
aagtcaaacc ataactttga gaattaggtg atcagggaat cagaaggaaa gatgcaaact
ttggctcttt taggcgaatc atgtgcctgc agatgaggtc atttattatc ttttacacag
                                                                     2760
tctataaaat tataatgtat tacatctttt tctaccttta gaatggttaa aaatatttct
                                                                     2820
ccggtagcca tatgattatt attcatccat tagataatat agtcaaatgg gccatgttat
                                                                     2880
ttactgttca tagaagaggg gctttttgca acttgggcta caaaggagat atgtaaggaa
                                                                     2940
tttaaggaat ggttacatgg aactagattt aattgaatct agtggtttaa ttgattcact
                                                                     3000
aggatatatg ctactgaaag gggaatctgc ttaaagtgct ttctgatatt tattattact
                                                                     3060
aaaacttaga atttattaaa aatactgact gtgaaaatta cttgggtcgt ttgccttttt
                                                                     3120
aaaaggattt ttggcatgtc tcattaaaaa aagaaatact agatatcttc agtgaagtta
                                                                     3180
caaatcgaat acacattggc tctgaaattc tgattgatac tgggtcataa aaagttttcc
                                                                     3240
caaatcagac ttggaaagtg atcactctct tgttactctt ttttccttgt catgggtgat
                                                                     3300
agccatttgt gtttattgga agatcggtga attttaagga acataggccc aaatttgagg
                                                                     3360
aagggccatg gtttttgatc cctccattct gaccggatct ctgcattgtg tctactaggg
                                                                     3420
gagaateget ttgtgteace attatettgg gaettggtgg gaegaaacet ettegeeatg
                                                                     3480
gccgtggaag gggtggtgtt cttcctcatt actgttctga tccagtacag attcttcatc
                                                                     3540
aggcccaggt gagctttttc ttagaacccg tggagcacct ggttgagggt cacagaggag
                                                                     3600
gcgcacaggg aaacactcac caatgggggt tgcattgaac tgaactcaaa atatgtgata
                                                                     3660
aaactgattt teetgatgtg ggeateeege ageeeetee etgeeeatee tggagaetgt
                                                                     3720
ggcaagtagg ttttataata ctacgttaga gactgaatct ttgtcctgaa aaatagtttg
                                                                     3780
aaaggttcat ttttcttgtt ttttccccca agacctgtaa atgcaaagct atctcctctg
                                                                     3840
aatgatgaag atgaagatgt gaggcgggaa agacagagaa ttcttgatgg tggaggccag
                                                                     3900
aatgacatct tagaaatcaa ggagttgacg aaggtgagag agtacaggtt acaatagctc
                                                                     3960
atcttcagtt tttttcagct ttatgtgctg taacccagca gtttgctgac ttgcttaata
                                                                     4020
aaagggcatg tgttcccaaa atgtacatct ataccaaggt tctgtcaatt ttattttaaa
                                                                     4080
aacaccatgg agacttetta aagaattett aetgagaatt ettttgtgat atgaatteee
                                                                     4140
attotogaat actitiggitt tatatgotta cattiatqiq tiaqtiatta aaacatacta
                                                                     4200
atattgtata tctagtcaaa ctgagtagag agataatggt gatt
                                                                     4244
<210> 28
<211> 5023
<212> DNA
<213> Homo sapiens
<400> 28
ttttaaaata cctgcaatac atatatatgt tgaatagatg aaaaattatg tagatgataa
                                                                       60
tgaatgatac ggttctaaaa agacaggtta aaaagtaagt tcacttttat tttgagcttc
                                                                       120
agaatcattc agaagccagt cgccacaaac gcagaccaag gctcttggca catcaaatat
                                                                       180
gcctatggct tagggttatt gacaagtett atgttgcagt gtatgtggtt tatagteetg
                                                                       240
ccttccacag ttgcttggga gagctgtgag tcactgaggc ttatgaatgt ttacattttg
                                                                       300
tttgttgcag atatatagaa ggaagcggaa gcctgctgtt gacaggattt gcgtgggcat
                                                                       360
tcctcctggt gaggtaaaga cactttgtct atattgcgtt tgtccctatt agttcaqact
                                                                       420
atctctaccc aatcaagcaa cgatgctcgt taagaggtaa aagtggattt taaaggcttc
                                                                       480
tgtatttatg ccaggatgga gcaattagtc atcgagaaga gagggaccct gtatgtcaag
                                                                       540
agaatgattt cagagaatcc aatacaattt aagaaaaagc atggggctgg gcgcagtgat
                                                                       600
tcactcctgt aatcccagca ctttgggagg ccgaggtggg cggactcacg aggtcaggag
                                                                       660
attgagacca tcctggccaa catggtgaaa ccccatctct actataaata caaaaattag
                                                                       720
```

780 ctgggcatag tagtgcattc ctgtagtccc agctactcgg gaggctgagg caggagaatt 840 gcttgaacct aggagggga ggttgcccag attgcgctgc tgcactccag cctggtgaca gagtgagact catgtcaaca acaaaaacag aaaaagcacg cacatctaaa acatgctttt 900 960 gtgatccatt tgggatggtg atgacattca aatagttttt taaaaataga ttttctcctt totggtttcc gtttgtgttc ttttatgccc ttttgccaga gtaggtggtg caatttggct 1020 1080 agctggcttt cattactgtt tttcacacat taactttggc ctcaacttga caactcaaat aatatttata aatacagcca cacttaaaat ggtcccatta tgaaatacat atttaaatat 1140 ctatacgatg tgttaaaacc aagaaaatat ttgattcttc tctgatattt aagaattgaa 1200 1260 ggtttgaggt agttacgtgt taggggcatt tatattcatg tttttagagt ttgcttatac 1320 aacttaatet tteettttea gtgetttggg eteetgggag ttaatgggge tggaaaatea tcaactttca agatgttaac aggagatacc actgttacca gaggagatgc tttccttaac 1380 aaaaataggt gagaaaagaa gtggcttgta ttttgctgca aagactttgt ttttaattta 1440 tttaaagaaa taggttgtta tttttgatta cagtggtatt tttagagttc ataaaaatgt 1500 tgaaatatag taaagggtaa agaagcacat aaaatcatcc atgatttcaa tatctagaga 1560 taatcacaat ttacatttcc tttcagtctc attctcttct tttaacagct ttattcaggt 1620 1680 ataatttaca tacaatataa tttgcttgtt ttttaagagt ataatttagt gatttttggt aaattgagag ttttgcaacc atcaccacaa tccagtttta gaacttttcc atcaccccac 1740 1800 atctgtctta tatacacata taaatgtgcc atacaattga gatcatactg tatgtagaat ttaaaattag tttttattgt taatgagtgt attatgaata tttcccagtg ggttacattt 1860 cctaagatgt ggaattttac attgctacat aaaatccccc tatgtacatg tacctataat 1920 ttatttaata aattoottat aaatgttgga cacattagtt tooattttto actatgtaaa 1980 tatgtccctg tatacatctt ttattatttc ctcaggaaca attcctacaa agtaaattgc 2040 cctctctaaa gagcatacaa attgactgag ccaccgttag gccattttct gagactgcac 2100 aggtcacaaa gcaatctgat ctttgggaat acagctacat tttataggct tcttagataa 2160 tgttactcta agtactttaa atatgtgggg cttctctggg cttttttttt tttgagacgg 2220 agtttcactc ttactgccca ggctggagag caatggcgcg accttggctc actgcaacct 2280 ccgcctccca ggttcaagcg attctcctgc ctcagcctcc tgagtagctg agattacagg 2340 tgcccgccac aatgcctgcc taattttttt gtattttcag tagagatggg gtttcaccat 2400 gttggccaga ctggtctcga gctcctgacc tcaggtgatc cacctgcctc agcctcccaa 2460 agttetggga ttacaggeat gagecactge geceggette tetggaetta ttatgtggag 2520 agatagtaca aggcagtggc tttcagagtt ttttgaccat gaccgttgtg ggaaatacat 2580 tttatatctc aacctagtat gtacacacag acatgtagac acatgtataa cctaaagttt 2640 cataaagcag tacctactgt tactaattgt agtgcactct gctatttctt attctacctt 2700 atactgcgtc attaaaaaag tgctggtcat gacccactaa atttatttcc caaaccacta 2760 atgaacaatg actcacaatt tgaacacact ggacaggggg atagccaata aaattgaaaa 2820 gagcaaggaa attaatgtat tcatgatctc ctctcctgtc tcttacattt ttgcagtagc 2880 aatgtaaagg aatcctaaga gaacagacat tctgggaata gcaggcctag cgctgcacaa 2940 ctgctttcct aggcttgctc ctagtaccaa gctcctgacg catatagcag tggcagtaat 3000 aaccagccca tagtaaggtt tgtcacaggg actggttgta agaactgatt tgrttggtat 3060 agctgtgagg gcctggcacg gtgtccacgt gtgcctcaat cctaattctg aaaaaggctg 3120 accetggggg tgetaattag atacacagag aggaatgaat getgecagaa ggecaagtte 3180 atggcaatgc cgctgtggct gaggtgcagt catcagtctg gaacgtgaac actgaacttc 3240 teteacatgt gattetteae ttgaetgget teatagaace ceaaageeae eecaecaea 3300 cataaattgt gtctctaggt tctgtgttgc tcacactcaa aatttctggg ccttctcatt 3360 tggtgcatgt gaatggtgca tatgagtgaa gtctaggatg gggccttagc gttaaagccc 3420 tggggtagtg tgactgagat tgttggtaaa gaatgtgcag tggttggcat gacctcagaa 3480 attetgaaat gggaetgeac etgeagaetg aagtgtteag agageeaggg aggtgeaagg 3540 actggggagg gtagaggcag gaaccctgcc tgccaggaag agctagcatc ctgggggcag 3600 aaaggctgtg ctttcaagta gcagcagatg tattggtatc tttgtaatgg agaagcatac 3660 tttacaggaa cattaggcca gattgtctaa ccagagtatc tctacctgct taaaatctaa 3720 gtagttttct tgtcctttgc agtatcttat caaacatcca tgaagtacat cagaacatgg 3780

```
gctactgccc tcagtttgat gccatcacag agctgttgac tgggagagaa cacgtggagt
                                                                    3840
                                                                    3900
tetttgeect tttgagagga gteecagaga aagaagttgg caaggtactg tgggcacetg
aaagccagcc tgtctccttt ggcatcctga caatatatac cttatggctt ttccacacgc
                                                                    3960
attgacttca ggctgttttt cctcatgaat gcagcagcac aaaatgctgg ttctttgtat
                                                                    4020
                                                                    4080
ctgctttcag ggtggaaacc tgtaacggtg gtggggcagg gctgggtggg cagagaggga
gtgctgctcc caccacacga gtcccttctc cctgctttgg ctcctcacca gttgtcaggt
                                                                    4140
tatgattata gaatctagtc ctactcagtg aaagaacttt catacatgta tgtgtaggac
                                                                    4200
agcatgataa aattoccaag ccagaccaaa gtcaaggtgc tttttatcac tgtaggttgg
                                                                    4260
tgagtgggcg attcggaaac tgggcctcgt gaagtatgga gaaaaatatg ctggtaacta
                                                                    4320
tagtggaggc aacaaacgca agctetetac agccatgget ttgatcggcg ggcetectgt
                                                                    4380
ggtgtttctg gtgagtataa ctgtggatgg aaaactgttq ttctgqcctq aqtqqaaaac
                                                                    4440
atgactgttc aaaagtccta tatgtccagg gctgttgtat gattggcttg tcttccccca
                                                                    4500
gggacagcag agcaaccttg gaaaagcaga gggaagcttc tcccttggca cacactgggg
                                                                    4560
tggctgtacc atgcctgcag atgctcccaa atagaggcac tccaagcact ttgtttctta
                                                                    4620
gcgtgattga ggctggatat gtgatttgat ctttctctgg aacattcttt ctaatcatct
                                                                    4680
ttgtgttcat tccctgaaaa tgaagagtgt ggacacagct ttaaaatccc caaggtagca
                                                                    4740
actaggtcat agttccttac acacggatag atgaaaaaca gatcagactg ggaagtggcc
                                                                    4800
cttgaccttt tttcttctgt agataagagc attgatgtta ttacgggaag aagcctttga
                                                                    4860
ggcttttatg tattccacct cggtctggaa tttgtttctg taaggctaac agttgcaata
                                                                    4920
4980
tactgacttc aatagaggtt tcagacaaaa agttgttttg tat
                                                                    5023
<210> 29
<211> 5138
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(5138)
<223> n = a, t, c, or g
<400> 29
ngccnngttn aaaangaaaa tttnnnnnaa attnaanntt annggngnnn tttccccaga
                                                                      60
aaaaacnaaa angattteen eeengggggg neeecenant enaaaaggee eenettnttt
                                                                     120
gnggngaggg aaagnttttt ttggaatttt taatttttgg tcccccaaaa cctattattg
                                                                     180
agaatttaat tacataaaaa agtactcaga atatttgagt ttcctgcatc aataagacat
                                                                     240
ttataataat gaccttgttt acaaatgaat ttgaaagtta ctctaattct ttgattcatc
                                                                     300
aagaaataac tagaatggca agttaaaatt taagctgttt caaagatgct tctqcattta
                                                                     360
aaaacaaatt tatctttgat tttttttccc cccaqcaaat aaqacttatt ttattctaat
                                                                     420
tacaggatga acccaccaca ggcatggatc ccaaagcccg gcggttcttg tggaattgtg
                                                                     480
ccctaagtgt tgtcaaggag gggagatcag tagtgcttac atctcatagg tccgtagtaa
                                                                     540
agtettgggt teeteactgt gggatgtttt aacttteeaa gtagaatatg egateatttt
                                                                     600
gtaaaaatta gaaaatacag aaaagcaaag agtaaaacaa ttattacctq aaattatata
                                                                     660
tgcatattct tacaaaaatg caagcccagt ataaatactg ctctttttca cttaatatat
                                                                     720
tgtaaacatt attccaagtc agtgcattta ggtgtcattt cttatagctg gatagtattc
                                                                     780
cattaggata tactcttatt taactattcc cccttttgta gacatttgga ttatttccaa
                                                                     840
cttgttcaca attgtaaaca ccactacact gaacagcatc atccctatat ccacatgtac
                                                                     900
```

960

ttgtaacaga atacaattcc ctaggaagct ggaatgctgg aagtcatggt gatgttctca

```
tggttacaga gaatctctct aaaactaaaa cctctttctg ttttaccgca gtatggaaga
                                                                      1020
atgtgaaget etttgeaeta ggatggeaat eatggteaat ggaaggttea ggtgeettgg
                                                                      1080
cagtgtccag catctaaaaa ataggtaata aagataattt ctttgggata gtgcctagtg
                                                                      1140
agaaggcttg atatttattc ttttgtgagt atataaatgg tgcctctaaa ataaagggaa
                                                                      1200
ataaaactga gcaaaacagt atagtggaaa gaatgagggc tttgaagtcc gaactgcatt
                                                                      1260
caaattetgt etttaccatt tactggttet gtgactettg ggcaagttac ttaactactg
                                                                      1320
                                                                      1380
taagagttag tttccctgga agatctacct cctagctttg tgctatagat gaaatgaaaa
aaatttacat gtgccagtac tggtgagagc gcaagctttg gagtcaaaca caaatgggtt
                                                                      1440
                                                                      1500
tgcatcctgg ccctaccaat tatgagctct gagccatggg caagtgacta actccctggg
cctcagtttc tctgtaacat ctgtcagact tcatgggtcc aggtgaggat taaaggagat
                                                                      1560
catgtattta cagcacatgg catggtgctt cacataaaat aagtatttag taaatgataa
                                                                      1620
ctggttcctt ctctcagaaa cttatttctg ggcctgccag gggccgccct ttttcatggc
                                                                      1680
acaagttggg ttcccagggt tcagtattct tttaaatagt tttctggaga tcctccattt
                                                                      1740
gggtattttt tcctgctttc aggtttggag atggttatac aatagttgta cgaatagcag
                                                                      1800
ggtccaaccc ggacctgaag cctgtccagg atttctttgg acttgcattt cctggaagtg
                                                                      1860
ttcyaaaaga gaaacaccgg aacatgctac aataccagct tccatcttca ttatcttctc
                                                                      1920
tggccaggat attcagcatc ctctcccaga gcaaaaagcg actccacata gaagactact
                                                                      1980
ctgtttctca gacaacactt gaccaagtaa gctttgagtg tcaaaacaga tttacttctc
                                                                      2040
agggtgtgga ttcctgcccc gacactcccg cccataggtc caagagcagt ttgtatcttg
                                                                     2100
aattggtgct tgaattcctg atctactatt cctagctatg ctttttacta aacctctctg
                                                                      2160
aacctgaaaa gggagatgat gcctatgtac tctataggat tattgtgaga atttactgta
                                                                      2220
ataataacca taaaaactac catttagtga gcacctacca tgggccaggc attttacttg
                                                                      2280
gtgcctaatc ctatttaaat tagataaaaa agtaccaaat aggtcctgac acttaagaag
                                                                      2340
tactcagtaa atattttctt ccctcttccc tttaatcaag accgtatgtg ccaaagtaaa
                                                                      2400
tggatgactg agcagttggt gatgtagggg tggggggga tatagaaagt cagtttttgg
                                                                      2460
ccgggcgtgg tggctcatgc ctgtaatccc agcactttgg gaggctgagg agcaggcaga
                                                                     2520
tcatgaggtc aggagatcca gataatcctg gccaacaggg tgaaaccccg tctctactaa
                                                                      2580
aaatacaaaa attagctggg catggtggtg cgcacttgta gtcccagcta cttgcgaggc
                                                                      2640
tgaggcagga gaattgctcg aacccaggag gtggaggtta cagtgagcca aggtctcgcc
                                                                      2700
actgcactcc agcctgggga cagagcaaga ccccatttca aggggggaaa aaaagtctat
                                                                      2760
ttttaagttg ttattgcttt tttcaagtat tcttccctcc ttcacacaca gttttctagt
                                                                     2820
taatccattt atgtaattct gtatgctcct acttgaccta atttcaacat ctggaaaaat
                                                                      2880
agaactagaa taaagaatga gcaagttgag tggtatttat aaaggtccat cttaatcttt
                                                                     2940
taacaggtat ttgtgaactt tgccaaggac caaagtgatg atgaccactt aaaagacctc
                                                                     3000
tcattacaca aaaaccagac agtagtggac gttgcagttc tcacatcttt tctacaqqat
                                                                      3060
gagaaagtga aagaaagcta tgtatgaaga atcctgttca tacggggtgg ctgaaagtaa
                                                                      3120
agaggaacta gactttcctt tgcaccatgt gaagtgttgt ggagaaaaga gccagaagtt
                                                                     3180
gatgtgggaa gaagtaaact ggatactgta ctgatactat tcaatgcaat gcaattcaat
                                                                     3240
gcaatgaaaa caaaattcca ttacaggggc agtgcctttg tagcctatgt cttgtatggc
                                                                      3300
tctcaagtga aagacttgaa tttagttttt tacctatacc tatgtgaaac tctattatgg
                                                                     3360
aacccaatgg acatatgggt ttgaactcac actttttttt ttttttttgt tcctgtgtat
                                                                     3420
tctcattggg gttgcaacaa taattcatca agtaatcatg gccagcgatt attgatcaaa
                                                                      3480
atcaaaaggt aatgcacatc ctcattcact aagccatgcc atgcccagga gactggtttc
                                                                      3540
ccggtgacac atccattgct ggcaatgagt gtgccagagt tattagtgcc aagtttttca
                                                                      3600
gaaagtttga agcaccatgg tgtgtcatgc tcacttttgt gaaagctgct ctgctcagag
                                                                     3660
tctatcaaca ttgaatatca gttgacagaa tggtgccatg cgtggctaac atcctgcttt
                                                                     3720
gattccctct gataagctgt tctggtggca gtaacatgca acaaaaatgt gggtgtctcc
                                                                     3780
aggcacggga aacttggttc cattgttata ttgtcctatg cttcgagcca tgggtctaca
                                                                     3840
gggtcatcct tatgagactc ttaaatatac ttagatcctg gtaagaggca aagaatcaac
                                                                     3900
agccaaactg ctggggctgc aactgctgaa gccagggcat gggattaaag agattgtgcg
                                                                     3960
ttcaaaccta gggaagcctg tgcccatttg tcctgactgt ctgctaacat qqtacactqc
                                                                     4020
```

```
atctcaagat gtttatctga cacaagtgta ttatttctqq ctttttqaat taatctaqaa
                                                                      4080
aatgaaaaga tggagttgta ttttqacaaa aatqtttqta ctttttaatq ttatttqqaa
                                                                      4140
ttttaagttc tatcagtgac ttctgaatcc ttagaatggc ctctttgtag aaccctgtgg
                                                                      4200
tatagaggag tatggccact gcccactatt tttattttct tatgtaagtt tgcatatcag
                                                                      4260
tcatgactag tgcctagaaa gcaatgtgat ggtcaggatc tcatgacatt atatttgagt
                                                                      4320
ttctttcaga tcatttagga tactcttaat ctcacttcat caatcaaata ttttttgagt
                                                                      4380
gtatgctgta gctgaaagag tatgtacgta cgtataagac tagagagata ttaagtctca
                                                                      4440
gtacacttcc tgtgccatgt tattcagctc actggtttac aaatataggt tgtcttgtgg
                                                                      4500
ttgtaggagc ccactgtaac aatactgggc agcctttttt tttttttt taattgcaac
                                                                      4560
aatgcaaaag ccaagaaagt ttaagggtca caagtctaaa caatgaattc ttcaacaggg
                                                                      4620
aaaacagcta gcttgaaaac ttgctgaaaa acacaacttg tgtttatggc atttagtacc
                                                                      4680
ttcaaataat tggctttgca gatattggat accccattaa atctgacagt ctcaaatttt
                                                                      4740
tcatctcttc aatcactagt caagaaaaaa tataaaaaaca acaaatactt ccatatqqaq
                                                                      4800
catttttcag agttttctaa cccagtctta tttttctagt cagtaaacat ttgtaaaaat
                                                                      4860
actgtttcac taatacttac tgttaactgt cttgagagaa aagaaaaata tgagagaact
                                                                      4920
attgtttggg gaagttcaag tgatctttca atatcattac taacttcttc cactttttcc
                                                                      4980
agaatttgaa tattaacgct aaaggtgtaa gacttcagat ttcaaattaa tctttctata
                                                                      5040
ttttttaaat ttacagaata ttatataacc cactgctgaa aaaqaaacaa atgattgttt
                                                                      5100
tagaagttaa aggtcaatat tgattttaaa atattaag
                                                                      5138
<210> 30
<211> 20
<212> DNA
<213> Homo sapiens
<400> 30
gtgttcctgc agagggcatg
                                                                        20
<210> 31
<211> 20
<212> DNA
<213> Homo sapiens
<400> 31
cacttccagt aacagctgac
                                                                        20
<210> 32
<211> 21
<212> DNA
<213> Homo sapiens
<400> 32
ctttgcgcat gtccttcatg c
                                                                        21
<210> 33
<211> 21
<212> DNA
<213> Homo sapiens
```

<400> 33 gacatcagcc ctcagcatct t	21
<210> 34 <211> 19	
<212> DNA <213> Homo sapiens	
<400> 34 caacaagcca tgttccctc	19
<210> 35 <211> 18 <212> DNA	
<213> Homo sapiens	
<400> 35 catgttccct cagccagc	18
<210> 36 <211> 19 <212> DNA	
<213> Homo sapiens	
<400> 36 cagageteae ageagggae	19
<210> 37 <211> 21 <212> PRT <213> Homo sapiens	
<400> 37	
Cys Ser Val Arg Leu Ser Tyr Pro Pro Tyr Glu Gln His Glu Cys His 1 5 10 15 Phe Pro Asn Lys Ala 20	
<210> 38 <211> 14 <212> DNA <213> Homo sapiens	
<400> 38	
gcctgtgtgt cccc	14
<210> 39 <211> 14 <212> DNA <213> Homo sapiens	

```
<220>
<221> misc_feature
<222> (1)...(14)
<223> n = t or c
<400> 39
gcctgtgngt cccc
                                                                          14
<210> 40
<211> 45
<212> DNA
<213> Homo sapiens
<400> 40
aagaagatgc tgcctgtgtg tcccccaggg gcagggggc tgcct
                                                                         45
<210> 41
<211> 15
<212> PRT
<213> Homo sapiens
<400> 41
Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
                                     10
<210> 42
<211> 15
<212> PRT
<213> Mus musculus
<400> 42
Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
1
                 5
                                     10
                                                          15
<210> 43
<211> 15
<212> PRT
<213> Homo sapiens
<400> 43
Lys Lys Met Leu Pro Val Arg Pro Pro Gly Ala Gly Gly Leu Pro
                                     10
<210> 44
<211> 5
<212> PRT
<213> Caenorhabditis elegans
<400> 44
Leu Leu Gly Gly Ser
 1
                 5
```

```
<210> 45
<211> 45
<212> DNA
<213> Homo sapiens
<400> 45
aagaagatgc tgcctgtgcg tcccccaggg gcagggggc tgcct
                                                                         45
<210> 46
<211> 14
<212> DNA
<213> Homo sapiens
<400> 46
gcctacttgc agga
                                                                         14
<210> 47
<211> 14
<212> DNA
<213> Homo sapiens
<400> 47
gcctacttgc ggga
                                                                         14
<210> 48
<211> 45
<212> DNA
<213> Homo sapiens
<400> 48
tgggggggct tcgcctactt gcaggatgtg gtggagcagg caatc
                                                                         45
<210> 49
<211> 15
<212> PRT
<213> Homo sapiens
<400> 49
Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
1
                 5
                                     10
                                                          15
<210> 50
<211> 15
<212> PRT
<213> Mus musculus
<400> 50
Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
                 5
                                     10
                                                          15
<210> 51
```

```
<211> 15
<212> PRT
<213> Homo sapiens
<400> 51
Trp Gly Gly Phe Ala Tyr Leu Arg Asp Val Val Glu Gln Ala Ile
                                     10
<210> 52
<211> 12
<212> PRT
<213> Caenorhabditis elegans
<400> 52
Phe Met Thr Val Gln Arg Ala Val Asp Val Ala Ile
                 5
                                     10
<210> 53
<211> 45
<212> DNA
<213> Homo sapiens
<400> 53
tggggggct tcgcctactt gcgggatgtg gtggagcagg caatc
                                                                         45
<210> 54
<211> 25
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(25)
<223> n is a, t, c, or g.
<400> 54
tcattcctct tgtnngcncn gnncn
                                                                         25
<210> 55
<211> 45
<212> DNA
<213> Homo sapiens
<400> 55
agtagcctca ttcctcttct tgtgagcgct ggcctgctag tggtc
                                                                         45
<210> 56
<211> 15
<212> PRT
<213> Homo sapiens
```

```
<400> 56
Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
                 5
                                     10
<210> 57
<211> 15
<212> PRT
<213> Mus musculus
<400> 57
Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
                 5
                                     10
<210> 58
<211> 14
<212> PRT
<213> Homo sapiens
<400> 58
Ser Ser Leu Ile Pro Leu Val Ser Ala Gly Leu Leu Val Val
                 5
                                     10
<210> 59
<211> 15
<212> PRT
<213> Caenorhabditis elegans
<400> 59
Ile Asn Tyr Ala Lys Leu Thr Phe Ala Val Ile Val Leu Thr Ile
1
                 5
                                     10
<210> 60
<211> 42
<212> DNA
<213> Homo sapiens
<400> 60
agtagectea tteetettgt gagegetgge etgetagtgg te
                                                                         42
<210> 61
<211> 25
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(25)
<223> n is a, t, c, or g.
<400> 61
tgatgaagat gananncngn ngcga
                                                                         25
```

```
<210> 62
<211> 36
<212> DNA
<213> Homo sapiens
<400> 62
aatgatgaag atgaagatgt gaggcgggaa agacag
                                                                         36
<210> 63
<211> 12
<212> PRT
<213> Homo sapiens
<400> 63
Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
                 5
                                     10
<210> 64
<211> 12
<212> PRT
<213> Mus musculus
<400> 64
Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
 1
<210> 65
<211> 10
<212> PRT
<213> Homo sapiens
<400> 65
Asn Asp Glu Asp Val Arg Arg Glu Arg Gln
<210> 66
<211> 15
<212> PRT
<213> Caenorhabditis elegans
<400> 66
Asp Glu Arg Asp Val Glu Asp Ser Asp Val Ile Ala Glu Lys Ser
                                                          15
<210> 67
<211> 30
<212> DNA
<213> Homo sapiens
<400> 67
aatgatgaag atgtgaggcg ggaaagacag
                                                                         30
```

<210> 68	
<211> 14	
<212> DNA	
<213> Homo sapiens	
<400> 68	
agttgtacga atag	14
ageegeaega acag	1-3
<210> 69	
<211> 14	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)(14)	
<223> n is t or c.	
<400> 69	
agttgtanga atag	14
<210> 70	
<211> 20	
<212> DNA	
<213> Homo sapiens	
12107 Hollo Baptons	
<400> 70	
ggctggatta gcagtcctca	20
ggorggarra goagroorea	۷(
<210> 71	
<211> 71 <211> 20	
<211> 20 <212> DNA	
<213> Homo sapiens	
400. 71	
<400> 71	
ggatttccca gatcccagtg	20
<210> 72	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 72	
gacagacttg gcatgaagca	20
<210> 73	
<211> 20	
<212> DNA	
<213> Homo sapiens	
400. 73	

gcacttggca	gtcacttctg	20
<210> 74		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 74		
cgtttctcca	ctgtcccatt	20
-5		
<210> 75		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 75		
acttcaagga	cccagcttcc	20
<210> 76		
<211> 24		
<212> DNA		
<213> Homo	sapiens	
<400> 76		
tcggtttctt	gtttgttaaa ctca	24
<210> 77		
<211> 77		
<211> 20 <212> DNA		
<213> Homo	sapiens	
1		
<400> 77		
tcccaaggct	ttgagatgac	20
<210> 78		
<211> 19		
<212> DNA		
<213> Homo	sapiens	
<400> 78		
ggctccaaag	cccttgtaa	19
-		
<210> 79		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 79		
gctgctgtga	tagagtatct	20
googoogoga		∠ ∪
<210> 80		

<pre> <210> 81 <211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 84 cagtgagtg tccctctagc <210 84 <211> 20 <212> DNA <213> Homo sapiens <400 84 cagtgagtg cttgggattg <210 84 cagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 </pre>	<211> 25	
<pre><400> 80 tttgtaaatt ttgtagtgct cctca <210> 81 <211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400 82 <211> 20 <212> DNA <213 Homo sapiens <400 82 aaagggctt ggtaagggta <210 83 <211> 20 <212> DNA <213> Homo sapiens <400 82 gatagtggtg tccctctagc <210 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccttagc <210 84 <211> 20 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210 86 <211> 20 <212> DNA</pre>	<212> DNA	
<pre>ctttgtaaatt ttgtagtgct cctca <210> 81 <211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212> DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212 DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212 DNA <213 Homo sapiens <400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212 DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210 86 <211> 20 <212> DNA <211> DNA <212 DNA <</pre>	<213> Homo sapiens	
<pre>ctttgtaaatt ttgtagtgct cctca <210> 81 <211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212> DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212 DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211> 20 <212 DNA <213 Homo sapiens <400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212 DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210 86 <211> 20 <212> DNA <211> DNA <212 DNA <</pre>		
<pre><210> 81 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400 83 gatgtgtgt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400 83 gatgtggtgt tccctctage <210> 84 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213> Homo sapiens </pre> <pre><400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213> Homo sapiens </pre> <pre><400 85 gcaaattcaa atttctccag g</pre> <pre><210 86 <211> 20 <212> DNA <213> Homo sapiens </pre>	<400> 80	
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 82 agggggtt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 cantagaggg cttgggattg <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 cangtagagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA <213> Homo sapiens <400< 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	tttgtaaatt ttgtagtgct cctca	25
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctccta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 82 agggggtt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 cantagaggg cttgggattg <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 cangtagagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA <213> Homo sapiens <400< 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre><212> DNA <213> Homo sapiens <400> 81 tagtcagccc ttgcctcta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400 82 aaagggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa attctccag g <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 gcaaattcaa attctccag g <210 86 <211> 20 <212> DNA <213 Homo sapiens <400 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 <211> 20 <212> DNA <213 Homo sapiens <400 85 <211> 20 <212> DNA <213 Homo sapiens <400 85 <211> 20 <212> DNA <213 Homo sapiens <400 85 <400 85</pre>	<210> 81	
<pre><213> Homo sapiens <4400> 81 tagtcagccc ttgcctcta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgct tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	<211> 20	
<pre><400> 81 tagtcagccc ttgcctcta <210> 82 <211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 83 <211> 20 <212> DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 84 <221> 20 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 85 <211> 21 <212> DNA <213 Homo sapiens <400 85 gcaaattcaa atttctccag g <210 86 <211> 20 <212> DNA <213 Homo sapiens <400 85 gcaaattcaa atttctccag g <210 86 <211> 20 <212> DNA</pre>	<212> DNA	
<pre>tagtcagccc ttgcctcta <210 82 <211 20 <212 DNA <213 Homo sapiens <400 82 aaaggggctt ggtaagggta <210 83 <211 20 <212 DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211 20 <212 DNA <213 Homo sapiens <400 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 85 <211 21 <212 DNA <213 Homo sapiens <400 85 gcaaattcaa attctccag g <210 86 <211 20 <212 DNA <213 Homo sapiens </pre>	<213> Homo sapiens	
<pre>tagtcagccc ttgcctcta <210 82 <211 20 <212 DNA <213 Homo sapiens <400 82 aaaggggctt ggtaagggta <210 83 <211 20 <212 DNA <213 Homo sapiens <400 83 gatgtggtgc tccctctagc <210 84 <211 20 <212 DNA <213 Homo sapiens <400 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 84 caagtgagtg cttgggattg <210 85 <211 21 <212 DNA <213 Homo sapiens <400 85 gcaaattcaa attctccag g <210 86 <211 20 <212 DNA <213 Homo sapiens </pre>		
<pre><210> 82 <211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400 84 caagtgagtg cttgggattg <210 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa attctccag g <210> 86 <211> 20 <212> DNA</pre>	<400> 81	
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caugtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	tagtcagccc ttgcctccta	20
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caugtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre><212> DNA <213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caugtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre><213> Homo sapiens <400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <211> 20 <212> DNA</pre>		
<pre><400> 82 aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <211> 20 <212> DNA <213> Homo sapiens <400> 84 cagtgagtg cttgggattg <210> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <211> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA	<213> Homo sapiens	
aaaggggctt ggtaagggta <210> 83 <211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <211> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
<pre><210> 83 <211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <211> Homo sapiens </pre> <pre><400> 84 caagtgagtg cttgggattg </pre> <pre><210> 85 <211> 21 <212> DNA <213> Homo sapiens </pre> <pre><400 85 gcaaattcaa atttctccag g</pre> <pre><210> 86 <211> 20 <212> DNA <213> Homo sapiens </pre>		
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tecetetage <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa attetecag g <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85</pre>	aaaggggctt ggtaagggta	20
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tecetetage <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa attetecag g <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85</pre>		
<pre><212> DNA <213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa attctccag g <210> 85 <211> 21 <212> DNA <213> Homo sapiens</pre>		
<pre><213> Homo sapiens <400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <210> 86 <211> 20 <210> 86 <211> 20 <210> 86</pre>		
<pre><400> 83 gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 c211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <210> 86 <211> 20 <212> DNA</pre>		
<pre>gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <210> 86 <211> 20 <212> DNA</pre>	<213> Homo sapiens	
<pre>gatgtggtgc tccctctagc <210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <210> 86 <211> 20 <212> DNA</pre>	.400. 02	
<210> 84 <211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	gatgtggtge teeetetage	20
<pre><211> 20 <212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	-210× 04	
<pre><212> DNA <213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre><213> Homo sapiens <400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre><400> 84 caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		
<pre>caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	(213) Homo sapiens	
<pre>caagtgagtg cttgggattg <210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	<400 × 84	
<210> 85 <211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		20
<pre><211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>		20
<pre><211> 21 <212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA</pre>	<210> 85	
<212> DNA <213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
<213> Homo sapiens <400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
<400> 85 gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA		
gcaaattcaa atttctccag g <210> 86 <211> 20 <212> DNA	<400> 85	
<210> 86 <211> 20 <212> DNA		21
<211> 20 <212> DNA		
<211> 20 <212> DNA	<210> 86	
<212> DNA		
<213> Homo sapiens	<212> DNA	
	<213> Homo sapiens	

tcaaggagga aatggacctg	20
<210> 87 <211> 20 <212> DNA	
<213> Homo sapiens	
<400> 87 ctgaaagttc aagcgcagtg	20
<210> 88 <211> 20 <212> DNA	
<213> Homo sapiens	
<400> 88	20
tgcagactga atggagcatc	20
<210> 89 <211> 20	
<212> DNA <213> Homo sapiens	
<400> 89	
gccaggggac actgtattct	20
<210> 90	
<211> 20 <212> DNA	
<213> Homo sapiens	
<400> 90	
aggtcctctg ccttcactca	20
<210> 91 <211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 91	
ccagtgctta cccctgctaa	20
<210> 92 <211> 21	
<211> 21 <212> DNA	
<213> Homo sapiens	
<400> 92	
cacacaacaa agottottaa a	21

<210> 93		
<211> 20		
<212> DNA		
<213> Homo	no sapiens	
<400> 93		
	za ggtgtggtgt	20
acceggaaca	,	2 (
<210> 94		
<211> 21		
<212> DNA		
<213> Homo	o sapiens	
400 04		
<400> 94		
gggctaacat	t gccactcagt a	21
<210> 95		
<211> 20		
<212> DNA		
<213> Homo	o sapiens	
<400> 95		
gtttgttgca	a gatggggaag	20
<210> 96		
<211> 20		
<212> DNA	L	
<213> Homo	o sapiens	
	•	
<400> 96		
	a aggagcatgg	20
, ,		2.
<210> 97		
<211> 20		
<212> DNA		
<213> Homo		
(213) 1101110	o saprons	
<400> 97		
	t agggatttgc	20
ceggaceegt	c agggaccege	20
<210> 98		
<210> 98		
<211> 21 <212> DNA		
<213> Homo	n sabrens	
100 00		
<400> 98		
gcctgtcaca	a gagaaatgct t	21
040		
<210> 99		
<211> 21		
<212> DNA	•	

<213> Homo	sapiens	
<400> 99		
	atcctgtgct c	21
<210> 100		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 100		
agreaggitt	ccggtcacac	20
<210> 101		
<211> 22		
<212> DNA		
<213> Homo	sapiens	
<400> 101		
ccgttcctta	tatcctcagg tg	22
<210> 102		
<211> 21		
<212> DNA		
<213> Homo	sapiens	
<400> 102		
cettgtacae	actcgcactg a	21
<210> 103		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 103		
tgttgtccac	aggttccaga	20
<210> 104		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 104		
tgaggtttat	gggcatggtt	20
<210> 105		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 105		

atgtttttcc	ttggctgtgc	:	20
<210> 106 <211> 20 <212> DNA			
<213> Homo	sapiens		
<400> 106 atctgccctt	tcttgtctga		20
<210> 107 <211> 20			
<212> DNA <213> Homo	sapiens		
<400> 107	agastagata		20
agggagctgc	acagiggata		20
<210> 108 <211> 24			
<211> 24 <212> DNA			
<213> Homo	sapiens		
<400> 108			
tcactcccat	atttcagaac	ttga :	24
<210> 109			
<211> 22 <212> DNA			
<213> Homo	sapiens		
<400> 109			
tgtttattgg	aagatcggtg	aa	22
<210> 110			
<211> 25 <212> DNA			
<213> Homo	sapiens		
<400> 110			
cgttagagac	tgaatctttg	teetg	25
<210> 111			
<211> 20 <212> DNA			
<213> Homo	sapiens		
<400> 111			
agtcctgcct	tccacagttg		20
<210> 112			

<211> 21			
<212> DNA <213> Homo	ganiena		
<213> HOIIIO	sapiens		
<400> 112			
	tgttaggggc	3	21
ggcagccacg	tgttaggggt	a	21
<210> 113			
<211> 21			
<212> DNA			
<213> Homo	saniens		
1207 1101110	Dapiens		
<400> 113			
	aggccagatt	q	21
33	55		
<210> 114			
<211> 23			
<212> DNA			
<213> Homo	sapiens		
<400> 114			
catgtatgtg	taggacagca	tga	23
<210> 115			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
.400. 115			
<400> 115	~~+~~++~+		
Cigilicaaa	gatgcttctg		21
<210> 116			
<211> 20			
<211> 20			
<213> Homo	saniens		
12207 1101110	papiens		
<400> 116			
	tggaatgctg		20
555-	-555		
<210> 117			
<211> 20			
<212> DNA			
<213> Homo	sapiens		
<400> 117			
gggttcccag	ggttcagtat		20
040			
<210> 118			
<211> 23			
<212> DNA			
<213> Homo	sapiens		

<400> 118 cttgacctaa	tttcaacatc tgg	23
<210> 119 <211> 20 <212> DNA <213> Homo	sapiens	
<400> 119 atccccaact	caaaaccaca	20
<210> 120 <211> 21 <212> DNA <213> Homo	sapiens	
<400> 120 aagtccaatt	tagcccacgt t	21
<210> 121 <211> 20 <212> DNA <213> Homo	sapiens	
<400> 121 ccagccattc	aaaattctcc	20
<210> 122 <211> 20 <212> DNA		
<213> Homo <400> 122	sapiens	
ggtgcaggtc	aatttccaat	20
<210> 123 <211> 20 <212> DNA <213> Homo	sapiens	
<400> 123 ccccttcacc	accattacaa	20
<210> 124 <211> 20 <212> DNA <213> Homo	sapiens	
<400> 124	aaagcctcac	2.0

<210> 125 <211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 125		
aggacctctt	gccagactca	20
33	J J	
<210> 126		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 126		
aggagatgac	acaggccaag	20
<210> 127		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 127		
cgcacacctc	tanagataga	20
cgcacacccc	Lydagetace	20
-010- 100		
<210> 128		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 128		
acctcactca	cacctgggaa	20
<210> 129		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
	•	
<400> 129		
gcctcctgcc	tgaaccttat	20
3		20
<210> 130		
<211> 23		
<211> 23 <212> DNA		
	ganiong	
<213> Homo	adhtena	
-400 700		
<400> 130		_
caaaatcatg	acaccaagtt gag	23
010 101		
<210> 131		
<211> 20		
<212> DNA		

<213> Homo	sapiens	
<400> 131		
catgcacatg	cacacacata	20
<210> 132		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 132		
ccttagcccg	tgttgagcta	20
<210> 133		
<211> 21		
<212> DNA		
<213> Homo	sapiens	
	•	
<400> 133		
tgcttttatt	cagggactcc a	21
<210> 134		
<211> 20 <212> DNA		
<212> DNA <213> Homo	ganieng	
(215) 110110	sapiens	
<400> 134		
cccatgcact	gcagagattc	20
<210> 135		
<211> 19		
<212> DNA		
<213> Homo	sapiens	
<400> 135		
aaggcaggag	acatcgctt	19
33 33 3		
<210> 136		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 136		
	taatttaata	20
gggatcagca	cygcoccca	∠U
<210> 137		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 137		

gcttaagtcc	cactcctccc	20
<210> 138		
<211> 20		
<212> DNA	,	
<213> Homo	sapiens	
<400> 138		
attttcctcc	gcatgtgtgt	20
<210> 139		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 139		
tcacagaagc	ctagccatga	20
<210> 140		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 140		
aacagagcag	ggagatggtg	20
<210> 141		
<211> 20		
<211> 20 <212> DNA		
	aniona	
<213> Homo	saprens	
<400> 141		
tctgcacctc	tcctcctctg	20
<210> 142		
<211> 20		
<212> DNA		
	anniona	
<213> Homo	saptens	
<400> 142		
actggggcca	acattaatca	20
<210> 143		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
.400. 140		
<400> 143		
cttccccatc	tgcaacaaac	20
<210> 144		

<211> 20 <212> DNA	
<213> Homo	sapiens
<400> 144	
	atccaaagaa
<210> 145	
<211> 20	
<212> DNA	
<213> Homo	sapiens
<400> 145	
tcaagtgcat	ctgggcataa
<210> 146	
<211> 20	
<212> DNA	. caniena
<213> Homo	, sahrens
<400> 146	
tctgaagtcc	attcccttgg
<210> 147	
<211> 20	
<212> DNA	aniona
<213> Homo	, sapiens
<400> 147	
caatgtggca	tgcagttgat
<210> 148	
<211> 19	
<212> DNA <213> Homo	sapiens
-2137 HOMO	. Subtems
<400> 148	
gaagctacca	gcccatcct
<210> 149	
<211> 20	
<212> DNA <213> Homo	sapiens
1225 110110	~~E + ~***
<400> 149	
catttcccc	actgtttcag
<210> 150	
<211> 20	
<212> DNA <213> Homo	sapiens
	_

<400> 150 ccaaggcttt	cttcaatcca	20
<210> 151		
<211> 20		
<211> 20 <212> DNA		
<213> Homo	sapiens	
<400> 151		
gatccgttta	acctgccaac	20
<210> 152		
<211> 19		
<212> DNA		
<213> Homo	sapiens	
<400> 152		
atgcccctgc	caactttac	19
<210> 153		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 153		
ctctgcagct	gttcccctac	20
<210> 154		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 154		
tatcaatcca	tggccctgac	20
<210> 155		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 155		
agagtccctg	ccctccttct	20
<210> 156		
<211> 20		
<212> DNA		
<213> Homo	sapiens	
<400> 156		
aaggcagtca	gcagtgtcaa	20

<210> 157	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 157	
ggggaacatc ctgtgcttag	20
<210> 158	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 158	
ccattggtga gtgtttccct	20
<210> 159	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 159	
agtcagcaaa ctgctgggtt	20
<210> 160	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 160	
attgctccat cctggcataa	20
<210> 161	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 161	
tcatggatga ttttatgtgc ttc	23
<210> 162	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 162	
gcgtgtggaa aagccataag	20
<210> 163	
<211> 20	
<212> DNA	

<213> Homo	sapiens		
<400> 163			
gccaatcata	caacagccct	:	20
<210> 164			
<211> 23			
<212> DNA			
<213> Homo	sapiens		
400 454			
<400> 164			
tgatcgcata	ttctacttgg	aaa	23
<210> 165			
<211> 22			
<212> DNA			
<213> Homo	sapiens		
<400> 165			
tccctttatt	ttagaggcac	ca	22
<210> 166			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 166			
	tcaagcacca	2	21
gaccaggaac	ccaagcacca	a .	<i>2</i> , 1
<210> 167			
<211> 24			
<212> DNA			
<213> Homo	sapiens		
<400> 167			
tgggttccat	aatagagttt	caca	24
<210> 168			
<210> 166			
<211> 22 <212> DNA			
<213> Homo	sapiens		
3_2, 1200			
<400> 168			
	tactggaagt	gg	22
<210> 169			
<211> 22			
<212> DNA			
<213> Homo	sapiens		
<400> 169			

tgtcagctgc	tgctggaagt	gg	22
<210> 170			
<211> 21			
<212> DNA			
<213> Homo	canienc		
\215> 110MO	sapiens		
<400> 170			
	cgaagccaca	2	21
aggageegge	cgaagccaca	α	4 1
<210> 171			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	2012		
<400> 171			
	tgaagccaca	a	21
33 3 33	5 5		
<210> 172			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 172			
aatgatgcca	ccaaacaaat	g	21
<210> 173			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
400 153			
<400> 173	+		0.1
aatgatgcca	tcaaacaaat	9	21
<210> 174			
<211> 21			
<211> 21 <212> DNA			
<213> Homo	saniens		
12137 1101110	bapiens		
<400> 174			
	cgatgaccac	a	21
3 33 33	5 5		
<210> 175			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 175			
gaggtggctc	tgatgaccac	a	21
<210 > 176			

<211> 21 <212> DNA		
<213> Homo	o sapiens	
<400> 176		
ttccttaaca	a gaaatagtat	C
<210> 177		
<211> 21		
<212> DNA <213> Homo	o sapiens	
1200	Japiens	
<400> 177		_
LLCCLLadCa	a aaaatagtat	Ç
<210> 178		
<211> 21		
<212> DNA <213> Homo	o sapiens	
	. E	
<400> 178		_
ggaagtgtt	c caaaagagaa	a
<210> 179		
<211> 21		
<212> DNA <213> Homo	o sapiens	
	_	
<400> 179	T taaaadadaa	э
ggaagegee	c taaaagagaa	а
<210> 180		
<211> 21		
<212> DNA <213> Homo		
	<u> </u>	
<400> 180	·	_
agtaaagagg	g gactagactt	t
<210> 181		
<211> 21		
<212> DNA <213> Homo	o sapiens	
	T	
<400> 181		
agtaaagag	g aactagactt	t
<210> 182		
<211> 21		
<212> DNA <213> Homo	o sapiens	

<400> 182 gcctacttgc	aggatgtggt	g	21
<210> 183			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 183			
gcctacttgc	gggatgtggt	g	21
<210> 184			
<211> 23			
<212> DNA			
<213> Homo	sapiens		
<400> 184			
cctcattcct	cttcttgtga	gcg	23
<210> 185			
<211> 20			
<212> DNA			
<213> Homo	sapiens		
<400> 185			
cctcattcct	cttgtgagcg		20
<210> 186			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 186			
gcaggactac	gtgggcttca	С	21
<210> 187			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 187			
gcaggactac	atgggcttca	С	21
<210> 188			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 188			
aaaagtctac	cgagatggga	t	21

<210> 189	
<211> 21	
<212> DNA	
<213> Homo sapiens	
(213) Homo sapiens	
<400> 189	
aaaagtctac tgagatggga t	
010 100	
<210> 190	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 190	
ggccagatca cctccttcct g	
<210> 191	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 191	
ggccagatca tctccttcct g	
<210> 192	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 192	
acacaccaca tggatgaagc g	
<210> 193	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 193	
acacaccaca cggatgaagc g	
<210> 194	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 194	
cctggaagaa gtaagttaag t	
<210> 195	
<211> 21	
<212> DNA	

<213> Homo	sapiens	
<400> 195	ctaagttaag t	21
<210> 196 <211> 21		
<212> DNA		
<213> Homo	sapiens	
<400> 196		
gctgcctgtg	tgtcccccag g	21
<210> 197		
<211> 21		
<212> DNA	aniona	
<213> Homo	sapiens	
<400> 197		
gctgcctgtg	cgtccccag g	21
<210> 198		
<211> 22		
<212> DNA		
<213> Homo	sapiens	
<400> 198		
tagccattat	ggaattactg ct	22
<210> 199		
<211> 21		
<212> DNA		
<213> Homo	sapiens	
<400> 199		
tagccattat	caattactgc t	21
<210> 200		
<211> 26		
<212> DNA <213> Homo	ganiong	
(213) HOIIIO	saptens	
<400> 200		
gatgaagatg	aagatgtgag gcggga	26
<210> 201		
<211> 20		
<212> DNA <213> Homo	sanjens	
	54P + 044P	
<400> 201		

gatgaagatg	tgaggcggga	:	20
<210> 202			
<211> 21			
<212> DNA			
<213> Homo	ganiong		
(213) HOMO	saprens		
<400> 202			
	cgaatagcag	a	21
aacagoogca	ogaacagcag	9	3 I
<210> 203			
<211> 21			
<212> DNA			
<213> Homo	canienc		
(213) 1101110	Бартень		
<400> 203			
	tgaatagcag	q	21
3 3	3 3 3	-	_
<210> 204			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	-		
<400> 204			
acacgctggg	ggtgctggct	g	21
<210> 205			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 205			
acacgctggg	cgtgctggct	g	21
.210 206			
<210> 206			
<211> 20			
<212> DNA			
<213> Homo	sapiens		
<400> 206			
gaccagccac	aggatagata		
gaccagccac	ggcgtccctg	2	20
<210> 207			
<211> 21			
<211> 21 <212> DNA			
<213> Homo	sapiens		
110110			
<400> 207			
	gggcgtccct	a	21
3 3	333 3		-
<210> 208			

<211> 22			
<212> DNA			
<213> Homo	sapiens		
	245 2 2112		
<400> 208			
catttttttta	gaaaagagag	gt	22
<210> 209			
<211> 22			
<212> DNA			
<213> Homo	sapiens		
<400> 209			
	gagaagagag	at	22
oaccccca	gagaagagag	30	22
<210> 210			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 210			
gaaaattagt	atgtaaggaa	g	21
<210> 211			
<211> 21			
<212> DNA			
<213> Homo	canienc		
\213\/ 1101110	sapiens		
400- 011			
<400> 211			
gaaaattagt	ctgtaaggaa	g	21
<210> 212			
<211> 25			
<212> DNA			
<213> Homo	sapiens		
<400> 212			
cctccaccta	ccaggttcag	cgatt	25
		9,400	20
<210> 213			
<211> 25			
<212> DNA			
<213> Homo	sapiens		
<400> 213			
cctccgcctg	ccgggttcag	cgatt	25
<210> 214			
<211> 25			
<212> DNA			
<213> Homo	sapiens		

<400> 214 tatgtgctga	ccatgggagc	ttgtt	25
<210> 215 <211> 25 <212> DNA			
<213> Homo	sapiens		
<400> 215 tatgtgctga	ccgtgggagc	ttgtt	25
<210> 216			
<211> 21			
<212> DNA <213> Homo	sapiens		
<400> 216			
gtgacaccca	acggagtagg	g	21
<210> 217			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 217			
gtgacaccca	gcggagtagg	g	21
<210> 218			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 218			
agtatccctt	gttcacgaga	a	21
<210> 219			
<211> 25			
<212> DNA			
<213> Homo	sapiens		
<400> 219			
agtatccctc	ccttgttcac	gagaa	25
<210> 220			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 220			
ctgggttcct	gtatcacaac	C	21

<210> 221 <211> 21 <212> DNA		
<213> Homo sapiens		
<400> 221		
ctgggttcct atatcacaac c		
<210> 222		
<211> 21		
<212> DNA		
<213> Homo sapiens		
<400> 222		
ggcctaccaa gggagaaact g		
<210> 223		
<210> 223 <211> 21		
<212> DNA		
<213> Homo sapiens		
20 <u>F</u> 2000		
<400> 223	•	
ggcctaccaa aggagaaact g		
<210> 224		
<211> 20		
<212> DNA		
<213> Homo sapiens		
<400> 224		
tttaaagggg gtgattagga		:
<210> 225		
<211> 20		
<212> DNA		
<213> Homo sapiens		
400 005		
<400> 225		
tttaaagggg ttgattagga		:
<210> 226		
<211> 22		
<212> DNA		
<213> Homo sapiens		
<400> 226		
gaagaaattt gtttttttga tt		:
<210> 227		
<211> 22		
<212> DNA		

<213> Homo :	sapiens	
<400> 227 gaagaaattt 1	ttttttttga tt	
<210> 228		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 228		
gcgggcatcc (gagggaggg g	
<210> 229		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 229		
gcgggcatcc t	gagggaggg g	
<210> 230		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 230		
agggaggggg	ctgaagatc a	
<210> 231		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 231		
agggagggg a	ctgaagatc a	
<210> 232		
<211> 20		
<212> DNA		
<213> Homo s	apiens	
<400> 232		
aggagccaaa c	gctcattgt	
	_	
<210> 233		
<211> 21 <212> DNA		
<212> DNA <213> Homo s	apiens	
<400> 233		

aggagccaaa	gcgctcattg	t :	21
<210> 234			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
12-01 2200	2012		
<400> 234			
	ttttaaccag	+	21
<210> 235			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	1		
<400> 235			
aagccactgt	atttaaccag	t	21
_	_		
<210> 236			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 236			
cgtgggcttc	acactcaaga	t ;	21
<210> 237			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
.400. 005			
<400> 237	~~~~		
cgcgggccc	ccactcaaga		21
<210> 238			
<211> 236			
<212> DNA			
<213> Homo	saniens		
12107 1101110	Dapiens		
<400> 238			
	gatcttcgct	q	21
	2 3		
<210> 239			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 239			
tcacactcaa	catcttcgct	g	21
<210> 240			

<211> 21		
<212> DNA		
<213> Homo s	apiens	
	-	
<400> 240		
gcagcctcac c	cactettee o	c 21
3 3	3	
<210> 241		
<211> 21		
<212> DNA		
<213> Homo s	aniena	
(213) HOMO B	aprens	
<400> 241		
		0.1
gcagcctcac t	egetettee (c 21
.010 040		
<210> 242		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 242		
agaagagaat a	itcagaaatc 1	t 23
<210> 243		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
<400> 243		
agaagagaat g	stcagaaatc	t 21
<210> 244		
<211> 21		
<212> DNA		
<213> Homo s	apiens	
	· •	
<400> 244		
gcgcagtgcc c	tatateett :	a 21
505005050		
<210> 245		
<211> 21		
<211> 21 <212> DNA		
<213> Homo s	aniena	
-2137 HOREO S	aprens	
<400> 245		
	+	
gcgcagtgcg c	rgrgreett :	a 23
.010. 046		
<210> 246		
<211> 21		
<212> DNA		
<213> Homo s	apiens	

<400> 246	tgtcattctg	а	21
J	-3	5	ــ ــ
<210> 247			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 247			
gatctaaggt	ggtcattctg	g	21
<210> 248			
<211> 23			
<212> DNA			
<213> Homo	sapiens		
<400> 248			
	agcacagaag	aαa	23
	J 		
<210> 249			
<211> 23			
<212> DNA			
<213> Homo	sapiens		
<400> 249			
ctcttctgtt	atcacagaag	aga	23
<210> 250			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 250			
	atcatagcca	t	21
	J		_
<210> 251			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 251			
cattctaggg	gtcatagcca	t	21
<210> 252			
<211> 22			
<212> DNA			
<213> Homo	sapiens		
<400> 252			
	qqaqqaacaq	ca	22
	-, -, -, -, -, -, -, -, -, -, -, -, -, -	U-1	44

<210> 253	
<211> 22	
<212> DNA	
<213> Homo sapiens	
nome supreme	
<400> 253	
	22
aagtacagtg tgaggaacag cg	22
<210> 254	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 254	
attcctaaaa aatagaaatg ca	22
<210> 255	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 255	
attcctaaaa agtagaaatg ca	22
accectada aytayaaaty ta	44
<210> 256	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 256	
ggcccctgcc ttattattac t	21
<210> 257	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 257	
ggcccctgcc gtattattac t	21
<210> 258	
<211> 22	
<212> DNA	
<213> Homo sapiens	
and we have a separate	
<400> 258	
	22
tgagagaatt acttgaaccc gg	22
<210> 259	
<211> 22	
<212> DNA	

<213> Homo	sapiens	,	
<400> 259			
tgagagaatt	gcttgaaccc	gg	22
<210> 260			
<211> 21			
<212> DNA			
<213> Homo	ganieng		
12137 1101110	Bapiens		
<400> 260			
	caatcactga	c	21
J J	-		_
<210> 261			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	-		
<400> 261			
tttgctgaaa	taatcactga	c	21
<210> 262			
<211> 22			
<212> DNA			
<213> Homo	sapiens		
<400> 262			
aacctcagtt	ccctcatctg	tg 2	22
.010 060			
<210> 263			
<211> 22 <212> DNA			
<212> DNA <213> Homo	ganiong		
(213) HOIIIO	saprens		
<400> 263			
	tcctcatctg	ta	22
aaceccagec	coccacccg	2	. 4
<210> 264			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	-		
<400> 264			
ctggacacca	gaaataatgt	C	21
	_		
<210> 265			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 265			

ctggacacca	aaaataatgt	С	21
<210> 266			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
	~		
<400> 266			
tcctatgtgt	cctccaccaa	t	21
<210> 267			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 267			
tcctatgtgt	gctccaccaa	t	21
<210> 268			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 268			
aagaagtggc	ttgtattttg	C	21
<210> 269			
<211> 21			
<212> DNA			
<213> Homo	sapiens		
<400> 269			
aagaagtggc	ctgtattttg	С	21
-010. 070			
<210> 270			
<211> 23 <212> DNA			
	ganiong		
<213> Homo	saprens		
<400> 270			
	attggtatag	cta	23
aaccgacccg	accygcacag	ccg	23
<210> 271			
<211> 271			
<212> DNA			
<213> Homo	sapiens		
	- <u>-</u>		
<400> 271			
	gttggtatag	ctg	23
- 3		-	
<210> 272			

<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 272	
cagggtccaa cccggacctg a	21
<210> 273	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 273	
cagggtccaa tccggacctg a	21
<210> 274	
<211> 22	
<212> DNA	
<213> Homo sapiens	
400 054	
<400> 274	
ttgggaggct aaggcaggag aa	22
210. 255	
<210> 275	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 275	
ttgggaggct gaggcaggag aa	22
tegggagget gaggeaggag aa	44
<210> 276	
<211> 15	
<212> DNA	
<213> Gallus gallus	
<400> 276	
accaggggaa tetee	15
<210> 277	
<211> 15	
<212> DNA	
<213> Gallus gallus	
<400> 277	
accagggaaa tctcc	15
<210> 278	
<211> 45	
<212> DNA	
<213> Gallus gallus	

```
<400> 278
      cgctacccaa caccagggga atctcctggt attgttggaa acttc
                                                                               45
      <210> 279
      <211> 15
      <212> PRT
      <213> Homo sapiens
      <400> 279
      Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
      <210> 280
      <211> 15
      <212> PRT
      <213> Mus musculus
      <400> 280
      Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
ı, Eğ
      <210> 281
T.J
      <211> 15
Ţ
      <212> PRT
      <213> Gallus gallus
ij
<400> 281
11
      Arg Tyr Pro Thr Pro Gly Glu Ser Pro Gly Ile Val Gly Asn Phe
                                           10
<210> 282
<211> 15
      <212> PRT
      <213> Gallus gallus
      <400> 282
      Arg Tyr Pro Thr Pro Gly Lys Ser Pro Gly Ile Val Gly Asn Phe
                                           10
      <210> 283
      <211> 45
      <212> DNA
      <213> Gallus gallus
      cgctacccaa caccagggaa atctcctggt attgttggaa acttc
                                                                               45
      <210> 284
      <211> 19
      <212> DNA
      <213> Homo sapiens
```

<400> 284	tagagagag	19
gcgtcaggga		
<210> 285		
<211> 20		
<212> DNA <213> Homo	sapiens	
<400> 285		
gcgtcaggga	ttggggacag	20
<210> 286		
<211> 17		
<212> DNA		
<213> Homo	sapiens	
<400> 286		
ccacttcggt	ctccatg	17
<210> 287		
<211> 17		
<212> DNA	anniona	
<213> Homo	saptens	
<400> 287		17
ccacttcgat	ctccatg	1.